{
  "filename": "ehaa554.pdf",
  "title": null,
  "type": "heart_failure",
  "year": 2005,
  "chapters": [
    {
      "number": "1",
      "title": "1 Representing the AEPC.",
      "start_page": 0,
      "end_page": 1,
      "content": "ESC entities having participated in the development of this document:\nAssociations : Association for Acute Cardiovascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).\nCouncils : Council for Cardiology Practice, Council of Cardio-Oncology, Council on Valvular Heart Disease.\nWorking Groups : Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Development Anatomy and Pathology, e-Cardiology, Pulmonary Circulation and Right Ventricular Function.\nThe content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the  European Heart Journal  and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).\nDisclaimer . The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge, and the evidence avail- able at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other ofﬁ- cial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of pre- ventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.\nV C  The European Society of Cardiology 2020. All rights reserved. For permissions please email: journals.permissions@oup.com.\nEuropean Heart Journal (2021)  42 , 563 \u0002 645\nESC GUIDELINES\ndoi:10.1093/eurheartj/ehaa554\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ........................................................................................................\nNatasja de Groot (Netherlands), Victoria Delgado (Netherlands), Giovanni Di Salvo (United Kingdom), Laura Dos Subira (Spain), Andreas Eicken 1   (Germany), Donna Fitzsimons (United Kingdom), Alexandra A. Frogoudaki (Greece), Michael Gatzoulis (United Kingdom), Stephane Heymans (Netherlands/Belgium), Ju¨ rgen Ho¨ rer (Germany), Lucile Houyel (France), Guillaume Jondeau (France), Hugo A. Katus (Germany), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Alexander Lyon (United Kingdom), Christian E. Mueller (Switzerland), Darren Mylotte (Ireland), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Marco Rofﬁ(Switzerland), Raphael Rosenhek (Austria), Evgeny Shlyakhto (Russia), Iain A. Simpson (United Kingdom), Miguel Sousa-Uva (Portugal), Christian Tobias Torp-Pedersen (Denmark), Rhian M. Touyz (United Kingdom), Alexander Van De Bruaene (Belgium)\nThe disclosure forms of all experts involved in the development of these Guidelines are available on the ESC website www.escardio.org/guidelines\nClick here to access the corresponding chapter in Section 17- Congenital heart disease in children and adults\n................................................................................................................................................................................................... Keywords Guidelines  •  congenital heart disease  •  disease  •  adult  •  diagnosis  •  imaging  •  late complications  •  medical treatment  •  congenital cardiac surgery  •  catheter intervention  •  patient follow-up  •  recommendations\nTable of contents\n",
      "keywords": [
        "representing",
        "aepc",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 568 2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
      "start_page": 1,
      "end_page": 1,
      "content": "",
      "keywords": [
        "preamble",
        "introduction"
      ],
      "tables": []
    },
    {
      "number": "3",
      "title": "2.1 Why do we need new Guidelines on the management of adult congenital heart disease? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570 2.2 Content of these Guidelines . . . . .",
      "start_page": 1,
      "end_page": 1,
      "content": "",
      "keywords": [
        "adult",
        "these",
        "need",
        "guidelines",
        "heart",
        "content",
        "management",
        "congenital",
        "disease"
      ],
      "tables": []
    },
    {
      "number": "4",
      "title": "3.1 Prevalence of adult congenital heart disease . . . . . . . . . . . . . . . . . 570 3.2 Organization of care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570 3.3 ",
      "start_page": 1,
      "end_page": 2,
      "content": "3.3.1 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577 3.3.2 Cardiovascular magnetic resonance imaging . . . . . . . . . . . . . 578 3.3.3 Cardiovascular computed tomography . . . . . . . . . . . . . . . . . . 578 3.3.4 Cardiopulmonary exercise testing . . . . . . . . . . . . . . . . . . . . . . 578 3.3.5 Cardiac catheterization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 578 3.3.6 Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 578 3.4 Therapeutic considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579\n3.4.1 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579 3.4.2 Arrhythmias and sudden cardiac death . . . . . . . . . . . . . . . . . . 579 3.4.2.1 Arrhythmia substrates  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579 3.4.2.2 Assessment in patients with suspected/documented arrythmias and arrythmia management  . . . . . . . . . . . . . . . . . . . . . . . 580 3.4.2.3 Sinus node dysfunction, atrioventricular block and infra-hisian conduction delay  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581 3.4.2.4 Sudden cardiac death and risk stratification  . . . . . . . . . . . . . 581 3.4.3 Pulmonary hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 582 3.4.3.1 Introduction and classification  . . . . . . . . . . . . . . . . . . . . . . . . . 582 3.4.3.2 Diagnosis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583 3.4.3.2.1 The diagnostic work-up of pulmonary hypertension in adult congenital heart disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . 583\n3.4.3.2.2 Risk assessment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583 3.4.3.3 Therapeutic management of pulmonary hypertension in adult congential heart disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583 3.4.3.3.1 Expert centres  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583 3.4.3.3.2 General measures  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583 3.4.3.3.3 Anticoagulation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583 3.4.3.3.4 Shunt repair  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 584 3.4.3.3.5 Pulmonary arterial hypertension-directed medical therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 584 3.4.4 Surgical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 584 3.4.5 Catheter intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585 3.4.6 Infective endocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585 3.4.7 Antithrombotic treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585 3.4.8 Management of cyanotic patients . . . . . . . . . . . . . . . . . . . . . . . . 585 3.4.8.1 Adoptive mechanisms  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586 3.4.8.2 Multisystem disorder  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586 3.4.8.3 Clinical presentation and natural history  . . . . . . . . . . . . . . . . 586 3.4.8.4 Late complications  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586 3.4.8.5 Diagnostic aspects  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586 3.4.8.6 Laboratory precautions  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587 3.4.8.7 Indications for intervention  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587 3.4.8.8 Medical therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587 3.4.8.9 Follow-up recommendations  . . . . . . . . . . . . . . . . . . . . . . . . . . 587 3.4.8.10 Additional considerations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588 3.5 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588\n3.5.1 Sex differences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588 3.5.2 Adult congenital heart disease at more advanced age . . . . . 588 3.5.3 Advance care planning and end-of-life care . . . . . . . . . . . . . . 588 3.5.4 Insurance and employment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588 3.5.5 Exercise and sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589 3.5.6 Non-cardiac surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589 3.5.7 Pregnancy, contraception, and genetic counselling . . . . . . . 589 3.5.7.1 Pregnancy and contraception  . . . . . . . . . . . . . . . . . . . . . . . . . 589 3.5.7.2 Genetic counselling and recurrence risk  . . . . . . . . . . . . . . . . . 590\n564 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4 Specific lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591\n",
      "keywords": [
        "adult",
        "sudden cardiac death",
        "genetic",
        "heart",
        "anticoagulation",
        "disease",
        "age",
        "hypertension",
        "risk stratification",
        "prevalence",
        "pulmonary hypertension",
        "arrhythmia",
        "sex",
        "echocardiography",
        "congenital",
        "heart failure",
        "exercise",
        "catheterization",
        "organization",
        "care"
      ],
      "tables": []
    },
    {
      "number": "5",
      "title": "4.1 Atrial septal defect and anomalous pulmonary venous connection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591",
      "start_page": 2,
      "end_page": 3,
      "content": "4.1.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 591 4.1.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 591 4.1.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591 4.1.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 591 4.1.5 Specific aspects of isolated anomalous pulmonary venous connections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 592 4.1.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 593 4.1.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594 4.2 Ventricular septal defect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594\n4.2.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 594 4.2.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 594 4.2.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594 4.2.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 595 4.2.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 595 4.2.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595 4.3 Atrioventricular septal defect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595\n4.3.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 595 4.3.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 596 4.3.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 596 4.3.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 596 4.3.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 597 4.3.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 597 4.4 Patent ductus arteriosus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .597\n4.4.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 597 4.4.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 597 4.4.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598 4.4.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 598 4.4.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 598 4.4.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598 4.5 Left ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . 598\n4.5.1 Valvular aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598 4.5.1.1 Introduction and background  . . . . . . . . . . . . . . . . . . . . . . . . . . 598 4.5.1.2 Clinical presentation and natural history  . . . . . . . . . . . . . . . . 598 4.5.1.3 Diagnostic work-up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598 4.5.1.4 Medical therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600 4.5.1.5 Surgical/catheter interventional treatment  . . . . . . . . . . . . . . 600 4.5.1.6 Follow-up recommendations  . . . . . . . . . . . . . . . . . . . . . . . . . . 600 4.5.1.7 Additional considerations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600 4.5.2 Supravalvular aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601 4.5.2.1 Introduction and background  . . . . . . . . . . . . . . . . . . . . . . . . . . 601 4.5.2.2 Clinical presentation and natural history  . . . . . . . . . . . . . . . . 601 4.5.2.3 Diagnostic work-up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601 4.5.2.4 Surgical/catheter interventional treatment  . . . . . . . . . . . . . . 602 4.5.2.5 Follow-up recommendations  . . . . . . . . . . . . . . . . . . . . . . . . . . 602 4.5.2.6 Additional considerations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602 4.5.3 Subaortic stenosis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602 4.5.3.1 Introduction and background  . . . . . . . . . . . . . . . . . . . . . . . . . . 602 4.5.3.2 Clinical presentation and natural history  . . . . . . . . . . . . . . . . 602 4.5.3.3 Diagnostic work-up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602 4.5.3.4 Surgical/catheter interventional treatment  . . . . . . . . . . . . . . 602 4.5.3.5 Follow-up recommendations  . . . . . . . . . . . . . . . . . . . . . . . . . . 602 4.5.3.6 Additional considerations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603 4.6 Coarctation of the aorta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603\n4.6.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 603\n4.6.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 603 4.6.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603 4.6.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 604 4.6.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 604 4.6.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605 4.7 Aortopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605\n4.7.1 Marfan syndrome and related heritable thoracic aortic diseases  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605 4.7.1.1 Introduction and background  . . . . . . . . . . . . . . . . . . . . . . . . . . 605 4.7.1.2 Clinical presentation and natural history  . . . . . . . . . . . . . . . . 606 4.7.1.3 Diagnostic work-up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606 4.7.1.4 Medical therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606 4.7.1.5 Surgical treatment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606 4.7.1.6 Follow-up recommendations  . . . . . . . . . . . . . . . . . . . . . . . . . . 607 4.7.1.7 Additional considerations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607 4.7.2 Bicuspid aortic disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607 4.7.3 Turner syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607 4.8 Right ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . 608\n4.8.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 608 4.8.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 608 4.8.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609 4.8.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 609 4.8.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 609 4.8.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609 4.9 Ebstein anomaly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610\n4.9.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . . 610 4.9.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . . 610 4.9.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 4.9.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . . . 611 4.9.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 4.9.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 4.10 Tetralogy of Fallot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 612\n4.10.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 612 4.10.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 612 4.10.3 Diagnostic work-up of repaired patients . . . . . . . . . . . . . . . 612 4.10.4 Late surgical/catheter interventional treatment . . . . . . . . . 613 4.10.5 Indications for electrophysiological testing and implantable cardioverter defibrillator . . . . . . . . . . . . . . . . . . . . . . . . . 614 4.10.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 615 4.10.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615 4.11 Pulmonary atresia with ventricular septal defect . . . . . . . . . . . . 615\n4.11.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 615 4.11.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 615 4.11.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615 4.11.4 Surgical/catheter interventional treatment . . . . . . . . . . . . . 616 4.11.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 616 4.11.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 616 4.12 Transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . . . . 616\n4.12.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 616 4.12.2 Atrial switch operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 616 4.12.2.1 Clinical presentation after atrial switch  . . . . . . . . . . . . . . . . 616 4.12.2.2 Diagnostic work-up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618 4.12.2.3 Medical treatment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618 4.12.2.4 Surgical/catheter interventional treatment  . . . . . . . . . . . . . 618 4.12.3 Arterial switch operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619 4.12.3.1 Clinical presentation after arterial switch  . . . . . . . . . . . . . . 619 4.12.3.2 Diagnostic work-up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619\nESC Guidelines 565\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.12.3.3 Surgical/catheter interventional treatment  . . . . . . . . . . . . . 620 4.12.4 Rastelli-type operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620 4.12.4.1 Clinical presentation after Rastelli-type repair  . . . . . . . . . . 620 4.12.4.2 Diagnostic work-up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620 4.12.4.3 Surgical/catheter interventional treatment  . . . . . . . . . . . . . 620 4.12.5 Follow-up recommendations (irrespective of type of repair) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620 4.12.6 Additional considerations (irrespective of type of repair) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620 4.13 Congenitally corrected transposition of the great arteries . . . 620\n4.13.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 620 4.13.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 621 4.13.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 621 4.13.4 Medical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 621 4.13.5 Surgical/catheter interventional treatment . . . . . . . . . . . . . 621 4.13.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 622 4.13.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622 4.14 Right ventricular to pulmonary artery conduit . . . . . . . . . . . . . . 622\n4.14.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 622 4.14.2 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622 4.14.3 Surgical/catheter interventional treatment . . . . . . . . . . . . . 622 4.14.4 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 623 4.14.5 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623 4.15 Univentricular heart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623\n4.15.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 623 4.15.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 623 4.15.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 624 4.15.4 Conservative management . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625 4.15.5 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 625 4.15.6 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625 4.16 Patients after Fontan operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625\n4.16.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 625 4.16.2 Clinical presentation and natural history . . . . . . . . . . . . . . . . 625 4.16.3 Diagnostic work-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626 4.16.4 Medical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626 4.16.5 Surgical/interventional treatment . . . . . . . . . . . . . . . . . . . . . . 626 4.16.6 Follow-up recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 627 4.16.7 Additional considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627 4.17 Coronary anomalies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627\n4.17.1 Introduction and background . . . . . . . . . . . . . . . . . . . . . . . . . . 627 4.17.1.1 Anomalous coronary artery from the pulmonary artery  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627 4.17.1.2 Anomalous aortic origin of a coronary artery  . . . . . . . . . . . 627 4.17.1.3 Coronary artery fistulae  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628 4.17.2 Diagnostic evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628 4.17.3 Surgical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628 5 Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628 6 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629\n",
      "keywords": [
        "aortic",
        "pulmonary",
        "defect",
        "anomalous",
        "connection",
        "stenosis",
        "septal",
        "aortic stenosis",
        "atrial",
        "coronary artery",
        "venous"
      ],
      "tables": []
    },
    {
      "number": "6",
      "title": "6.1 General aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629",
      "start_page": 3,
      "end_page": 3,
      "content": "6.1.1 Organization of care and patient evaluation . . . . . . . . . . . . . . 629 6.1.2 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629 6.1.3 Arrhythmia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629 6.1.4 Pulmonary arterial hypertension . . . . . . . . . . . . . . . . . . . . . . . . 629 6.1.5 Cyanotic patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629 6.2 Specific lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629\n6.2.1 Shunt lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629\n6.2.2 Left ventricular outflow tract obstruction and coarctation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629 6.2.3 Aortopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629 6.2.4 Right ventricular outflow tract obstruction . . . . . . . . . . . . . . 629 6.2.5 Ebstein anomaly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630 6.2.6 Tetralogy of Fallot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630 6.2.7 Transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . 630 6.2.8 Congenitally corrected transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630 6.2.9 Univentricular heart and Fontan operation . . . . . . . . . . . . . . 630 6.2.10 Coronary anomalies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630 7 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630\n",
      "keywords": [
        "aspects",
        "arrhythmia",
        "general",
        "hypertension",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "7",
      "title": "7.1 General aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630",
      "start_page": 3,
      "end_page": 5,
      "content": "7.1.1 Organization of care and patient evaluation . . . . . . . . . . . . . . 630 7.1.2 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630 7.1.3 Arrhythmia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630 7.1.4 Pulmonary arterial hypertension . . . . . . . . . . . . . . . . . . . . . . . . 630 7.1.5 Cyanotic patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631 7.2 Specific lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631\n7.2.1 Shunt lesions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631 7.2.2 Left ventricular outflow tract obstruction . . . . . . . . . . . . . . . 631 7.2.3 Aortic coarctation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631 7.2.4 Aortopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631 7.2.5 Right ventricular outflow tract obstruction . . . . . . . . . . . . . . 631 7.2.6 Ebstein anomaly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631 7.2.7 Tetralogy of Fallot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631 7.2.8 Transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . 631 7.2.9 Congenitally corrected transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631 7.2.10 Univentricular heart and Fontan operation . . . . . . . . . . . . . 632 7.2.11 Coronary anomalies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 632 8 ‘What to do’ and ‘what not to do’ messages . . . . . . . . . . . . . . . . . . . . . . 632 9 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 635 10 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 636\nTables of Recommendations\nRecommendations for treatment of arrhythmias in adult congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581 Recommendations for treatment of pulmonary arterial hypertension associated with congenital heart disease . . . . . . . . . . . . . . 584 Recommendations for intervention in atrial septal defect (native and residual) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 592 Recommendations for intervention in ventricular septal defect (native and residual) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595 Recommendations for intervention in atrioventricular septal defect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 597 Recommendations for intervention in patent ductus arteriosus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598 Recommendations for intervention in valvular aortic stenosis . . . . . . . 600 Recommendations for intervention in supravalvular aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602 Recommendations for intervention in subaortic stenosis . . . . . . . . . . . 603 Recommendations for intervention in coarctation and re-coarctation of the aorta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604 Recommendations for aortic surgery in aortopathies . . . . . . . . . . . . . . . 608\n566 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ Recommendations for intervention in right ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609 Recommendations for intervention in Ebstein anomaly . . . . . . . . . . . . . 611 Recommendations for intervention after repair of tetralogy of Fallot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 614 Recommendations for intervention in transposition of the great arteries after atrial switch operation . . . . . . . . . . . . . . . . . . . . . . . . . 619 Recommendations for intervention in transposition of the great arteries after arterial switch operation . . . . . . . . . . . . . . . . . . . . . . . 620 Recommendations for intervention in congenitally corrected transposition of the great arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 621 Recommendations for intervention in right ventricular to pulmonary artery conduits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622 Special considerations and Recommendations for intervention in univentricular heart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 624 Special considerations and Recommendations for intervention after Fontan operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627 Recommendations for the management of patients with anomalous coronary arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628\nList of tables\nTable 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 569 Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 569 Table 3 Selected revised recommendations, new recommendations, and new concepts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 571 Table 4 Classification of congenital heart disease complexity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 575 Table 5 Staff requirements for specialist ACHD centres . . . . . . . . . . . . 577 Table 6 Indications for cardiovascular magnetic resonance imaging in ACHD patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577 Table 7 Risk estimates for arrhythmic events and bradycardias in ACHD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580 Table 8 Definitions of pulmonary hypertension subtypes and their occurrence in ACHD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 583 Table 9 Risk reduction strategies in patients with cyanotic congenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587 Table 10 Congenital heart disease with high risk and extremely high risk for pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 590 Table 11 Recurrence rates for various congenital heart lesions according to the sex of the affected parent . . . . . . . . . . . . . . . . . 590 Table 12 Diagnostic criteria for degree of aortic stenosis severity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599\nList of figures\nFigure 1 Central illustration. Congenital heart disease is a lifelong chronic condition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 576 Figure 2 Management of atrial septal defect . . . . . . . . . . . . . . . . . . . . . . . . 593 Figure 3 Management of ventricular septal defect . . . . . . . . . . . . . . . . . . 596 Figure 4 Management of patent ductus arteriosus . . . . . . . . . . . . . . . . . . 599 Figure 5 Management of left ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601 Figure 6 Management of coarctation and re-coarctation of the aorta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605\nFigure 7 Management of right ventricular outflow tract obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610 Figure 8 Management of repaired tetralogy of Fallot: long-term complications to address during follow-up . . . . . . . . . . . . . . 613 Figure 9 Management of transposition of the great arteries: long-term complications to address during follow-up . . . . . . . . . . . . . . 617\nAbbreviations and acronyms\n3D Three-dimensional 6MWT 6-minute walk test AAOCA Anomalous aortic origin of a coronary artery AAOLCA Anomalous aortic origin of the left coronary artery ACAPA Anomalous coronary artery from the pulmonary artery ACE Angiotensin-converting enzyme ACHD Adult congenital heart disease AF Atrial ﬁbrillation ALCAPA Anomalous left coronary artery from the pulmonary artery AR Aortic regurgitation ARB Angiotensin II receptor blocker ARCAPA Anomalous right coronary artery from the pulmonary artery AS Aortic stenosis ASD Atrial septal defect ASI Aortic size index AT Atrial tachycardia AV Atrioventricular AVA Aortic valve area AVAi Indexed aortic valve area AVNRT Atrioventricular node reentrant tachycardia AVRT Atrioventricular reentrant tachycardia AVSD Atrioventricular septal defect BAV Bicuspid aortic valve BNP B-type natriuretic peptide BSA Body surface area CAD Coronary artery disease CABG Coronary artery bypass graft CCT Cardiovascular computed tomography ccTGA Congenitally corrected transposition of the great arteries CHD Congenital heart disease CMR Cardiovascular magnetic resonance CoA Coarctation of the aorta CONCOR CONgenital CORvitia CPET Cardiopulmonary exercise testing CRT Cardiac resynchronization therapy DCRV Double-chambered right ventricle EACVI European Association of Cardiovascular Imaging EAT Ectopic atrial tachycardia ECG Electrocardiogram EF Ejection fraction EP Electrophysiology/electrophysiological ERA Endothelin receptor antagonist ESC European Society of Cardiology\nESC Guidelines 567\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ......................................................................................................................................................................... HLHS Hypoplastic left heart syndrome HTAD Heritable thoracic aortic disease IART Intraatrial reentrant tachycardia ICD Implantable cardioverter deﬁbrillator IE Infective endocarditis INR International normalized ratio IVC Inferior vena cava LA Left atrium/atrial L \u0002 R Left-to-right LV Left ventricle/ventricular LVEF Left ventricular ejection fraction LVESD Left ventricular end systolic diameter LVH Left ventricular hypertrophy LVOT Left ventricular outﬂow tract LVOTO Left ventricular outﬂow tract obstruction MAPCAs Major aortic pulmonary collaterals MCV Mean corpuscular volume mWHO Modiﬁed World Health Organization NOAC Non-vitamin K antagonist oral anticoagulant NT-pro-BNP N-terminal-pro-B-type natriuretic peptide NYHA New York Heart Association PA Pulmonary artery PAH Pulmonary arterial hypertension PAH-CHD Pulmonary arterial hypertension associated with congenital heart disease PAP Pulmonary artery pressure PDA Patent ductus arteriosus PDE-5 Phosphodiesterase type 5 PES Programmed electrical stimulation PFO Patent foramen ovale PH Pulmonary hypertension PM Pacemaker PR Pulmonary regurgitation PS Pulmonary stenosis PVD Pulmonary vascular disease PVR Pulmonary vascular resistance PVRep Pulmonary valve replacement QIs Quality indicators Qp:Qs Pulmonary to systemic ﬂow ratio RA Right atrium/atrial R \u0002 L Right-to-left rTOF Repaired tetralogy of Fallot RV Right ventricle/ventricular RVEDVi Right ventricular end diastolic volume indexed RVEF Right ventricular ejection fraction RVESVi Right ventricular end systolic volume indexed RVH Right ventricular hypertrophy RVOT Right ventricular outﬂow tract RVOTO Right ventricular outﬂow tract obstruction RVSP Right ventricular systolic pressure SCD Sudden cardiac death SND Sinus node dysfunction SubAS Subaortic stenosis SupraAS Supravalvular aortic stenosis SVC Superior vena cava SVT Supraventricular tachycardia\nTGA Transposition of the great arteries TOE Transoesophageal echocardiography TOF Tetralogy of Fallot TPVI Transcatheter pulmonary valve implantation TR Tricuspid regurgitation TTE Transthoracic echocardiography TV Tricuspid valve UVH Univentricular heart VE/VCO2 Ventilation to carbon dioxide output VF Ventricular ﬁbrillation VKA Vitamin K antagonist Vmax Maximum Doppler velocity VSD Ventricular septal defect VT Ventricular tachycardia WHO World Health Organization WU Wood units\n",
      "keywords": [
        "ejection fraction",
        "crt",
        "sudden cardiac death",
        "electrocardiogram",
        "pacemaker",
        "systolic",
        "tachycardia",
        "aspects",
        "anticoagulant",
        "tricuspid",
        "general",
        "hypertension",
        "scd",
        "nyha",
        "pulmonary hypertension",
        "ventricular tachycardia",
        "lvef",
        "diastolic",
        "aortic",
        "arrhythmia",
        "icd",
        "valve replacement",
        "sex",
        "arb",
        "bnp",
        "echocardiography",
        "ecg",
        "heart failure",
        "exercise",
        "stenosis"
      ],
      "tables": []
    },
    {
      "number": "8",
      "title": "1 Preamble",
      "start_page": 5,
      "end_page": 7,
      "content": "Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final deci- sions concerning an individual patient must be made by the responsi- ble health professional(s) in consultation with the patient and caregiver as appropriate. A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other soci- eties and organizations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been estab- lished in order to make all decisions transparent to the user. The rec- ommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines/ Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC- Guidelines ). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.\nIn addition to the publication of Clinical Practice Guidelines, the ESC carries out the EurObservational Research Programme of inter- national registries of cardiovascular diseases and interventions which are essential to assess, diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at pro- viding a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice. Furthermore, the ESC has developed and embedded in this docu- ment a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the Guidelines and may be used by the ESC, hospitals, healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes. The Members of this Task Force were selected by the ESC, includ- ing representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of\n568 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. .................................... patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and thera- peutic procedures was performed, including assessment of the risk \u0002 benefit ratio. The level of evidence and the strength of the rec- ommendation of particular management options were weighed and graded according to predefined scales, as outlined below. The experts of the writing and reviewing panels provided declara- tion of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest\nrules and can be found on the ESC website (http://www.escardio.org/ guidelines ). This process ensures transparency and prevents potential biases in the development and review processes. Any changes in dec- larations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.\nThe ESC CPG supervises and coordinates the preparation of new Guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task\nTable 1 Classes of recommendations\nClasses of recommendations\nClass I  Evidence and/or general agreement  that a given treatment or procedure is\nIs recommended or is indicated\nWording to use\nClass III  Evidence or general agreement that the  given treatment or procedure is not  useful/effective, and in some cases  may be harmful .\nIs not recommended\nClass IIb\nestablished by evidence/opinion. May be considered\nClass IIa Weight of evidence/opinion is in  Should be considered\nClass II\n©ESC 2020\nTable 2 Levels of evidence\nLevel of  evidence A Data derived from multiple randomized clinical trials  or meta-analyses.\nLevel of  evidence B Data derived from a single randomized clinical trial or large non-randomized studies.\nLevel of  evidence C Consensus of opinion of the experts and/or small studies,  retrospective studies, registries.\n©ESC 2020\nESC Guidelines 569\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ Force. The finalized document is approved by the CPG for publica- tion in the European Heart Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recom- mendations including condensed pocket guideline versions, summary slides, booklets with essential messages, summary cards for non- specialists and an electronic version for digital applications (smart- phones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the Guidelines, which is freely available via the ESC website and hosted on the EHJ website. The National Cardiac Societies of the ESC are encouraged to endorse, adopt, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influ- enced by the thorough application of clinical recommendations. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devi- ces at the time of prescription.\n",
      "keywords": [
        "class iii",
        "recommended",
        "should be considered",
        "may be considered",
        "class i",
        "class ii",
        "preamble",
        "guideline",
        "weight"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 569",
          "page_number": 6,
          "content": "Class I Evidence and/or general agreement Is recommended or is indicated\nthat a given treatment or procedure is\nClass II\nClass IIa Weight of evidence/opinion is in Should be considered\nClass IIb May be considered\nestablished by evidence/opinion.\nClass III Evidence or general agreement that the Is not recommended\ngiven treatment or procedure is not\nuseful/effective, and in some cases\nmay be harmful. |  |  | \n | Class III | Evidence or general agreement that the\ngiven treatment or procedure is not\nuseful/effective, and in some cases\nmay be harmful. | Is not recommended",
          "bbox": [
            134.86102294921875,
            104.37701416015625,
            476.7990020751953,
            300.6429748535156
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 569",
          "page_number": 6,
          "content": "Class I | Evidence and/or general agreement\nthat a given treatment or procedure is | Is recommended or is indicated",
          "bbox": [
            140.59800720214844,
            110.78399658203125,
            476.7990020751953,
            149.2650146484375
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 569",
          "page_number": 6,
          "content": "Class II |  |  | \n |  |  | \nClass IIa | Weight of | evidence/opinion is in | Should be considered\n |  |  | \nClass IIb | establishe | d by evidence/opinion. | May be considered",
          "bbox": [
            140.59800720214844,
            154.85003662109375,
            476.7990020751953,
            247.29773712158203
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 569",
          "page_number": 6,
          "content": "Level of Data derived from multiple randomized clinical trials\nevidence A or meta-analyses.\nLevel of Data derived from a single randomized clinical trial\nevidence B or large non-randomized studies.\nLevel of Consensus of opinion of the experts and/or small studies,\nevidence C retrospective studies, registries. |  | \n | Level of\nevidence C | Consensus of opinion of the experts and/or small studies,\nretrospective studies, registries.",
          "bbox": [
            117.4949951171875,
            377.7149963378906,
            476.7990020751953,
            557.5880126953125
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 569",
          "page_number": 6,
          "content": "Level of\nevidence A | Data derived from multiple randomized clinical trials\nor meta-analyses.",
          "bbox": [
            123.0469970703125,
            384.20599365234375,
            476.7990020751953,
            438.1289978027344
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 569",
          "page_number": 6,
          "content": "Level of\nevidence B | Data derived from a single randomized clinical trial\nor large non-randomized studies.",
          "bbox": [
            123.0469970703125,
            443.9349670410156,
            476.7990020751953,
            497.8589782714844
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "9",
      "title": "2 Introduction",
      "start_page": 7,
      "end_page": 7,
      "content": "",
      "keywords": [
        "introduction"
      ],
      "tables": []
    },
    {
      "number": "10",
      "title": "2.1 Why do we need new Guidelines on the management of adult congenital heart disease? Since the previous version of the Guidelines on the management of grown-up congenital heart disease (CHD) was pub",
      "start_page": 7,
      "end_page": 7,
      "content": "",
      "keywords": [
        "version",
        "adult",
        "since",
        "previous",
        "need",
        "guidelines",
        "heart",
        "management",
        "congenital",
        "grown",
        "disease"
      ],
      "tables": []
    },
    {
      "number": "11",
      "title": "2.2 Content of these Guidelines Decision making in ACHD involves accurate diagnosis, timing of intervention, risk assessment, and selection of the most suitable type of intervention. In addition, spec",
      "start_page": 7,
      "end_page": 7,
      "content": "disease, and aortic disease, refer to the relevant separate guideline documents published by the European Society of Cardiology (ESC).\n",
      "keywords": [
        "addition",
        "assessment",
        "these",
        "accurate",
        "guideline",
        "intervention",
        "type",
        "risk",
        "timing",
        "aortic",
        "spec",
        "selection",
        "guidelines",
        "achd",
        "suitable",
        "most",
        "decision",
        "making",
        "content",
        "involves",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "12",
      "title": "2.3 New format of the Guidelines The new Guidelines have been adapted to facilitate their use in clini- cal practice and to meet the readers’ demands by focusing on con- densed, clearly presented reco",
      "start_page": 7,
      "end_page": 7,
      "content": "",
      "keywords": [
        "readers",
        "adapted",
        "meet",
        "clini",
        "presented",
        "format",
        "clearly",
        "their",
        "guidelines",
        "practice",
        "focusing",
        "densed",
        "demands",
        "reco",
        "facilitate"
      ],
      "tables": []
    },
    {
      "number": "13",
      "title": "2.4 How to use these Guidelines The Committee emphasizes that many factors ultimately determine the most appropriate treatment in individual patients within a given community. These factors include av",
      "start_page": 7,
      "end_page": 7,
      "content": "",
      "keywords": [
        "ultimately",
        "patients",
        "factors",
        "treatment",
        "community",
        "include",
        "these",
        "given",
        "individual",
        "guidelines",
        "appropriate",
        "many",
        "committee",
        "emphasizes",
        "within",
        "determine",
        "most"
      ],
      "tables": []
    },
    {
      "number": "14",
      "title": "2.5 What is new in the 2020 Guidelines? Selected revised recommendations, new recommendations, and new concepts are summarized in  Table  3 .",
      "start_page": 7,
      "end_page": 7,
      "content": "",
      "keywords": [
        "revised",
        "selected",
        "concepts",
        "what",
        "guidelines",
        "summarized",
        "table",
        "recommendations"
      ],
      "tables": []
    },
    {
      "number": "15",
      "title": "3 General aspects",
      "start_page": 7,
      "end_page": 7,
      "content": "",
      "keywords": [
        "aspects",
        "general"
      ],
      "tables": []
    },
    {
      "number": "16",
      "title": "3.1 Prevalence of adult congenital heart disease To date, the prevalence of CHD worldwide is  \u0003 9 per 1000 new- borns, with substantial geographic variation. 2 , 3   While the prevalence of severe con",
      "start_page": 7,
      "end_page": 7,
      "content": "",
      "keywords": [
        "geographic",
        "worldwide",
        "borns",
        "variation",
        "while",
        "severe",
        "adult",
        "heart",
        "prevalence",
        "substantial",
        "congenital",
        "disease",
        "date"
      ],
      "tables": []
    },
    {
      "number": "17",
      "title": "3.2 Organization of care When patients with CHD are approaching adulthood, they require transfer to ACHD care. This transfer should be preceded by a pre- paratory transition phase, which continues int",
      "start_page": 7,
      "end_page": 12,
      "content": "570 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\nTable 3 Selected revised recommendations (R), new recommendations (N), and new concepts\nArrhythmia\nN There were no formal recommendations on arrhythmia in the 2010 edition  \u0002  these have now been included  \u0002  for details see recom-\nmendation tables in  Sections 3.4.2 and 4.10 . Summary of the most important items:\n\u0004  Emphasizing the importance of understanding the cause, the mechanism of the arrhythmia, and the anatomy of the underlying CHD \u0004  Emphasizing the importance of a multidisciplinary approach for optimal arrhythmia treatment prior to, or concomitant with, percutane-\nous or surgical interventions\n\u0004  Consideration of early catheter ablation as an alternative to long-term medical treatment for symptomatic SVT and VT provided that the procedure is performed in experienced centres\n\u0004  Targeting VT-related anatomical isthmuses in repaired tetralogy of Fallot patients with sustained VTs before percutaneous or surgical\nreintervention in the RVOT, as these procedures may lead to inaccessibility of the VT substrates \u0004  Recognizing the association between bradycardia and IART and the potential beneﬁt of PM implantation.\nEisenmenger sydrome /pulmonary arterial hypertension\nN It is recommended that patients with CHD and conﬁrmed pre-capillary PH are counselled against pregnancy.\nN Risk assessment is recommended in all patients with PAH-CHD.\nN In low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH, initial oral combination therapy or sequential combination therapy is recommended, and high-risk patients should be treated with initial combination therapy including parenteral\nprostanoids.\nR Emphasize the importance of sequential PAH therapy strategy\nin Eisenmenger syndrome and use of 6MWT for the decision to initiate therapy.\nIn Eisenmenger patients with reduced exercise capacity\n(6MWT distance <450 m), a treatment strategy with initial endothelin receptor antagonist monotherapy should be con-\nsidered followed by combination therapy if patients fail to\nimprove.\nShunt lesions\nN In patients with shunt lesions and non-invasive signs of PAP elevation, invasive measurement of PVR is mandatory.\nN/R Adjusted recommendations for shunt closure (when Qp:Qs >1.5) according to calculated PVR:\n<3 WU: class I for ASD, VSD, and PDA\n3 \u0002 5 WU: class IIa for ASD, VSD, and PDA\n>_5 WU but decreasing to <5 WU after targeted PAH treatment: class IIb for ASD (fenestrated closure only)\n>_5 WU for VSD and PDA (careful individual decision in expert centres); class IIb\n>_5 WU despite targeted PAH treatment: class III for ASD.\nN In patients with ASD and LV disease, it is recommended to perform balloon testing and carefully weigh the beneﬁt of eliminating L \u0002 R\nshunt against the potential negative impact of ASD closure on outcome due to increase in ﬁlling pressure (taking closure, fenestrated clo- sure, and no closure into consideration).\nN Take older age into account in the decision for surgical ASD\nclosure.\nIn elderly patients not suitable for device closure, it is recom-\nmended to weigh the surgical risk against the potential beneﬁt\nof ASD closure.\nR Transcatheter VSD closure has become an alternative to sur-\ngery in selected patients, particularly in residual VSD.\nTranscatheter VSD closure has become an alternative, partic-\nularly in residual VSDs, VSDs poorly accessible by surgery,\nand in muscular VSDs centrally located in the interventricular septum.\nR Specify the requirement for a congenital cardiac surgeon for\npartial AVSD closure.\nSurgical closure is recommended in patients with signiﬁcant\nRV volume overload and should only be performed by a con-\ngenital cardiac surgeon.\nR Specify the presence of atrial ﬁbrillation or PH as require-\nments for valve repair in AVSD.\nIn asymptomatic patients with severe left-sided AV valve\nregurgitation, preserved LV function (LVESD <45 mm and/or\nLVEF >60%), high likelihood of successful valve repair, and low surgical risk, intervention should be considered when\natrial ﬁbrillation or systolic PAP >50 mmHg is present.\nR Specify the option of fenestrated ASD closure. In patients with PVR >_5 WU, fenestrated ASD closure may be\nconsidered when PVR falls below 5 WU after targeted PAH treatment and signiﬁcant L \u0002 R shunt is present (Qp:Qs >1.5).\nR Include desaturation on exercise as a contraindication for\nASD, VSD, AVSD, and PDA closure.\nShunt closure is not recommended in patients with severe\nPAH (PVR >_5 WU) presenting with desaturation on exercise.\nContinued\nESC Guidelines 571\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\nLeft ventricular outﬂow tract obstruction and aortopathies\nR Increase the recommendation class from IIa to I in low-ﬂow,\nlow-gradient AS for intervention.\nIntervention is indicated in patients with severe low-ﬂow, low-\ngradient (mean gradient <40 mmHg) AS with reduced EF and\nevidence of ﬂow (contractile) reserve excluding pseudosevere AS.\nR Lower mean Doppler gradient threshold for LVOTO inter-\nvention from 50 to 40 mmHg.\nIn symptomatic patients with valvular, subvalvular, or supra-\nvalvular AS and mean Doppler gradient >_40 mmHg surgery is recommended.\nR Include BNP levels and increased PAP in the indication for\nintervention in valvular AS.\nIntervention should be considered in asymptomatic patients\nwith normal EF and no exercise test abnormalities (see Section 4.5.1 ) if the surgical risk is low and one of the following\nﬁndings is present:\n\u0004  Markedly elevated BNP levels (>3-fold age- and sex-cor- rected normal range) conﬁrmed by repeated measurements\nwithout other explanation.\n\u0004  Severe PH (systolic PAP at rest >60 mmHg conﬁrmed by invasive measurement) without other explanation.\nR Conﬁrm pressure gradients by invasive measurement and pre-\nfer stenting in coarctation and re-coarctation when technically\nfeasible.\nRepair of coarctation or re-coarctation (surgically or catheter\nbased) is indicated in hypertensive patients with an increased\nnon-invasive gradient between upper and lower limbs con- ﬁrmed by invasive measurement (peak-to-peak >_20 mmHg),\nwith preference for catheter treatment (stenting) when tech-\nnically feasible.\nN Catheter treatment (stenting) of coarctation should be considered in normotensive patients with an increased non-invasive gradient con-\nﬁrmed with invasive measurement (peak-to-peak >_20 mmHg) when technically feasible.\nN In aortopathies, aortic valve repair using the reimplantation or remodelling with aortic annuloplasty technique is recommended in young\npatients with Marfan syndrome or related HTAD with aortic root dilation and tricuspid aortic valves, when performed by experienced surgeons.\nN Surgery should be considered in patients with a  TGFBR1  or  TGFBR2  mutation (including Loeys \u0002 Dietz syndrome) who have aortic root dis-\nease with maximal aortic sinus diameter >_45 mm.\nN In Turner syndrome, elective surgery for aneurysms of the aortic root and/or ascending aorta should be considered for women who are >16 years of age, have an ascending ASI >25 mm/m 2 , and have associated risk factors for aortic dissection.\nN In Turner syndrome, elective surgery for aneurysms of the aortic root and/or ascending aorta may be considered for women who are\n>16 years of age, have an ascending aortic size index >25 mm/m 2 , and do not have associated risk factors for aortic dissection.\nRight ventricular outﬂow tract obstruction / tetralogy of Fallot /Ebstein\nR Adjust recommendations for surgical intervention in RVOTO\naccording to symptoms.\nIf surgical valve replacement is the only option, it is indicated\nin patients with severe stenosis who are symptomatic.\nIf surgical valve replacement is the only option in patients with\nsevere stenosis who are asymptomatic, it is indicated in the presence of one or more of the following:\n\u0004  Objective decrease in exercise capacity\n\u0004  Decreasing RV function and/or progressive TR to at least moderate\n\u0004  RVSP >80 mmHg\n\u0004  R \u0002 L shunting via an ASD or VSD.\nR Include preference for catheter intervention for pulmonary\nvalve implantation in TOF.\nIn patients with no native outﬂow tract, catheter intervention\n(TPVI) should be preferred if anatomically feasible.\nR Specify RV dilatation in the setting of pulmonary valve replace-\nment for TOF and for RVOT conduits.\nPulmonary valve replacement should be considered in asymp-\ntomatic patients with severe PR and/or RVOTO, in the pres- ence of progressive RV dilation to RVESVi >_80 mL/m 2 , and/or\nRVEDVi >_160 mL/m 2 , and/or progression of TR to at least\nmoderate.\nContinued\n572 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\nR In case of ASDs in Ebstein anomaly, add caution about RA\npressure rise or fall in cardiac output.\nIn the case of documented systemic embolism probably\ncaused by paradoxical embolism, isolated device closure of\nASD/PFO should be considered but requires careful evalua- tion before intervention to exclude induction of RA pressure\nincrease or fall in cardiac output.\nIf cyanosis (oxygen saturation at rest <90%) is the leading problem, isolated device closure of ASD/PFO may be consid-\nered but requires careful evaluation before intervention to\nexclude induction of RA pressure increase or fall in cardiac output.\nTransposition of the great arteries\nR Downgrade level of recommendation for AV valve repair in\nTGA/atrial switch from I to IIa in symptomatic patients.\nIn patients with severe systemic (tricuspid) AV valve regurgita-\ntion without signiﬁcant ventricular systolic dysfunction (EF >40%), valve repair or replacement should be considered\nregardless of symptoms .\nR In patients with TGA/atrial switch requiring PM/ICD implanta-\ntion: pay attention to the presence of bafﬂe leaks.\nIn patients with a bafﬂe leak who require a PM/ICD, closure of\nthe bafﬂe leak should be considered, when technically feasible, prior to insertion of transvenous leads.\nN In ccTGA, biventricular pacing should be considered in case of complete AV block or >40% ventricular pacing requirement.\nR Revise indications for TV replacement in ccTGA, according to\nsymptoms and systemic ventricular function. (Upgrade level of recommendation for symptomatic ccTGA\npatients from IIa to I).\nIn  symptomatic  patients with severe TR and preserved or\nmildly impaired systemic RV systolic function (EF >40%), TV replacement is indicated.\nIn  asymptomatic  patients with severe TR and progressive sys-\ntemic RV dilatation and/or mildly impaired systemic RV sys- tolic function (EF >40%), TV replacement should be\nconsidered.\nIn  symptomatic  patients with severe TR and more than mildly\nreduced systemic RV systolic function (EF <_40%), TV replace- ment may be considered.\nR Anatomic repair (atrial  þ  arterial switch) for ccTGA removed\nfrom the recommendations.\nUniventricular heart\nN It is recommended that adults with unoperated or palliated UVHs undergo careful evaluation in specialized centres including multimodality\nimaging as well as invasive work-up to decide whether they may beneﬁt from surgical or interventional procedures.\nFontan circulation\nN Sustained atrial arrhythmia with rapid AV conduction is a medical emergency and should promptly be treated with electrical cardioversion.\nN Anticoagulation is indicated in the presence, or with a history, of atrial thrombus, atrial arrhythmias, or thromboembolic events.\nN It is recommended that women with a Fontan circulation and any complication are counselled against pregnancy.\nN Cardiac catheterization is recommended at a low threshold in cases of unexplained oedema, exercise deterioration, new-onset arrhyth-\nmia, cyanosis, and haemoptysis.\nN In patients with arrhythmias, a proactive approach of electrophysiological evaluation and ablation (where appropriate) should be\nconsidered.\nN Regular liver imaging (ultrasound, computed tomography, magnetic resonance) should be considered.\nN Endothelin receptor antagonists and phosphodiesterase-5 inhibitors may be considered in selected patients with elevated pulmonary pres- sures/resistance in the absence of elevated ventricular end diastolic pressure.\nN In selected patients with signiﬁcant cyanosis, device closure of a fenestration may be considered but requires careful evaluation before\nintervention to exclude induction of systemic venous pressure increase or fall in cardiac output.\nCoronary artery anomalies\nN Non-pharmacological functional imaging (e.g. nuclear study, echocardiography or CMR with physical stress) is recommended in patients with coronary anomalies to conﬁrm/exclude myocardial ischaemia.\nA) Anomalous coronary artery from the pulmonary artery (ACAPA)\nN Surgery is recommended in patients with ALCAPA.\nN Surgery is recommended in patients with ARCAPA and symptoms attributable to anomalous coronary artery.\nContinued\nESC Guidelines 573\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ........................................................ three levels: (i) patients who require care exclusively in a specialist centre, (ii) patients for whom shared care can be established with the appropriate general adult cardiac services, and (iii) patients who can be managed in non-specialist clinics (with access to specialized care if required). The proposed staff requirements for specialist centres are described in  Table  5 . The complexity of the heart defect should not be the only criterion to assign patients to a certain level of care. Although patients with complex defects can easily be assigned to a high level of care, even anatomically simple defects may require specialist care under certain circumstances [e.g. atrial septal defect (ASD) with pul- monary arterial hypertension (PAH)]. Therefore, it is recommended that all ACHD patients are seen once in a specialist centre, allowing ACHD specialists to determine the most appropriate level of care and follow-up intervals for each individual patient. 8   Networks of specialist centres with general adult care should be established for each catch- ment area. Indeed, with the growing population of adults with CHD, more patients will first present to general cardiologists for acute condi- tions, such as arrhythmia, heart failure, or endocarditis. In such cases, general cardiologists should not delay treatment in haemodynamically\nunstable patients but ought to liaise with the patient’s ACHD centre immediately to discuss appropriate management strategies or transfer of the patient. Special attention is necessary for patients after Fontan correction presenting with arrhythmia, as even supraventricular arrhythmias are not well tolerated. Detailed advice on emergency care for ACHD patients will follow in a separate future position paper.\nTransfer of adolescents to ACHD care is vital as they approach adulthood without gaps in care, and should be preceded by a prepar- atory transition phase with additional transition support that contin- ues into early adulthood according to the needs of the patient. 10\nTransition requires a special healthcare organization. 10 , 11   It is recom- mended that specialist ACHD centres have teams including specialist nurses, psychologists, and social workers given that anxiety, depres- sion, or problems coping with the medical condition are well known concerns in adult patients with CHD. 12   They also play a critical role in the transition process by taking over the transitional care of patients after the transfer from paediatric cardiology. Aspects that have to be addressed by allied health professionals include mental health, psychic well-being, and quality of life. 12 , 13   During the ACHD\nN Surgery should be considered for ARCAPA in asymptomatic patients with ventricular dysfunction, or myocardial ischaemia attributable to\ncoronary anomaly.\nB) Anomalous aortic origin of a coronary artery (AAOCA)\nN Surgery is recommended for AAOCA in patients with typical angina symptoms who present with evidence of stress-induced myocardial ischaemia in a matching territory or high-risk anatomy.\nN Surgery should be considered in  asymptomatic  patients with AAOCA (right or left) and evidence of myocardial ischaemia.\nN Surgery should be considered in  asymptomatic  patients with AAOLCA and no evidence of myocardial ischaemia but a high-risk anatomy.\nN Surgery may be considered for symptomatic patients with AAOCA even if they have neither evidence of myocardial ischaemia nor high-\nrisk anatomy.\nN Surgery may be considered for  asymptomatic  patients with AAOLCA without myocardial ischaemia and without high-risk anatomy when\nthey present at young age (<35 years).\nN Surgery is not recommended for AAORCA in  asymptomatic  patients without myocardial ischaemia and without high-risk anatomy.\nNew concepts\nNaming (ACHD).\nDisease complexity classiﬁcation.\nStafﬁng requirements for an ACHD expert centre.\nEmerging role of biomarkers in follow-up of ACHD.\nDetailed and speciﬁc recommendations on arrhythmia management.\nMore speciﬁc and adjusted recommendations for PAH treatment.\nRecommendations on the use of anticoagulants.\nConsideration of ageing and advance care planning.\nCategories of high-risk pregnancies in accordance with the pregnancy guidelines.\nExpand Marfan syndrome section to aortopathies (and include HTAD, Turner syndrome, and bicuspid aortic disease).\nEmerging role of catheter intervention in ACHD.\n6MWT = 6-minute walk test; AAOCA = anomalous aortic origin of a coronary artery; AAOLCA = anomalous aortic origin of the left coronary artery; ACAPA = anomalous coronary artery from the pulmonary artery; ACHD = adult congenital heart disease; AF = atrial ﬁbrillation; ALCAPA = anomalous left coronary artery from the pulmonary artery; ARCAPA = anomalous right coronary artery from the pulmonary artery; AS = aortic stenosis; ASD = atrial septal defect; AV = atrioventricular; AVSD = atrioventricular septal defect; BNP = B-type natriuretic peptide; ccTGA = congenitally corrected transposition of the great arteries; CHD = congenital heart disease; CMR = cardiovascular magnetic resonance; EF = ejection fraction; HTAD = heritable thoracic aortic disease; IART = intraatrial reentrant tachycardia; ICD = implantable cardioverter deﬁbrillator; L \u0002 R = left-to-right; LV = left ventricle/ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end systolic diameter; LVOT = left ventricular outﬂow tract; LVOTO = left ventricular outﬂow tract obstruction; N = new recommendation; PAH = pulmonary arterial hypertension; PAH-CHD = pulmonary arterial hypertension associated with congenital heart disease; PAP = pulmonary artery pressure; PDA = patent ductus arteriosus; PFO = patent foramen ovale; PH = pulmonary hypertension; PR = pulmonary regurgitation; PVR = pulmonary vascular resistance; Qp:Qs = pulmonary to systemic ﬂow ratio; R = revised recommendation; RA = right atrium/atrial; R \u0002 L = right- to-left; RV = right ventricle/ventricular; RVEDVi = right ventricular end diastolic volume indexed; RVESVi = right ventricular end systolic volume indexed; RVOT = right ventric- ular outﬂow tract; RVOTO = right ventricular outﬂow tract obstruction; RVSP = right ventricular systolic pressure; SVT = supraventricular tachycardia; TGA = transposition of the great arteries; TGFBR = transforming growth factor beta receptor; TOF = tetralogy of Fallot; TPVI = transcatheter pulmonary valve implantation; TR = tricuspid regurgita- tion; TV = tricuspid valve; UVH = univentricular heart; VSD = ventricular septal defect; VT = ventricular tachycardia; WU = Wood units.\n574 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ................................... care journey, advance care planning choices and strategies relating to end of life also require expert support.\n",
      "keywords": [
        "continues",
        "ejection fraction",
        "should be considered",
        "contraindication",
        "older",
        "class i",
        "bradycardia",
        "valve repair",
        "paratory",
        "systolic",
        "when",
        "anticoagulation",
        "tachycardia",
        "transition",
        "age",
        "preceded",
        "phase",
        "tricuspid",
        "hypertension",
        "require",
        "they",
        "pulmonary hypertension",
        "ventricular tachycardia",
        "lvef",
        "diastolic",
        "aortic",
        "arrhythmia",
        "icd",
        "class iii",
        "which"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 571",
          "page_number": 8,
          "content": "Arrhythmia |  | \nN There were no formal recommendations on arrhythmia in the 2010 edition \u0002 these have now been included \u0002 for details see recom-\nmendation tables in Sections 3.4.2 and 4.10. Summary of the most important items:\n\u0004 Emphasizing the importance of understanding the cause, the mechanism of the arrhythmia, and the anatomy of the underlying CHD\n\u0004 Emphasizing the importance of a multidisciplinary approach for optimal arrhythmia treatment prior to, or concomitant with, percutane-\nous or surgical interventions\n\u0004 Consideration of early catheter ablation as an alternative to long-term medical treatment for symptomatic SVT and VT provided that\nthe procedure is performed in experienced centres\n\u0004 Targeting VT-related anatomical isthmuses in repaired tetralogy of Fallot patients with sustained VTs before percutaneous or surgical\nreintervention in the RVOT, as these procedures may lead to inaccessibility of the VT substrates\n\u0004 Recognizing the association between bradycardia and IART and the potential benefit of PM implantation. |  | \nEisenmenger sydrome /pulmonary arterial hypertension |  | \nN | It is recommended that patients with CHD and confirmed pre-capillary PH are counselled against pregnancy. | \nN | Risk assessment is recommended in all patients with PAH-CHD. | \nN | In low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH, initial oral combination therapy or sequential\ncombination therapy is recommended, and high-risk patients should be treated with initial combination therapy including parenteral\nprostanoids. | \nR | Emphasize the importance of sequential PAH therapy strategy\nin Eisenmenger syndrome and use of 6MWT for the decision\nto initiate therapy. | In Eisenmenger patients with reduced exercise capacity\n(6MWT distance <450 m), a treatment strategy with initial\nendothelin receptor antagonist monotherapy should be con-\nsidered followed by combination therapy if patients fail to\nimprove.\nShunt lesions |  | \nN | In patients with shunt lesions and non-invasive signs of PAP elevation, invasive measurement of PVR is mandatory. | \nN/R | Adjusted recommendations for shunt closure (when Qp:Qs >1.5) according to calculated PVR: | \n | <3 WU: class I for ASD, VSD, and PDA | \n | 3\u00025 WU: class IIa for ASD, VSD, and PDA | \n | >5 WU but decreasing to <5 WU after targeted PAH treatment: class IIb for ASD (fenestrated closure only)\n_ | \n | >5 WU for VSD and PDA (careful individual decision in expert centres); class IIb\n_ | \n | >5 WU despite targeted PAH treatment: class III for ASD.\n_ | \nN | In patients with ASD and LV disease, it is recommended to perform balloon testing and carefully weigh the benefit of eliminating L\u0002R\nshunt against the potential negative impact of ASD closure on outcome due to increase in filling pressure (taking closure, fenestrated clo-\nsure, and no closure into consideration). | \nN | Take older age into account in the decision for surgical ASD\nclosure. | In elderly patients not suitable for device closure, it is recom-\nmended to weigh the surgical risk against the potential benefit\nof ASD closure.\nR | Transcatheter VSD closure has become an alternative to sur-\ngery in selected patients, particularly in residual VSD. | Transcatheter VSD closure has become an alternative, partic-\nularly in residual VSDs, VSDs poorly accessible by surgery,\nand in muscular VSDs centrally located in the interventricular\nseptum.\nR | Specify the requirement for a congenital cardiac surgeon for\npartial AVSD closure. | Surgical closure is recommended in patients with significant\nRV volume overload and should only be performed by a con-\ngenital cardiac surgeon.\nR | Specify the presence of atrial fibrillation or PH as require-\nments for valve repair in AVSD. | In asymptomatic patients with severe left-sided AV valve\nregurgitation, preserved LV function (LVESD <45 mm and/or\nLVEF >60%), high likelihood of successful valve repair, and\nlow surgical risk, intervention should be considered when\natrial fibrillation or systolic PAP >50 mmHg is present.\nR | Specify the option of fenestrated ASD closure. | In patients with PVR >5 WU, fenestrated ASD closure may be\n_\nconsidered when PVR falls below 5 WU after targeted PAH\ntreatment and significant L\u0002R shunt is present (Qp:Qs >1.5).\nR | Include desaturation on exercise as a contraindication for\nASD, VSD, AVSD, and PDA closure. | Shunt closure is not recommended in patients with severe\nPAH (PVR >5 WU) presenting with desaturation on exercise.\n_",
          "bbox": [
            47.97540953851515,
            81.40207926432292,
            552.3685375395276,
            743.6271286010742
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "572 ESC Guidelines",
          "page_number": 9,
          "content": "Left ventricular outflow tract obstruction and aortopathies |  | \nR | Increase the recommendation class from IIa to I in low-flow,\nlow-gradient AS for intervention. | Intervention is indicated in patients with severe low-flow, low-\ngradient (mean gradient <40 mmHg) AS with reduced EF and\nevidence of flow (contractile) reserve excluding pseudosevere\nAS.\nR | Lower mean Doppler gradient threshold for LVOTO inter-\nvention from 50 to 40 mmHg. | In symptomatic patients with valvular, subvalvular, or supra-\nvalvular AS and mean Doppler gradient >40 mmHg surgery is\n_\nrecommended.\nR | Include BNP levels and increased PAP in the indication for\nintervention in valvular AS. | Intervention should be considered in asymptomatic patients\nwith normal EF and no exercise test abnormalities (see\nSection 4.5.1) if the surgical risk is low and one of the following\nfindings is present:\n\u0004 Markedly elevated BNP levels (>3-fold age- and sex-cor-\nrected normal range) confirmed by repeated measurements\nwithout other explanation.\n\u0004 Severe PH (systolic PAP at rest >60 mmHg confirmed by\ninvasive measurement) without other explanation.\nR | Confirm pressure gradients by invasive measurement and pre-\nfer stenting in coarctation and re-coarctation when technically\nfeasible. | Repair of coarctation or re-coarctation (surgically or catheter\nbased) is indicated in hypertensive patients with an increased\nnon-invasive gradient between upper and lower limbs con-\nfirmed by invasive measurement (peak-to-peak >20 mmHg),\n_\nwith preference for catheter treatment (stenting) when tech-\nnically feasible.\nN | Catheter treatment (stenting) of coarctation should be considered in normotensive patients with an increased non-invasive gradient con-\nfirmed with invasive measurement (peak-to-peak >20 mmHg) when technically feasible.\n_ | \nN | In aortopathies, aortic valve repair using the reimplantation or remodelling with aortic annuloplasty technique is recommended in young\npatients with Marfan syndrome or related HTAD with aortic root dilation and tricuspid aortic valves, when performed by experienced\nsurgeons. | \nN | Surgery should be considered in patients with a TGFBR1 or TGFBR2 mutation (including Loeys\u0002Dietz syndrome) who have aortic root dis-\nease with maximal aortic sinus diameter >45 mm.\n_ | \nN | In Turner syndrome, elective surgery for aneurysms of the aortic root and/or ascending aorta should be considered for women who are\n>16 years of age, have an ascending ASI >25 mm/m2, and have associated risk factors for aortic dissection. | \nN | In Turner syndrome, elective surgery for aneurysms of the aortic root and/or ascending aorta may be considered for women who are\n>16 years of age, have an ascending aortic size index >25 mm/m2, and do not have associated risk factors for aortic dissection. | \nRight ventricular outflow tract obstruction / tetralogy of Fallot /Ebstein |  | \nR | Adjust recommendations for surgical intervention in RVOTO\naccording to symptoms. | If surgical valve replacement is the only option, it is indicated\nin patients with severe stenosis who are symptomatic.\n |  | If surgical valve replacement is the only option in patients with\nsevere stenosis who are asymptomatic, it is indicated in the\npresence of one or more of the following:\n\u0004 Objective decrease in exercise capacity\n\u0004 Decreasing RV function and/or progressive TR to at least\nmoderate\n\u0004 RVSP >80 mmHg\n\u0004 R\u0002L shunting via an ASD or VSD.\nR | Include preference for catheter intervention for pulmonary\nvalve implantation in TOF. | In patients with no native outflow tract, catheter intervention\n(TPVI) should be preferred if anatomically feasible.\nR | Specify RV dilatation in the setting of pulmonary valve replace-\nment for TOF and for RVOT conduits. | Pulmonary valve replacement should be considered in asymp-\ntomatic patients with severe PR and/or RVOTO, in the pres-\nence of progressive RV dilation to RVESVi >80 mL/m2, and/or\n_\nRVEDVi >160 mL/m2, and/or progression of TR to at least\n_\nmoderate.",
          "bbox": [
            43.44526238277041,
            59.91553751627604,
            547.8424072265625,
            701.7311401367188
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 573",
          "page_number": 10,
          "content": "R | In case of ASDs in Ebstein anomaly, add caution about RA\npressure rise or fall in cardiac output. | In the case of documented systemic embolism probably\ncaused by paradoxical embolism, isolated device closure of\nASD/PFO should be considered but requires careful evalua-\ntion before intervention to exclude induction of RA pressure\nincrease or fall in cardiac output.\n |  | If cyanosis (oxygen saturation at rest <90%) is the leading\nproblem, isolated device closure of ASD/PFO may be consid-\nered but requires careful evaluation before intervention to\nexclude induction of RA pressure increase or fall in cardiac\noutput.\nTransposition of the great arteries |  | \nR | Downgrade level of recommendation for AV valve repair in\nTGA/atrial switch from I to IIa in symptomatic patients. | In patients with severe systemic (tricuspid) AV valve regurgita-\ntion without significant ventricular systolic dysfunction (EF\n>40%), valve repair or replacement should be considered\nregardless of symptoms.\nR | In patients with TGA/atrial switch requiring PM/ICD implanta-\ntion: pay attention to the presence of baffle leaks. | In patients with a baffle leak who require a PM/ICD, closure of\nthe baffle leak should be considered, when technically feasible,\nprior to insertion of transvenous leads.\nN | In ccTGA, biventricular pacing should be considered in case of complete AV block or >40% ventricular pacing requirement. | \nR | Revise indications for TV replacement in ccTGA, according to\nsymptoms and systemic ventricular function.\n(Upgrade level of recommendation for symptomatic ccTGA\npatients from IIa to I). | In symptomatic patients with severe TR and preserved or\nmildly impaired systemic RV systolic function (EF >40%), TV\nreplacement is indicated.\n |  | In asymptomatic patients with severe TR and progressive sys-\ntemic RV dilatation and/or mildly impaired systemic RV sys-\ntolic function (EF >40%), TV replacement should be\nconsidered.\n |  | In symptomatic patients with severe TR and more than mildly\nreduced systemic RV systolic function (EF <40%), TV replace-\n_\nment may be considered.\nR | Anatomic repair (atrial þ arterial switch) for ccTGA removed\nfrom the recommendations. | \nUniventricular heart |  | \nN | It is recommended that adults with unoperated or palliated UVHs undergo careful evaluation in specialized centres including multimodality\nimaging as well as invasive work-up to decide whether they may benefit from surgical or interventional procedures. | \nFontan circulation |  | \nN | Sustained atrial arrhythmia with rapid AV conduction is a medical emergency and should promptly be treated with electrical\ncardioversion. | \nN | Anticoagulation is indicated in the presence, or with a history, of atrial thrombus, atrial arrhythmias, or thromboembolic events. | \nN | It is recommended that women with a Fontan circulation and any complication are counselled against pregnancy. | \nN | Cardiac catheterization is recommended at a low threshold in cases of unexplained oedema, exercise deterioration, new-onset arrhyth-\nmia, cyanosis, and haemoptysis. | \nN | In patients with arrhythmias, a proactive approach of electrophysiological evaluation and ablation (where appropriate) should be\nconsidered. | \nN | Regular liver imaging (ultrasound, computed tomography, magnetic resonance) should be considered. | \nN | Endothelin receptor antagonists and phosphodiesterase-5 inhibitors may be considered in selected patients with elevated pulmonary pres-\nsures/resistance in the absence of elevated ventricular end diastolic pressure. | \nN | In selected patients with significant cyanosis, device closure of a fenestration may be considered but requires careful evaluation before\nintervention to exclude induction of systemic venous pressure increase or fall in cardiac output. | \nCoronary artery anomalies |  | \nN | Non-pharmacological functional imaging (e.g. nuclear study, echocardiography or CMR with physical stress) is recommended in patients\nwith coronary anomalies to confirm/exclude myocardial ischaemia. | \nA) Anomalous coronary artery from the pulmonary artery (ACAPA) |  | \nN | Surgery is recommended in patients with ALCAPA. | \nN | Surgery is recommended in patients with ARCAPA and symptoms attributable to anomalous coronary artery. | ",
          "bbox": [
            47.95224409392386,
            59.88903013865153,
            552.3962470160591,
            738.87861328125
          ],
          "function_potential": "raw"
        },
        {
          "title": "574 ESC Guidelines",
          "page_number": 11,
          "content": "N | Surgery should be considered for ARCAPA in asymptomatic patients with ventricular dysfunction, or myocardial ischaemia attributable to\ncoronary anomaly.\nB) Anomalous aortic origin of a coronary artery (AAOCA) | \nN | Surgery is recommended for AAOCA in patients with typical angina symptoms who present with evidence of stress-induced myocardial\nischaemia in a matching territory or high-risk anatomy.\nN | Surgery should be considered in asymptomatic patients with AAOCA (right or left) and evidence of myocardial ischaemia.\nN | Surgery should be considered in asymptomatic patients with AAOLCA and no evidence of myocardial ischaemia but a high-risk anatomy.\nN | Surgery may be considered for symptomatic patients with AAOCA even if they have neither evidence of myocardial ischaemia nor high-\nrisk anatomy.\nN | Surgery may be considered for asymptomatic patients with AAOLCA without myocardial ischaemia and without high-risk anatomy when\nthey present at young age (<35 years).\nN | Surgery is not recommended for AAORCA in asymptomatic patients without myocardial ischaemia and without high-risk anatomy.\nNew concepts | \nNaming (ACHD). | \nDisease complexity classification. | \nStaffing requirements for an ACHD expert centre. | \nEmerging role of biomarkers in follow-up of ACHD. | \nDetailed and specific recommendations on arrhythmia management. | \nMore specific and adjusted recommendations for PAH treatment. | \nRecommendations on the use of anticoagulants. | \nConsideration of ageing and advance care planning. | \nCategories of high-risk pregnancies in accordance with the pregnancy guidelines. | \nExpand Marfan syndrome section to aortopathies (and include HTAD, Turner syndrome, and bicuspid aortic disease). | \nEmerging role of catheter intervention in ACHD. | ",
          "bbox": [
            43.369998931884766,
            59.93634033203125,
            549.7898947975852,
            371.65026092529297
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "18",
      "title": "3.3 Diagnostic work-up Besides a thorough clinical evaluation, the medical history, including detailed information about palliative or reparative surgery and catheter-based interventions, is of critic",
      "start_page": 12,
      "end_page": 16,
      "content": "objective measures of exercise capacity. 14   Therefore, cardiopulmo- nary exercise testing (CPET) has gained importance for objective assessment of exercise intolerance in both apparently asymptomatic and symptomatic patients. In addition, the patient should be ques- tioned about his/her lifestyle to detect progressive changes in daily activity in order to limit the subjectivity of symptom analysis. In symp- tomatic patients, alternative causes such as anaemia, depression, weight gain, and physical deconditioning, besides the congenital defect and its sequelae or residuae, should be kept in mind and fur- ther excluded if necessary.\nClinical examination plays a major role and includes careful evalua- tion of any changes in auscultation findings, blood pressure, or\nTable 4 Classiﬁcation of congenital heart disease complexity\nMILD: •   Isolated congenital aortic valve disease and bicuspid aortic disease •   Isolated congenital mitral valve disease (except parachute valve, cleft leaﬂet) •   Mild isolated pulmonary stenosis (infundibular, valvular, supravalvular) •   Isolated small ASD, VSD, or PDA •   Repaired secundum ASD, sinus venosus defect, VSD, or PDA without residuae or sequellae, such as chamber enlargement, ventricular dysfunction,\nor elevated PAP.\nMODERATE:  (Repaired or unrepaired where not speciﬁed; alphabetical order) •   Anomalous pulmonary venous connection (partial or total) •   Anomalous coronary artery arising from the PA •   Anomalous coronary artery arising from the opposite sinus •   Aortic stenosis - subvalvular or supravalvular •   AVSD, partial or complete, including primum ASD (excluding pulmonary vascular disease) •   ASD secundum, moderate or large unrepaired (excluding pulmonary vascular disease) •   Coarctation of the aorta •   Double chambered right ventricle •   Ebstein anomaly •   Marfan syndrome and related HTAD, Turner Syndrome •   PDA, moderate or large unrepaired (excluding pulmonary vascular disease) •   Peripheral pulmonary stenosis •   Pulmonary stenosis (infundibular, valvular, supravalvular), moderate or severe •   Sinus of Valsalva aneurysm/ﬁstula •   Sinus venosus defect •   Tetralogy of Fallot  \u0002  repaired •   Transposition of the great arteries after arterial switch operation •   VSD with associated abnormalities (excluding pulmonary vascular disease) and/or moderate or greater shunt.\nSEVERE:  (Repaired or unrepaired where not speciﬁed; alphabetical order) •   Any CHD (repaired or unrepaired) associated with pulmonary vascular disease (including Eisenmenger syndrome) •   Any cyanotic CHD (unoperated or palliated) •   Double-outlet ventricle •   Fontan circulation •   Interrupted aortic arch •   Pulmonary atresia (all forms) •   Transposition of the great arteries (except for patients with arterial switch operation) •   Univentricular heart (including double inlet left/right ventricle, tricuspid/mitral atresia, hypoplastic left heart syndrome, any other anatomic abnormality with a functionally single ventricle) •   Truncus arteriosus •   Other complex abnormalities of AV and ventriculoarterial connection (i.e. crisscross heart, heterotaxy syndromes, ventricular inversion).\nASD = atrial septal defect; AV = atrioventricular; AVSD = atrioventricular septal defect; CHD = congenital heart disease; HTAD = heritable thoracic aortic disease; LV = left ventricle/ventricular; PA = pulmonary artery; PAP = pulmonary artery pressure; PDA = patent ductus arteriosus; VSD = ventricular septal defect.\nESC Guidelines 575\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n©ESC\nEmergency admissions\nNeed for  f repeated operations and interventions\nCongenital heart disease ~ A lifelong ch f ronic condition\nHospitalisations\nRecurrence of CHD\nLifelong medical ther f apy\nPregnancy complications Maternal mortality Neonatal complication ions tion\nReduced life expectancy f\nStroke k Neurological  complications\nCoronary complications Aortic syndrome\nExercise intolerance Depressive symptoms Reduced quality of lifef\nArrhythmia\nHypertension\nSudden cardiac death\nEndocarditis\nFigure 1  Central illustration. Congenital heart disease is a lifelong chronic condition. CHD = congenital heart disease; SCD = sudden cardiac death.\n576 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ..............................................................\ndevelopment of signs of heart failure. An electrocardiogram (ECG) and pulse oximetry are routinely carried out alongside clinical examination. A chest X-ray provides information on changes in heart size and configuration, as well as pulmonary vascularization. Non- invasive imaging is routinely performed by transthoracic echocardiog- raphy (TTE) involving transoesophageal echocardiography (TOE) and cardiovascular magnetic resonance (CMR) imaging where indi- cated. Thus, patients with CHD may particularly benefit from mag- netic resonance-conditional/compatible pacemakers and defibrillators. Echocardiography is superior to CMR in estimating pressure gra- dients and pulmonary artery (PA) pressure (PAP), and detecting small, highly mobile structures such as vegetations. CMR is ideal for accurate quantification of ventricular volumes, ejection fraction (EF), valvular regurgitation, 15   calculation of pulmonary and systemic blood flow, and myocardial fibrosis assessment. Cardiovascular computed tomography (CCT) with modern single or dual source scanners can be performed with dose-saving protocols and may be required for special indications  \u0002  as indicated in  Table  6 . Interdisciplinary expert collaboration is important: imaging CHD experts need to respond to feedback from CHD surgeons, interventionalists, and electrophysiol- ogists to optimize imaging contribution to care, as well as work with each other to enhance appropriate use of multimodality imaging. Advanced imaging is usually best reserved for when patients are seen in the specialist centre rather than be repeated.\nEchocardiography, CMR, and CCT require staff with expertise in CHD as well as in imaging, which has training and resource implica- tions. Within the ESC, this is recognized by a certification examina- tion of the European Association of Cardiovascular Imaging (EACVI), separate from the standard TTE, TOE, or CMR examination, and specific to CHD.\n3.3.1 Echocardiography Echocardiography remains the first-line imaging modality. 16   M-mode, two-dimensional, and three-dimensional (3D) echocardiography are all used for imaging, whereas tissue Doppler imaging and deformation imaging, especially longitudinal strain and strain rate, are becoming integral parts of functional assessment. 17\nEchocardiography provides information on cardiac anatomy, situs (including orientation and position of the heart), connection of the atria and ventricles, heart valves, and connection of ventricles with the great arteries. For assessment of morphology and function of car- diac valves, TTE and, if necessary, TOE (nowadays often combined with 3D echocardiography), is the preferred imaging modality. This is also true for shunt lesions, such as ASDs or ventricular septal defects (VSDs): 3D echocardiography enables an en face view, which can be helpful in the assessment of the size and shape of a defect and its rela- tion to surrounding structures. Ventricular size, shape, volume, and EF can be measured and calcu- lated with TTE. Signs of volume overload, in the case of a shunt or valvular regurgitation, or pressure overload, in the case of increased afterload, are detected in a good-quality TTE. Even older techniques using M-mode for measurement of tricuspid annular plane systolic\nTable 5 Staff requirements for specialist ACHD centres a\nDiscipline Required number\nAdult/paediatric cardiologist with ACHD certiﬁcation >_2\nACHD imaging specialist (certiﬁed in TTE/TOE, CMR, CCT) >_2\nCongenital interventional cardiologist >_2\nCHD surgeon >_2\nAnaesthesiologist with CHD experience and expertise >_2\nSpecialist nurse (if national professional nursing bodies allow specialization) >_2\nInvasive electrophysiologist with ACHD experience >_1\nPulmonary vascular disease expert >_1\nClinical geneticist >_1\nPsychologist >_1\nSocial worker >_1\nPalliative care team\nACHD = adult congenital heart disease; CHD = congenital heart disease; CMR = cardiovascular magnetic resonance; CCT = cardiovascular computed tomogra- phy; TOE = transoesophageal echocardiography; TTE = transthoracic echocardiography. a Modiﬁed from Baumgartner  et al . 8\nTable 6 Indications for cardiovascular magnetic reso- nance imaging in ACHD patients\nIndications for CMR in ACHD patients •   Quantiﬁcation of RV volumes, EF (including subpulmonary RV, sys-\ntemic RV, and single ventricle) •   Evaluation of RVOTO and RV \u0002 PA conduits •   Quantiﬁcation of PR •   Evaluation of PAs (stenoses, aneurysms) and the aorta [aneurysm, dis-\nsection, coarctation (CCT may be superior)] •   Evaluation of systemic and pulmonary veins (anomalous connection,\nobstruction, coronary venous anatomy pre-procedure, etc.) •   Collaterals and arteriovenous malformations (CCT may be superior) •   Coronary anomalies and CAD (CCT is superior for intramural course,\nslit-like course, acute angle take-off, myocardial bridging, and plaque\nassessment) •   Detection and quantiﬁcation of myocardial ischaemia by CMR stress\nperfusion •   Evaluation of intra- and extracardiac masses •   Quantiﬁcation of myocardial mass (LV and RV) •   Detection and quantiﬁcation of myocardial ﬁbrosis/scar (late gadoli-\nnium enhancement, T1 mapping) tissue characterization (ﬁbrosis, fat, iron, etc.) •   Quantiﬁcation of systemic and pulmonary blood ﬂow to calculate\nQp:Qs •   Quantiﬁcation of perfusion distribution to the right/left lung •   Measurement of pulmonary blood ﬂow in patients with multiple sour-\nces of blood supply (i.e. with major aorto-pulmonary collateral arteries)\nACHD = adult congenital heart disease; CAD = coronary artery disease; CMR = cardiovascular magnetic resonance; CCT = cardiovascular computed tomogra- phy; EF = ejection fraction; LV = left ventricle/ventricular; PA = pulmonary artery; PR = pulmonary regurgitation; Qp:Qs = pulmonary to systemic ﬂow ratio; RV = right ventricle/ventricular; RVOTO = right ventricular outﬂow tract obstruction.\nESC Guidelines 577\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ excursion and mitral annular plane systolic excursion are still valid, especially in longitudinal follow-up. For left ventricular (LV) systolic function, 3D echocardiography, tissue Doppler imaging, and two-dimensional deformation imaging have proved to be robust tools and deserve to be integrated into clinical practice. Even accounting for newer techniques, echocardiography retains a key role in longitudinal follow-up assessment of systolic function of a right or single ventricle, although for more accurate measurements addi- tional imaging is often needed in the form of CMR.\n3.3.2 Cardiovascular magnetic resonance imaging CMR has become an essential facility in the specialist unit. It enables 3D anatomical reconstruction, which is not restricted by body size or acoustic windows, and has rapidly improving spatial and temporal reso- lution. 18   CMR requires a regular heart rhythm for optimal image quality, however, diagnostic CMR studies are often achievable even in patients with irregular heart rhythms [frequent ectopy or atrial fibrillation (AF)] and metallic artefacts. CMR is the gold-standard imaging method for quantification of volumes. It may be an alternative when echocardiogra- phy cannot be obtained with sufficient quality, or used as a second method when echocardiography measurements are borderline or ambiguous. Furthermore, the lack of radiation makes it a useful tool when serial evaluations are needed (e.g. for monitoring aortic dimen- sions). CMR allows calculation of systemic and pulmonary blood flow in patients with multiple sources of blood supply and, in combination with invasive catheterization, of pulmonary vascular resistance (PVR). Tissue characterisation for myocardial fibrosis is a unique capability of CMR. Late gadolinium enhancement CMR for focal fibrosis and interstitial fib- rosis T1 mapping imaging are increasingly being applied in ACHD for their potential diagnostic and prognostic value. However, large CHD lesion-specific studies to determine if they predict survival are ongoing.\nTo mitigate the low risk of nephrogenic systemic fibrosis, gadoli- nium contrast should be avoided in patients with a low glomerular fil- tration rate (<30 mL/min/1.73 m 2 ). It is therefore recommended that creatinine levels are checked prior to CMR. Even though clinical repercussions have not yet been seen, long-term brain deposits of gadolinium  \u0002  regardless of renal function  \u0002  raised concerns about cumulative lifetime doses in CHD patients who undergo serial CMR from a young age. It is preferred, therefore, that gadolinium is selec- tively administered in specialist centres using a macrocyclic, rather than linear chelated, gadolinium contrast, which presents a decreased risk at the lowest dose to achieve image enhancement. 19\nAdults with CHD with conventional pacemakers (PM) and defibril- lators (ICD) can undergo CMR within guidelines where local support is available. 20\n3D CMR imaging can be integrated into electrophysiology (EP) procedures to inform and guide them. 3D CCT and CMR recon- structions can also be used for virtual reality rehearsal of interven- tions or planning from patient-specific 3D prints. Indications for CMR are summarized in  Table  6 .\n3.3.3 Cardiovascular computed tomography CCT has high spatial resolution and rapid acquisition time; it is partic- ularly relevant for imaging the great vessels, coronary arteries, and collateral arteries, and for parenchymal lung disease ( Table  6 ). In many institutions, CCT is the preferred imaging modality in planning for transcatheter valve implantation. Ventricular size and function can\nbe assessed, with inferior temporal resolution compared with CMR, typically with an increased radiation dose, and is therefore not used serially for this indication. Recent rapid developments have substan- tially reduced the amount of radiation exposure, achieving <5 mSv for a combined CCT coronary, pulmonary, and aortic angiogram. For ACHD patients, this has made CCT more attractive for specific indi- cations such as assessment, in particular for coronary artery pathol- ogy, and detailed assessment of collaterals. 21\nCCT is particularly useful in emergency settings including dissec- tion, pulmonary embolism, and paravalvular abscess in the setting of endocarditis, where it may have advantages over echocardiography and CMR due to being less susceptible to prosthetic valve artefact. In patients with prosthetic valves (in situ >3 months), fluorine-18- fluorodeoxyglucose positron emission tomography/computed tomog- raphy is useful for early diagnosis of inflammation and infection at the site of the valve, and also for identifying infection at secondary sites. 22\n3.3.4 Cardiopulmonary exercise testing Formal exercise testing has an important role in the CHD population, in which quality of life and functional capacity are key measures of the success of intervention. CPET, including assessment of objective exercise capacity (peak oxygen consumption), ventilatory efficiency [ventilation to carbon dioxide output (VE/VCO 2 ) slope], chrono- tropic and blood pressure response, as well as exercise-induced arrhythmia and desaturation, gives a broader evaluation of functional capacity and physical fitness, and has endpoints which correlate well with morbidity and mortality in ACHD patients. 23   Serial exercise testing should therefore be a part of long-term follow-up protocols. It plays an important role in the timing of interventions and reinter- ventions. CPET is also a useful tool for recommending the intensity of physical activity based on an individualized exercise prescription. 24\nThe 6-minute walk test (6MWT) is another simple test for quantifica- tion of exercise capacity; it relates to outcome in patients with PAH.\n3.3.5 Cardiac catheterization Cardiac catheterization is mainly reserved for resolution of specific anatomical and physiological questions, or for intervention. Indications include assessment of PVR, ventricular diastolic function (including constrictive and restrictive physiology), pressure gradients, shunt quantification, coronary angiography, and evaluation of extrac- ardiac vessels such as aortic pulmonary collateral arteries when non- invasive evaluation leaves uncertainty. In shunt lesions with Doppler echocardiographic signs of PH, cath- eterization  \u0002  including testing of vasoreactivity  \u0002  remains essential in the decision on shunt closure. Inhaled nitric oxide is the most widely used agent for this purpose. Estimation of PVR in shunt lesions requires accurate calculation of pulmonary flow using the Fick princi- ple. This method with measured oxygen consumption allows the most accurate cardiac output quantification. Before surgery, coronary artery imaging should be performed (by CCT or invasive coronary angiography) in men >40 years of age, postmenopausal women, and patients with signs of, or one or more risk factors for, coronary artery disease (CAD). 25\n3.3.6 Biomarkers Different classes of biomarkers have been reported to be associated with adverse events in the CHD population, including\n578 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ neurohormones and markers of myocardial injury (high-sensitivity troponins) or inflammation (high-sensitivity C-reactive protein). Among the neurohormones, natriuretic peptides [B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP)] are best studied in ACHD patients. They carry important prognostic informa- tion, but are less useful to diagnose heart failure across different car- diac lesions due to a cut-off variability depending on the underlying defect and type of repair. 26   They are most useful in patients with biventricular circulation and least useful in patients with a Fontan cir- culation. 27   Serial testing of natriuretic peptides plays a role in identify- ing patients at risk for adverse events. Of note, natriuretic peptides may be increased in cyanotic heart disease simply due to hypoxia- induced peptide secretion. 28\n",
      "keywords": [
        "detailed",
        "ejection fraction",
        "older",
        "sudden cardiac death",
        "prosthetic valve",
        "plaque",
        "physical activity",
        "electrocardiogram",
        "diagnostic",
        "systolic",
        "thorough",
        "pulmonary embolism",
        "about",
        "catheter",
        "surgery",
        "age",
        "information",
        "interventions",
        "tricuspid",
        "hypertension",
        "medical",
        "scd",
        "blood pressure",
        "including",
        "evaluation",
        "reparative",
        "based",
        "aneurysm",
        "diastolic",
        "weight"
      ],
      "tables": [
        {
          "title": "576 ESC Guidelines",
          "page_number": 13,
          "content": "Congenital heart disease ~ A lifelong chronic condition\nNeed for repeated\noperations and interventions\nHospitalisations\nEmergency admissions\nRecurrence of CHD\nPregnancy complications\nExercise intolerance\nMaternal mortality\nDepressive symptoms\nEndocarditis\nNeonatal complications\nReduced quality of life\nHypertension\nLifelong medical therapy\nSudden cardiac death\nArrhythmia\nStroke\nNeurological\ncomplications\nCoronary complications\nAortic syndrome\nReduced life expectancy\n©ESC |  | \n | ©ESC | \n |  | ",
          "bbox": [
            61.92369588216146,
            60.053629557291664,
            529.020751953125,
            717.2789916992188
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 577",
          "page_number": 14,
          "content": "Discipline |  | Required\nnumber\nAdult/paediatric cardiologist with ACHD certification |  | >2\n_\nACHD imaging specialist (certified in TTE/TOE,\nCMR, CCT) |  | >2\n_\nCongenital interventional cardiologist |  | >2\n_\nCHD surgeon |  | >2\n_\nAnaesthesiologist with CHD experience and expertise |  | >2\n_\nSpecialist nurse (if national professional nursing\nbodies allow specialization) |  | >2\n_\nInvasive electrophysiologist with ACHD experience |  | >1\n_\nPulmonary vascular disease expert |  | >1\n_\nClinical geneticist |  | >1\n_\nPsychologist |  | >1\n_\nSocial worker |  | >1\n_\nPalliative care team |  | ",
          "bbox": [
            48.02638283754006,
            91.3329833984375,
            288.9915217185507,
            293.6480293273926
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "19",
      "title": "3.4 Therapeutic considerations 3.4.1 Heart failure The development of heart failure is a common problem affecting 20 \u0002 50% of the ACHD population, and is a main cause of death. 29   The incidence is i",
      "start_page": 16,
      "end_page": 25,
      "content": "might alleviate symptoms. Treatment of symptomatic patients with a failing single ventricle in a Fontan circulation, or in the case of a persis- tent right-to-left (R \u0002 L) shunt, should always be carefully initiated, tak- ing the labile balance of ventricular preload and systemic afterload into account. In ACHD patients with heart failure, there are currently only a few small studies looking at the new drug sacubitril/valsartan, which was found to decrease morbidity and mortality and implemented in the therapy of chronic heart failure in recent ESC Guidelines 31 , how- ever, no recommendation can be made at this moment. Heart failure with preserved EF is also not uncommon in ACHD patients. Therapeutic recommendations should follow the general heart failure guidelines. On top of medical treatment, cardiac resynchronization therapy (CRT) has gained increasing interest for use in ACHD patients with congestive heart failure, despite little evidence on indications and outcomes. Efficacy of CRT in CHD may vary with the underlying struc- tural and functional substrate, such as anatomy of the systemic ventricle (left, right, or functionally single), presence and degree of structural sys- temic atrioventricular (AV) valve regurgitation, primary myocardial dis- ease or scarring, and type of electrical conduction delay. 32\nIt is expected that the incidence of acute heart failure in ACHD patients will also increase over time due to increasing age and more complex diseases. The knowledge of correct use of inotropes, the availability of extra-corporal membrane oxygenation, and advanced bridging techniques are the minimum requirements to adequately support ACHD patients with acute heart failure; transfer to an expert centre is recommended. 33\nHeart transplantation may also be considered as a therapeutic option for end-stage heart failure. Outcome after transplant surgery is continu- ously improving, particularly in CHD patients, but perioperative mortal- ity still remains higher than in other underlying diseases. This is mainly related to previous cardiac surgery, complex anatomy and pathophysiol- ogy, and comorbidities (multisystem disorder). The increased use of ven- tricular assist devices can bridge patients to transplantation; in selected patients, it may be an option as destination therapy. Some patients may have extreme complex anatomy or high levels of antibodies against the human leucocyte antigens and are not eligible for transplantation. In some patients, multiorgan transplantation is required. Heart- lung transplantation is applied in CHD patients with irreversible PAH such as Eisenmenger syndrome, however, the lack of donor organs is a major limitation. Simultaneous heart-liver transplantation is rarely done in liver fail- ure after Fontan palliation or in patients with long-standing hepatic pressure load due to right heart failure [e.g. unrecognized Ebstein’s malformation of the tricuspid valve (TV)]; experience of this kind of surgery is limited. In all cases, timely evaluation for transplantation by ACHD heart failure specialists in a transplant centre with ACHD expertise is rec- ommended. Advance care planning, eventually including palliative care, should be offered to all advanced heart failure patients.\n3.4.2 Arrhythmias and sudden cardiac death 3.4.2.1 Arrhythmia substrates The entire spectrum of arrhythmias may be encountered in ACHD patients. However, some congenital arrhythmia substrates are related to the malformation itself ( Table  7  and  section 4 ). Longer life expectancy (in conjunction with exposure to conventional risk fac- tors for arrhythmogenic substrates) increases the prevalence of\nESC Guidelines 579\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ......................................... arrhythmias related to structural remodelling, which may occur at a younger age than in the general population, e.g. AF. Other arrhythmias are related to the type and timing of the ACHD repair. Right atrial (RA) incisions, together with cardiac remodelling secondary to haemodynamic overload, contribute to the high preva- lence of atrial tachycardias (AT) in various CHDs. Most frequently encountered is late intraatrial reentrant tachycardia (IART), in particu- lar cavotricuspid isthmus-dependent atrial flutter. Atrial rates between 150 and 250 beats per minute may lead to rapid AV conduction, hae- modynamic compromise, and sudden cardiac death (SCD). Monomorphic ventricular tachycardia (VT) also depends on the mal- formation ( Table  7 ) and type of repair, 34 , 35   with the critical part of the macro-reentry circuit typically located within anatomically well-defined isthmuses bordered by surgical scars and patch material. In contrast, in\npatients with progressive failure of the systemic or subpulmonary ven- tricle, more complex EP changes may occur. These changes involve ion channel remodelling, alterations in calcium handling, and remodelling of the extracellular matrix leading to different arrythmias including less well-organized fast polymorphic VT and ventricular fibrillation (VF). 36\n3.4.2.2 Assessment in patients with suspected/documented arrhythmias and arrhythmia management In symptomatic patients without arrhythmia documentation at pre- sentation, evaluation depends on the frequency [Holter registration, device interrogation (if present), event recorder] and circumstances (exercise testing) of symptoms. The usefulness of periodic evaluation beyond 12-lead ECGs (e.g. periodic Holter) in asymptomatic patients is less clear. A high\nTable 7 Risk estimates for arrhythmic events and bradycardias in ACHD\nAF = atrial ﬁbrillation; ASD = atrial septal defect; AV = atrioventricular; AVRT = atrioventricular reentrant tachycardia; AVSD = atrioventricular septal defect; ccTGA = congenitally corrected transposition of the great arteries; CHD = congenital heart disease; EAT = ectopic atrial tachycardia; IART = intraatrial reentrant tachycardia; SCD = sudden cardiac death; SND = sinus node dysfunction; TGA = transposition of the great arteries; TOF = tetralogy of Fallot; VSD = ventricular septal defect; VT = ventricular tachycardia. a Considering the high prevalence of VSD, the overall risk in unselected patients with VSD is considered to be minimal. b SCD may be due to supraventricular arrhythmias with rapid AV conduction. c VT higher estimated risk in complex dextro-TGA. d Non-arrhythmic.\n580 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ................................................................................... prevalence of asymptomatic findings has been reported that rarely change management. 37\nIn all patients, evaluation for a reversible cause of the arrhythmia (e.g. hyperthyroidism, inflammatory process) and new or residual haemodynamic abnormalities is important. Arrhythmias causing hae- modynamic instability require immediate termination irrespective of duration/anticoagulation following current recommendations. 32\nPost-conversion, sinus arrest/bradycardia may occur and availability of back-up pacing needs to be considered in patients at risk for sinus node dysfunction (SND) ( Table  7 ). If IART/AF is tolerated and lasting >_48 h, cardiac thrombus needs to be ruled out (TOE) and/or appro- priate anticoagulation (>3 weeks) and pharmacological rate control needs to be initiated before cardioversion using a beta blocker or cal- cium channel blocker (in patients with normal systemic ventricular function and absent preexcitation). 32 , 37 , 38   Maintenance of sinus rhythm is the aim in all CHD patients. 32 , 37   Catheter ablation is rec- ommended as first-line therapy and preferred over long-term phar- macological treatment, in case of amenable, circumscribed substrates, as antiarrhythmic drugs are often associated with negative inotropic and/or dromotropic effects. 32   Antiarrhythmic drugs such as class IC drugs may slow the rate of IART without blocking AV con- duction allowing 1:1 conduction with worsening haemodynamics. 32\nAmiodarone may be considered for AT/AF recurrence prevention in patients with CHD and systemic ventricular dysfunction, hypertro- phy of systemic ventricle, or CAD, in whom catheter ablation fails or is otherwise no option. Side effects of amiodarone are frequent and it should be used with caution in cyanotic CHD, low body weight, hep- atic, thyroid, or pulmonary disease, or prolonged QT interval. Long- term amiodarone therapy is not advised in young CHD patients. 32\nFor optimal chronic arrhythmia management, referral to a centre with a multidisciplinary team and expertise in CHD-related arrhyth- mias is mandatory. 32 , 37   For more specifications on anticoagulation see  section 3.4.7 .\n3.4.2.3 Sinus node dysfunction, atrioventricular block, and infra-hisian conduction delay Periodic Holter for patients at risk for SND and AV block should be considered in asymptomatic patients. Chronic SND/bradycardia with ineffective atrial haemodynamics may affect atrial remodelling and facilitate IART. Patients with post-operative AV block are considered at increased risk for SCD. Accordingly, broader indications for pace- maker implantation compared with patients with structurally normal hearts have been suggested. 20 , 32\nIn ACHD patients with a biventricular circulation and a systemic LV, indications for CRT follow standard criteria. Of note, conven- tional ventricular pacing rather than bundle branch block is the major cause of systemic ventricular dysfunction. Accordingly, CRT is rec- ommended in ACHD with a systemic EF <_35% and intrinsic narrow QRS, and an anticipated requirement for significant pacing and new device placement. Alternatively, his bundle pacing could be consid- ered. Efficacy of CRT in ACHD may vary across defects and may depend on the individual anatomy and causes of dyssynchrony (e.g. systemic RV/single ventricle, AV valve regurgitation, scarring). In gen- eral, QRS duration alone may not be a sufficient predictor and follow-up data are limited. In addition, thoracotomy or hybrid lead implantation is often required and data on longevity of CRT are lacking. 32\n3.4.2.4 Sudden cardiac death and risk stratification SCD related to ventricular arrhythmia is of concern (7 \u0002 26% of all deaths in adults). 29 , 39 , 40   Although the incidence in the CHD popula- tion at large is relatively low (<0.1% per year), some defects place patients at higher risk, with occasional disease-specific substrates and risk factors ( Table  7 ). Identifying patients at risk for SCD remains a challenge.\nICD implantation for secondary prevention of SCD and for pri- mary prevention in patients with biventricular physiology and a sys- temic LV follows standard criteria. 37 , 41   Antiarrhythmic drugs may be used as an adjunct to an ICD in order to reduce the ventricular arrhythmia burden. 32   The benefit of ICD therapy in primary preven- tion for single or systemic RVs is less well established.\nAccordingly, with the exception of tetralogy of Fallot (TOF), spe- cific guidelines regarding ICD implantation for primary prevention in CHD remain elusive. 32 , 37   Transvenous ICD systems have been used, but in patients with limited venous access to the ventricle or intracar- diac shunt, the subcutaneous ICD may be an alternative. However, not all patients are eligible due to the risk of inappropriate sensing and lack of antitachycardia and antibradycardia pacing.\nThe usefulness of programmed electrical stimulation (PES) in asymptomatic patients with CHD is unclear. It seems reasonable in patients with ventricular incisions and/or a substrate for ventricular reentry typically, but not exclusively, encountered in repaired TOF (rTOF). It is important to recognize other causes of SCD due to bra- dycardia/total AV block and bradycardia-induced ventricular arrhyth- mia with or without long QT, and IART/AF with rapid conduction.\nRecommendations for treatment of arrhythmias in adult congenital heart disease\nRecommendations Class a Level b\nIn patients with moderate and severe CHD com-\nplexity ( Table  4 ) and documented arrhythmias, referral to a centre with a multidisciplinary team\nand expertise in ACHD patients and ACHD-\nrelated arrhythmia is indicated.\nI C\nIn CHD patients with documented arrhythmias\nor at high risk for post-procedural arrhythmias\n(e.g. ASD closure at older age) considered for percutaneous or surgical (re)interventions,\nreferral to a centre with a multidisciplinary team\nwith expertise in these interventions and in inva- sive treatment of arrhythmias is indicated.\nI C\nIn mild CHD, catheter ablation is recommended\nover long-term medical therapy for sympto-\nmatic, sustained recurrent SVT (AVNRT, AVRT, AT, and IART), or if SVT is potentially related to\nSCD ( Table  7 ).\nI C\nIn moderate and severe CHD, catheter ablation should be considered for symptomatic, sustained\nrecurrent SVT (AVNRT, AVRT, AT, and IART),\nor if SVT is potentially related to SCD ( Table  7 ), provided that the procedure is performed in\nexperienced centres.\nIIa C\nContinued\nESC Guidelines 581\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ..............................................................................................\n3.4.3 Pulmonary hypertension 3.4.3.1 Introduction and classification PH is an important prognostic factor in patients with CHD, 42   requir- ing particular attention in pregnancy 43   or prior to reparative cardiac or other major surgery. Until recently, PH was defined by an increase in invasively measured mean PAP >_25 mmHg at rest. 44   While this has now been reduced to >20 mmHg, 45   classification as pre-capillary PH \u0002  also called PAH  \u0002  additionally requires an increase in PVR >_3 Wood units (WU) ( Table  8 ). 45   This increase in resistance in this group is due to an obstructive pulmonary vasculopathy which is driven by genetic background, modifier genes, vascular shear stress, and environmental triggers. 44   It is important to separate PAH associ- ated with CHD (PAH-CHD, in group 1 of the PH classification 44 ) from conditions with an LV filling pressure >15 mmHg (post-capillary PH due to passive transmission of LV filling pressures in groups 2 and 5 of the PH classification), 44   because of the futility of PAH-targeted treatments in post-capillary PH. Clinical subtypes of PAH-CHD are PAH with congenital systemic-pulmonary shunts, Eisenmenger syn- drome, repaired defects, and PAH that appears coincidental with CHD, frequently with small defects. Fontan circulation is another condition with pulmonary vascular disease (PVD) and sometimes ele- vated PVR. An increase in PAP in these patients is, however, more frequently caused post-capillary (increase in ventricular filling pres- sure and/or AV valve regurgitation). In complex CHD, PAH may be restricted to certain segments of the pulmonary vascular bed (seg- mental PAH). 46   This is most frequently encountered in complex pul- monary atresia with VSD.\nAlthough PAH-CHD can occur in males and females of any age, the disease is more frequently encountered in females, and increases with biological age and age at defect closure. 47   The sex bias disappears in PAH-CHD after defect repair. 48   More recently, a nationwide CHD\nCatheter ablation is indicated as adjunctive ther-\napy to ICDs in patients who present with recur-\nrent monomorphic VT, incessant VT, or electrical storm not manageable by medical ther-\napy or ICD reprogramming.\nI C\nCatheter ablation should be considered for symptomatic, monomorphic sustained VT in\npatients for whom medical therapy is not\ndesired, provided that the procedure is per- formed in experienced centres.\nIIa C\nImplantable cardiac deﬁbrillator\nICD implantation is indicated in adults with\nCHD who are survivors of an aborted cardiac arrest due to VF or haemodynamically untoler-\nated VT after evaluation to deﬁne the cause of\nthe event and exclusion of reversible causes.\nI C\nICD implantation is indicated in adults with CHD and sustained VT after haemodynamic\nevaluation and repair when indicated. EP evalua-\ntion is required to identify patients in whom catheter ablation or surgical ablation may be\nbeneﬁcial as adjunctive treatment or in whom it\nmay offer a reasonable alternative.\nI C\nICD implantation should be considered in adults\nwith CHD with biventricular physiology and a\nsystemic LV presenting with symptomatic heart failure (NYHA II/III) and EF <_35% despite >_ 3\nmonths of optimal medical treatment, provided\nthey are expected to survive substantially longer than one year with good functional status. c\nIIa C\nICD implantation should be considered in\npatients with CHD and unexplained syncope\nand suspicion for arrhythmia aetiology and either advanced ventricular dysfunction or indu-\ncible VT/VF at programmed electrical\nstimulation.\nIIa C\nICD implantation should be considered in\nselected TOF patients with multiple risk factors\nfor SCD, including LV dysfunction, non-sus- tained, symptomatic VT, QRS duration >_180 ms,\nextensive RV scarring on CMR, or inducible VT\nat programmed electrical stimulation.\nIIa C\nICD implantation may be considered in patients with advanced single or systemic RV dysfunction\n(EF systemic RV <35%) in the presence of addi-\ntional risk factors. d\nIIb C\nPacemaker\nPM implantation should be considered in ACHD\npatients with bradycardia-tachycardia syndrome\nto prevent IART, if ablation fails or is not possible.\nIIa C\nPM implantation should be considered for\npatients with severe CHD and sinus or IIa C\nContinued\njunctional bradycardia (daytime heart rate <40\nbeats per minute or pauses >3 s).\nPM implantation should be considered for\npatients with CHD and compromised haemody- namics due to sinus bradycardia or loss of AV\nsynchrony.\nIIa C\nPM implantation may be considered for patients with moderate CHD and sinus or junctional bra-\ndycardia (daytime heart rate <40 beats per\nminute or pauses >3 s).\nIIb C\nACHD = adult congenital heart disease; ASD = atrial septal defect; AT = atrial tachycardia; AV = atrioventricular; AVNRT = atrioventricular node reentrant tachycardia; AVRT = atrioventricular reentrant tachycardia; CHD = congenital heart disease; CMR = cardiovascular magnetic resonance; EF = ejection fraction; EP = electrophysiology/electrophysiological; IART = intraatrial reentrant tachy- cardia; ICD = implantable cardioverter deﬁbrillator; LV = left ventricle/ventricu- lar; NYHA = New York Heart Association; PM = pacemaker; RV = right ventricle/ventricular; SCD = sudden cardiac death; SVT = supraventricular tachy- cardia; TGA = transposition of the great arteries; TOF = tetralogy of Fallot; VF = ventricular ﬁbrillation; VT = ventricular tachycardia. a Class of recommendation. b Level of evidence. c Considering the broad spectrum of ACHD with LV pathologies that may differ from acquired heart diseases, the potentially higher risk of ICD-related complica- tions in ACHD, and the paucity of data on the beneﬁt of ICDs for primary pre- vention of SCD in ACHD, a personalized approach seems appropriate. d Data are sparse and risk factors may be lesion speciﬁc, including non-sustained VT, NYHA II/III, severe AV valve regurgitation, and wide QRS >_140 ms (TGA).\n582 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ........................................................................................................... population study reported a PAH prevalence of 3.2% in CHD patients, accounting for 100 per million in the general adult population. 47\n3.4.3.2 Diagnosis The 2015 guidelines for the diagnosis and treatment of PH presented a haemodynamic algorithm for the diagnosis of PH, highlighting the role of right heart catheterization to differentiate pre- from post- capillary PH. 44   The algorithm has recently been modified, 45   and Table  8  illustrates current definitions of different types of PH and the settings in which they may occur in ACHD. In this definition, mean PAP threshold is >20 instead of >_25 mmHg in the presence of a PVR >_3 WU to define pre-capillary PH. 45\n3.4.3.2.1 Diagnostic work-up of pulmonary hypertension in adult congenital heart disease. The diagnostic work-up includes medical history, physical examination, lung function tests, arterial blood gas analysis, imaging (especially echo- cardiography), and laboratory testing (including total blood cell counts, serum iron levels, haematocrit, infectious diseases, and NT-pro-BNP measurements). In general, right heart catheterization with compartmen- tal oximetry is required for major decisions such as start and follow-up of vasodilator therapy, pregnancy, or surgery. The threshold for invasive assessment is, however, higher in patients with Eisenmenger syndrome. Invasive haemodynamic assessment is usually not required for guiding therapeutic interventions over time. Because higher haematocrit levels lead to higher PVR, this may have to be taken into account. 49\n3.4.3.2.2 Risk assessment. Outcomes of PAH-CHD patients have improved with the availability of new PAH therapies, advances in surgical and perioperative man- agement, and use of a team-based, multidisciplinary approach. 44 , 50 , 51\nIn recent series, outcomes of PAH-CHD patients appear to be better than in idiopathic PAH, 48   but depend on the PH subset. Outcomes of PAH associated with small defects resemble the dismal outcomes of idiopathic PAH, presumably because these conditions are based on a\nsimilar vascular proliferative disorder. PAH after defect repair carries even worse prognosis. 48\n3.4.3.3 Therapeutic management of pulmonary hypertension in adult congenital heart disease\n3.4.3.3.1 Expert centres. Successful management of an ACHD patient with PH requires a mul- tidisciplinary management team comprising experts in imaging, cardi- ology, respiratory medicine, haematology, infectious diseases, obstetrics, anaesthesiology, neonatology, PH, thoracic and cardiovas- cular surgery, nursing, and medical genetics.\n3.4.3.3.2 General measures. The main general measures are social and psychological support, vaccination, and avoidance of excessive physical stress. Follow-up visits are planned individually. Pregnancy must be avoided in all cases of pre-capillary PH. Continuous supplemental oxygen is recommended when the arterial blood oxygen pressure is consis- tently <60 mmHg, 44   except in Eisenmenger patients in whom it is only recommended when it produces a documented, consistent, and signif- icant increase in oxygen saturation and improvement of symptoms.\n3.4.3.3.3 Anticoagulation. Anticoagulation with vitamin K antagonists (VKAs) in the absence of atrial arrhythmia, mechanical valves, or vascular prosthesis is not gen- erally recommended in PAH-CHD, and has to be decided on an indi- vidual basis, e.g. large PA aneurysms with thrombus or previous thromboembolic events. No data exist on the use of non-vitamin K antagonist oral anticoagulants (NOACs). In patients with Eisenmenger syndrome, data supporting the routine use of anticoa- gulation are lacking, but oral anticoagulation should be considered in patients with atrial arrhythmias and may be considered in the pres- ence of PA thrombosis or embolism and low bleeding risk. As the risk of bleeding is increased in cyanotic patients, the use of oral\n....................................................................................................................................................................................................................\nTable 8 Deﬁnitions of pulmonary hypertension subtypes and their occurrence in ACHD\nPulmonary Hypertension in Adult Congenital Heart Disease\nDefinition Haemodynamic characteristics a Clinical settings\nPulmonary Hypertension (PH) Mean PAP >20 mmHg All\nPre-capillary PH (PAH) Mean PAP >20 mmHg\nPAWP <_15 mmHg PVR >_3 WU\nShunt lesions prior to and after repair (including Eisenmenger syndrome)\nComplex CHD (including UVH, segmental PAH)\nIsolated post-capillary PH Mean PAP >20 mmHg\nPAWP >15 mmHg PVR <3 WU\nSystemic ventricular dysfunction\nSystemic AV valve dysfunction Pulmonary vein obstruction\nCor triatriatum\nCombined pre- and post-capillary PH Mean PAP >20 mmHg\nPAWP >15 mmHg PVR >_3 WU\nSettings listed under isolated post-capillary PH\nSettings listed under isolated post-capillary PH in combination with shunt lesions/complex CHD\nACHD = adult congenital heart disease; AV = atrioventricular; CHD = congenital heart disease; PAH = pulmonary arterial hypertension; PAP = pulmonary artery pressure; PAWP = pulmonary artery wedge pressure; PH = pulmonary hypertension; PVR = pulmonary vascular resistance; UVH = univentricular heart; WU = Wood units. a The most recent deﬁnition of PH 45  lowers mean PAP from >_25 mmHg 44  to >20 mmHg but additionally requires a PVR >_3 WU for pre-capillary PH.\nESC Guidelines 583\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................... anticoagulation and antiplatelet agents should be considered carefully on a case-by-case basis.\n3.4.3.3.4 Shunt repair. Because endothelial shear triggers PH, 52   surgical/interventional repair of conditions of increased flow are conceptualized to protect the pulmo- nary vasculature. The threshold PVR permitting reparative surgical clo- sure of a left-to-right (L \u0002 R) shunt without right heart failure differs for the different shunt lesions (see  sections 4.1 \u0002 4.4 ). However, the decision to close a shunt is made using all the available information and is not solely dependent on the haemodynamics obtained at cardiac catheter- ization; 53 , 54   the decision should only be taken in expert centres.\nThere is no prospective evidence that a treat-and-repair approach in patients with PAH-CHD confers long-term benefits. 44 , 55   No pro- spective data are available on the usefulness of vasoreactivity testing, closure test, or lung biopsy for assessment of operability. 53 , 54 , 56 \u0002 60\n3.4.3.3.5 Pulmonary arterial hypertension-directed medical therapy. Advanced therapies benefit patients with Eisenmenger syndrome, 51\nand likely also other PAH-CHD. 61 , 62   According to the 2015 ESC/ERS Guidelines on PH, 44 pre-capillary PH (PAH), including Eisenmenger syndrome, is a moderate- to high-risk condition and requires a proac- tive approach using initial 63   or sequential combination treatment, 64 , 65\nincluding parenteral prostacyclins. 44   Parenteral prostaglandins work best when started early. 66   The presence of a central intravenous catheter for parenteral therapy, however, increases the risk of para- doxical embolism and infection in Eisenmenger patients and those with R \u0002 L shunt lesions. In this setting, subcutaneous or inhaled forms of administration are therefore generally preferred.\nExclusions to this rule are patients with closed or coincidental defects meeting strict criteria for vasodilator responsiveness (mainly a decrease of mean PAP >10 mmHg and below 40 mmHg acutely under nitric oxide inhalation) who may be treated with calcium chan- nel blocker therapy only. However, such patients are extremely rare among adults with PAH-CHD. General vasoreactivity testing is not recommended in PAH-CHD. 44\nLong-term home oxygen therapy may improve symptoms but has not been shown to augment survival in Eisenmenger patients. The use of supplemental oxygen should be restricted to those cases in which it produces a documented, consistent, and significant increase in arterial oxygen saturation and improves symptoms. Secondary erythrocytosis is beneficial for adequate oxygen trans- port and delivery, and routine phlebotomy should be avoided; for more details see  section 3.4.8 . In Eisenmenger patients, the endothelin receptor antagonist (ERA) bosentan has been shown to improve 6MWT and decrease PVR after 16 weeks of treatment in World Health Organization (WHO) func- tional class III patients. 67   Although a beneficial effect of bosentan has been shown on exercise capacity and quality of life in this group of patients, an effect on mortality is less well documented. Long-term fol- low-up showed sustained improvement in symptoms. Experiences with other ERAs and the phosphodiesterase type 5 (PDE-5) inhibitors, sildenafil and tadalafil, show favourable functional and haemodynamic results in patients with PAH-CHD and Eisenmenger syndrome, with less robust evidence. Experience is limited for latest-generation PAH drugs such as macitentan, selexipag, or riociguat in the setting of CHD. 66   While patients with simple repaired lesions have been\nincluded in the landmark studies for these substances, and are likely to benefit similarly to idiopathic PAH patients, data are currently limited for Eisenmenger patients. A recent randomized controlled trial investi- gating efficacy of macitentan to improve 6MWT in Eisenmenger syn- drome was neutral. 68   Most centres follow a sequential symptom- orientated treatment strategy in Eisenmenger syndrome, generally starting with an oral ERA or PDE-5 inhibitor and escalating therapy if symptoms persist or in the case of clinical deterioration. Should an adequate improvement in symptoms not be achieved with oral ther- apy, parenteral options should be considered proactively.\nThe effect of PAH therapy in patients with segmental PAH remains a matter of debate. While some series reported promising results, there have been cases where therapies were not tolerated. 46\nHeart-lung or lung transplantation with heart surgery is an option in special cases not responsive to medical treatment but is limited by surgical complexity and organ availability.\n3.4.4 Surgical treatment Cardiac surgery in ACHD patients deserves special attention. Even small operations can carry a high risk due to the dysregulation of the delicate balance in which ACHD patients often thrive. This risk can- not be calculated using conventional surgical risk scores. The adult congenital heart surgery score was derived from the Society of\nRecommendations for treatment of pulmonary arterial hypertension associated with congenital heart disease\nRecommendations Class a Level b\nIt is recommended that patients with CHD and\nconﬁrmed pre-capillary PH c   are counselled against pregnancy.\nI C\nRisk assessment is recommended in all patients\nwith PAH-CHD. d I C\nIn low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH,\ninitial oral combination therapy or sequential\ncombination therapy is recommended and high- risk patients should be treated with initial com-\nbination therapy including parenteral prosta-\nnoids. e  63 \u0002 65\nI A\nIn Eisenmenger patients with reduced exercise\ncapacity (6MWT distance <450 m), a treatment\nstrategy with initial endothelin receptor antago- nist monotherapy should be considered fol-\nlowed by combination therapy if patients fail to\nimprove. 67 \u0002 69\nIIa B\n6MWT = 6-minute walk test; CHD = congenital heart disease; PAH-CHD = pul- monary arterial hypertension associated with congenital heart disease; PH = pul- monary hypertension. a Class of recommendation. b Level of evidence. c The risk of pregnancy in patients with pre-capillary PH is very high. It may be less in pregnancies of patients with post-capillary PH, therefore, a right heart cathe- terization is necessary in all patients with a suspicion of pre-capillary PH to con- ﬁrm the diagnosis. d For details see 2015 ESC/ERS Guidelines for diagnosis and treatment of PH. 44\ne For details about choice of drugs and the recommended risk-adjusted treatment algorithm see 2015 ESC/ERS Guidelines for diagnosis and treatment of PH. 44\n584 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ Thoracic Surgeons Congenital Heart Surgery Database as the first evidence-based score, designed specifically for surgery in ACHD. 70\nUpon evaluation, the score reached a good predictive power in ACHD, although the corresponding paediatric score performed bet- ter in children, 71   indicating that in ACHD, individual patients’ comor- bidities may play a more important role in determining outcomes. The ACHD mortality score, an expert-based score that accounts for comorbidities, may therefore also be considered for evaluating the risk of cardiac surgery in ACHD. 72\nApart from the need for personalized risk assessment, under- standing the specific anatomy and haemodynamics, experience with redo surgery, and special requirements in intensive care units are factors that determine short- and long-term outcomes. When ACHD patients are operated on by a congenital cardiac surgeon, outcome is proven to be superior. 73   Therefore, the strict recom- mendation is that all ACHD patients are operated on by a congeni- tal cardiac surgeon in a multidisciplinary environment with expertise in ACHD. This holds true for all ACHD cardiac surgery in the present recommendations except for surgery of uncompli- cated bicuspid aortic valve (BAV), heritable thoracic aortic disease (HTAD) such as Marfan syndrome, and secundum-type ASD with- out anomalous pulmonary venous connection and/or absence of PVD. The multidisciplinary expert environment also favours the growing interest in, and need for, hybrid procedures, where (con- genital) cardiac surgeons, vascular surgeons, interventional congen- ital cardiologists, and electrophysiologists collaborate in technically challenging procedures.\n3.4.5 Catheter intervention Catheter-based interventions, either as stand-alone or hybrid proce- dures, are an appealing alternative to conventional open-heart sur- gery, obviating the need for redo sternotomy/thoracotomy and cardiopulmonary bypass. The most frequent percutaneous interven- tions are closure of shunt lesions (in particular secundum-type ASD, rarely VSD, and persistent arterial duct), fistula, or unusual collaterals; balloon dilatation of the pulmonary valve and valved grafts; balloon dilatation and/or stenting of narrowed great vessels [e.g. (re-coarcta- tion of the aorta (CoA) and pulmonary arterial stenosis]; and trans- catheter pulmonary valve implantation (TPVI). ACHD diagnosis and, in particular, interventional care should be delivered by people who are trained as CHD caregivers and are part of an ACHD care centre, where individual procedures are reviewed and discussed within a multidisciplinary team. 74   It is of particular importance that a pro- gramme performing transcatheter interventions in ACHD patients should be co-located with appropriate congenital cardiac services for the management of procedural complications. In many programmes, experienced paediatric interventional cardiologists form an impor- tant component of ACHD intervention services, but in others (e.g. those based in a separate paediatric hospital), paediatric intervention- alists may be uncomfortable with the interventional management of adults with congenital cardiac problems. Therefore, full collaboration between adult and paediatric cardiology is recommended. Concentration of ACHD catheterization in a limited number of des- ignated centres allows quality assurance as well as co-location of key cardiovascular services. 74   Minimum annual numbers of interventions per centre have been proposed in a recent recommendation paper. 74\n3.4.6 Infective endocarditis The risk of infective endocarditis (IE) in ACHD patients is higher than in the general population, with marked variation between lesions. The 2015 ESC Guidelines on IE maintain the restriction of antibiotic prophylaxis to patients at high risk of IE undergoing at-risk dental pro- cedures. 22   High-risk conditions are prosthetic valves, including trans- catheter valves, valve repair using a prosthetic ring, previous IE, any cyanotic CHD, and any CHD repaired with prosthetic material up to 6 months after the procedure or lifelong if residual shunt or valvular regurgitation remains.\nNon-specific hygiene measures should be applied in all ACHD patients: good oral and cutaneous hygiene, and aseptic measures dur- ing healthcare and any invasive procedure. Piercings and tattoos are discouraged and otherwise should be performed in optimal hygienic conditions. All patients need to be educated about symptoms of IE and appro- priate behaviour (seeking medical advice, importance of blood cul- tures before starting antibiotic treatment) at occurrence of such symptoms. Recent studies confirmed the relatively high risk of IE in patients after valve surgery, particularly previous IE and bovine jugular vein conduits. 75 \u0002 78   Specific awareness is needed after TPVI using a Melody valve prosthesis. 75\n3.4.7 Antithrombotic treatment Patients with ACHD are at increased risk of thromboembolic events, but evidence on prevention is limited. In patients with IART or AF, the CHA 2 DS 2 -VASc and HAS-BLED scores have proven beneficial in adult patients with acquired heart disease. 38   However, as their valid- ity in the CHD population is uncertain, the scores should only be used in combination with individually assessed risks. Traditionally, VKAs are used for thromboembolic prevention, but in general cardi- ology, NOACs are currently recommended in preference to VKA. Also, in the CHD population, NOACs seem similarly safe and effec- tive, in the absence of mechanical valves or severe mitral valve steno- sis. 79 , 80   Anticoagulation therapy is recommended in paroxysmal and persistent AF/IART in patients with moderate or severe CHD, but an individualized approach remains necessary. In patients with mild CHD, the CHA 2 DS 2 -VASc and HAS-BLED scores 38   should be used as per general recommendations. 81   Whether all Fontan patients ben- efit from anticoagulation is unclear at the moment. Bleeding risk should also be considered and weighed against thrombogenic risk, especially in cyanotic patients. For secondary prevention, anticoagula- tion is recommended in patients with a thromboembolic event or incidental intracardiac or intravascular thrombus (see also 2017 ESC/ EACTS Guidelines on valvular heart disease and 2018 ESC Guidelines on pregnancy).\n3.4.8 Management of cyanotic patients Cyanosis is caused by R \u0002 L shunt due to an anatomical communica- tion between the systemic and pulmonary circulation at the atrial, ventricular, or arterial level. Cyanotic heart disease comprises a het- erogeneous group of lesions with different underlying anatomy and pathophysiology: normal or restricted pulmonary blood flow in the presence of an obstruction across the pulmonary outflow tract or increased pulmonary blood flow in the absence of such an obstruc- tion which, in some defects, may result in development of PAH and\nESC Guidelines 585\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ eventually Eisenmenger syndrome (see  sections 3.4.3  and  4.15 ). They may present with or without prior palliative intervention. Cyanotic patients are complex and must be followed by an ACHD specialist.\n3.4.8.1 Adaptive mechanisms Cyanosis induces adaptive mechanisms to improve oxygen transport and delivery to the tissue: secondary erythrocytosis, rightward shift of the oxyhaemoglobin dissociation curve, and increase in cardiac output. 82 , 83   Erythrocytosis secondary to erythropoietin stimulus is the physiological response to chronic hypoxaemia.  Compensated erythrocytosis reflects an equilibrium and  decompensated  erythrocy- tosis indicates failure of an equilibrium (excessive red blood cell/hae- moglobin increase and unstable, rising haematocrit with major hyperviscosity symptoms). 82 , 84\n3.4.8.2 Multisystem disorder Cyanosis and secondary erythrocytosis imply profound consequen- ces for the entire organ system: 82 , 84 , 85\n•   Blood viscosity is increased and is directly related to red blood cell mass. 84\n•   Haemostatic abnormalities are common and complex and are attributed to abnormalities in platelets (thrombocytopaenia and thrombasthenia), coagulation pathways, and other abnormal coagulation mechanisms. Vitamin K-dependent clotting factors and factor V are reduced, fibrinolytic activity is increased, and the largest von Willebrand multimers are depleted. •   Increased turnover of red blood cells/haemoglobin and impaired urate filtration lead to hyperuricaemia. 86   The increased concen- tration of unconjugated bilirubin puts cyanotic patients at risk for calcium bilirubinate gallstones. •   Severe endothelial dysfunction is evident by the striking impair- ment of endothelium-dependent vasodilation. 85\n•   Chronic hypoxaemia, increased blood viscosity, and endothelial dysfunction affect microcirculation, myocardial function, and the function of other organ systems.\n3.4.8.3 Clinical presentation and natural history Clinical presentation includes central cyanosis, a result of an increased quantity of reduced haemoglobin (>5 g/100 mL blood), clubbing, and frequently scoliosis. The underlying anatomy/patho- physiology characterizes cardiac findings. Mortality is significantly higher in cyanotic patients than in acyanotic patients. 87   Outcome is determined by the underlying anatomy, patho- physiology, palliative procedures, complications of cyanosis, and preventive measures. 88 , 89   Low platelet count, severe hypoxia, cardio- megaly, and elevated haematocrit during childhood are parameters to predict premature death and adverse events in patients with and with- out PVD. 90   Iron deficiency is associated with adverse late outcome; 91 , 92\nBNP can predict outcome in Eisenmenger patients. 93 , 94   However, in a multicentre study, 89   only age, pre-tricuspid shunt, absence of sinus rhythm, lower oxygen saturation at rest, and presence of pericardial effusion, but not BNP, were the strongest predictors for death.\n3.4.8.4 Late complications\n•   Hyperviscosity symptoms include headache, faintness, dizziness, fatigue, tinnitus, blurred vision, paraesthesia of fingers, toes, and\nlips, muscle pain, and weakness (classified moderate when they interfere with some activities, severe when they interfere with most activities). 82 , 83   Hyperviscosity symptoms are unlikely in an iron-replete patient with haematocrit <65%. •   Bleeding and thrombotic diathesis occur; both cause a therapeu- tic dilemma (risks of thrombosis and bleeding). Spontaneous bleeding is usually minor, self-limiting (dental bleeding, epistaxis, easy bruising, menorrhagia). Haemoptysis is the most common major bleeding event and is an external manifestation of an intra- pulmonary haemorrhage not reflecting the extent of parenchy- mal bleeding (reported in up to 100% of Eisenmenger patients). 95 , 96   Thrombosis is caused by coagulation abnormalities, stasis of blood in dilated chambers and vessels, atherosclerosis and/or endothelial dysfunction, the presence of thrombogenic material (e.g. conduits), and arrhythmias. The haemostatic abnor- malities do not protect against thrombotic complications. Laminated thrombi in large, partially calcified and aneurysmal PAs are common (up to 30%). 97 \u0002 100   Female sex, low oxygen satura- tion, older age, biventricular dysfunction, and dilated PAs have been identified as risk factors. 97 , 100 , 101\n•   Cerebrovascular infarctions are common, but underreported. 97\nThey may be caused by thromboembolic events (paradoxical embolism, supraventricular arrhythmia), rheological factors (microcytosis), endothelial dysfunction, and traditional athero- sclerotic risk factors. The severity of secondary erythrocytosis is not in itself a risk factor. 102   Microcytosis caused by iron defi- ciency, due to inappropriate phlebotomies, was the strongest independent predictor for cerebrovascular events in one study. 91\nSeverity of cyanosis and CHD complexity are other risk factors. 97\n•   Paradoxical emboli may be caused by transvenous leads or catheters. •   Iron deficiency is frequently caused by, and may be exacerbated by, inappropriate phlebotomies or heavy menstruation in female patients. •   Arrhythmias  \u0002  supraventricular and ventricular. •   Infectious complications include endocarditis, cerebral abscess, and pneumonia. Fever, associated with a new or different head- ache, raises suspicion of a brain abscess. •   Renal dysfunction is common and is due to functional and struc- tural abnormalities of the kidneys. •   Cholelithiasis is common and can be complicated by cholecysti- tis/choledocholithiasis. •   Rheumatological complications include gouty arthritis, hypertro- phic osteoarthropathy, and kyphoscoliosis. 83\n3.4.8.5 Diagnostic aspects Particular attention must be paid to hyperviscosity symptoms and bleeding/ischaemic complications. Oxygen saturation must be obtained with pulse oximetry at rest for at least 5 min, and exercise capacity should be assessed on a regular basis, preferably with a 6MWT. Blood work must include cellular blood count, mean corpuscular volume (MCV), serum ferritin (serum iron, iron saturation, transfer- rin, and transferrin saturation may be required for earlier detection of iron deficiency), creatinine, serum uric acid, clotting profile, BNP/ NT-pro-BNP, folic acid, and vitamin B12 in the presence of elevated MCV or normal MCV and low serum ferritin.\n586 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ......................................................................................................... 3.4.8.6 Laboratory precautions\n•   Coagulation parameters: plasma volume is reduced due to sec- ondary erythrocytosis; the amount of sodium citrate must be adjusted to haematocrit if haematocrit is >55%. •   Haematocrit determined with automated electronic particle counts (micro-haematocrit centrifugation) results in falsely high haematocrit due to plasma trapping. •   Glucose level can be reduced (increased in vitro glycolysis, which results from the increased number of erythrocytes).\n3.4.8.7 Indications for intervention Risk and benefit must be carefully considered and require expertise. Cyanotic patients without PAH/Eisenmenger syndrome must be periodically evaluated for any procedure that may improve quality of life and reduce morbidity, or for eligibility for physiological repair (see section 4.15 ).\n3.4.8.8 Medical therapy •   Specific PAH treatment: see  section 3.4.3 . •   Arrhythmias: sinus rhythm should be maintained whenever possi- ble. Antiarrhythmic therapy must be individualized (medications, ablation, epicardial PM/ICD). Antiarrhythmic therapy is extremely difficult; drug therapy should be initiated with particu- lar care and generally in a hospital. •   Therapeutic phlebotomy should only be performed in the pres- ence of moderate/severe hyperviscosity symptoms due to secon- dary erythrocytosis (haematocrit at least >65%), in the absence of dehydration and iron deficiency. 82   Isovolumetric fluid replace- ment (750 \u0002 1000 mL of isotonic saline while removing 400 \u0002 500 mL of blood) should be undertaken. •   Blood transfusion may be required in the presence of iron- replete anaemia (haemoglobin inadequate to oxygen saturation) and should not be based on conventional indications.\n•   Iron supplementation should be performed in the presence of iron deficiency (MCV <80 fL, low iron stores) and carefully fol- lowed (rebound effect). •   Routine anticoagulation/aspirin: currently available data do not sup- port any benefit in cyanotic patients to prevent thromboembolic complications. There is, however, an increased risk of bleeding. •   Indication for anticoagulation: atrial flutter/AF (target INR 2 \u0002 2.5; higher target INR in the presence of other risk factors). Note lab- oratory precautions: false high INR values are measured due to the high haematocrit. There are no data and only anecdotal expe- riences about the use of NOACs (see also  section 3.4.7 ). •   Haemoptysis: requires chest computed tomography if there is an infiltrate on the chest X-ray. Bronchoscopy puts the patient at risk and seldom provides useful information. Therapy includes discontinuation of aspirin, non-steroidal anti-inflammatory agents, oral anticoagulants; treatment of hypovolaemia and anae- mia; reduction of physical activity; and suppression of non- productive cough. Selective embolization of bronchial arteries may be required for refractory intrapulmonary haemorrhage/ haemoptysis. Antifibrinolytic agents (e.g. inhaled tranexamic acid) are under investigation and may be a novel approach to treat haemoptysis. 103   More trials are needed. •   Hyperuricaemia: no indication to treat asymptomatic hyperuricaemia. •   Acute gouty arthritis (atypical presentation) is treated with oral or intravenous colchicine, probenecid, and anti-inflammatory drugs, with attention paid to the risk of renal failure and bleeding. Uricosuric (e.g. probenecid) or uricostatic agents (e.g. allopuri- nol) avoid recurrence.\n3.4.8.9 Follow-up recommendations All cyanotic patients require lifelong evaluation with follow-up visits every 6 \u0002 12 months in a specialized ACHD centre in close collabora- tion with the family physician. Evaluation includes:\nTable 9 Risk reduction strategies in patients with cyanotic congenital heart disease\nProphylactic measures are the mainstay of care to avoid complications. 83\nThe following exposures/activities should be avoided: Other risk reduction strategies include: •   Pregnancy in patients with Eisenmenger syndrome and in cyanotic\npatients without PAH, but arterial oxygen saturation <90% •   Use of an air ﬁlter in an intravenous line to prevent air embolism\n•   Iron deﬁciency and anaemia (no routine, inappropriate phlebotomies\nto maintain a pre-determined haemoglobin)  \u0002  treat iron deﬁciency\nand iron-deﬁcient anaemia\n•   Consultation with an ACHD cardiologist before administration of any agent\nand performance of any surgical/interventional procedure\n•   Inappropriate anticoagulation •   Prompt antibiotic therapy of upper respiratory tract infections •   Dehydration •   Cautious use or avoidance of agents that impair renal function •   Infectious disease: administer inﬂuenza and pneumococcal vaccines •   Contraceptive advice at each clinic visit •   Cigarette smoking, recreational drug abuse including excessive alcohol •   Transvenous PM/ICD leads •   Strenuous exercise •   Acute exposure to heat (sauna, hot tub, or hot shower) or extreme cold •   Oestrogen-containing contraception\nCHD = congenital heart disease; ICD = implantable cardioverter deﬁbrillator; PAH = pulmonary arterial hypertension; PM = pacemaker.\nESC Guidelines 587\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ •   Comprehensive evaluation and systematic review of potential complications. •   Blood tests (see  section 3.4.8.8 ) •   Education about risk reduction strategies ( Table  9 ).\n3.4.8.10 Additional considerations\n•   Air flight: commercial air travel is well tolerated. 104 , 105 Risk- reduction strategies include avoidance of travel- and non-travel- related stress, dehydration, alcoholic drinks, and measures to prevent deep vein thrombosis. •   Exposure to high altitude: acute exposure to high altitude (>2500 m) should be avoided. Gradual ascent up to 2500 m may be tolerated. •   Pregnancy :  pregnancy in cyanotic patients, without PH, results in significant maternal and foetal complications and requires follow- up by a Pregnancy Heart Team. Oxygen saturation (>85%) and haemoglobin (<200 g/L) before pregnancy were the strongest predictors for live birth in one series. 106   Pregnancy should be strongly discouraged in Eisenmenger syndrome and in cyanotic patients without PAH, but an arterial oxygen saturation <90% 43\n(see  section 3.5.7 ). •   IE prophylaxis: recommended in all patients (see  section 3.4.6 ).\n",
      "keywords": [
        "risk factor",
        "ejection fraction",
        "should be considered",
        "smoking",
        "echo",
        "older",
        "problem",
        "secondary prevention",
        "bradycardia",
        "crt",
        "sudden cardiac death",
        "valve repair",
        "genetic",
        "physical activity",
        "heart",
        "considerations",
        "pacemaker",
        "tachycardia",
        "anticoagulation",
        "therapeutic",
        "age",
        "glucose",
        "tricuspid",
        "death",
        "hypertension",
        "main",
        "scd",
        "incidence",
        "risk stratification",
        "nyha"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 581",
          "page_number": 18,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with moderate and severe CHD com-\nplexity (Table 4) and documented arrhythmias,\nreferral to a centre with a multidisciplinary team\nand expertise in ACHD patients and ACHD-\nrelated arrhythmia is indicated. | I | C | \nIn CHD patients with documented arrhythmias\nor at high risk for post-procedural arrhythmias\n(e.g. ASD closure at older age) considered for\npercutaneous or surgical (re)interventions,\nreferral to a centre with a multidisciplinary team\nwith expertise in these interventions and in inva-\nsive treatment of arrhythmias is indicated. | I | C | \nIn mild CHD, catheter ablation is recommended\nover long-term medical therapy for sympto-\nmatic, sustained recurrent SVT (AVNRT, AVRT,\nAT, and IART), or if SVT is potentially related to\nSCD (Table 7). | I | C | \nIn moderate and severe CHD, catheter ablation\nshould be considered for symptomatic, sustained\nrecurrent SVT (AVNRT, AVRT, AT, and IART),\nor if SVT is potentially related to SCD (Table 7),\nprovided that the procedure is performed in\nexperienced centres. | IIa | C | ",
          "bbox": [
            311.4618265252364,
            413.0252207438151,
            556.4978748668324,
            716.8151441301618
          ],
          "function_potential": "raw"
        },
        {
          "title": "582 ESC Guidelines",
          "page_number": 19,
          "content": "Catheter ablation is indicated as adjunctive ther-\napy to ICDs in patients who present with recur-\nrent monomorphic VT, incessant VT, or\nelectrical storm not manageable by medical ther-\napy or ICD reprogramming. | I | C | \nCatheter ablation should be considered for\nsymptomatic, monomorphic sustained VT in\npatients for whom medical therapy is not\ndesired, provided that the procedure is per-\nformed in experienced centres. | IIa | C | \nImplantable cardiac defibrillator |  |  | \nICD implantation is indicated in adults with\nCHD who are survivors of an aborted cardiac\narrest due to VF or haemodynamically untoler-\nated VT after evaluation to define the cause of\nthe event and exclusion of reversible causes. | I | C | \nICD implantation is indicated in adults with\nCHD and sustained VT after haemodynamic\nevaluation and repair when indicated. EP evalua-\ntion is required to identify patients in whom\ncatheter ablation or surgical ablation may be\nbeneficial as adjunctive treatment or in whom it\nmay offer a reasonable alternative. | I | C | \nICD implantation should be considered in adults\nwith CHD with biventricular physiology and a\nsystemic LV presenting with symptomatic heart\nfailure (NYHA II/III) and EF <35% despite > 3\n_ _\nmonths of optimal medical treatment, provided\nthey are expected to survive substantially longer\nthan one year with good functional status.c | IIa | C | \nICD implantation should be considered in\npatients with CHD and unexplained syncope\nand suspicion for arrhythmia aetiology and\neither advanced ventricular dysfunction or indu-\ncible VT/VF at programmed electrical\nstimulation. | IIa | C | \nICD implantation should be considered in\nselected TOF patients with multiple risk factors\nfor SCD, including LV dysfunction, non-sus-\ntained, symptomatic VT, QRS duration >180 ms,\n_\nextensive RV scarring on CMR, or inducible VT\nat programmed electrical stimulation. | IIa | C | \nICD implantation may be considered in patients\nwith advanced single or systemic RV dysfunction\n(EF systemic RV <35%) in the presence of addi-\ntional risk factors.d | IIb | C | \nPacemaker |  |  | \nPM implantation should be considered in ACHD\npatients with bradycardia-tachycardia syndrome\nto prevent IART, if ablation fails or is not\npossible. | IIa | C | \nPM implantation should be considered for\npatients with severe CHD and sinus or | IIa | C | ",
          "bbox": [
            42.45112465523385,
            59.87801892416818,
            287.6030126953125,
            710.1312648228237
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "582 ESC Guidelines",
          "page_number": 19,
          "content": "junctional bradycardia (daytime heart rate <40\nbeats per minute or pauses >3 s). |  | \nPM implantation should be considered for\npatients with CHD and compromised haemody-\nnamics due to sinus bradycardia or loss of AV\nsynchrony. | IIa | C\nPM implantation may be considered for patients\nwith moderate CHD and sinus or junctional bra-\ndycardia (daytime heart rate <40 beats per\nminute or pauses >3 s). | IIb | C",
          "bbox": [
            306.79405364990237,
            59.87801892416818,
            549.7761840820312,
            182.6860580444336
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 583",
          "page_number": 20,
          "content": "Pulmonary Hypertension in Adult Congenital Heart Disease\n.................................................................................................................................................................................................................... |  |  |  |  | \nDefinition |  | Haemodynamic characteristicsa |  | Clinical settings | \nPulmonary Hypertension (PH) |  | Mean PAP >20 mmHg |  | All | \nPre-capillary PH (PAH) |  | Mean PAP >20 mmHg\nPAWP <15 mmHg\n_\nPVR >3 WU\n_ |  | Shunt lesions prior to and after repair (including Eisenmenger syndrome)\nComplex CHD (including UVH, segmental PAH) | \nIsolated post-capillary PH |  | Mean PAP >20 mmHg\nPAWP >15 mmHg\nPVR <3 WU |  | Systemic ventricular dysfunction\nSystemic AV valve dysfunction\nPulmonary vein obstruction\nCor triatriatum | \nCombined pre- and post-capillary PH |  | Mean PAP >20 mmHg\nPAWP >15 mmHg\nPVR >3 WU\n_ |  | Settings listed under isolated post-capillary PH\nSettings listed under isolated post-capillary PH in combination\nwith shunt lesions/complex CHD | ",
          "bbox": [
            48.13582556588309,
            81.29803466796875,
            553.869992463485,
            253.50297685102984
          ],
          "function_potential": "raw"
        },
        {
          "title": "584 ESC Guidelines",
          "page_number": 21,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIt is recommended that patients with CHD and\nconfirmed pre-capillary PHc are counselled\nagainst pregnancy. | I | C\nRisk assessment is recommended in all patients\nwith PAH-CHD.d | I | C\nIn low- and intermediate-risk patients with\nrepaired simple lesions and pre-capillary PH,\ninitial oral combination therapy or sequential\ncombination therapy is recommended and high-\nrisk patients should be treated with initial com-\nbination therapy including parenteral prosta-\nnoids.e 63\u000265 | I | A\nIn Eisenmenger patients with reduced exercise\ncapacity (6MWT distance <450 m), a treatment\nstrategy with initial endothelin receptor antago-\nnist monotherapy should be considered fol-\nlowed by combination therapy if patients fail to\nimprove.67\u000269 | IIa | B",
          "bbox": [
            306.9268421373869,
            286.3163604736328,
            549.2560706505409,
            530.0752476283482
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 587",
          "page_number": 24,
          "content": "83 |  |  | \nProphylactic measures are the mainstay of care to avoid complications. |  |  | \n |  |  | \nThe following exposures/activities should be avoided: | Other risk reduction strategies include: |  | \n• Pregnancy in patients with Eisenmenger syndrome and in cyanotic\npatients without PAH, but arterial oxygen saturation <90% | • Use of an air filter in an intravenous line to prevent air embolism |  | \n• Iron deficiency and anaemia (no routine, inappropriate phlebotomies\nto maintain a pre-determined haemoglobin) \u0002 treat iron deficiency\nand iron-deficient anaemia | • Consultation with an ACHD cardiologist before administration of any agent\nand performance of any surgical/interventional procedure |  | \n• Inappropriate anticoagulation | • Prompt antibiotic therapy of upper respiratory tract infections |  | \n• Dehydration | • Cautious use or avoidance of agents that impair renal function |  | \n• Infectious disease: administer influenza and pneumococcal vaccines | • Contraceptive advice at each clinic visit |  | \n• Cigarette smoking, recreational drug abuse including excessive alcohol |  |  | \n• Transvenous PM/ICD leads |  |  | \n• Strenuous exercise |  |  | \n• Acute exposure to heat (sauna, hot tub, or hot shower) or extreme\ncold |  |  | \n• Oestrogen-containing contraception |  |  | ",
          "bbox": [
            48.12266445159912,
            510.20799255371094,
            553.4280520708134,
            714.4230270385742
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "20",
      "title": "3.5 Additional considerations 3.5.1 Sex differences Women have been appropriately included in trials, and sex-stratified analyses are available to some extent. Data regarding sex difference on prevale",
      "start_page": 25,
      "end_page": 27,
      "content": "Whether these differences relate to genetic and inherent biological difference, smaller body size, or other not yet defined differences warrants further exploration. 112\nSex differences are important for diagnostic evaluation and clinical decision making. Although recommendations are usually not sex spe- cific, body surface area (BSA)-normalized cut-offs of aortic and car- diac chamber dimensions may correct for smaller BSA in women. 113\nPersonalized counselling is essential in women contemplating preg- nancy, as indications for intervention in females may set lower abso- lute values for aortic surgery (hereditary/CHD-associated aortopathy) or for pulmonary valve replacement (PVRep) in patients with TOF. 112\nThere are data showing different impacts for men than women for employment, 114   gaps in medical care, 115   and physical activity. 116\nClinical evaluation, decision making, and counselling may require tai- loring to the individual to help ensure equity of outcomes.\n3.5.2 Adult congenital heart disease at more advanced age To date,  \u0003 90% of patients with mild, 75% with moderate, and 40% with complex heart defects reach the age of 60 years. 117   These proportions are expected to rise further in the upcoming decades. Hence, there is a growing population of older persons with CHD and unique healthcare needs. These older patients are\ncharacterized by more comorbidities, inherent age-related risk for arrhythmia (especially AF), accelerated ageing, acquired disease, changed responses to medication, earlier onset of geriatric syn- dromes (e.g. cognitive decline, immobility/falls, failure to thrive, sensory alterations), and an altered psychosocial profile. 118 , 119\nDedicated guidelines for older patients with CHD ought to be consulted to provide adequate care to this more vulnerable patient population. 120   The onset of acquired diseases starts early in life, therefore, prevention strategies ought to be implemented in the first decades of life (at paediatric cardiology).\n3.5.3 Advance care planning and end-of-life care Most patients, independent of defect complexity, wish to discuss life expectancy prior to being confronted with life-threatening complications. 121   Such complications may occur during high-risk interventions or reflect an uncertain illness trajectory. Timely dis- cussion of advance care planning is a critical component of patient-centred, comprehensive care. 121 , 122   Initiation of this demanding conversation is difficult. Unplanned hospital admis- sions, ICD insertion, or functional decline can serve as a trigger for such conversations. Most patients do not start advance care planning discussions on their own and wait for the provider’s initiative. The content of advance care planning discussions depends on the patient’s physical and psychological health and preferences. Initially, discussion about life expectancy and treat- ment preferences may be all the patient wants. With deteriorat- ing health, a holistic assessment of the patient’s wishes and values, advance directives, nomination of a surrogate decision maker, and decisions regarding device therapies in ICD patients are required.\nDuring the process of care, active disease-specific treatment may progressively become supported and eventually substituted by pallia- tive care. Involvement of palliative care specialists can be supportive. At any time, it is important to emphasize that active disease-specific care might continue during the advance care planning process, even near the end of life, keeping in line with patients’ preferences and goals. The role of palliative care and family support continues after the patient’s death in managing bereavement care. 123\nWhenever possible, family members should be involved in all steps. Patient preferences can change over time and periodic re- evaluation of the patient’s wishes is necessary.\n3.5.4 Insurance and employment For ACHD patients, it is often difficult to obtain life-, health-, or travel insurance, and mortgages. 124 \u0002 126   If insurance is granted, patients fre- quently need to pay an extra charge or the heart defect as a pre- existing condition excludes them from insurance. In general, obtain- ing insurance or not, and the higher fee, are mostly unrelated to the complexity of the defect, the functional status of the patient, or the prognosis, 124 , 126   but are rather a function of the policies of insurance companies and reflect a large inter- and intra-country variation. Patients currently need to shop around, and both clinicians and patient associations may be of help. Insurability is a definite issue that should be discussed during patient counselling. Also, employment, in particular the requirements for specific professions, needs atten- tion. 127   Starting in adolescence, choices about education should be\n588 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ made based on the possibilities to perform heavy exercise and work night shifts, and the use of specific medication such as oral anticoagulation.\n3.5.5 Exercise and sports Recommendations for exercise and sports need to be based on the underlying congenital heart defect and its potential complications, the haemodynamic and EP status of the patient, and their pre-existing fit- ness. 24   Counselling must consider the type of sport and the anticipated effort levels. In general, physicians have been over-conservative in their advice, especially as physical activity has well-documented benefits for fitness, psychological well-being, and social interaction, as well as a posi- tive effect on the future risk of acquired heart disease; symptoms do not exclude physical activity. Dynamic exercise is more suitable than static exercise. In addition, in patients with known cardiac conditions, complications during exercise, including SCD, are rare. 128\nRecommendations for participation in low- to high-intensity sports are discussed in the position paper of Budts  et al . 24   Guidelines on elite sports in athletes with CHD are described in the 2020 ESC Guidelines on sports cardiology. 129   Assessment of physical exercise capacity should be done before recommending recreational exercise or sport in order to avoid intense exercise in untrained patients. Most patients with CHD can safely engage in regular, moderate physical activity. A few conditions, such as systemic ventricular systolic dysfunction, sys- temic ventricular outflow tract obstruction, PH, haemodynamically sig- nificant arrhythmias, or aortic dilation, warrant more caution.\n3.5.6 Non-cardiac surgery The evaluation and management of ACHD patients should follow the principles of the 2014 ESC Guidelines on non-cardiac surgery 130\nand consider the specificities of CHD. Factors associated with increased risk of perioperative morbidity and mortality are cyanosis, congestive heart failure, poor general health, younger age, PH, opera- tions on the respiratory and nervous systems, complex CHD, and urgent/emergency procedures. In patients with complex CHD (Fontan, Eisenmenger syndrome, cyanotic patients), non-cardiac sur- gical and interventional procedures should be performed in an expert centre. 130 , 131   Issues to consider are endocarditis prophylaxis, compli- cations related to underlying haemodynamics, abnormal venous and/ or arterial anatomy affecting venous and arterial access, persistent shunts, valvular disease, arrhythmias including bradyarrhythmias, erythrocytosis, pulmonary vascular disease (PVD), prevention of venous thrombosis, monitoring of renal and liver function, periproce- dural anticoagulation, possible need for non-conventional drug dos- ing, increased prevalence of hepatitis C infection because of prior procedures and remote blood transfusions and, finally, developmen- tal disability.\n3.5.7 Pregnancy, contraception, and genetic counselling 3.5.7.1 Pregnancy and contraception The majority of ACHD patients tolerate pregnancy well, but women with complex CHD have higher risks. Detailed ESC Guidelines on pregnancy and heart disease were published in 2018. 43\nPre-pregnancy counselling should be provided to all women with CHD. Specialist care is best provided in a multidisciplinary team set- ting by the Pregnancy Heart Team. This team should have input from\nACHD cardiology, obstetrics, and anaesthesia, and where necessary from other specialists, including clinical geneticists. The team should be involved in all patients with at least moderate to complex heart disease before pregnancy for timely counselling and advice during pregnancy in order to plan antenatal care, including delivery and post-partum follow-up and need for cardiac monitoring. Risk estima- tion should be individualized and based on the modified WHO (mWHO) classification ( Table  10 ). 43\nFunctional status before pregnancy, ventricular function, severity of the lesions, and history of previous cardiac events are also of prog- nostic value. 132   CPET performed before conception can predict maternal and neonatal outcomes. A blunted heart rate response to exercise is associated with a higher risk of maternal cardiac and neo- natal adverse events.\nMaternal mortality is 0 \u0002 1% and heart failure complicates pregnancy in 11% of women with heart disease, with PAH being associated with the highest risks. 133 , 134   Cyanosis poses a significant risk to the foetus, with live birth unlikely (<12%) if oxygen saturation is <85%. 106\nWomen with cardiac disease also have an increased risk of obstet- ric complications, including premature labour, pre-eclampsia, and postpartum haemorrhage. 135   The potential for drugs affecting the foetus should always be considered; angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), in par- ticular, should not be used. Women requiring oral anticoagulation deserve special attention. VKAs are teratogenic, especially at higher doses. A dose-adjusted treatment algorithm is proposed in the 2018 ESC Guidelines on pregnancy. 43\nThe pregnancy duration and mode of delivery should be decided by the Pregnancy Heart Team, taking the CHD severity into account. Contraception should be discussed in a timely fashion with specific attention to effectiveness and safety. 136   Barrier methods are safe and protect against sexually transmitted diseases, however, they only have a high contraceptive efficacy with compliant couples. Hormonal contraceptives are highly efficacious, but there are few data on their safety in the ACHD population. The combined oral contraceptive is highly effective (99.9%), but is best avoided in patients with a pre- existing thrombotic risk (cyanosis, Fontan physiology, mechanical valves, prior thrombotic events, PAH), especially as there are few data to suggest that concomitant oral anticoagulation therapy will negate this risk. Progesterone-only contraceptives, on the other hand, do not pose such a high thrombosis risk, and newer prepara- tions available for oral administration or with intrauterine implants have a high efficacy (>95%). The risk of endocarditis after insertion of progesterone-coated intrauterine devices is probably low. However, there is a risk of vasovagal reactions (5%) at the time of insertion or removal. Patients with a fragile physiology (e.g. patients with a Fontan circulation, PH, cyanotic CHD, Eisenmenger syndrome) should have their intrauterine device inserted/removed in a safe environment (i.e. in an environment with expertise in ACHD). Female sterilization or male partner sterilization should only be considered after careful dis- cussion, with particular reference to long-term prognosis.\nAssisted reproduction has added risks above those of pregnancy alone, and consultation with an ACHD specialist must be performed before treatment. Superovulation is prothrombotic and can be com- plicated by ovarian hyperstimulation syndrome, with marked fluid shifts and an even greater risk of thrombosis. 137   The risk of ovarian\nESC Guidelines 589\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ...........\nhyperstimulation syndrome can be reduced by careful cycle monitor- ing, using low-dose follicle-stimulating hormone in combination with a gonadotropin-releasing hormone antagonist, freezing all embryos, and only transferring a single embryo. The last option is strongly advised in women with heart disease, since conceiving a multiple pregnancy is associated with greater cardiovascular changes and more maternal and foetal complications. 138   Pregnancy and fertility treatment are contraindicated in women with mWHO classification of maternal cardiovascular risk class IV. 43   In women with mWHO class III, or those who are anticoagulated, the risk of superovulation is very high and the alternative of natural cycle  in vitro  fertilization should be considered.\nSexuality is an important element of quality of life. The few avail- able data suggest that sexual function is a concern in both women and men and should be discussed more often. 139\n3.5.7.2 Genetic counselling and recurrence risk Genetic counselling, whether supplemented with further genetic testing or not, should at least be considered for every ACHD patient. Demonstrating a genetic abnormality can be important to further adjust the patient’s own management and is evidently also important for family planning. It is estimated that 10 \u0002 30% of all structural CHD would have a genetic basis. This rate is higher in cases of associated organ disorders and familial occurrence, and lower in isolated cases. With the rapid technical progress and possibilities of genetic testing, the reliability of these tests is further improving. Naturally, genetic elaboration in each patient must be multidisciplinary, with integration of necessary clinical data and adequate interpretation of found genetic variants. A detailed consensus document on this subject, pro- viding an algorithm for genetic testing and an overview of the main syndromes to consider, has recently been published. 140\nOne of the important and specific aspects of genetic counselling is the assessment of recurrence risk, which needs consideration in both men and women. The recurrence rate of CHD in offspring ranges\nfrom 2 \u0002 50% and is higher in affected women than men. The highest recurrence risks are found in single gene disorders and/or chromoso- mal abnormalities such as Marfan, Noonan, 22q11 deletion syn- drome, and Holt-Oram syndrome. Among patients with isolated,\nTable 10 Congenital heart disease with high risk and extremely high risk for pregnancy\nSignificantly increased risk of maternal mortality or severe morbidity (mWHO class III) (cardiac event rate 19 \u0002 27 % )\nExtremely high risk of maternal mortality or severe mor- bidity (mWHO class IV) a   (cardiac event rate 40 \u0002 100 % )\nUnrepaired cyanotic heart disease Pulmonary arterial hypertension\nModerate LV impairment (EF 30 \u0002 45%) Severe LV impairment (EF <30% or NYHA class III \u0002 IV)\nSystemic RV with good or mildly decreased ventricular function Systemic RV with moderate or severely decreased ventricular\nfunction\nFontan circulation. If the patient is otherwise well and the cardiac\ncondition uncomplicated\nFontan with any complication\nSevere asymptomatic AS Severe symptomatic AS\nModerate mitral stenosis Severe mitral stenosis\nModerate aortic dilatation (40 \u0002 45 mm in Marfan syndrome or other\nHTAD; 45 \u0002 50 mm in BAV, 20 \u0002 25 mm/m 2   in Turner syndrome)\nSevere aortic dilatation (>45 mm in Marfan syndrome or other\nHTAD, >50 mm in BAV, >25 mm/m 2   in Turner syndrome)\nMechanical valve Severe (re-)coarctation\nAS = aortic stenosis; ASI = aortic size index; BAV = bicuspid aortic valve; CHD = congenital heart defect; EF = ejection fraction; HTAD = heritable thoracic aortic disease; LV = left ventricle/ventricular; mWHO = modiﬁed World Health Organization; NYHA = New York Heart Association; RV = right ventricle/ventricular; TOF = tetralogy of Fallot. a Pregnancy should deﬁnitely be avoided in women with these conditions. Modiﬁed from the 2018 ESC guidelines for the management of cardiovascular disease during pregnancy. 43\n.................................................\nTable 11 Recurrence rates for various congenital heart lesions according to the sex of the affected parent a\nRecurrence rate (%)*\nWomen Men\n",
      "keywords": [
        "ejection fraction",
        "should be considered",
        "older",
        "vasovagal",
        "genetic",
        "mitral stenosis",
        "physical activity",
        "considerations",
        "systolic",
        "anticoagulation",
        "differences",
        "age",
        "additional",
        "hypertension",
        "scd",
        "nyha",
        "difference",
        "aortic",
        "some",
        "arrhythmia",
        "icd",
        "class iii",
        "male",
        "valve replacement",
        "sex",
        "hereditary",
        "included",
        "prevale",
        "stratified",
        "analyses"
      ],
      "tables": [
        {
          "title": "590 ESC Guidelines",
          "page_number": 27,
          "content": "Significantly increased risk of maternal mortality or\nsevere morbidity (mWHO class III) (cardiac event rate\n19\u000227%) |  | Extremely high risk of maternal mortality or severe mor-\nbidity (mWHO class IV)a (cardiac event rate 40\u0002100%)\nUnrepaired cyanotic heart disease |  | Pulmonary arterial hypertension\nModerate LV impairment (EF 30\u000245%) |  | Severe LV impairment (EF <30% or NYHA class III\u0002IV)\nSystemic RV with good or mildly decreased ventricular function |  | Systemic RV with moderate or severely decreased ventricular\nfunction\nFontan circulation. If the patient is otherwise well and the cardiac\ncondition uncomplicated |  | Fontan with any complication\nSevere asymptomatic AS |  | Severe symptomatic AS\nModerate mitral stenosis |  | Severe mitral stenosis\nModerate aortic dilatation (40\u000245 mm in Marfan syndrome or other\nHTAD; 45\u000250 mm in BAV, 20\u000225 mm/m2 in Turner syndrome) |  | Severe aortic dilatation (>45 mm in Marfan syndrome or other\nHTAD, >50 mm in BAV, >25 mm/m2 in Turner syndrome)\nMechanical valve |  | Severe (re-)coarctation\nAS = aortic stenosis; ASI = aortic size index; BAV = bicuspid aortic valve; CHD = congenital heart defect; EF = ejection fraction; HTAD = heritable thoracic aortic disease; LV |  | ",
          "bbox": [
            43.49913208572953,
            74.49395751953125,
            548.7366729736328,
            260.39801025390625
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "590 ESC Guidelines",
          "page_number": 27,
          "content": " |  | Recurrence rate (%)*\n................................................. |  | \n |  | Women |  | Men\nASD |  | 4\u00026 |  | 1.5\u00023.5\nVSD |  | 6\u000210 |  | 2\u00023.5\nAVSD |  | 11.5\u000214 |  | 1\u00024.5\nPDA |  | 3.5\u00024 |  | 2\u00022.5\nCoA |  | 4\u00026.5 |  | 2\u00023.5\nMarfan/HTAD 50b |  |  |  | \nLVOTO |  | 8\u000218 |  | 3\u00024\nRVOTO (PS) |  | 4\u00026.5 |  | 2\u00023.5\nEisenmenger syndrome |  | 6 |  | NR\nTOF |  | 2\u00022.5 |  | 1.5\nPulmonary atresia/VSD |  | NR |  | NR\nTGA 2b |  |  |  | \nccTGA 3\u00025b |  |  |  | \nUVH (HLHS) 21b |  |  |  | \n |  |  |  | ",
          "bbox": [
            307.85244849420366,
            362.0409851074219,
            548.7366729736328,
            573.9099731445312
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "21",
      "title": "ASD 4 \u0002 6 1.5 \u0002 3.5",
      "start_page": 27,
      "end_page": 27,
      "content": "",
      "keywords": [],
      "tables": []
    },
    {
      "number": "22",
      "title": "VSD 6 \u0002 10 2 \u0002 3.5",
      "start_page": 27,
      "end_page": 27,
      "content": "",
      "keywords": [],
      "tables": []
    },
    {
      "number": "23",
      "title": "AVSD 11.5 \u0002 14 1 \u0002 4.5",
      "start_page": 27,
      "end_page": 27,
      "content": "",
      "keywords": [
        "avsd"
      ],
      "tables": []
    },
    {
      "number": "24",
      "title": "PDA 3.5 \u0002 4 2 \u0002 2.5",
      "start_page": 27,
      "end_page": 27,
      "content": "CoA 4 \u0002 6.5 2 \u0002 3.5\nMarfan/HTAD 50 b\n",
      "keywords": [],
      "tables": []
    },
    {
      "number": "25",
      "title": "LVOTO 8 \u0002 18 3 \u0002 4",
      "start_page": 27,
      "end_page": 27,
      "content": "",
      "keywords": [
        "lvoto"
      ],
      "tables": []
    },
    {
      "number": "26",
      "title": "RVOTO (PS) 4 \u0002 6.5 2 \u0002 3.5",
      "start_page": 27,
      "end_page": 28,
      "content": "Eisenmenger syndrome 6 NR\nTOF 2 \u0002 2.5 1.5\nPulmonary atresia/VSD NR NR\nTGA 2 b\nccTGA 3 \u0002 5 b\nUVH (HLHS) 21 b\nASD = atrial septal defect; AVSD = atrioventricular septal defect; ccTGA = con- genitally corrected transposition of the great arteries; CHD = congenital heart disease; CoA = coarctation of the aorta; HLHS = hypoplastic left heart syn- drome; HTAD = heritable thoracic aortic disease; LVOTO = left ventricular out- ﬂow tract obstruction; NR = not reported; PDA = patent ductus arteriosus; PS = pulmonary stenosis; RVOTO = right ventricular outﬂow tract obstruction; TGA = transposition of the great arteries; TOF = tetralogy of Fallot; UVH = univen- tricular heart; VSD = ventricular septal defect. *Except for Marfan syndrome, rates apply to patients with isolated cardiac lesions in whom known genetic/syndromic entities have been excluded. a Modiﬁed from Pierpont  et al . 141\nb Sex-speciﬁc data not available or not relevant.\n590 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................ non-familial CHD, the recurrence rate varies from 1 \u0002 21%, 141\naccording to the underlying lesion. An overview is provided in Table  11 . Foetal echocardiography in affected couples is recom- mended at 19 \u0002 22 weeks gestation and can be done as early as 15 \u0002 16 weeks gestation.\n",
      "keywords": [
        "aortic",
        "rvoto",
        "stenosis",
        "sex",
        "genetic",
        "echocardiography"
      ],
      "tables": []
    },
    {
      "number": "27",
      "title": "4 Specific lesions",
      "start_page": 28,
      "end_page": 28,
      "content": "",
      "keywords": [
        "lesions",
        "specific"
      ],
      "tables": []
    },
    {
      "number": "28",
      "title": "4.1 Atrial septal defect and anomalous pulmonary venous connection 4.1.1 Introduction and background ASD can remain undiagnosed until adulthood. ASD types include:",
      "start_page": 28,
      "end_page": 31,
      "content": "•   Secundum ASD (80% of ASDs; located in the region of the fossa ovalis and its surrounding). •   Primum ASD [15%; synonyms: partial AV septal defect [atrioven- tricular septal defect (AVSD) with communication on the atrial level only], partial AV canal; located near the crux, AV valves are typically malformed, resulting in various degrees of regurgitation (see  section 4.3) ]. •   Superior sinus venosus defect [5%; located near the superior vena cava (SVC) entry, associated with partial or complete con- nection of right pulmonary veins to SVC/RA]. •   Inferior sinus venosus defect [<1%; located near the inferior vena cava (IVC) entry]. •   Unroofed coronary sinus [<1%; separation from the left atrium (LA) can be partially or completely missing].\nAssociated lesions include anomalous pulmonary venous connec- tion, persistent left SVC, pulmonary valve stenosis, and mitral valve prolapse. Interatrial defects are the most frequently associated defects in Ebstein anomaly (see  section 4.9 ). Treatment decisions are more complex in the latter combination. The present section deals with isolated ASD. The shunt volume depends on RV/LV compliance, defect size, and LA/RA pressure. A simple ASD results in L \u0002 R shunt because of the higher compliance of the RV compared with the LV (relevant shunt in general with defect sizes >_10 mm), and causes RV volume overload and pulmonary overcirculation. Reduction in LV compliance, or any condition with elevation of LA pressure (hypertension, ischaemic heart disease, cardiomyopathy, aortic and mitral valve disease), increases L \u0002 R shunt. As a consequence, an ASD may become haemodynami- cally more important with age. Reduced RV compliance (pulmonic stenosis, PAH, other RV disease) or TV disease may decrease L \u0002 R shunt or eventually cause shunt reversal, resulting in cyanosis.\n4.1.2 Clinical presentation and natural history Patients frequently remain asymptomatic until adulthood. However, the majority develop symptoms beyond the fourth decade including reduced functional capacity, exertional shortness of breath, and palpi- tations (supraventricular tachyarrhythmias), and less frequently pul- monary infections and right heart failure. Life expectancy is reduced\noverall, but survival is much better than previously assumed. 142   PAP can be normal, but on average increases with age. Severe PVD is nevertheless very rare (<5%); its development presumably requires additional factors and the disease course is similar to idiopathic PAH. 48   With increasing age, and with increasing PAP, tachyarrhyth- mias become more common (atrial flutter, AF). 143   Systemic embolism may be caused by paradoxical embolism (rare) or AF and atrial flutter.\n4.1.3 Diagnostic work-up See  section 3.3  for general principles. Key clinical findings include fixed splitting of the second heart sound and a systolic pulmonary flow murmur. ECG typically shows an incomplete right bundle branch block and right-axis deviation (superior left-axis deviation in partial AVSD). An increased pulmo- nary vascularity on chest X-ray is frequently overlooked.\n•   Echocardiography is the first-line diagnostic technique, providing diagnosis and quantification. RV volume overload, which may be the first unexpected finding in a patient with previously undiag- nosed ASD, is the key finding and best characterizes the haemo- dynamic relevance of the defect (preferable to the shunt ratio). Sinus venosus defects in general require TOE for accurate diag- nosis (CMR/CCT is an alternative and superior in case of inferior sinus venosus defects). TOE is also required for precise evalua- tion of secundum defects before device closure, which should include sizing, exploration of the residual septum’s morphology, the rim size and quality, exclusion of additional defects, and con- firmation of a normal pulmonary venous connection. 3D echo- cardiography provides visualization of ASD morphology. Other key information to be provided includes PAP and tricuspid regur- gitation (TR). •   CMR is rarely required but may be useful for assessment of RV volume overload, identification of inferior sinus venosus defect, quantification of pulmonary to systemic flow ratio (Qp:Qs), and evaluation of pulmonary venous connection (alternatively for the latter, use CCT). •   Cardiac catheterization is required in case of non-invasive signs of PAP elevation (calculated systolic PAP >40 mmHg or indirect signs when PAP cannot be estimated) to determine PVR. •   Exercise testing should be performed in patients with PAH to exclude desaturation.\n4.1.4 Surgical/catheter interventional treatment Indications for intervention are summarized in the  Recommendations for intervention in atrial septal defect (native and residual)  table and in Figure  2 . Surgical repair has low mortality (<1% in patients without signifi- cant comorbidity) and good long-term outcome when performed early (childhood, adolescence) and in the absence of PH. 144 , 145\nAlthough surgical repair can be performed with very low risk, even in the elderly, comorbidities that may affect operative risk need to be considered and then risk weighed against potential benefit.\nESC Guidelines 591\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................\nDevice closure has become the first choice for secundum defect clo- sure, when feasible, based on the morphology (includes stretched diameter <_38 mm and sufficient rim of 5 mm except towards the aorta). This is the case in  \u0003 80% of patients. Although it cannot be\nassumed to be zero, several recent studies have reported no mortality. Serious complications have been observed in <_1% of patients. 148 , 149\nAtrial tachyarrhythmias occurring early after intervention are mostly transient. Erosion of the atrial wall, anterior mitral leaflet, or the aorta, as well as thromboembolic events, appear to be very rare. 150 , 151\nAntiplatelet therapy is required for at least 6 months (aspirin 75 mg o.d. minimum). Potential incidence of late arrhythmias or adverse events still requires investigation. Studies comparing surgery and cathe- ter intervention have reported similar success rates and mortality, but morbidity was lower and hospital stays shorter with catheter interven- tion while reintervention rate was slightly higher. 148 , 152\nOutcome is best with repair at age <25 years. 144 , 145   ASD closure after the age of 40 years appears not to affect the frequency of arrhythmia development during follow-up. 146 , 153   However, the patient’s morbidity benefits from closure at any age (exercise capacity, shortness of breath, right heart failure), particularly when it can be done by catheter intervention. 146 , 153\nIn patients with impaired LV function (systolic and diastolic), ASD closure may worsen heart failure. These patients must be carefully eval- uated and may require pre-interventional testing (balloon occlusion with reassessment of haemodynamics) to decide between complete, fenestrated, or no closure, considering that an increase in filling pres- sure due to ASD closure may worsen symptoms and outcome. 154\nPatients with PH must be evaluated with particular care. Calculation of PVR is mandatory. In patients with PVR <5 WU, ASD closure has been shown to be safe and associated with a decrease in PAP and improvement of symptoms. 60 , 153 , 155   However, even in this group, the extent of improvement decreases with increasing PAP. Patients with PVR >_5 WU are unlikely to improve 60   and likely to have an even worse outcome with complete ASD closure. 48 , 156\nVasoreactivity testing is not recommended when making the decision whether to close an ASD in patients with PVR >_5 WU. It appears safer to treat PAH, re-evaluate haemodynamics during follow-up, and consider fenestrated closure only when PVR falls below 5 WU in the presence of significant L \u0002 R shunt. If this is not the case, ASD closure should be avoided.\nIn patients with atrial flutter/AF, cryo- or radiofrequency ablation (modified maze procedure) should be considered at the time of sur- gery. Device closure may restrict access to the LA for later EP interventions. In patients of advanced age with ASDs not suitable for device clo- sure, individual surgical risk due to comorbidities must be carefully weighed against the potential benefits of ASD closure.\n4.1.5 Specific aspects of isolated anomalous pulmonary venous connections Anomalous pulmonary venous connections do not only occur in association with ASD (typically in sinus venous defects) but can also be isolated. This results in volume overload of the right heart, with a physiological effect similar to that of an ASD, but when isolated, dif- fers in that there is no potential for R \u0002 L shunting, and the magnitude of the L \u0002 R shunt is not exacerbated by the development of acquired left heart disease. Most common is the connection of the right upper pulmonary vein to the SVC. Other abnormal connections include right pulmonary vein(s) to the IVC (‘scimitar vein’, which may be associated with sequestration of the right lower lobe), left upper\nRecommendations for intervention in atrial septal defect (native and residual)\nRecommendations Class a Level b\nIn patients with evidence of RV volume over-\nload c   and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3\nWU in case of such signs) or LV disease, ASD\nclosure is recommended regardless of symptoms. 146 , 147\nI B\nDevice closure is recommended as the method\nof choice for secundum ASD closure when technically suitable.\nI C\nIn elderly patients not suitable for device clo-\nsure, it is recommended to carefully weigh the\nsurgical risk against the potential beneﬁt of ASD closure.\nI C\nIn patients with non-invasive signs of PAP eleva-\ntion, invasive measurement of PVR is mandatory.\nI C\nIn patients with LV disease, it is recommended\nto perform balloon testing and carefully weigh\nthe beneﬁt of eliminating L \u0002 R shunt against the potential negative impact of ASD closure on\noutcome due to an increase in ﬁlling pressure\n(taking closure, fenestrated closure, and no clo- sure into consideration).\nI C\nIn patients with suspicion of paradoxical embo-\nlism (exclusion of other causes), ASD closure should be considered regardless of size provid-\ning there is absence of PAH and LV disease.\nIIa C\nIn patients with PVR 3 \u0002 5 WU, ASD closure\nshould be considered when signiﬁcant L \u0002 R shunt is present (Qp:Qs >1.5).\nIIa C\nIn patients with PVR >_5 WU, fenestrated ASD\nclosure may be considered when PVR falls below 5 WU after targeted PAH treatment and\nsigniﬁcant L \u0002 R shunt is present (Qp:Qs >1.5).\nIIb C\nASD closure is not recommended in patients\nwith Eisenmenger physiology, patients with PAH and PVR >_5 WU despite targeted PAH treat-\nment, or desaturation on exercise. d\nIII C\nASD = atrial septal defect; L \u0002 R = left-to-right; LV = left ventricle/ventricular; PAH = pulmonary arterial hypertension; PAP = pulmonary artery pressure; PVR = pulmonary vascular resistance; Qp:Qs = pulmonary to systemic ﬂow ratio; RV = right ventricle/ventricular; WU = Wood units. a Class of recommendation. b Level of evidence. c RV enlargement with increased stroke volume. d There are limited data available for a precise cut-off, but by clinical experience, this would be given by a fall of arterial oxygen saturation <90%.\n592 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ......................................................... pulmonary vein(s) to the left innominate vein, and right upper pulmo- nary vein(s) connecting high on the SVC. Long-term sequelae of anomalous pulmonary venous connections reflect the impact of right heart volume overload and are similar to the sequelae of ASDs. Surgical repair can be challenging as low-velocity venous flow imparts risk of thrombosis of the surgically operated vein, particularly in scimitar syndrome; it should only be performed by a congenital cardiac surgeon. Indications for surgery follow the principals of recommendation for ASD closure, but technical suitability for repair and operative risk must be weighed against the potential benefit of intervention. It is unusual for a single anomalous pulmonary venous connection of only one pulmo- nary lobe to result in a sufficient volume load to justify surgical repair.\n4.1.6 Follow-up recommendations Follow-up evaluation should include assessment of a residual shunt, RV size and function, TR and PAP by echocardiography, and assessment of arrhythmias by history, ECG, and  \u0002  only if indicated  \u0002  Holter monitor- ing. Patients repaired at age <25 years without relevant sequelae or\nresidua (no residual shunt, normal PAP, normal RV, no arrhythmias) do not require regular follow-up. However, patients and referring physicians should be informed about the possible late occurrence of tachyarrhythmias. Patients with residual shunt, elevated PAP, or arrhythmias (before or after repair) and those repaired at adult age (particularly >40 years) should be followed on a regular basis, including evaluation in special- ized ACHD centres (intervals depending on the severity of residual problems). After device closure, regular follow-up during the first 2 years and then, depending on results, every 3 \u0002 5 years is reasonable. Late post-operative arrhythmias after surgical repair at age <40 years are most frequently IART or atrial flutter, which can be successfully treated with radiofrequency or cryoablation. Without repair or with repair after age 40 years, AF becomes more common. In patients who undergo ASD closure aged >40 years, the prevalence of atrial arrhyth- mias is up to 40 \u0002 60%. Access to the LA may be restricted after device closure. SVC stenosis may occur after repair of a sinus venosus defect, as well as stenoses of redirected pulmonary veins.\n©ESC 2020\nFigure 2  Management of atrial septal defect. ASD = atrial septal defect; L \u0002 R = left-to-right; LV = left ventricle/ventricular; PAH = pulmonary arterial hypertension; PVR = pulmonary vascular resist- ance; Qp:Qs = pulmonary to systemic flow ratio; RV = right ventricle/ventricular; WU = Wood units. a RV enlargement with increased stroke volume. b Providing there is no PAH or LV disease. c In elderly patients not suitable for device closure, carefully weigh surgical risk vs. potential benefit of ASD closure. d Carefully weigh the benefit of eliminating L \u0002 R shunt against the potential negative impact of ASD closure on outcome due to an increase in filling pres- sure (taking closure, fenestrated closure, and no closure into consideration).\nESC Guidelines 593\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.1.7 Additional considerations\n•   Exercise/sports: no restrictions in asymptomatic patients before or after intervention without PH, significant arrhythmias, or RV dysfunction; limitation to low-intensity recreational sports in PAH patients (see  section 3.5.5 ). •   Pregnancy: low risk in patients without PH, although there may be an increased risk of paradoxical embolism. Patients with pre-capillary PH should be counselled against pregnancy (see  section 3.5.7 ). •   IE prophylaxis: recommended for 6 months after device closure (see  section 3.4.6 ).\n",
      "keywords": [
        "pulmonary",
        "should be considered",
        "echo",
        "septal",
        "undiagnosed",
        "systolic",
        "types",
        "age",
        "defect",
        "tricuspid",
        "include",
        "hypertension",
        "remain",
        "diastolic",
        "aortic",
        "arrhythmia",
        "anomalous",
        "background",
        "echocardiography",
        "level b",
        "cardiomyopathy",
        "ecg",
        "elderly",
        "introduction",
        "until",
        "heart failure",
        "exercise",
        "connection",
        "recommended",
        "may be considered"
      ],
      "tables": [
        {
          "title": "592 ESC Guidelines",
          "page_number": 29,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIn patients with evidence of RV volume over-\nloadc and no PAH (no non-invasive signs of PAP\nelevation or invasive confirmation of PVR <3\nWU in case of such signs) or LV disease, ASD\nclosure is recommended regardless of\nsymptoms.146,147 | I | B\nDevice closure is recommended as the method\nof choice for secundum ASD closure when\ntechnically suitable. | I | C\nIn elderly patients not suitable for device clo-\nsure, it is recommended to carefully weigh the\nsurgical risk against the potential benefit of ASD\nclosure. | I | C\nIn patients with non-invasive signs of PAP eleva-\ntion, invasive measurement of PVR is\nmandatory. | I | C\nIn patients with LV disease, it is recommended\nto perform balloon testing and carefully weigh\nthe benefit of eliminating L\u0002R shunt against the\npotential negative impact of ASD closure on\noutcome due to an increase in filling pressure\n(taking closure, fenestrated closure, and no clo-\nsure into consideration). | I | C\nIn patients with suspicion of paradoxical embo-\nlism (exclusion of other causes), ASD closure\nshould be considered regardless of size provid-\ning there is absence of PAH and LV disease. | IIa | C\nIn patients with PVR 3\u00025 WU, ASD closure\nshould be considered when significant L\u0002R\nshunt is present (Qp:Qs >1.5). | IIa | C\nIn patients with PVR >5 WU, fenestrated ASD\n_\nclosure may be considered when PVR falls\nbelow 5 WU after targeted PAH treatment and\nsignificant L\u0002R shunt is present (Qp:Qs >1.5). | IIb | C\nASD closure is not recommended in patients\nwith Eisenmenger physiology, patients with PAH\nand PVR >5 WU despite targeted PAH treat-\n_\nment, or desaturation on exercise.d | III | C",
          "bbox": [
            42.5258575888241,
            86.47422485351562,
            284.80118465423584,
            576.2232513427734
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "29",
      "title": "4.2 Ventricular septal defect 4.2.1 Introduction and background VSD is mostly diagnosed and  \u0002  when indicated  \u0002  treated before adult- hood. Spontaneous closure is frequent in childhood. Several loc",
      "start_page": 31,
      "end_page": 31,
      "content": "•   Perimembranous/paramembranous/subaortic/conoventricular (most common,  \u0003 80% of VSDs; located in the membranous sep- tum with possible extension into inlet, trabecular, or outlet sep- tum; adjacent to tricuspid and aortic valve; so-called aneurysms of the membranous septum  \u0002  i.e. tissue from the septal leaflet of the TV  \u0002  are frequent and may result in partial or complete closure). •   Muscular/trabecular (up to 15 \u0002 20%; completely surrounded by muscle; various locations; frequently multiple; spontaneous clo- sure particularly frequent). •   Outlet (with or without malalignment of the outlet septum)/ supracristal/subarterial/subpulmonary/infundibular/conal/doubly committed juxta-arterial [ \u0003 5%; located beneath the semilunar valves in the conal or outlet septum; may be associated with pro- gressive aortic regurgitation (AR) due to prolapse of the right aortic cusp and aneurysm of the sinus of Valsalva]. •   Inlet/AV canal/AVSD type (inlet of the ventricular septum imme- diately inferior to the AV valve apparatus; associated with a com- mon AV valve; may be associated with AV septal malalignment and straddling TV; typically occurring in Down syndrome).\nOften there is one single defect, but multiple defects do occur. VSD is also a common component of complex anomalies, such as TOF, transposition of the great arteries (TGA), and congenitally cor- rected TGA (ccTGA). Spontaneous closure occurs mainly during childhood and is uncommon in outlet defects. 158\nThe direction and magnitude of the shunt are determined by PVR and systemic vascular resistance, the size of the defect, LV/RV systolic and diastolic function, and the presence of right ventricular outflow tract (RVOT) obstruction (RVOTO) and left ventricular outflow tract (LVOT) obstruction (LVOTO).\n4.2.2 Clinical presentation and natural history The usual clinical presentations in adults include:\n•   VSD operated on in childhood, without residual VSD and no PH. •   VSD operated on in childhood, with residual VSD. The residual shunt size determines the degree of LV volume overload and the development of PH.\n•   Small VSD with insignificant L \u0002 R shunt, without LV volume over- load or PH (restrictive VSD), which was not considered for sur- gery in childhood. •   VSD with L \u0002 R shunt, PH (various degrees), and various degrees of LV volume overload (rare). •   VSD with R \u0002 L shunt (Eisenmenger syndrome): large, non- restrictive, VSD with originally large L \u0002 R shunt and development of severe PVD eventually resulting in shunt reversal (cyanosis; see  sections 3.4.3  and  3.4.8 ).\nA large majority of patients with a VSD that has been closed entirely in childhood (spontaneously or surgically), or patients with a small VSD who were either never operated on or who had a residual defect after surgical repair with no LV volume overload on echocar- diography, usually remain asymptomatic and do not require further surgery. 159   However, an unknown percentage of patients with a small residual VSD develop problems later in life. 160   Survival 40 years after closure appears to remain slightly lower than in the general population. 161\n",
      "keywords": [
        "adult",
        "septal",
        "systolic",
        "when",
        "frequent",
        "treated",
        "childhood",
        "defect",
        "tricuspid",
        "several",
        "aneurysm",
        "diastolic",
        "spontaneous",
        "aortic",
        "background",
        "introduction",
        "diagnosed",
        "closure",
        "indicated",
        "before",
        "aortic regurgitation",
        "ventricular",
        "hood",
        "mostly"
      ],
      "tables": []
    },
    {
      "number": "30",
      "title": "Several possible problems may occur with advancing age:",
      "start_page": 31,
      "end_page": 32,
      "content": "•   A double-chambered RV (DCRV) can develop over time, mostly in perimembranous defects, and may be a result of the jet lesion of the RV endothelium caused by the high-velocity VSD jet. •   In the case of an outlet (supracristal) VSD (less commonly perimembranous), there is a risk for prolapse of the right cor- onary (or non-coronary) cusp of the aortic valve, resulting in progressive AR and formation of a sinus of Valsalva aneurysm. •   Arrhythmias can occur, but are less frequent than in other forms of CHD 162 . •   Complete heart block  \u0002  rare nowadays  \u0002  was not uncommon in the earlier years of cardiac smurgery, so can occur, especially in older patients. These patients usually require lifelong pacing. •   Late LV dysfunction and heart failure. •   Endocarditis.\n4.2.3 Diagnostic work-up See  section 3.3  for general principles. Specific clinical findings include a holosystolic murmur over the third to fourth left intercostal space, and a precordial thrill may be felt.\n•   Echocardiography is the key diagnostic technique, in general providing the diagnosis and assessment of disease severity. Key findings to provide are location, number, and size of defects, severity of LV volume overload, and estimated PAP. AR due to prolapse of the right or non-coronary cusp must be checked for, especially in the case of outlet (supracristal) and high perimem- branous VSDs. DCRV and sinus of Valsalva aneurysm must be excluded. •   CMR can serve as an alternative if echocardiography is insuffi- cient, particularly for assessment of LV volume overload and shunt quantification. •   Cardiac catheterization is required in case of non-invasive signs of PAP elevation (calculated systolic PAP >40 mmHg or indirect signs when PAP cannot be estimated) to determine PVR. •   Exercise testing should be performed in patients with PAH to exclude desaturation.\n594 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ........................................................................................................................................................................ 4.2.4 Surgical/catheter interventional treatment Indications for intervention are summarized in the  Recommendations for intervention in ventricular septal defect (native and residual)  table and in  Figure  3 . Surgical closure can be performed with low operative mortality (1 \u0002 2%) and good long-term results. 163   Transcatheter closure has become an alternative, particularly in residual VSDs, in VSDs that are poorly accessible for surgical closure, and in muscular VSDs that are located centrally in the interventricular septum. In perimembranous VSD, it has been shown to be feasible. Whether the risk of complete AV block and entrapment of TV tissue leading to TR, or the risk of AR that has been observed in children, is relevant in adults under- going interventional closure of a perimembranous VSD remains to be seen.\nPatients eligible for VSD closure at adult age are rare. Most patients have either small VSDs with insignificant shunt or have already developed PH. The latter must be evaluated with particular caution. Patients with shunt closure and persistent/progressive PAH appear to have a particularly poor outcome. 48\n4.2.5 Follow-up recommendations Development of AR or TR, degree of (residual) shunt, LV dysfunc- tion, elevation of PAP, or development of DCRV, should be excluded or assessed if present by echocardiography. Possible development of complete AV block requires attention (patients who develop bifascicular block or transient trifascicular block after VSD closure are at risk in later years for the development of complete AV block). Patients with more than small residual VSD, valvular lesions, or haemodynamic impairment (LV dysfunction or PAH) should be seen every year, including evaluation in specialized ACHD centres. In patients with a small VSD (native or residual, normal LV, normal PAP, asymptomatic) and no other lesion, 3 \u0002 5-year intervals may be rea- sonable. After device closure, regular follow-up during the first 2 years and then, depending on the results, every 2 \u0002 5 years is reason- able. After surgical closure without residual abnormality, 5-year inter- vals may be reasonable.\n4.2.6 Additional considerations\n•   Exercise/sports: no restrictions are required in patients after VSD closure, or with small VSD without PH, significant arrhythmias, or LV dysfunction. Patients with PAH must limit themselves to low-intensity recreational activity/sports (see  sec- tion 3.5.5 ). •   Pregnancy: patients with pre-capillary PH (PAH) should be coun- selled against pregnancy. The risk is low in asymptomatic patients with normal LV and no PAH (see  section 3.5.7 ). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n",
      "keywords": [
        "aortic",
        "exercise",
        "age",
        "occur",
        "recommended",
        "advancing",
        "possible",
        "older",
        "catheterization",
        "problems",
        "several",
        "echocardiography",
        "systolic",
        "aneurysm",
        "heart failure"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 595",
          "page_number": 32,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIn patients with evidence of LV volume over-\nloadc and no PAH (no non-invasive signs of PAP\nelevation or invasive confirmation of PVR <3\nWU in case of such signs), VSD closure is rec-\nommended regardless of symptoms. | I | C\nIn patients with no significant L\u0002R shunt, but a\nhistory of repeated episodes of IE, VSD closure\nshould be considered. | IIa | C\nIn patients with VSD-associated prolapse of an\naortic valve cusp causing progressive AR, sur-\ngery should be considered. | IIa | C\nIn patients who have developed PAH with PVR\n3\u00025 WU, VSD closure should be considered\nwhen there is still significant L\u0002R shunt (Qp:Qs\n>1.5). | IIa | C\nIn patients who have developed PAH with PVR\n>5 WU, VSD closure may be considered when\n_\nthere is still significant L\u0002R shunt (Qp:Qs >1.5),\nbut careful individual decision in expert centres\nis required. | IIb | C\nVSD closure is not recommended in patients\nwith Eisenmenger physiology and patients with\nsevere PAH (PVR >5 WU) presenting with\n_\ndesaturation on exercise.d | III | C",
          "bbox": [
            47.08686996459961,
            321.4662292480469,
            289.3828903509646,
            639.6562020438058
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "31",
      "title": "4.3 Atrioventricular septal defect 4.3.1 Introduction and background An AVSD (AV canal or endocardial cushion defect) is character- ized by the presence of a common AV junction. The partial AVSD usual",
      "start_page": 32,
      "end_page": 34,
      "content": "Recommendations for intervention in ventricular septal defect (native and residual)\nRecommendations Class a Level b\nIn patients with evidence of LV volume over-\nload c   and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3\nWU in case of such signs), VSD closure is rec-\nommended regardless of symptoms.\nI C\nIn patients with no signiﬁcant L \u0002 R shunt, but a\nhistory of repeated episodes of IE, VSD closure\nshould be considered.\nIIa C\nIn patients with VSD-associated prolapse of an aortic valve cusp causing progressive AR, sur-\ngery should be considered.\nIIa C\nIn patients who have developed PAH with PVR 3 \u0002 5 WU, VSD closure should be considered\nwhen there is still signiﬁcant L \u0002 R shunt (Qp:Qs\n>1.5).\nIIa C\nIn patients who have developed PAH with PVR >_5 WU, VSD closure may be considered when\nthere is still signiﬁcant L \u0002 R shunt (Qp:Qs >1.5),\nbut careful individual decision in expert centres is required.\nIIb C\nVSD closure is not recommended in patients\nwith Eisenmenger physiology and patients with severe PAH (PVR >_5 WU) presenting with\ndesaturation on exercise. d\nIII C\nAR = aortic regurgitation; IE = infective endocarditis; L \u0002 R = left-to-right; LV = left ventricle/ventricular; PAH = pulmonary arterial hypertension; PAP = pulmo- nary artery pressure; PVR = pulmonary vascular resistance; Qp:Qs = pulmonary to systemic ﬂow ratio; VSD = ventricular septal defect; WU = Wood units. a Class of recommendation. b Level of evidence. c LV enlargement with increased stroke volume. d There are limited data available for a precise cut-off, but by clinical experience, this would be given by a fall of arterial oxygen saturation <90%.\nESC Guidelines 595\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ....................................................................... 4.3.2 Clinical presentation and natural history Clinical presentation depends on the presence and size of the ASD and VSD and competence of the left-sided AV valve. Symptoms are not specific for an AVSD and are caused by intracardiac shunt- ing (L \u0002 R, R \u0002 L, or bidirectional), PH, AV valve regurgitation, ven- tricular dysfunction, or LVOTO. Exercise intolerance, dyspnoea, arrhythmia, and cyanosis may be present. LVOTO (subvalvular) may be present or develop over time. Complete AV block may develop late. The history of unoperated complete AVSD is that of Eisenmenger syndrome unless the VSD is only small (see  sections 3.4.3  and  3.4.8 ). Unrepaired primum ASD (partial AVSD) is not uncommon in adults. The presenting clinical symptoms are that of an L \u0002 R shunt at the atrial level (see  section 4.1 ) and/or that of left-sided AV valve regurgitation (‘cleft’). Patients may still be asymptomatic, but symp- toms tend to increase with age; most adults are symptomatic by 40 years of age.\n4.3.3 Diagnostic work-up See  section 3.3  for general principles. Clinical findings depend on the individual variant (see  sections 4.3.1 and  4.3.2 ).\n•   Echocardiography is the key diagnostic technique. It provides assessment of each anatomic component of the AVSD, of the AV valves and their connections, the severity and exact substrate of AV valve regurgitation, the magnitude and direction of intracar- diac shunting, LV and RV function, PAP, and assessment of the presence/absence of LVOTO. •   CMR is indicated when additional quantification of ventricular volumes and function, AV valve regurgitation, or intracardiac shunting is required for decision making. •   Cardiac catheterization is required in case of non-invasive signs of PAP elevation (calculated systolic PAP >40 mmHg or indirect signs when PAP cannot be estimated) to determine PVR. •   Exercise testing should be performed in patients with PAH to exclude desaturation.\n4.3.4 Surgical/catheter interventional treatment Catheter closure of AVSDs is not feasible, and intervention is there- fore surgical (defect closure, valve repair). In cases of residual intera- trial or interventricular communications, endocardial pacing causes an elevated risk of paradoxical emboli; this should be taken into account when pacing is indicated. Epicardial pacing may be required. The expertise of a congenital cardiac surgeon is recommended for all kinds of AVSD defect closures and AV valve repairs.\n©ESC 2020\nFigure 3  Management of ventricular septal defect. AR = aortic regurgitation; IE = infective endocarditis; LV = left ventricle/ventricular; Qp:Qs = pulmonary to systemic flow ratio; PAH = pulmonary artery hypertension; PVR = pulmonary vascular resistance; VSD = ventricular septal defect; WU = Wood units. a LV enlargement with increased stroke volume. b Includes all patients with desaturation at rest (Eisenmenger physiology) or on exercise. c Careful individual decision in expert centres is required.\n596 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................\n4.3.5 Follow-up recommendations Lifelong regular follow-up of all patients with an AVSD, operated and unoperated, is recommended, including evaluation in specialized ACHD centres. Particular attention should be paid to residual shunt, AV valve malfunction, LV and RV enlargement and dysfunction, PAP\nelevation, LVOTO, and arrhythmias. 164   The frequency of outpatient visits depends on the presence and severity of residual abnormalities. A patient with a surgically repaired AVSD without significant residual abnormalities should be seen at least every 2 \u0002 3 years. In the case of residual abnormalities, the intervals should be shorter.\nIndications for reoperation for residual abnormalities are compara- ble with the indications for primary surgery. In operated patients, the most frequently occurring problem is left-sided AV valve regurgita- tion. 165 , 166   It has to be emphasized that these valves are different from mitral valves and more difficult to repair. Left-sided AV valve stenosis (most often a result of previous repair) that causes symp- toms should be operated on.\n4.3.6 Additional considerations\n•   Exercise/sports: for most patients with uncomplicated, repaired AVSD, physical activity does not need restriction. Many will, however, have subnormal exercise performance when measured objectively. Patients with important residual problems require individual recommendations (see  section 3.5.5 ). •   Pregnancy: well tolerated in patients with complete repair and no significant residual lesions. An unoperated partial AVSD increases the risk of paradoxical embolization. Patients with pre-capillary PH should be counselled against pregnancy. As a rule, patients with residual left-sided AV valve regurgitation, who have no indi- cation for surgery, tolerate pregnancy relatively well, although arrhythmias and worsening of AV valve regurgitation may occur 167   (see  section 3.5.7 ). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n",
      "keywords": [
        "should be considered",
        "ized",
        "septal",
        "valve repair",
        "character",
        "physical activity",
        "systolic",
        "junction",
        "avsd",
        "endocardial",
        "age",
        "defect",
        "hypertension",
        "partial",
        "presence",
        "canal",
        "aortic",
        "usual",
        "arrhythmia",
        "atrioventricular",
        "background",
        "echocardiography",
        "level b",
        "introduction",
        "common",
        "exercise",
        "recommended",
        "may be considered",
        "stenosis",
        "catheterization"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 597",
          "page_number": 34,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nComplete AVSD |  | \nSurgical repair is not recommended in patients\nwith Eisenmenger physiology, and patients\nwith PAH (PVR >5 WU) presenting with desa-\n_\nturation on exercise.c | III | C\nFor recommendations on intervention see also recommendations for\nintervention in VSD (section 4.2). |  | \nPartial AVSD (primum ASD) |  | \nSurgical closure is recommended in patients\nwith significant RV volume overload and\nshould only be performed by a congenital car-\ndiac surgeon. | I | C\nFor further details see recommendations for intervention in\nASD (section 4.1). |  | \nAV valve regurgitation |  | \nValve surgery, preferably AV valve repair, is\nrecommended in symptomatic patients with\nmoderate to severe AV valve regurgitation\nand should be performed by a congenital car-\ndiac surgeon. | I | C\nIn asymptomatic patients with severe left-\nsided AV valve regurgitation, valve surgery is\nrecommended when LVESD\n>45 mmd and/or LVEF <60% provided other\n_ _\ncauses of LV dysfunction are excluded. | I | C\nIn asymptomatic patients with severe left-\nsided AV valve regurgitation, preserved LV\nfunction (LVESD <45 mmd and/or LVEF\n>60%), high likelihood of successful valve\nrepair, and low surgical risk, intervention\nshould be considered when atrial fibrillation\nor systolic PAP >50 mmHg is present. | IIa | C\nLeft ventricular outflow tract obstruction |  | \nSee recommendations for intervention in SubAS (section 4.5.3). |  | ",
          "bbox": [
            47.04970368884859,
            86.47422485351562,
            289.23228767590643,
            531.845703125
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "32",
      "title": "4.4 Patent ductus arteriosus 4.4.1 Introduction and background Patent ductus arteriosus (PDA) is the persistent communication between the proximal left PA and the descending aorta just distal to the l",
      "start_page": 34,
      "end_page": 35,
      "content": "4.4.2 Clinical presentation and natural history Presentations of adult patients with PDA include:\n•   Small duct with no LV volume overload (normal LV) and normal PAP (generally asymptomatic). •   Moderate PDA with predominant LV volume overload: large LV with normal or reduced function (may present with left heart failure). •   Moderate PDA with predominant PAH: pressure-overloaded RV (may present with right heart failure). •   Large PDA: Eisenmenger physiology with differential hypoxaemia and differential cyanosis (lower extremities cyanotic, sometimes left arm too); see  sections 3.4.3  and  3.4.8 . Aneurysm formation of the duct is a very rare complication.\nRecommendations for intervention in atrioventricular septal defect\nRecommendations Class a Level b\nComplete AVSD\nSurgical repair is not recommended in patients with Eisenmenger physiology, and patients\nwith PAH (PVR >_5 WU) presenting with desa-\nturation on exercise. c\nIII C\nFor recommendations on intervention see also recommendations for intervention in VSD ( section 4.2 ).\nPartial AVSD (primum ASD)\nSurgical closure is recommended in patients\nwith signiﬁcant RV volume overload and should only be performed by a congenital car-\ndiac surgeon.\nI C\nFor further details see recommendations for intervention in ASD ( section 4.1 ).\nAV valve regurgitation\nValve surgery, preferably AV valve repair, is\nrecommended in symptomatic patients with moderate to severe AV valve regurgitation\nand should be performed by a congenital car-\ndiac surgeon.\nI C\nIn asymptomatic patients with severe left- sided AV valve regurgitation, valve surgery is\nrecommended when LVESD\n>_45 mm d   and/or LVEF <_60% provided other causes of LV dysfunction are excluded.\nI C\nIn asymptomatic patients with severe left-\nsided AV valve regurgitation, preserved LV function (LVESD <45 mm d   and/or LVEF\n>60%), high likelihood of successful valve\nrepair, and low surgical risk, intervention should be considered when atrial ﬁbrillation\nor systolic PAP >50 mmHg is present.\nIIa C\nLeft ventricular outﬂow tract obstruction\nSee recommendations for intervention in SubAS ( section 4.5.3 ).\nASD = atrial septal defect; AV = atrioventricular; AVSD = atrioventricular septal defect; LV = left ventricle/ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end systolic diameter; LVOTO = left ventricular outﬂow tract obstruction; PAH = pulmonary artery hypertension; PAP = pulmonary artery pressure; PVR = pulmonary vascular resistance; RV = right ventricle/ven- tricular; SubAS = subaortic stenosis; VSD = ventricular septal defect; WU = Wood units. a Class of recommendation. b Level of evidence. c There are limited data available for a precise cut-off, but by clinical experience, this would be given by a fall of arterial oxygen saturation <90%. d Cut-off refers to average-sized adults and may require adaption in patients with unusually small or large stature.\nESC Guidelines 597\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.4.3 Diagnostic work-up See  section 3.3  for general principles. Specific clinical findings include a continuous murmur that disap- pears with development of Eisenmenger syndrome (for differential cyanosis, see  section 4.4.2 ; oxygen saturation should be measured at the upper and lower extremities).\n•   Echocardiography is the key diagnostic technique and provides the diagnosis (may be difficult in patients with Eisenmenger physi- ology), the degree of LV volume overload, PAP, PA size, and right heart changes. •   CMR is indicated when additional quantification of LV volumes and quantification of shunt (Qp:Qs) is needed. •   CMR/CCT can further evaluate the anatomy where required. •   Cardiac catheterization is required in the case of non-invasive signs of PAP elevation (calculated systolic PAP >40 mmHg or indirect signs when PAP cannot be estimated) to determine PVR. Measure- mentofpulmonarybloodflowischallenginginthissetting.Measure- mentofoxygensaturationinbothleftandrightPAsismandatory. •   Exercise testing should be performed in patients with PAH to exclude desaturation of lower limbs.\n4.4.4 Surgical/catheter interventional treatment Indications for intervention are summarized in the  Recommendation for intervention in patent ductus arteriosus  table and in  Figure  4 .\nIn adults, calcification of the PDA may cause a problem for surgical closure. Device closure is the method of choice, even if cardiac oper- ations are indicated due to other concomitant cardiac lesions, and can be successfully performed in the vast majority of adults with a very low complication rate. 168 \u0002 170   Surgery is reserved for the rare patient with a duct too large for device closure or with unsuitable anatomy such as aneurysm formation.\n4.4.5 Follow-up recommendations Echocardiographic evaluation should include LV size and function, PAP, residual shunt, and associated lesions. Patients with no residual shunt, normal LV, and normal PAP do not require regular follow-up after 6 months. Patients with LV dysfunction and patients with residual PAH should be followed at intervals of 1 \u0002 3 years, depending on severity, including evaluation in specialized ACHD centres.\n4.4.6 Additional considerations\n•   Exercise/sports: no restrictions in asymptomatic patients before or after intervention without PH; limitation to low-intensity sports in PAH patients. •   Pregnancy: no significantly increased risk for patients without PH. Patients with pre-capillary PH should be counselled against preg- nancy (see  section 3.5.7 ). •   IE prophylaxis: limited to high-risk patients (see  section 3.4.6 ).\n",
      "keywords": [
        "communication",
        "just",
        "ejection fraction",
        "should be considered",
        "left",
        "ductus",
        "valve repair",
        "systolic",
        "patent",
        "hypertension",
        "proximal",
        "lvef",
        "aneurysm",
        "background",
        "between",
        "introduction",
        "echocardiography",
        "level b",
        "heart failure",
        "descending",
        "exercise",
        "recommended",
        "aorta",
        "stenosis",
        "distal",
        "arteriosus",
        "persistent",
        "catheterization"
      ],
      "tables": [
        {
          "title": "598 ESC Guidelines",
          "page_number": 35,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIn patients with evidence of LV volume overloadc\nand no PAH (no non-invasive signs of PAP eleva-\ntion or invasive confirmation of PVR <3 WU in\ncase of such signs), PDA closure is recommended\nregardless of symptoms. | I | C\nDevice closure is recommended as the method of\nchoice when technically suitable. | I | C\nIn patients who have developed PAH with PVR\n3\u00025 WU, PDA closure should be considered\nwhen there is still significant L\u0002R shunt\n(Qp:Qs >1.5). | IIa | C\nIn patients who have developed PAH with PVR\n>5 WU, PDA closure may be considered when\n_\nthere is still significant L\u0002R shunt (Qp:Qs >1.5)\nbut careful individual decision in expert centres is\nrequired. | IIb | C\nPDA closure is not recommended in patients with\nEisenmenger physiology and patients with lower\nlimb desaturation on exercise.d | III | C",
          "bbox": [
            42.56508879228072,
            393.4662261962891,
            284.8811458240856,
            650.4281812395368
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "33",
      "title": "4.5 Left ventricular outflow tract obstruction 4.5.1 Valvular aortic stenosis 4.5.1.1 Introduction and background The most common cause for congenital valvular aortic stenosis (AS) is BAV. Up to 80% o",
      "start_page": 35,
      "end_page": 40,
      "content": "4.5.1.2 Clinical presentation and natural history Patients frequently remain asymptomatic for many years. Progression of stenosis varies and depends on initial severity, degree of calcifica- tion, age, and atherosclerotic risk factors. In BAV, progression is faster in those patients with greater closure-line eccentricity and an anteroposterior-oriented line of closure. Prognosis is good and sudden death is rare in asymptomatic patients with good exercise tolerance, even when stenosis is severe. 171\nOnce symptoms (angina pectoris, dyspnoea, or syncope) occur, the prognosis deteriorates rapidly. In patients with BAV, cardiac mor- tality has been reported to be 0.3% per patient-year of follow-up, the frequency of aortic dissection 0.03%, and endocarditis 0.3%. Dilated aortic sinuses and/or ascending aorta have been found in 45% of patients after 9 years of follow-up. 172\n4.5.1.3 Diagnostic work-up See  section 3.3  for general principles. Diagnostic criteria for degree of AS are summarized in  Table  12 .\nRecommendations for intervention in patent ductus arteriosus\nRecommendations Class a Level b\nIn patients with evidence of LV volume overload c\nand no PAH (no non-invasive signs of PAP eleva-\ntion or invasive conﬁrmation of PVR <3 WU in\ncase of such signs), PDA closure is recommended regardless of symptoms.\nI C\nDevice closure is recommended as the method of\nchoice when technically suitable. I C\nIn patients who have developed PAH with PVR 3 \u0002 5 WU, PDA closure should be considered\nwhen there is still signiﬁcant L \u0002 R shunt\n(Qp:Qs >1.5).\nIIa C\nIn patients who have developed PAH with PVR\n>_5 WU, PDA closure may be considered when\nthere is still signiﬁcant L \u0002 R shunt (Qp:Qs >1.5) but careful individual decision in expert centres is\nrequired.\nIIb C\nPDA closure is not recommended in patients with\nEisenmenger physiology and patients with lower limb desaturation on exercise. d III C\nL \u0002 R = left-to-right; LV = left ventricle/ventricular; PAH = pulmonary arterial hypertension; PAP = pulmonary artery pressure; PDA = patent ductus arteriosus; PVR = pulmonary vascular resistance; Qp:Qs = pulmonary to systemic ﬂow ratio; WU = Wood units. a Class of recommendation. b Level of evidence. c LV enlargement with increased stroke volume. d There are limited data available for a precise cut-off, but by clinical experience, this would be given by a fall of arterial oxygen saturation <90%.\n598 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ...................\nSpecific clinical findings include the typical systolic ejection mur- mur over the aortic valve, radiating into the carotid arteries. An ejection click can be heard and a thrill may be palpable. The ECG may show LV hypertrophy (LVH) with or without strain. In patients diagnosed with a BAV, CoA should be excluded (see  sec- tion 4.6 ).\n•   Echocardiography is the gold standard for the diagnosis of AS and for assessing the degree of calcification, LV function, LVH, and associated lesions including ascending aortic dilatation. With Doppler echocardiography, the degree of AS severity is deter- mined from transvalvular peak velocity (V max ), mean gradient, and continuity equation-calculated aortic valve area (AVA). For more details, see recent recommendations for the echocardio- graphic assessment of AS. 173\n•   TOE may occasionally provide more anatomical details about valve dysfunction or AVA planimetry in non-calcified valves. •   Exercise testing is recommended in asymptomatic patients, par- ticularly in moderate-to-severe AS, to confirm asymptomatic sta- tus and evaluate exercise tolerance, blood pressure response, and arrhythmias for risk stratification and timing of surgery. •   Low-dose dobutamine or exercise stress echocardiography is helpful in AS with reduced stroke volume and impaired LV func- tion (classical low-flow, low-gradient AS). 173\n•   CMR/CCT, despite having potential for assessing AS, is mainly required to assess dilation of the ascending aorta, in cases where measurement is unreliable with echocardiography. •   CCT has become particularly important for the quantification of valve calcification when assessing AS severity in low- gradient AS, although it should be noted that aortic valve\n©ESC 2020\nFigure 4  Management of patent ductus arteriosus. LV = left ventricle/ventricular; Qp:Qs = pulmonary to systemic flow ratio; PAH = pulmonary artery hypertension; PDA = patent ductus arteriosus; PVR = pulmonary vascular resistance; WU = Wood units. a LV enlargement with increased stroke volume. b Includes all patients with lower limb desaturation at rest (Eisenmenger physiology) or on exercise. c Careful individual decision in expert centres is required.\nTable 12 Diagnostic criteria for degree of aortic stenosis severity 173\nMild AS Moderate AS Severe AS\nV max  (m/s) a 2.6 \u0002 2.9 3.0 \u0002 3.9 >_4.0\nMean gradient (mmHg) a <20 20 \u0002 39 >_40\nAVA (cm 2 ) >1.5 1.0 \u0002 1.5 <1.0\nAVAi (cm 2 /m 2   BSA) >0.85 0.60 \u0002 0.85 <0.60\nLVOT velocity/aortic valve velocity >0.50 0.25 \u0002 0.50 <0.25\nAS = aortic stenosis; AVA = aortic valve area; AVAi = indexed aortic valve area; BSA = body surface area; LVOT = left ventricular outﬂow tract; V max  = maximum Doppler velocity. a At normal transvalvular ﬂow.\nESC Guidelines 599\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ stenosis in young patients is not necessarily associated with sig- nificant calcification. •   Cardiac catheterization is only required if non-invasive evaluation yields uncertain results, for evaluation of coronary arteries, or when percutaneous balloon angioplasty is considered.\n4.5.1.4 Medical therapy Symptomatic patients require urgent surgery. Medical treatment for AS-related heart failure is reserved for non-operable patients. Neither statin treatment, nor any other medical treatment, has so far been shown to retard progression of AS.\n4.5.1.5 Surgical/catheter interventional treatment Indications for intervention are summarized in the  Recommendations for intervention in valvular aortic stenosis table  and in  Figure  5 . In selected adolescents and young adults with non-calcified valves, balloon valvuloplasty may be considered. This may be the case in haemodynamically unstable patients as a bridge to surgery or to delay valve replacement in women with anatomically suitable valves and desire of pregnancy. In patients with calcified valves, the treatment of choice is valve replacement. Mechanical valves are more durable than biological valves or homografts but require life- long anticoagulation. The Ross procedure (two-valve operation) has been suggested for patients of childbearing age and for those wanting to avoid anticoagulation. Progressive degeneration of the homograft after the Ross procedure is the most frequent reason for reintervention during follow-up. Transcatheter pulmonary valve implantation has become an alternative technique for surgi- cal treatment of the degenerated pulmonary valve. Transcatheter aortic valve implantation currently has no place in the treatment of congenital AS, except in very rare cases with high surgical risk, when technically feasible.\n4.5.1.6 Follow-up recommendations Lifelong and regular follow-up is required, and the intervals depend upon the degree of stenosis severity. It is also necessary after valve intervention at minimum yearly intervals. Echocardiographic imaging of the aortic valve and aortic root to determine progression of valve stenosis and aortic dilation is manda- tory. CMR or CCT of the aorta is recommended in patients with a native BAV, patients with a history of isolated valve replacement where the ascending aorta is not well visualized on TTE, and in patients with root/ascending diameters >40mm. 176\n4.5.1.7 Additional considerations\n•   Exercise/sports: patients with severe symptomatic and asympto- matic AS, and those with moderate stenosis due to BAV and dilated aorta, should avoid isometric exercise and high-intensity sports. In mild and moderate AS, more intensive physical activity is allowed. A prior exercise test to guide counselling is recommended. 24\n•   Pregnancy: contraindicated in severe symptomatic AS. Treatment by either balloon valvuloplasty or surgery should be performed before conception. In asymptomatic patients with severe AS and a normal exercise test, pregnancy may be possible in selected patients. The aorta requires particular attention as BAV-related\nRecommendations for intervention in valvular aortic stenosis\nRecommendations Class a Level b\nSymptomatic patients with aortic valve stenosis\nIn symptomatic patients with severe high-gra- dient AS (mean gradient >_40 mmHg), inter-\nvention is recommended. 25 , 171 , 174 , 175\nI B\nIntervention is indicated in symptomatic\npatients with severe low-ﬂow, low-gradient (mean gradient <40 mmHg) AS with reduced\nEF and evidence of ﬂow (contractile) reserve\nexcluding pseudosevere AS.\nI C\nAsymptomatic patients with severe aortic valve stenosis\nIntervention is indicated in asymptomatic\npatients with severe AS and an abnormal exer-\ncise test showing symptoms on exercise clearly related to AS.\nI C\nIntervention is indicated in asymptomatic\npatients with severe AS and systolic LV dys- function (LVEF <50%) not due to another\ncause.\nI C\nIntervention should be considered in asympto-\nmatic patients with severe AS when they present with a fall in blood pressure below\nbaseline during exercise testing.\nIIa C\nIntervention should be considered in asympto- matic patients with normal EF and none of the\nabove-mentioned exercise test abnormalities\nif the surgical risk is low and one of the follow- ing ﬁndings is present: •   Very severe AS deﬁned by a V max   >5.5 m/s. •   Severe valve calciﬁcation and a rate of V max progression >_0.3 m/s/year. •   Markedly elevated BNP levels (>3-fold age-\nand sex-corrected normal range) conﬁrmed by repeated measurements without other\nexplanation. •   Severe PH (systolic PAP at rest >60 mmHg conﬁrmed by invasive measurement) with-\nout other explanation.\nIIa C\nConcomitant aortic valve surgery at the time of other cardiac/\nascending aorta surgery\nSurgery is recommended when patients with\nsevere AS undergo surgery of the ascending\naorta or of another valve, or CABG.\nI C\nPatients with moderate AS undergoing CABG surgery or surgery of the ascending aorta or\nanother valve should be considered for addi-\ntional valve replacement.\nIIa C\nAS = aortic stenosis; BNP = B-type natriuretic peptide; CABG = coronary artery bypass graft; EF = ejection fraction; LV = left ventricle/ventricular; LVEF = left ventricular ejection fraction; PAP = pulmonary artery pressure; PH = pulmonary hypertension; V max  = maximum Doppler velocity. a Class of recommendation. b Level of evidence.\n600 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. .............................................................. aortic dilation may be induced and progress during and after preg- nancy; there is a risk of dissection (see  section 3.5.7 ). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n4.5.2 Supravalvular aortic stenosis 4.5.2.1 Introduction and background Supravalvular AS (SupraAS) may occur as a characteristic feature of Williams \u0002 Beuren syndrome or be isolated/familial, which are respectively caused by deletion of the elastin gene located on chro- mosome 7q11.23 or a mutation in this same gene. These genetic defects lead to obstructive arteriopathy of varying severity, which is most pronounced at the sinotubular junction. 177\nSupraAS may also be encountered in the setting of familial homo- zygous hypercholesterolaemia. 178   SupraAS occurs as a localized fibrous diaphragm just distal to the coronary ostia or, most com- monly, as an external hourglass deformity with a corresponding lumi- nal narrowing of the aorta, or as diffuse stenosis of the ascending aorta. It may be associated with aortic valve abnormalities, hypoplasia of the entire aorta, involvement of coronary ostia, or stenosis of major branches of the aorta or PAs.\n4.5.2.2 Clinical presentation and natural history The majority of patients present in childhood with symptoms of either outflow obstruction or myocardial ischaemia. While progression of SupraAS is rare in adulthood, adults remain at risk for cardiac complica- tions. 179   Sudden death occurs rarely, but it is more common in SupraAS with Williams \u0002 Beuren syndrome, with diffuse peripheral PA stenosis, or with CAD, particularly related to anaesthetic procedures.\n4.5.2.3 Diagnostic work-up See  section 3.3  for general principles. Auscultation typically reveals a loud systolic ejection murmur best heard at the left lower sternal border without associated ejection click or diastolic murmur of AR.\n•   Echocardiography enables the anatomic diagnosis of SupraAS when the acoustic window allows. Doppler echocardiography provides pressure gradients, but these may over- or underesti- mate the actual pressure drop across the obstruction. TOE allows good visualization of the coronary ostia and 3D TOE can be used for detailed evaluation of the stenotic region. 180\n•   For exercise testing, see valvular AS ( section 4.5.1 ).\n©ESC 2020\nFigure 5  Management of severe left ventricular outflow tract obstruction. AS = aortic stenosis; LVEF = left ventricular ejection fraction; LVOTO = left ventricular outflow tract obstruction; PAP = pulmonary artery pressure; PH = pulmonary hypertension; SubAS = subaortic stenosis SupraAS = supravalvular aortic stenosis. a See  Section 4.5 . There are fundamental differences in management decisions compared to valvular AS, particularly because a valve substitute with its con- sequences is generally not required. b Peak velocity >5.5m/s; severe calcification  þ  peak velocity progression >_0.3 m/s/y; markedly elevated neurohormones (>3-fold age- and sex-corrected normal range); severe PH (systolic PAP >60 mmHg without other explanation).\nESC Guidelines 601\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ •   CMR/CCT is useful for detailed evaluation of supravalvular anat- omy, in particular, when multilevel LVOTO is present or for (pre-operative) assessment of coronary artery anatomy and other aortic or aortic branch lesions (e.g. carotid and renal artery stenosis), and central and branch PAs. •   Cardiac catheterization: haemodynamic assessment is recom- mended when non-invasive quantification remains uncertain. •   Genetic evaluation, with counselling and subsequent testing using micro-array techniques to diagnose Williams \u0002 Beuren syndrome and sequencing of the elastin gene in non-syndromic presenta- tions, is useful.\n4.5.2.4 Surgical/catheter interventional treatment Surgery is the primary treatment: the operative mortality rate for fibrous diaphragm and hourglass deformity is <5%. Since the coronary arteries are under high pressure, surgery might be considered earlier than in patients with valvular AS, particularly when no valve substitute is required. Following operative repair, the survival rate has been reported to be 80 \u0002 85% at 20 years. 181   AR may be present in  \u0003 25% of patients, but usually it is not progressive after surgical relief of SupraAS.\n4.5.2.5 Follow-up recommendations Lifelong and regular follow-up, including echocardiography, is required to determine progression of obstruction (rare), LV size/ function, and development of symptoms, as well as after surgery to detect late restenosis, development of aneurysm (CMR/CCT), and the occurrence or progression of CAD. Follow-up should include evaluation in specialized ACHD centres.\n4.5.2.6 Additional considerations\n•   Exercise/sports: see valvular AS ( section 4.5.1 ). •   Pregnancy: See valvular AS ( section 4.5.1 ). Male and female patients with Williams \u0002 Beuren syndrome and elastin gene mutations have a 50% transmission risk (family screening recommended). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n4.5.3 Subaortic stenosis 4.5.3.1 Introduction and background Subaortic stenosis (SubAS) occurs as an isolated lesion, but is frequently associated with aortic valve disease, VSD, AVSD, or Shone complex (multilevel left heart obstruction). It may also develop after repair of these lesions. It is caused by a fibrous ridge/ring in the LVOT proximal to the aortic valve or as a fibromuscular narrowing. SubAS has to be dif- ferentiated from obstructive hypertrophic cardiomyopathy.\n4.5.3.2 Clinical presentation and natural history The clinical course is highly variable. The presence of associated CHD, particularly a VSD, is related with SubAS progression; age seems not to play a role in disease. AR is frequent but rarely haemo- dynamically significant or progressive. 182   Although infrequent, sudden death has been reported in SubAS patients.\n4.5.3.3 Diagnostic work-up See  section 3.3  for general principles. Clinical findings mainly include a systolic ejection murmur at the left sternal border without systolic ejection click. A diastolic murmur refers to AR.\n•   Echocardiography visualizes LVOT anatomy, associated aortic valve abnormality, degree of AR, LV function, LVH, and associ- ated lesions. With Doppler echocardiography, the severity of the subvalvular obstruction is determined, but Doppler-derived gra- dients may overestimate the obstruction and may require confir- mation by cardiac catheterization. Occasionally, TOE is necessary to better demonstrate the membrane or ring. 3D TOE can be helpful to characterize the complex LVOT anatomy and estimate the area of obstruction by planimetry. •   CMR may be useful to characterize complex LVOTO anatomies, especially in patients with poor acoustic window.\n4.5.3.4 Surgical/catheter interventional treatment Surgical treatment is the only effective intervention and involves a complete resection of the fibrous ridge/ring and parts of the muscular base along the left septal surface. Fibromuscular or tunnel-type SubAS requires more extensive resection or a Konno procedure. Surgical results are good, but restenosis may occur. In patients with low surgical risk and morphologically well suited to repair, the thresh- old for intervention is lower than in aortic valve stenosis since no valve implant is required. In the case of moderate or severe AR, the aortic valve must be repaired or replaced at the time of surgery.\n4.5.3.5 Follow-up recommendations Lifelong regular follow-up, including echocardiography, is required in the non-operated state to determine progression of obstruction, AR, and LV hypertrophy, function, and size. Regular post-operative follow-\nRecommendations for intervention in supravalvular aortic stenosis\nRecommendations Class a Level b\nIn patients with symptoms (spontaneous or on\nexercise test) and mean Doppler gradient >_40 mmHg, surgery is recommended.\nI C\nIn patients with mean Doppler gradient <40\nmmHg, surgery is recommended when one or more of the following ﬁndings are present:\n\u0004  Symptoms attributable to obstruction (exer-\ntional dyspnoea, angina, syncope). \u0004  LV systolic dysfunction (EF <50% without\nother explanation).\n\u0004  Surgery required for signiﬁcant CAD or valvu- lar disease.\nI C\nPatients with mean Doppler gradient >_40\nmmHg c   \u0002  but without symptoms, LV systolic\ndysfunction, LVH, or abnormal exercise test  \u0002 may be considered for repair when the surgical\nrisk is low.\nIIb C\nCAD = coronary artery disease; EF = ejection fraction; LV = left ventricle/ven- tricular; LVH = left ventricular hypertrophy. a Class of recommendation. b Level of evidence. c Doppler-derived gradients may overestimate the obstruction and may need con- ﬁrmation by left heart catheterization.\n602 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ........................................................................................................................................................................ up is also necessary to detect and observe late restenosis, progressive AR, and complications such as arrhythmias, heart block, and iatrogenic VSD. Follow-up should include evaluation in specialized ACHD centres, and the frequency is related to the expected disease progression.\n4.5.3.6 Additional considerations\n•   Exercise/sports: see valvular AS ( section 4.5.1 ). •   Pregnancy: only contraindicated in severe, symptomatic SubAS where surgery should be performed before pregnancy (even in asymptomatic severe SubAS, surgery should be considered) (see section 3.5.7 ). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n",
      "keywords": [
        "ejection fraction",
        "should be considered",
        "left",
        "tract",
        "obstruction",
        "genetic",
        "physical activity",
        "systolic",
        "outflow",
        "anticoagulation",
        "valvular",
        "age",
        "hypertension",
        "blood pressure",
        "risk stratification",
        "pulmonary hypertension",
        "syncope",
        "lvef",
        "aneurysm",
        "diastolic",
        "cause",
        "aortic",
        "carotid",
        "male",
        "valve replacement",
        "sex",
        "background",
        "bnp",
        "echocardiography",
        "level b"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 599",
          "page_number": 36,
          "content": " | Mild AS | Moderate AS | Severe AS\nV (m/s)a\nmax | 2.6\u00022.9 | 3.0\u00023.9 | >4.0\n_\nMean gradient (mmHg)a | <20 | 20\u000239 | >40\n_\nAVA (cm2) | >1.5 | 1.0\u00021.5 | <1.0\nAVAi (cm2/m2 BSA) | >0.85 | 0.60\u00020.85 | <0.60\nLVOT velocity/aortic\nvalve velocity | >0.50 | 0.25\u00020.50 | <0.25",
          "bbox": [
            310.94520430131394,
            471.45806884765625,
            553.651353624132,
            559.3568987165179
          ],
          "function_potential": "raw"
        },
        {
          "title": "600 ESC Guidelines",
          "page_number": 37,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nSymptomatic patients with aortic valve stenosis |  | \nIn symptomatic patients with severe high-gra-\ndient AS (mean gradient >40 mmHg), inter-\n_\nvention is recommended.25,171,174,175 | I | B\nIntervention is indicated in symptomatic\npatients with severe low-flow, low-gradient\n(mean gradient <40 mmHg) AS with reduced\nEF and evidence of flow (contractile) reserve\nexcluding pseudosevere AS. | I | C\nAsymptomatic patients with severe aortic valve stenosis |  | \nIntervention is indicated in asymptomatic\npatients with severe AS and an abnormal exer-\ncise test showing symptoms on exercise\nclearly related to AS. | I | C\nIntervention is indicated in asymptomatic\npatients with severe AS and systolic LV dys-\nfunction (LVEF <50%) not due to another\ncause. | I | C\nIntervention should be considered in asympto-\nmatic patients with severe AS when they\npresent with a fall in blood pressure below\nbaseline during exercise testing. | IIa | C\nIntervention should be considered in asympto-\nmatic patients with normal EF and none of the\nabove-mentioned exercise test abnormalities\nif the surgical risk is low and one of the follow-\ning findings is present:\n• Very severe AS defined by a V >5.5 m/s.\nmax\n• Severe valve calcification and a rate of V\nmax\nprogression >0.3 m/s/year.\n_\n• Markedly elevated BNP levels (>3-fold age-\nand sex-corrected normal range) confirmed\nby repeated measurements without other\nexplanation.\n• Severe PH (systolic PAP at rest >60 mmHg\nconfirmed by invasive measurement) with-\nout other explanation. | IIa | C\nConcomitant aortic valve surgery at the time of other cardiac/\nascending aorta surgery |  | \nSurgery is recommended when patients with\nsevere AS undergo surgery of the ascending\naorta or of another valve, or CABG. | I | C\nPatients with moderate AS undergoing CABG\nsurgery or surgery of the ascending aorta or\nanother valve should be considered for addi-\ntional valve replacement. | IIa | C",
          "bbox": [
            42.519301585662056,
            86.47422485351562,
            285.54363992769424,
            674.6422576904297
          ],
          "function_potential": "raw"
        },
        {
          "title": "602 ESC Guidelines",
          "page_number": 39,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIn patients with symptoms (spontaneous or on\nexercise test) and mean Doppler gradient >40\n_\nmmHg, surgery is recommended. | I | C\nIn patients with mean Doppler gradient <40\nmmHg, surgery is recommended when one or\nmore of the following findings are present:\n\u0004 Symptoms attributable to obstruction (exer-\ntional dyspnoea, angina, syncope).\n\u0004 LV systolic dysfunction (EF <50% without\nother explanation).\n\u0004 Surgery required for significant CAD or valvu-\nlar disease. | I | C\nPatients with mean Doppler gradient >40\n_\nmmHgc \u0002 but without symptoms, LV systolic\ndysfunction, LVH, or abnormal exercise test \u0002\nmay be considered for repair when the surgical\nrisk is low. | IIb | C",
          "bbox": [
            42.60677194595337,
            336.4897745768229,
            284.9793737074908,
            567.0382603236607
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 603",
          "page_number": 40,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIn symptomatic patients (spontaneous or on\nexercise test) with a mean Doppler gradient\n>40 mmHgc or severe AR, surgery is\n_\nrecommended. | I | C\nAsymptomatic patients should be considered\nfor surgery when one or more of the following\nfindings are present:\n• Mean gradient <40 mmHg but LVEF <50%.\n• AR is severe and LVESD >50 mm\n(or 25 mm/m2 BSA) and/or EF <50%d.\n• Mean Doppler gradient is > _40 mmHgc and\nmarked LVH present.\n• Mean Doppler gradient is >40 mmHgc and\n_\nthere is a fall in blood pressure below baseline\non exercise. | IIa | C\nAsymptomatic patients may be considered for\nsurgery when one or more of the following find-\nings are present:\n• Mean Doppler gradient is > _40 mmHg,c LV is\nnormal (EF >50% and no LVH), exercise test-\ning is normal, and surgical risk is low.\n• Progression of AR is documented and AR\nbecomes more than mild (to prevent further\nprogression). | IIb | C",
          "bbox": [
            47.14195919036865,
            132.90536702473958,
            289.5152130126953,
            447.4671827043806
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "34",
      "title": "4.6 Coarctation of the aorta 4.6.1 Introduction and background CoA is considered as part of a generalized arteriopathy, and not only as narrowing of the aorta. It occurs as a discrete stenosis or as a",
      "start_page": 40,
      "end_page": 41,
      "content": "area where the ductus arteriosus inserts, and only in rare cases occurs ectopically (ascending, descending, or abdominal aorta). Associated lesions include BAV (up to 85%), ascending aortic aneurysm, SubAS, or SupraAS, (supra)mitral valve stenosis (including parachute mitral valve), Shone complex, or complex congenital heart defects. CoA can be associated with Turner syndrome and Williams \u0002 Beuren syndrome. Extracardiac vascular anomalies have been reported in CoA patients including anomalous origin of the right subclavian artery (in 4 \u0002 5% of cases), collateral arterial circula- tion, and intracerebral aneurysms (in up to 10%).\n4.6.2 Clinical presentation and natural history Signs and symptoms depend on the severity of CoA. Patients with severe CoA usually present with signs and symptoms early in life, while particularly mild cases may not become evident until adult- hood, where CoA is detected in the work-up of arterial hypertension. Key symptoms may include headache, nosebleeds, dizziness, tinnitus, shortness of breath, abdominal angina, claudication, and cold feet. Patients with CoA who reach adolescence demonstrate very good long-term survival up to age 60 years. Long-term morbidity is com- mon, however, largely related to aortic complications and longstand- ing hypertension. 183\nThe natural course may be complicated by left heart failure, intra- cranial haemorrhage (from berry aneurysm), IE, aortic rupture/dis- section, premature coronary and cerebral artery disease, and associated heart defects.\n4.6.3 Diagnostic work-up See  section 3.3  for general principles. Office blood pressure measurement in the upper and lower extremities are the primary studies required in all coarctation patients. A blood pressure gradient between upper and lower extremities (systolic >_20 mmHg) indicates significant CoA. Weak or absent pulses in the lower extremities or radiofemoral pulse delay also indicate significant coarctation.\n•   Ambulatory blood pressure measurements (right arm) are rec- ommended to detect/confirm arterial hypertension (24-h mean systolic >130 mmHg and/or diastolic >80 mmHg). •   Other findings consist of a suprasternal thrill (proximal obstruc- tion), an interscapular (systolic) murmur, or continuous murmurs (due to collateral vessels). In the case of a pinpoint CoA, mur- murs may be completely absent. •   Chest X-ray findings may be characterized by rib notching of the third and fourth (to the eighth) ribs due to the collaterals. •   Echocardiography provides information regarding site, structure, and extent of CoA, LV function and LVH, associated cardiac abnormalities, and aortic and supra-aortic vessel diameters. Doppler gradients are not useful for quantification, neither in native nor in post-operative coarctation. In the presence of extensive collateral arteries, gradients are not reliable and are often underestimated. After surgical repair or stenting, increased systolic flow rates may develop, even in the absence of significant narrowing, due to decreased/absent aortic compliance and\nRecommendations for intervention in subaortic stenosis\nRecommendations Class a Level b\nIn symptomatic patients (spontaneous or on exercise test) with a mean Doppler gradient\n>_40 mmHg c   or severe AR, surgery is\nrecommended.\nI C\nAsymptomatic patients should be considered\nfor surgery when one or more of the following\nﬁndings are present: •   Mean gradient <40 mmHg but LVEF <50%. •   AR is severe and LVESD >50 mm\n(or 25 mm/m 2   BSA) and/or EF <50% d . •   Mean Doppler gradient is >_40 mmHg c  and\nmarked LVH present. •   Mean Doppler gradient is >_40 mmHg c  and there is a fall in blood pressure below baseline\non exercise.\nIIa C\nAsymptomatic patients may be considered for\nsurgery when one or more of the following ﬁnd- ings are present: •   Mean Doppler gradient is >_40 mmHg, c  LV is\nnormal (EF >50% and no LVH), exercise test- ing is normal, and surgical risk is low. •   Progression of AR is documented and AR\nbecomes more than mild (to prevent further progression).\nIIb C\nAR = aortic regurgitation; BSA = body surface area; EF = ejection fraction; ESC = European Society of Cardiology; LV = left ventricle/ventricular; LVEF = left ven- tricular ejection fraction; LVESD = left ventricular end systolic diameter; LVH = left ventricular hypertrophy. a Class of recommendation. b Level of evidence. c Doppler-derived gradients may overestimate the obstruction and may need con- ﬁrmation by cardiac catheterization. d See 2017 ESC Guidelines on the management of valvular heart disease. 25\nESC Guidelines 603\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ..................................................................\nDoppler-related pressure recovery. The gradient is then overes- timated. A diastolic tail in the descending aorta and diastolic for- ward flow in the abdominal aorta are findings of significant (re-)CoA. •   CMR and CCT, including 3D reconstruction, are the preferred non-invasive techniques to evaluate the entire aorta in adoles- cents and adults. Both depict site, extent, and degree of the aortic narrowing, the aortic arch and head and neck vessels, the pre- and post-stenotic aorta, and collaterals. Both methods detect complications such as aneurysms, false aneurysms, restenosis, or residual stenosis. 184\n•   Imaging of intracerebral vessels is indicated in the case of symp- toms and/or clinical manifestations of aneurysms/rupture. •   Cardiac catheterization with manometry (a peak-to-peak gra- dient >_20 mmHg) indicates a haemodynamically significant CoA in the absence of well-developed collaterals and is performed in the setting of interventional treatment. It should be noted that, in patients under general anaesthesia, invasive measurement of gra- dient may be underestimated.\n4.6.4 Surgical/catheter interventional treatment Indications for intervention are summarized in the  Recommendations for intervention in coarctation and re-coarctation of the aorta  table and in Figure  6 . In native CoA, as well as re-coarctation with appropriate anatomy, stenting has become the first-choice treatment in many ACHD centres. 185   The use of covered stents is preferred because of lower short- and long-term complication rates. 186   Biodegradable stents are in development but are mainly applied in children when the aorta is still expected to grow.\nBalloon angioplasty in adults is only indicated for re-dilatation of previously stented aortas. While paediatric surgical techniques include resection and end-to- end anastomosis, resection and extended end-to-end anastomosis, prosthetic patch aortoplasty, subclavian flap aortoplasty, interposi- tion of a (tube) graft, and bypass tube (jump) grafts, only the latter two are generally feasible in adults. Ascending-to-descending aorta conduits may be preferable in adults with difficult anatomy. Although the surgical risk in simple CoA may currently be <1%, it increases sig- nificantly beyond the age of 30 \u0002 40 years. Spinal cord injury has become extremely rare. 187\n",
      "keywords": [
        "ejection fraction",
        "should be considered",
        "systolic",
        "age",
        "hypertension",
        "blood pressure",
        "discrete",
        "considered",
        "aneurysm",
        "lvef",
        "diastolic",
        "aortic",
        "only",
        "coarctation",
        "arteriopathy",
        "background",
        "echocardiography",
        "level b",
        "introduction",
        "heart failure",
        "narrowing",
        "exercise",
        "recommended",
        "may be considered",
        "stenosis",
        "aorta",
        "catheterization",
        "occurs",
        "aortic regurgitation",
        "generalized"
      ],
      "tables": [
        {
          "title": "604 ESC Guidelines",
          "page_number": 41,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nRepair of coarctation or re-coarctation (surgi-\ncally or catheter based) is indicated in hyperten-\nsive patientsc with an increased non-invasive\ngradient between upper and lower limbs con-\nfirmed with invasive measurement (peak-to-\npeak >20 mmHg) with preference for catheter\n_\ntreatment (stenting), when technically feasible. | I | C\nCatheter treatment (stenting) should be consid-\nered in hypertensive patientsc with >50% nar-\n_\nrowing relative to the aortic diameter at the\ndiaphragm, even if the invasive peak-to-peak gra-\ndient is <20 mmHg, when technically feasible. | IIa | C\nCatheter treatment (stenting) should be consid-\nered in normotensive patientsc with an\nincreased non-invasive gradient confirmed with\ninvasive measurement (peak-to-peak >20\n_\nmmHg), when technically feasible. | IIa | C\nCatheter treatment (stenting) may be consid-\nered in normotensive patientsc with >50% nar-\n_\nrowing relative to the aortic diameter at the\ndiaphragm, even if the invasive peak-to-peak gra-\ndient is <20 mmHg, when technically feasible. | IIb | C",
          "bbox": [
            306.9268421373869,
            86.47422485351562,
            549.2560706505409,
            378.24516732352123
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "35",
      "title": "As coarctation is not a localized disease of the aorta, associated lesions that may require structural interventions have to be considered:",
      "start_page": 41,
      "end_page": 42,
      "content": "•   Associated significant aortic valve stenosis or regurgitation (BAV). •   Aneurysm of the ascending aorta with a diameter >50 mm or rapid progression of diameter. •   Aneurysm and false aneurysms at the previous CoA site. •   Symptomatic or large aneurysms of the circle of Willis.\nTreatment should be performed in centres with extensive experi- ence in the treatment of CHD.\n4.6.5 Follow-up recommendations Residua, sequelae, and complications are listed below:\n•   Arterial hypertension at rest or during exercise is common, even after successful treatment, and is an important risk factor for pre- mature CAD, ventricular dysfunction, and rupture of aortic or cerebral aneurysms. 188\n•   The geometry of the arch (gothic, crenel, normal) and smaller aortic size in the stented region may play a role in the develop- ment of hypertension. Right arm 24-h ambulatory blood pressure measurement better detects hypertension than a one-off meas- urement. 189   The significance of isolated, exercise-induced hyper- tension is a matter of debate. •   An increased pressure gradient (systolic >_20 mmHg) between upper and lower extremities indicates re-coarctation and war- rants invasive assessment for confirmation and treatment. •   Medical treatment of arterial hypertension should follow the 2018 ESC/ESH Guidelines. 190\n•   Recurring or residual CoA may induce or aggravate systemic arterial hypertension and its complications. •   Aneurysms of the ascending aorta or at the intervention site present a risk of rupture and death. Patch repairs (e.g. with Dacron) are at particular risk of repair-site aneurysms, while\nRecommendations for intervention in coarctation and re-coarctation of the aorta\nRecommendations Class a Level b\nRepair of coarctation or re-coarctation (surgi-\ncally or catheter based) is indicated in hyperten- sive patients c   with an increased non-invasive\ngradient between upper and lower limbs con-\nﬁrmed with invasive measurement (peak-to- peak >_20 mmHg) with preference for catheter\ntreatment (stenting), when technically feasible.\nI C\nCatheter treatment (stenting) should be consid- ered in hypertensive patients c   with >_50% nar-\nrowing relative to the aortic diameter at the\ndiaphragm, even if the invasive peak-to-peak gra- dient is <20 mmHg, when technically feasible.\nIIa C\nCatheter treatment (stenting) should be consid-\nered in normotensive patients c   with an\nincreased non-invasive gradient conﬁrmed with invasive measurement (peak-to-peak >_20\nmmHg), when technically feasible.\nIIa C\nCatheter treatment (stenting) may be consid- ered in normotensive patients c   with >_50% nar-\nrowing relative to the aortic diameter at the\ndiaphragm, even if the invasive peak-to-peak gra- dient is <20 mmHg, when technically feasible.\nIIb C\na Class of recommendation. b Level of evidence. c Right arm ambulatory blood pressure monitoring should be considered for the diagnosis of hypertension.\n604 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................ interposition grafts are at particular risk of false aneurysms, 191\nand both should be imaged on a regular basis. •   Attention is required for BAV, mitral valve disease, premature CAD, and berry aneurysms of the circle of Willis (routine screen- ing in asymptomatic patients is not recommended).\nAll CoA patients require regular follow-up at least every year. Imaging of the aorta (preferably with CMR) is required to document post-repair or post-interventional anatomy and complications (restenosis, aneurysm, false aneurysm formation). Recommended imaging intervals are com- monly every 3 \u0002 5 years but also depend on baseline pathology.\n4.6.6 Additional considerations\n•   Exercise/sports: patients without residual obstruction, who are normotensive at rest and with exercise, can usually lead normally active lives without restriction. Patients with arterial hyperten- sion, residual obstruction, or other complications should avoid heavy isometric exercises in proportion to the severity of their problems. •   Pregnancy: after successful treatment of CoA, many women toler- ate pregnancy without major problems. 43   In particular, women with unrepaired CoA  \u0002  but also those after repair with arterial hypertension, residual CoA, or aortic aneurysms  \u0002  have an increased risk of aortic rupture and rupture of a cerebral\naneurysm during pregnancy and delivery. An excess of miscar- riages and hypertensive disorders has been reported 192   (see  sec- tion 3.5.7 ). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n",
      "keywords": [
        "risk factor",
        "should be considered",
        "systolic",
        "disease",
        "interventions",
        "hypertension",
        "require",
        "blood pressure",
        "considered",
        "aneurysm",
        "lesions",
        "aortic",
        "coarctation",
        "level b",
        "localized",
        "structural",
        "exercise",
        "associated",
        "recommended",
        "aorta",
        "stenosis"
      ],
      "tables": []
    },
    {
      "number": "36",
      "title": "4.7 Aortopathies 4.7.1 Marfan syndrome and related heritable thoracic aortic diseases 4.7.1.1 Introduction and background Marfan syndrome is the prototype of syndromic HTAD entities, comprising a clin",
      "start_page": 42,
      "end_page": 47,
      "content": "©ESC 2020\nFigure 6  Management of coarctation and re-coarctation of the aorta. CoA = coarctation of the aorta. a Right arm ambulatory blood pressure should be considered for diagnosis. b Invasively confirmed measurement. c Relative to the aortic diameter at the diaphragm.\nESC Guidelines 605\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ...................................................................................................................................................................... 4.7.1.2 Clinical presentation and natural history Although thoracic aortic disease  \u0002  either aneurysms detected by screening or dissection in an emergency setting  \u0002  is the principal characteristic in Marfan syndrome /HTAD, extra-aortic features in the skeletal/ocular organ system may be the key to diagnosis in some patients. Prognosis in all HTAD entities is mainly determined by progres- sive dilation of the aorta, leading to aortic dissection or rupture. Prognosis varies according to the underlying genetic defect. The average age at death in untreated Marfan syndrome patients is <40 years, but can approach that of the general population in patients in whom the diagnosis is known and who are properly managed. 29 , 194   More rare cardiovascular causes of death include heart failure and SCD. 29\nIn Marfan syndrome, the major determinant of type A aortic dis- section is the aortic root diameter with increased risk of rupture >_50 mm. 195   Other risk factors include family history of aortic dissection at low diameter, 193   aortic root growth rate, pregnancy, and hyper- tension. Increasing evidence for gene-based differences in aortic risk are emerging and need to be considered. Other parts of the aorta  \u0002 or in the case of some entities, major branching vessels  \u0002  may also dilate or dissect.\nThe presence of significant aortic, tricuspid, or mitral regurgita- tion  \u0002  usually related to valve prolapse  \u0002  may lead to symptoms of ventricular volume overload. However, LV disease may also occur independently of valvular dysfunction and this may be asso- ciated with arrhythmia. Mitral valve prolapse in patients with Marfan syndrome manifests early and progresses to severe regur- gitation, need for surgery, and IE earlier than idiopathic mitral valve prolapse. 196\n4.7.1.3 Diagnostic work-up Early identification and establishment of the correct diagnosis is crit- ical since prophylactic surgery can prevent aortic dissection and rup- ture. This requires a multidisciplinary team approach with integration of clinical and genetic findings. 197   The diagnosis of Marfan syndrome is based on the Ghent criteria, with aortic root aneurysm/dissection and ectopia lentis as cardinal features. 198   Criteria for the other HTAD entities are less well defined.\nGene panel testing is meaningful for confirmation of the diagnosis and to guide management. Mutation pick-up rate in syndromic forms is higher (>90%) than in non-syndromic entities (20 \u0002 30%). 199   Once a pathogenic variant is identified, presymptomatic genetic screening of family members is mandatory to allow early and appropriate management.\n•   Echocardiographic assessment of the aortic root should include measurements at the annulus, sinus, sinotubular junc- tion, distal ascending, arch, and descending thoracic aortic lev- els. In adults, measurement at end diastole using the leading- to-leading edge principle is recommended. The values obtained should be corrected for the individual’s age, sex, and body size using standardized nomograms. 200 , 201   Valvular mor- phology (mitral valve prolapse, BAV) and function must be assessed, as well as the presence of a PDA. LV dimension and\nfunction should be addressed according to standard recommendations. •   CMR or CCT angiography from head to pelvis should be per- formed in every patient at baseline, providing imaging of the entire aorta and branching vessels. In addition to measuring aortic diameters, information on aortic/vertebral artery tor- tuosity is important for diagnostic and prognostic purposes. 202 , 203\n•   Holter monitoring should be performed in symptomatic patients, as ventricular arrhythmias, conduction disturbances, and SCD can occur.\n4.7.1.4 Medical therapy Although no reduction in mortality or dissection rate has been established in any trial, beta blockers remain the mainstay for medical treatment in Marfan/HTAD patients, reducing wall shear stress and aortic growth rate. 204   Rigorous antihypertensive medi- cal treatment aimed at a 24-h ambulatory systolic blood pressure <130 mmHg (110 mmHg in patients with aortic dissection) is important, although there are no data to establish outright blood pressure thresholds. ARBs did not prove to have a superior effect when compared with beta blockers or in addition to beta blockers in several trials, but may be considered as an alternative in patients intolerant to beta blockers. 205 , 206   Medical treatment should be continued after surgery.\nOngoing meta-analyses of medical treatment trials may help define subgroups  \u0002  based on genetic and clinical data  \u0002  who benefit from specific treatment. 207   Since no medical trials have been conducted in non-Marfan HTAD, medical treatment is usually adopted from Marfan data.\n4.7.1.5 Surgical treatment Indications for intervention are summarized in the Recommendations for aortic surgery in aortopathies table. Prophylactic aortic root surgery is the only definitive treatment for the prevention of aortic dissection in Marfan syndrome and related HTADs. In patients with anatomically normal aortic valves and low-grade regurgitation, a valve-sparing aortic root replace- ment by a Dacron prosthesis and reimplantation of the coronary arteries into the prosthesis (David procedure) has become the preferred surgical procedure with good long-term outcome, including in Marfan patients. 193 , 208   Composite graft replacement, usually with a mechanical valve, is a more durable alternative but does require lifelong anticoagulation. The decision on which tech- nique to use should be made on an individual basis, and patient preferences and surgical experience should be taken into account. 209\nMarfan and related HTADs are associated with a risk of re- dissection and recurrent aneurysm in the distal aorta, especially in patients with previous dissection. 210 , 211   With improved life expect- ancy, these complications now occur more frequently. Open aortic surgery remains the reference method for treatment of distal aortic disease, although hybrid procedures with endovascular stenting  \u0002 where proximal and distal landing is possible in a Dacron tube  \u0002 could be considered in selected cases.\n606 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ........................................................................................................................................................... 4.7.1.6 Follow-up recommendations Lifelong and regular multidisciplinary follow-up at an expert centre is required. Echocardiography and CCT/CMR are the principal examinations.\n4.7.1.7 Additional considerations\n•   Exercise/sports: patients should be advised to avoid exertion at maximal capacity, competitive, contact, and isometric sports. Risk estimation based on aortic size has been suggested by Budts et al . 24\n•   Pregnancy: in genetically confirmed Marfan/HTAD, there is a 50% transmission risk for both men and women. Proper and timely genetic counselling is needed. Women with an aortic root diameter >45 mm are strongly discouraged from becom- ing pregnant without prior repair because of the increased risk of dissection. 43   An aortic root diameter <40 mm rarely presents a problem, although a completely safe diameter does not exist. With an aortic root 40 \u0002 45 mm, previous aortic growth and family history are important factors when consid- ering repair prior to pregnancy. After repair of the ascending aorta, Marfan patients remain at risk for dissection of the residual aorta (see  section 3.5.7 ). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n4.7.2 Bicuspid aortic disease Depending on the reported series, 20 \u0002 84% of patients with a BAV will develop ascending aortic dilatation, 212   indicating that BAV should be regarded as part of a spectrum of valvluo-aortopathy and that bicuspid aortic disease may be a more appropriate term. Although the relative contribution of intrinsic/genetic wall abnormalities and altered haemodynamics remains debated, both factors are probably involved.\nIn the absence of significant valvular dysfunction, aortic dilatation in the setting of bicuspid aortic disease typically evolves asymptomatically. With increasing diameters, however, the risk for acute aortic dissection rises. Compared with the general population, the dissection incidence in bicuspid aortic disease patients is eight times higher, which is in absolute num- bers still a low risk (31/100 000 patient years) 172 , 176 , 213   and much lower than in Marfan/HTAD. Observational studies indicate that the clinical outcome in bicuspid aortic disease patients is more similar to that of the general population with aneurysms and represents a more benign aortopathy than Marfan/ HTAD. 176 , 214\nCoA is associated with an increased risk for dissection. 215\nFor diagnostic work-up see section  4.7.1.3 . To this date, no evidence for medical treatment of aortic dilatation in the setting of bicuspid aortic disease is available, but it may be\nreasonable to consider beta blockers or ARBs as first-line treatment for arterial hypertension. Indications for intervention are summarized in the Recommendations for aortic surgery in aortopathies  table. Familial occurrence of BAV has clearly been established with rates of 5 \u0002 10% in first-degree relatives in various studies. 216\nEchocardiographic screening in first-degree relatives of BAV patients is recommended and may be appropriate, particularly in boys, in athletes, and if hypertension is present. Rare pathogenic variants in a number of genes account for <5% of all bicuspid aortic disease cases and routine genetic testing in this setting is not indicated but may be considered in familial cases. 140\nThere are no data on the risk for dissection related to pregnancy in women with a dilated aorta. According to the 2018 ESC Guidelines for the management of cardiovascular disease during pregnancy, 43   women should be counselled against pregnancy when the aortic diameter is >50 mm.\nFor treatment of AR, see 2017 ESC/EACTS Guidelines on the management of valvular heart disease. 25\n4.7.3 Turner syndrome Turner syndrome is caused by a partial or complete monosomy of the X-chromosome and occurs in 1 in 2500 live-born females. 217\nTurner syndrome is associated with short stature, delayed pub- erty, ovarian dysgenesis, hypergonadotropic hypogonadism, infer- tility, congenital malformations of the heart, diabetes mellitus, osteoporosis, and autoimmune disorders. CHD, occurring in approximately 50% of women with Turner syndrome, includes a high incidence of BAV, CoA, partial anomalous pulmonary venous connection, left SVC, elongated transverse aortic arch, dilatation of the brachiocephalic arteries, and aortic dilatation. Given this high prevalence of abnormalities, every woman with Turner syn- drome should be seen by a cardiologist at least once. 217   Even in the absence of CHD, all individuals with Turner syndrome have a generalized arteriopathy and Turner syndrome alone is an inde- pendent risk factor for thoracic aortic dilation. Aortic dissection (both type A and type B) occurs in approximately 40 per 100 000 person-years compared with 6 per 100 000 person-years in the general population. 218\nFor diagnostic work-up see section  4.7.1.3 . Indications for intervention are summarized in the Recommendations for aortic surgery in aortopathies  table. With advances in assisted reproductive technology and oocyte donation, an increasing number of women with Turner syndrome are now able to become pregnant. The presence of aortic dilatation and CHD increases the risks of pregnancy and Turner syndrome women are also at increased risk of hypertensive disorders, including pre-eclampsia. All women with Turner syndrome should be coun- selled about the increased cardiovascular risk of pregnancy and fertil- ity treatment. 43\nESC Guidelines 607\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.8 Right ventricular outflow tract obstruction 4.8.1 Introduction and background RVOTO can occur at the sub-infundibular, infundibular, valvular, or supravalvular levels.\n•   Sub-infundibular stenosis, or DCRV, is commonly associated with a VSD. It is caused by narrowing between prominent and hypertrophied muscle bands or ridges that separate the hyper- trophied, high-pressure inlet and apical portions from a low- pressure, non-hypertrophied and non-obstructive infundibular portion of the RV. 219\n•   Infundibular stenosis usually occurs in combination with other lesions, particularly VSD, TOF, and secondary to valvular pulmo- nary stenosis (PS) (reactive myocardial hypertrophy). At the infundibular level, and to some extent the sub-infundibular level, the obstruction tends to be dynamic, meaning that the orifice narrows during systole. •   Valvular PS is usually an isolated lesion. Mainly due to intrinsic wall abnormalities, and independent of haemodynamics, dilation of the PA may occur. Most often, there is a typical dome-shaped pulmonary valve with a narrow central opening but a preserved mobile valve base. A dysplastic pulmonary valve, with poorly mobile cusps and myxomatous thickening, is less common (15 \u0002 20%; even less in untreated adults) and frequently part of Noonan syndrome. In adults, a stenotic pulmonary valve may cal- cify late in life. •   Supravalvular PS, or pulmonary arterial stenosis, is caused by narrowing of the main pulmonary trunk, pulmonary arterial bifurcation, or pulmonary branches. It seldom occurs in isola- tion, and may occur in Williams \u0002 Beuren syndrome, Noonan syndrome, congenital rubella syndrome, or Alagille syndrome. The stenosis may be located in the main branches or more peripherally; it may be discrete or diffuse (hypoplastic) or there may be frank occlusion, and it may occur as single or multiple stenoses. Stenosis may be secondary to previous placement of a PA band or at a previous shunt site. A diameter narrowing >_50% is usually considered to be significant and would be expected to have a pressure gradient and result in hypertension in the proximal PA.\n4.8.2 Clinical presentation and natural history\n•   Sub-infundibular/infundibular: adult patients with DCRV may be asymptomatic or they may present with dyspnoea, chest discom- fort, dizziness, or syncope during exertion. The degree of obstruction is progressive over time. 220\n•   Valvular: patients with mild-to-moderate valvular PS are usually asymptomatic. Mild valvular PS in unoperated adults is usually not progressive. 221   Moderate PS can progress at the valvular level (cal- cification) or at the subvalvular level due to reactive myocardial hypertrophy. Patients with severe stenosis may present with dysp- noea and reduced exercise capacity and have a worse prognosis. •   Supravalvular: patients may be asymptomatic or have symptoms of dyspnoea and reduced exercise capacity. They are usually recog- nized in the context of certain syndromes or in patients referred for suspicion of PH. Peripheral PA stenosis may progress in severity.\nRecommendations for aortic surgery in aortopathies\nRecommendations Class a Level b\nMarfan syndrome and HTAD\nAortic valve repair, using the reimplantation\nor remodelling with aortic annuloplasty tech-\nnique, is recommended in young patients with Marfan syndrome or related HTAD with\naortic root dilation and tricuspid aortic valves,\nwhen performed by experienced surgeons.\nI C\nSurgery is indicated in patients with Marfan syndrome who have aortic root disease with a\nmaximal aortic sinus diameter >_50 mm. c I C\nSurgery should be considered in patients with Marfan syndrome who have aortic root dis-\nease with maximal aortic sinus diameter >_45\nmm c   and additional risk factors. d\nIIa C\nSurgery should be considered in patients with a  TGFBR1  or  TGFBR2  mutation (including\nLoeys \u0002 Dietz syndrome) who have aortic\nroot disease with maximal aortic sinus diame- ter >_45mm. c\nIIa C\nBicuspid aortic disease\nAortic surgery should be considered if the\nascending aorta is: •   >_50 mm in the presence of a bicuspid valve\nwith additional risk factors e   or coarctation. •   >_55 mm for all other patients.\nIIa C\nTurner syndrome\nElective surgery for aneurysms of the aortic\nroot and/or ascending aorta should be consid-\nered for women with Turner syndrome who are >16 years of age, have an ascending aortic\nsize index >25 mm/m 2 , and have associated\nrisk factors for aortic dissection. f\nIIa C\nElective surgery for aneurysms of the aortic\nroot and/or ascending aorta may be consid-\nered for women with Turner syndrome who are >16 years of age, have an ascending aortic\nsize index >25 mm/m 2 , and do not have asso-\nciated risk factors for aortic dissection. f\nIIb C\nAR = aortic regurgitation; BAV = bicuspid aortic valve; ECG = electrocardiogram; BSA = body surface area; CoA = coarctation of the aorta; HTAD = heritable thoracic aortic disease. a Class of recommendation. b Level of evidence. c At the extreme ends of the BSA range, recommended cut-offs may require appropriate adjustment. d Family history of aortic dissection at a low diameter (or personal history of spontaneous vascular dissection), progressive AR, desire for pregnancy, uncon- trolled hypertension, and/or aortic size increase >3 mm/year (on repeated meas- urements using the same ECG-gated imaging technique measured at the same level of the aorta with side-by-side comparison and conﬁrmed by another technique). e Family history of dissection at a low diameter, desire for pregnancy, systemic hypertension, and/or size increase >3 mm/year (on repeated measurements using the same ECG-gated imaging technique, measured at the same level of the aorta with side-by-side comparison and conﬁrmed by another technique). f BAV, elongation of the transverse aorta, CoA, and/or hypertension.\n608 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ...........................................\n4.8.3 Diagnostic work-up See  section 3.3  for general principles. Clinical findings include a harsh systolic murmur across the obstruction and wide splitting of the second heart sound. In periph- eral PS, the systolic murmur is typically heard over the lung fields.\n•   Echocardiography: size, shape, and function of the RV can be assessed and the exact position/level of the RVOTO can be visualized, as well as pulmonary valve, main PA, and proximal PA branches. For quantification of RV sizes, volumes, and EF, CMR is a more robust and more reliable technique. Doppler ultrasound is used for measurements of flow velocities across an obstruction to assess severity. Correlation between flow velocities and pres- sure gradients is only good in the case of discrete stenosis, e.g. isolated valvular PS. In the presence of normal RV function and normal transvalvular flow, RVOTO is considered mild when the peak gradient across the obstruction is <36 mmHg, moderate if 36 \u0002 64 mmHg, and severe when the gradient is >64 mmHg. If the narrowing is elongated, or if more than one stenosis is present in series (e.g. subvalvular and valvular), application of the Bernoulli equation will lead to an overestimation of the pressure gradient. Doppler flow velocity of TR then gives a more reliable estimation of RV pressures  \u0002  and with that, severity of the RVOTO  \u0002  than the flow velocity across the RVOTO. Gradients only represent severity of an obstruction if a good systolic RV function is present. In a low-flow, low-gradient situation, it is very difficult to assess severity of a RVOTO. 222\n•   CMR and CCT frequently provide additional important informa- tion identifying the level(s) of obstruction, including at the sub- infundibular (DCRV), conduit, or branch PA levels, and assess- ment of RV volumes, pulmonary annulus, outflow tract and artery dimensions, and differential pulmonary blood flow. CMR and CCT are the methods of choice for visualization of pulmo- nary dilation and peripheral PS. •   Cardiac catheterization may be required to confirm the extent, severity, and level of obstruction (e.g. DCRV).\n4.8.4 Surgical/catheter interventional treatment Catheter-based balloon valvotomy is recommended for patients with non-dysplastic valvular PS and with peripheral PS (often with stent implantation). 223   Surgery is recommended for patients with sub-infundibular or infundibular PS and hypoplastic pulmonary annu- lus, with dysplastic pulmonary valves, and for patients with associated lesions which need a surgical approach, such as severe pulmonary regurgitation (PR) or severe TR. Peripheral PS can rarely be addressed with surgery.\nBoth surgical and catheter interventions should only be performed in centres specialized in CHD. In patients with subvalvular, valvular, and supravalvular PS, a mark- edly dilated pulmonary trunk may be present. Rupture is extremely rare in these low-pressure, highly elastic vessels and these pulmonary aneurysms generally do not require intervention. 224\nFor RV \u0002 PA conduit, see  section 4.14 . Indications for intervention are summarized in the Recommendations for intervention in right ventricular outflow tract obstruc- tion  table and in  Figure  7 .\n4.8.5 Follow-up recommendations Patients with RVOTO need lifelong follow-up with regular echocar- diographic imaging. The frequency of follow-up depends on the severity of the lesion, but most patients will need a yearly visit, includ- ing evaluation in specialized ACHD centres except for patients with mild or well repaired valvular stenosis. After surgical or catheter intervention, a residual PR may need reintervention later in life for patients who become symptomatic or when progressive RV dilata- tion or dysfunction occurs (see  section 4.10 ). Patients with mild valvu- lar or mild residual PS need to be seen only once in 5 years.\n4.8.6 Additional considerations\n•   Exercise/sports: no restrictions for patients with mild (residual) PS. Patients with moderate PS should avoid high-intensity and\nRecommendations for intervention in right ventricular outﬂow tract obstruction\nRecommendations Class a Level b\nIn valvular PS, balloon valvuloplasty is the inter- vention of choice, if anatomically suitable. I C\nProvided that no valve replacement is required,\nRVOTO intervention at any level is recommended\nregardless of symptoms when the stenosis is severe (Doppler peak gradient is >64 mmHg c ).\nI C\nIf surgical valve replacement is the only option, it\nis indicated in patients with severe stenosis who are symptomatic. d I C\nIf surgical valve replacement is the only option d   in\npatients with severe stenosis who are asympto-\nmatic, it is indicated in the presence of one or more of the following. •   Objective decrease in exercise capacity. •   Decreasing RV function and/or progression of TR to at least moderate. •   RVSP >80 mmHg. •   R \u0002 L shunting via an ASD or VSD.\nI C\nIntervention in patients with a Doppler peak gra- dient <64 mmHg should be considered in the presence of one or more of the following. •   Symptoms related to PS. •   Decreasing RV function and/or progressive TR\nto at least moderate. •   R \u0002 L shunting via an ASD or VSD.\nIIa C\nPeripheral PS, regardless of symptoms, should be considered for catheter interventional treatment if >50% diameter narrowing, and RVSP >50 mmHg, and/or related reduced lung perfusion is present.\nIIa C\nASD = atrial septal defect; PS = pulmonary stenosis; R \u0002 L = right-to-left; RV = right ventricle/ventricular; RVOTO = right ventricular outﬂow tract obstruction; RVSP = right ventricular systolic pressure; TR = tricuspid regurgitation; VSD = ventricular septal defect. a Class of recommendation. b Level of evidence. c RVSP estimated from TR velocity should conﬁrm severe PS. d The threshold for intervention is higher when a valve substitute is required because long-term risks, such as endocarditis and re-intervention for prosthetic valve failure, need to be taken into account.\nESC Guidelines 609\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ................................................................... static sports. Patients with severe PS should be restricted to low- intensity sports. •   Pregnancy: well tolerated unless the RVOTO is extremely severe or unless RV failure is a major issue. Transcatheter balloon val- votomy can be performed during pregnancy but is rarely neces- sary (see  section 3.5.7 ). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n",
      "keywords": [
        "clin",
        "risk factor",
        "antihypertensive",
        "should be considered",
        "comprising",
        "family history",
        "risk estimation",
        "valve repair",
        "genetic",
        "prosthetic valve",
        "electrocardiogram",
        "systolic",
        "anticoagulation",
        "age",
        "diabetes",
        "tricuspid",
        "hypertension",
        "syndrome",
        "scd",
        "blood pressure",
        "related",
        "syncope",
        "aneurysm",
        "aortopathies",
        "aortic",
        "arrhythmia",
        "heritable",
        "htad",
        "valve replacement",
        "sex"
      ],
      "tables": [
        {
          "title": "608 ESC Guidelines",
          "page_number": 45,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nMarfan syndrome and HTAD |  | \nAortic valve repair, using the reimplantation\nor remodelling with aortic annuloplasty tech-\nnique, is recommended in young patients with\nMarfan syndrome or related HTAD with\naortic root dilation and tricuspid aortic valves,\nwhen performed by experienced surgeons. | I | C\nSurgery is indicated in patients with Marfan\nsyndrome who have aortic root disease with a\nmaximal aortic sinus diameter >50 mm.c\n_ | I | C\nSurgery should be considered in patients with\nMarfan syndrome who have aortic root dis-\nease with maximal aortic sinus diameter >45\n_\nmmc and additional risk factors.d | IIa | C\nSurgery should be considered in patients with\na TGFBR1 or TGFBR2 mutation (including\nLoeys\u0002Dietz syndrome) who have aortic\nroot disease with maximal aortic sinus diame-\nter >45mm.c\n_ | IIa | C\nBicuspid aortic disease |  | \nAortic surgery should be considered if the\nascending aorta is:\n• > _50 mm in the presence of a bicuspid valve\nwith additional risk factorse or coarctation.\n• >55 mm for all other patients.\n_ | IIa | C\nTurner syndrome |  | \nElective surgery for aneurysms of the aortic\nroot and/or ascending aorta should be consid-\nered for women with Turner syndrome who\nare >16 years of age, have an ascending aortic\nsize index >25 mm/m2, and have associated\nrisk factors for aortic dissection.f | IIa | C\nElective surgery for aneurysms of the aortic\nroot and/or ascending aorta may be consid-\nered for women with Turner syndrome who\nare >16 years of age, have an ascending aortic\nsize index >25 mm/m2, and do not have asso-\nciated risk factors for aortic dissection.f | IIb | C",
          "bbox": [
            42.52474890814887,
            76.49621378580729,
            284.71833374921016,
            567.4352329799107
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 609",
          "page_number": 46,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIn valvular PS, balloon valvuloplasty is the inter-\nvention of choice, if anatomically suitable. | I | C\nProvided that no valve replacement is required,\nRVOTO intervention at any level is recommended\nregardless of symptoms when the stenosis is\nsevere (Doppler peak gradient is >64 mmHgc). | I | C\nIf surgical valve replacement is the only option, it\nis indicated in patients with severe stenosis who\nare symptomatic.d | I | C\nIf surgical valve replacement is the only optiond in\npatients with severe stenosis who are asympto-\nmatic, it is indicated in the presence of one or\nmore of the following.\n• Objective decrease in exercise capacity.\n• Decreasing RV function and/or progression of\nTR to at least moderate.\n• RVSP >80 mmHg.\n• R\u0002L shunting via an ASD or VSD. | I | C\nIntervention in patients with a Doppler peak gra-\ndient <64 mmHg should be considered in the\npresence of one or more of the following.\n• Symptoms related to PS.\n• Decreasing RV function and/or progressive TR\nto at least moderate.\n• R\u0002L shunting via an ASD or VSD. | IIa | C\nPeripheral PS, regardless of symptoms, should be\nconsidered for catheter interventional treatment if\n>50% diameter narrowing, and RVSP >50 mmHg,\nand/or related reduced lung perfusion is present. | IIa | C",
          "bbox": [
            311.4322235107422,
            86.47422485351562,
            553.7145485391422,
            455.6372560773577
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "37",
      "title": "4.9 Ebstein anomaly 4.9.1 Introduction and background Ebstein anomaly is characterized by abnormally formed and apically displaced leaflets of the TV. The anterior leaflet usually originates at the an",
      "start_page": 47,
      "end_page": 49,
      "content": "Multiple accessory pathways in conjunction with AT and AF are asso- ciated with SCD. Ebstein-like anomaly of the systemic TV is present in one-third of ccTGA. Haemodynamic changes depend on the severity of the TV dysfunc- tion, the degree of atrialization of the RV, contractility of the remain- ing functional RV and the systemic ventricle, type and severity of concomitant anomalies, and arrhythmias. The pathophysiology is characterized by systolic regurgitation of blood from the functional RV, across the TV, and into the atrialized ventricle or RA, which tend to dilate. An interatrial connec- tion permits a L \u0002 R shunt or, especially during exercise, a R \u0002 L shunt. Ebstein anomaly may result in a chronically low systemic cardiac output.\n4.9.2 Clinical presentation and natural history The clinical presentation ranges from trivial symptoms to the presen- tation of a profound cyanotic heart defect. Patients with mild forms can be asymptomatic over decades until they are diagnosed. Typical complications include high-grade TR, RV dysfunction, RV failure, liver cirrhosis, cerebral abscesses, paradoxical embolism, pulmonary embolism, tachyarrhythmias, SCD, and IE. Key symptoms are arrhythmias [atrioventricular reentrant tachycardia (AVRT) is most\n©ESC 2020\nFigure 7  Management of right ventricular outflow tract obstruction. ASD = atrial septal defect; PS = pulmonary stenosis; R \u0002 L = right-to-left; RV = right ventricle/ventricular; RVOTO = right ventricular outflow tract obstruction; RVSP = right ventricular systolic pressure; TR = tricuspid regurgitation; VSD = ventricular septal defect. a In peripheral PS, regardless of symptoms, catheter interventional treatment should be considered if >50% diameter narrowing and RVSP >50 mmHg and/ or related reduced lung perfusion is present. b In valvular PS, balloon valvuloplasty is the intervention of choice if anatomically suitable.\n610 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ......................................\ncommon], dyspnoea, fatigue, poor exercise tolerance, chest pain, and peripheral and/or central cyanosis.\n4.9.3 Diagnostic work-up See  section 3.3  for general principles. Clinical findings may include cyanosis and hepatomegaly. Auscultation findings include a widely split first sound and second sound, serial clicks, third and fourth sound, and a systolic murmur from TR. ECG may show RA hypertrophy, a prolonged PR interval, right bundle branch block (often with a splintered QRS com- plex), deep Q in II, III, aVF, and V1 \u0002 V4, pre-excitation, low voltage, multiple pathways (AVRT), and supraventricular and ventricular arrhythmias.\n•   Chest X-ray is helpful to follow changes in the heart’s size. •   Echocardiography provides information on: anatomy and func- tion of the TV; apical distal displacement of the septal or poste- rior leaflet (in adults >_0.8 cm/m 2   BSA); size of the anterior leaflet; tethering of the septal or posterior TV leaflet on the septum or ventricular wall; size and function of the different cardiac sections (RA, atrialized ventricle, remaining functional RV, and LV); and RVOTO and associated lesions. •   CMR has value with regards to prognostication 225 , and for evalu- ation before and after surgery, as it offers unrestricted views for assessment and quantification of the dilated right heart, RV func- tion, and TV function.\n4.9.4 Surgical/catheter interventional treatment Clinical symptoms determine the treatment. Conservative therapy can alleviate symptoms temporarily and create a beneficial basis for the fol- lowing operation. 226   Oral anticoagulation is recommended for patients with a history of paradoxical embolism or AF. In the presence of an increased thromboembolic risk or a R \u0002 L shunt, oral anticoagulation may be considered. Symptomatic rhythm disorders can be treated conservatively or, preferably, with EP intervention. 227   Transcatheter access to right-sided accessory pathways and the slow pathway in AV node reentry may be hindered by TV surgery, such that it may be rea- sonable to assess for arrhythmia substrates and proceed with catheter ablation, if identified, before surgery. Occasionally, there may be an indication to close the atrial communication in isolation. However, this needs to be discussed carefully, as it may lead to a further increase in right heart pressures and a decrease in systemic cardiac output. Surgical repair remains challenging and should only be performed by surgeons with specific experience in this lesion. TV repair, if feasible, is preferred over TV replacement (with closure of an associated intera- trial communication). If the RV is too small for repair or RV dysfunction has developed, an additional bidirectional cavopulmonary (Glenn) anastomosis may be considered in adults with preserved LV function when LA pressure and LV end diastolic pressure are not elevated. 228\nIn patients with failed repair, or in severe biventricular dysfunction, heart transplantation may be the only option.\nThe previously high operative mortality (>25%) has fallen to <6% in specialized centres. Over 90% of patients operated on by an expe- rienced surgeon survive >10 years, many in functional class I or II. Late fatalities are probably due to arrhythmias. In a large series, sur- vival free of late reoperation was 86%, 74%, 62%, and 46% at 5, 10, 15, and 20 years, respectively. 229\n4.9.5 Follow-up recommendations Regular follow-up (at least yearly) is required in all patients in special- ized ACHD centres. Typical post-operative residual anomalies to look for are persisting or new TR, the usual complications after valve replacement, failure of RV or LV, residual atrial shunts, arrhythmias, and higher-grade AV blocks. Reintervention may become necessary for recurrent TR and fail- ure of prosthetic valves.\n4.9.6 Additional considerations\n•   Exercise/sports: patients without residual anomalies can usually lead normally active lives without restriction, except for extensive static\nRecommendations for intervention in Ebstein anomaly\nRecommendations Class a Level b\nIndications for surgery\nSurgical repair is recommended in patients with\nsevere TR and symptoms or objective deterio-\nration of exercise capacity.\nI C\nIt is recommended that surgical repair is per- formed by a congenital surgeon with speciﬁc\nexperience in Ebstein surgery.\nI C\nIf there is an indication for TV surgery, ASD/ PFO closure is recommended at the time of\nvalve repair if it is expected to be haemodynami-\ncally tolerated.\nI C\nSurgical repair should be considered regardless of symptoms in patients with progressive right\nheart dilation or reduction of RV systolic\nfunction.\nIIa C\nIndications for catheter intervention\nIn patients with symptomatic arrhythmias, or\npre-excitation on the ECG, electrophysiologic\ntesting followed by ablation therapy, if feasible, or surgical treatment of the arrhythmias in the\ncase of planned heart surgery is recommended.\nI C\nIn the case of documented systemic embolism, probably caused by paradoxical embolism, iso-\nlated device closure of ASD/PFO should be con-\nsidered but requires careful evaluation before intervention to exclude induction of RA pres-\nsure increase or fall in cardiac output.\nIIa C\nIf cyanosis (oxygen saturation at rest <90%) is\nthe leading problem, isolated device closure of ASD/PFO may be considered but requires care-\nful evaluation before intervention to exclude\ninduction of RA pressure increase or fall in car- diac output.\nIIb C\nASD = atrial septal defect; ECG = electrocardiogram; PFO = patent foramen ovale; RA = right atrium/atrial; RV = right ventricle/ventricular; TR = tricuspid regurgitation; TV = tricuspid valve. a Class of recommendation. b Level of evidence.\nESC Guidelines 611\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ sports. Patients with more than mild TR, ventricular dysfunction, shunting, arrhythmias, or other complications should avoid heavy isometric exercises, in proportion to the severity of their problems. •   Pregnancy: asymptomatic females with good ventricular function may tolerate pregnancy well. There is a certain risk of RV failure, arrhythmia, and paradoxical embolism. Pregnancy will be of higher risk in the presence of significant cyanosis, serious arrhyth- mia, and right heart failure (see  section 3.5.7 ). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n",
      "keywords": [
        "originates",
        "should be considered",
        "apically",
        "class i",
        "valve repair",
        "electrocardiogram",
        "systolic",
        "anterior",
        "anticoagulation",
        "tachycardia",
        "pulmonary embolism",
        "tricuspid",
        "usually",
        "characterized",
        "scd",
        "diastolic",
        "arrhythmia",
        "valve replacement",
        "background",
        "echocardiography",
        "level b",
        "introduction",
        "ecg",
        "heart failure",
        "exercise",
        "formed",
        "anomaly",
        "recommended",
        "may be considered",
        "stenosis"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 611",
          "page_number": 48,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIndications for surgery |  | \nSurgical repair is recommended in patients with\nsevere TR and symptoms or objective deterio-\nration of exercise capacity. | I | C\nIt is recommended that surgical repair is per-\nformed by a congenital surgeon with specific\nexperience in Ebstein surgery. | I | C\nIf there is an indication for TV surgery, ASD/\nPFO closure is recommended at the time of\nvalve repair if it is expected to be haemodynami-\ncally tolerated. | I | C\nSurgical repair should be considered regardless\nof symptoms in patients with progressive right\nheart dilation or reduction of RV systolic\nfunction. | IIa | C\nIndications for catheter intervention |  | \nIn patients with symptomatic arrhythmias, or\npre-excitation on the ECG, electrophysiologic\ntesting followed by ablation therapy, if feasible,\nor surgical treatment of the arrhythmias in the\ncase of planned heart surgery is recommended. | I | C\nIn the case of documented systemic embolism,\nprobably caused by paradoxical embolism, iso-\nlated device closure of ASD/PFO should be con-\nsidered but requires careful evaluation before\nintervention to exclude induction of RA pres-\nsure increase or fall in cardiac output. | IIa | C\nIf cyanosis (oxygen saturation at rest <90%) is\nthe leading problem, isolated device closure of\nASD/PFO may be considered but requires care-\nful evaluation before intervention to exclude\ninduction of RA pressure increase or fall in car-\ndiac output. | IIb | C",
          "bbox": [
            311.4123613762133,
            76.49621378580729,
            553.5987238808284,
            506.25816454206193
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "38",
      "title": "4.10 Tetralogy of Fallot 4.10.1 Introduction and background TOF is characterized by the following four features: a non- restrictive VSD; overriding aorta (but <50%); infundibular, valvu- lar, supraval",
      "start_page": 49,
      "end_page": 52,
      "content": "4.10.2 Clinical presentation and natural history Surgical repair of TOF has evolved over time, with relief of the RVOTO usually involving infundibulotomy, resection of obstructive muscle bundles, and the use of a patch to enlarge the pathway from the RV to the PAs. In some patients, a palliative shunt procedure  \u0002  in order to increase pulmonary blood flow  \u0002  has been performed before repair. Common complications in adulthood are:\n•   PR: significant PR is almost always encountered following a transan- nular patch repair. PR is usually well tolerated for years. Severe chronic PR, however, eventually leads to symptomatic RV dilation and dysfunction. 232   The severity of PR and its deleterious long-term effects are augmented by co-existing distal PA stenoses or PAH. •   Residual RVOTO can occur at the infundibulum, at the level of the pulmonary valve and main pulmonary trunk, and into the branches of the left and right PA. Elevated RV pressure and RVH have been described as independent risk factors for poor outcome and a decreased exercise performance, despite smaller RV volumes 233 . •   Residual VSD can be due to partial patch dehiscence or failure of complete closure at the time of surgery; it may lead to LV volume overload. •   Aortic complications may occur many years after the initial surgi- cal repair and include progressive aortic dilation and AR (rarely aortic dissection). The underlying mechanism is incompletely understood, and may include ascending aorta dilation, abnormal aortic elasticity, or type of surgical repair 234 . •   RV and LV dysfunction/heart failure: RV dilation is usually due to residual longstanding free PR ± RVOTO. Significant TR may occur as a consequence of RV dilation, which begets more RV dilation. LV dilatation may result from longstanding palliative arte- rial shunts, residual VSDs, and/or AR. Both RV and LV dysfunc- tion may be due to longstanding cyanosis before repair and/or inadequate myocardial protection during repair, adverse\nventricular \u0002 ventricular interactions, electromechanical dyssyn- chrony, 235 , 236   and coronary artery abnormalities. A reduced LV free wall longitudinal strain has been reported despite preserved LVEF. 237   The incidence of clinical heart failure, with its typical signs and symptoms, increases significantly with age. 238\nUnderlying mechanisms may also be: damage to myocardium, sequelae from surgical repair strategies, or electrical conduction abnormalities. Management strategies effective in acquired heart disease are frequently applied in these patients, although its effec- tiveness for RV failure remains uncertain. 239\n•   Atrial/ventricular arrhythmias and SCD: arrhythmias and sud- den death are important late complications. The estimated lifetime prevalence of atrial arrhythmias is 20%. IART involving the cavotricuspid isthmus and RA incision are related to RA enlargement, whereas AF is facilitated by LA dilatation. Ventricular arrythmias encompass polymorphic VT/VF, typi- cally related to severely impaired RV and LV function, and monomorphic sustained VT, which are particularly relevant in rTOF. 34   Although both polymorphic VT/VF and monomor- phic VT can lead to SCD, with a reported frequency of 1 \u0002 3.5% in retrospective studies, 32   the different underlying ventricular arrhythmia substrates need to be recognized for risk stratification and treatment. LV systolic or diastolic dys- function, and ventricular and atrial tachyarrhythmias are pre- dictive of death and sustained VT in adults with rTOF. 240\nPossible risk factors associated with any ventricular arrhyth- mia and SCD in rTOF are QRS duration >_180 ms, LV systolic or diastolic dysfunction, and inducible VT at EP testing. Older age at PVRep and pre-PVRep RVH and dysfunction may be predictive of shorter time to post-operative death and sus- tained ventricular arrhythmia. 241   The dominant substrates for monomorphic VT are anatomically defined isthmuses, bor- dered by unexcitable tissue. Isthmus dimension and conduc- tion properties can be evaluated by catheter mapping and likely determine susceptibility to arrhythmias. Targeting the anatomical isthmuses by catheter ablation has been highly effective to control VT. 242   Whether catheter mapping can contribute to individualized risk stratification requires further investigation. •   Endocarditis can be encountered after both surgical and per- cutaneous PVRep. Valve-containing prosthetics are an impor- tant independent risk factor for IE in the short- and long-term after implantation, whereas non-valve-containing prosthetics are a risk factor only during the first 6 months after implantation. 76\nA schematic overview of long-term complications after repair of TOF is provided in  Figure  8 .\n4.10.3 Diagnostic work-up of repaired patients See  section 3.3  for general principles.\n•   Clinical findings mostly include a wide split in the second heart sound. A low-pitched early ending diastolic murmur suggests severe PR. A long, loud ejection systolic murmur indicates RVOTO, a high-pitched diastolic murmur indicates AR, and a pansystolic murmur indicates a residual VSD.\n612 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................. •   ECG often shows complete right bundle branch block dependent on the surgical approach. The QRS width may also be influenced by the degree of RV dilation. •   Echocardiography provides assessment of residual RVOTO and PR, residual VSD, RV and LV size and function, 241   TR, RV pres- sure, aortic root size, and AR. Strain measurements are helpful in quantifying the degree of electromechanical dyssychrony. 243\n•   CMR is the method of choice for assessment of RV volume and function; PR; size, shape, and expansion of the PAs; infundibulum; the ascending aorta; the position of great vessels or conduits in relation to the sternum (resternotomy); and evaluation for resid- ual shunt (Qp:Qs). Late gadolinium enhancement demonstrates fibrosis, the extent of which relates to other risk factors for VT and SCD. 244   T1 mapping may have an emerging role. •   CCT provides information on coronary arteries (particularly impor- tant for the assessment of the spatial relationship with the RVOT prior to TPVI or surgery), the extent of conduit calcification (percu- taneous valve anchoring), and the presence of major aortic pulmo- nary collaterals (MAPCAs). CCT may also be considered as an alternative for RV quantification in patients unable to undergo CMR. •   CPET assists timing of reintervention and provides prognostic information. 23\n•   Holter monitoring, event recorder, and EP evaluation are required for selected patients (high risk, suspected or clinical arrhythmia, and/or before RVOT reoperation). Inducible sus- tained VT carries prognostic value for clinical VT and SCD. 245\n•   Cardiac catheterization should be restricted to patients under- going catheter-based interventions (i.e. relief of distal PA stenosis, transcatheter valve implantation) and when non-invasive evalua- tion is inconclusive. Before surgery, coronary angiography may visualize the coronary arteries, which is important to assess the spatial relationship with the RVOT prior to TPVI.\n4.10.4 Late surgical/catheter interventional treatment PVRep and/or relief of RVOTO can be performed with low mor- tality risk in patients without heart failure and/or advanced ven- tricular dysfunction. 246   PR is the most frequent reason for consideration of surgery. Optimal timing remains challenging. Longitudinal data are more important than single measurements to assist timing for reintervention. 247   Normalization of RV size after reintervention becomes unlikely as soon as the end systolic index exceeds 80 mL/m 2   and the end diastolic volume index exceeds 160 mL/m 2 , 248 \u0002 250   but this cut-off for reintervention may not correlate with clinical benefit. A recent meta-analysis demon- strated that PVRep can improve symptoms and reduce RV vol- ume, but a survival benefit still needs to be shown. 251\nDistal PA stenosis must be addressed, either at the time of surgery (including intra-operative stenting) or with a percutaneous approach. A biological pulmonary valve (xenograft or homograft) seems to have a mean lifespan of 10 \u0002 20 years, 248 , 252 , 253   and future replace- ment could be performed by transcatheter valve-in-valve\n©ESC 2020\nFigure 8  Management of repaired tetralogy of Fallot: long-term complications to address during follow-up. Ao = aorta; LV = left ventricle; RV = right ventricle; PA = Pulmonary artery; TV = tricuspid valve; RA = right atrium; RV = right ventricular; LA = left atrium; PA = pulmonary artery; PS = pulmonary stenosis; SCD = sudden cardiac death; VSD = ventricular septal defect.\nESC Guidelines 613\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. .............................\nprocedures. There is little experience with mechanical valves in this setting and there is concern about adequate anticoagulation.\nIndications for TV annuloplasty, closure of residual VSDs, and/or aortic root dilation/AR surgery should also be addressed at the time of surgery. The indication for aortic root surgery does not differ from the general population. 254\nTPVI techniques have become an alternative to open heart surgery primarily in patients with RVOT conduit stenosis/regurgitation, but also in selected patients with native RVOT regurgitation/stenosis. TPVI, when technically feasible, provides outcomes comparable to surgical PVRep and is intended to extend the lifetime of a conduit, hence reducing the number of reoperations during a patient’s life- time. 255   Stent fracture  \u0002  the initially most common complication  \u0002 has become less of a problem with careful preparation of the ‘landing zone’ using additional stents. Best long-term results were reported when a residual gradient of <15 mmHg could be achieved. 256\nUncommon complications, occurring in <2% of patients, include con- duit rupture and coronary artery compression. The risk of endocardi- tis after TPVI remains a concern with an annual incidence rate of 2 \u0002 3%. 257 , 258   Since coronary artery compression may be life- threatening, a balloon test to exclude potential coronary artery com- pression must be performed prior to TPVI, although this test carries a risk for conduit rupture. In case of severe circumscript conduit cal- cification, TPVI should only be performed if a CCT scan shows suffi- cient distance between the conduit and the coronary arteries. The strong link between slowly conducting anatomical isthmuses and sus- tained monomorphic VT, and the potential loss of accessibility to the anatomical isthmus by catheter ablation after surgical PVRep or after transcutaneous insertion of valves in patch augmented RVOTs, has important implications for patients who undergo reinterventions. 259\nWhether pre-interventional mapping and preventive ablation of slowly conducting anatomical isthmuses before or during interven- tion in patients  without  documented spontaneous sustained VT is beneficial is under investigation.\n4.10.5 Indications for electrophysiological testing and implantable cardioverter defibrillator An ICD should be implanted for secondary prevention of SCD (patients with cardiac arrest or sustained VT) (IC recommendation). ICD implantation for primary prevention remains controversial, and no ideal risk stratification scheme has so far been developed. Patients with unexplained syncope and impaired ventricular function or other risk factors for SCD should undergo haemodynamic and EP evalua- tion. In the absence of a reversible cause, ICD implantation should be considered (see  section 3.4.2 ). 260 , 261\nRecommendations for intervention after repair of tet- ralogy of Fallot\nRecommendations Class a Level b\nPVRep is recommended in symptomatic patients\nwith severe PR c   and/or at least moderate\nRVOTO. d\nI C\nIn patients with no native outﬂow tract, e   cathe- ter intervention (TPVI) should be preferred if\nanatomically feasible.\nI C\nPVRep should be considered in asymptomatic patients with severe PR and/or RVOTO when\none of the following criteria is present. •   Decrease in objective exercise capacity. •   Progressive RV dilation to RVESVi >_80 mL/\nm 2 , and/or RVEDVi >_160 mL/m 2 f , and/or\nprogression of TR to at least moderate. •   Progressive RV systolic dysfunction. •   RVOTO with RVSP >80 mmHg.\nIIa C\nContinued\nVSD closure should be considered in patients\nwith residual VSD and signiﬁcant LV volume\noverload or if the patient is undergoing pulmo- nary valve surgery.\nIIa C\nIn patients with sustained VT who are under-\ngoing surgical PVRep or transcutaneous valve insertion, pre-operative catheter mapping and\ntranssection of VT-related anatomical isthmuses\nbefore or during the intervention should be considered.\nIIa C\nElectrophysiologic evaluation, including pro-\ngrammed electrical stimulation, should be con-\nsidered for risk stratiﬁcation for SCD in patients with additional risk factors (LV/RV dysfunction;\nnon-sustained, symptomatic VT; QRS duration\n>_180 ms, extensive RV scarring on CMR).\nIIa C\nICD implantation should be considered in\nselected TOF patients with multiple risk factors\nfor SCD, including LV dysfunction, non-sus- tained, symptomatic VT, QRS duration >_180\nms, extensive RV scarring on CMR, or inducible\nVT at programmed electrical stimulation.\nIIa C\nCatheter ablation or concomitant surgical abla- tion for symptomatic monomorphic sustained\nVT may be considered in those with a preserved\nbiventricular function as an alternative to ICD therapy, provided that the procedure is per-\nformed in highly experienced centres and that\nestablished ablation endpoints have been reached (e.g. non-inducibility, conduction block\nacross ablation lines).\nIIb C\nCMR = cardiovascular magnetic resonance; ICD = implantable cardioverter deﬁbrillator; LV = left ventricle/ventricular; PR = pulmonary regurgitation; PVRep = pulmonary valve replacement; RV = right ventricle/ventricular; RVESVi = right ventricular end systolic volume indexed; RVEDVi = right ventricular end diastolic volume indexed; RVOT = right ventricular outﬂow tract; RVOTO = right ventric- ular outﬂow tract obstruction; RVSP = right ventricular systolic pressure; SCD = sudden cardiac death; TOF = tetralogy of Fallot; TPVI = transcatheter pulmonary valve implantation; TR = tricuspid regurgitation; VSD = ventricular septal defect; VT = ventricular tachycardia. a Class of recommendation. b Level of evidence. c Regurgitant fraction by CMR >30 \u0002 40%. d Peak velocity >3 m/s. e Patients with previous RVOT surgery using homografts, bovine jugular vein grafts, bioprostheses/conduits. f Conﬁrmed by repeated measurements.\n614 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ................................................................................................................................................................... 4.10.6 Follow-up recommendations All patients with TOF should have periodic cardiac follow-up in a spe- cialized ACHD centre, which  \u0002  in most patients  \u0002  should be done annually. Follow-up evaluation needs to look for the complications listed in  section 4.10.2 . All patients should have CMR at regular inter- vals, dependent on the pathology found.\n4.10.7 Additional considerations\n•   Exercise/sports: there are no restrictions in asymptomatic repaired patients with good haemodynamics. Patients at high risk for clinical arrhythmia/SCD, patients with advanced biventricular dysfunction, and patients with marked ascending aortopathy should be limited to low-intensity activity/sports and avoid iso- metric exercise. •   Pregnancy: in unrepaired patients constitutes a considerable risk of maternal and foetal complications and death. The risk of preg- nancy in repaired patients depends on their haemodynamic sta- tus (low in patients with good haemodynamics). In patients with significant residual lesions, there is a risk of arrhythmia and right heart failure. Pregnancy is unlikely to have an adverse long-term effect on cardiovascular function 262   (see  section 3.5.7 ). •   IE prophylaxis: recommended only for high-risk patients (see  sec- tion 3.4.6 ).\n",
      "keywords": [
        "risk factor",
        "should be considered",
        "older",
        "secondary prevention",
        "sudden cardiac death",
        "infundibular",
        "systolic",
        "anticoagulation",
        "tachycardia",
        "age",
        "tricuspid",
        "characterized",
        "restrictive",
        "scd",
        "risk stratification",
        "four",
        "valvu",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "diastolic",
        "fallot",
        "aortic",
        "arrhythmia",
        "icd",
        "following",
        "valve replacement",
        "background",
        "tetralogy",
        "echocardiography"
      ],
      "tables": [
        {
          "title": "614 ESC Guidelines",
          "page_number": 51,
          "content": "VSD closure should be considered in patients\nwith residual VSD and significant LV volume\noverload or if the patient is undergoing pulmo-\nnary valve surgery. | IIa | C\nIn patients with sustained VT who are under-\ngoing surgical PVRep or transcutaneous valve\ninsertion, pre-operative catheter mapping and\ntranssection of VT-related anatomical isthmuses\nbefore or during the intervention should be\nconsidered. | IIa | C\nElectrophysiologic evaluation, including pro-\ngrammed electrical stimulation, should be con-\nsidered for risk stratification for SCD in patients\nwith additional risk factors (LV/RV dysfunction;\nnon-sustained, symptomatic VT; QRS duration\n>180 ms, extensive RV scarring on CMR).\n_ | IIa | C\nICD implantation should be considered in\nselected TOF patients with multiple risk factors\nfor SCD, including LV dysfunction, non-sus-\ntained, symptomatic VT, QRS duration >180\n_\nms, extensive RV scarring on CMR, or inducible\nVT at programmed electrical stimulation. | IIa | C\nCatheter ablation or concomitant surgical abla-\ntion for symptomatic monomorphic sustained\nVT may be considered in those with a preserved\nbiventricular function as an alternative to ICD\ntherapy, provided that the procedure is per-\nformed in highly experienced centres and that\nestablished ablation endpoints have been\nreached (e.g. non-inducibility, conduction block\nacross ablation lines). | IIb | C",
          "bbox": [
            306.7975969314575,
            59.87817600795201,
            549.5265909830729,
            437.7222475324358
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "614 ESC Guidelines",
          "page_number": 51,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nPVRep is recommended in symptomatic patients\nwith severe PRc and/or at least moderate\nRVOTO.d | I | C | \nIn patients with no native outflow tract,e cathe-\nter intervention (TPVI) should be preferred if\nanatomically feasible. | I | C | \nPVRep should be considered in asymptomatic\npatients with severe PR and/or RVOTO when\none of the following criteria is present.\n• Decrease in objective exercise capacity.\n• Progressive RV dilation to RVESVi > _80 mL/\nm2, and/or RVEDVi >160 mL/m2 f, and/or\n_\nprogression of TR to at least moderate.\n• Progressive RV systolic dysfunction.\n• RVOTO with RVSP >80 mmHg. | IIa | C | ",
          "bbox": [
            42.60677194595337,
            523.9561767578125,
            287.60301378038196,
            730.535175868443
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "39",
      "title": "4.11 Pulmonary atresia with ventricular septal defect 4.11.1 Introduction and background Adult patients with pulmonary atresia with VSD are a heterogeneous population in terms of underlying anatomy, p",
      "start_page": 52,
      "end_page": 53,
      "content": "Patients with discordant cardiac connections and/or a single ven- tricle physiology and their management will be discussed in the appropriate sections. There are three patterns of PAs:\n•   Unifocal with confluent, good-sized PAs supplied by a PDA. •   Multifocal, with confluent but hypoplastic PAs (‘seagull’ appear- ance) supplied by multiple MAPCAs. •   Multifocal with non-confluent or absent PAs supplied by MAPCAs.\nSurgical management is a heavily debated topic due to the lack of consensus on the optimal treatment. Patients with confluent, good-sized PAs and a pulmonary trunk (usually with valvular atresia) are suitable for a Fallot-like repair using a transannular patch. Patients with good-sized PAs but without a pul- monary trunk should undergo repair with a RV \u0002 PA conduit. Patients with confluent but hypoplastic PAs often require an arterial shunt or\nreconstruction of the RVOT (without VSD closure), which may enhance PA growth, and then be reviewed at a later stage for repair using a valved conduit. Patients with non-confluent PAs with adequate, but not excessive, pulmonary blood flow in infancy can sur- vive into adulthood without surgery. There are proponents of a staged unifocalization approach for this latter challenging group of infants, ultimately aiming for a conduit repair. 264\n4.11.2 Clinical presentation and natural history At adult age, clinical presentation for repaired patients is similar to those with TOF (see  sections 4.10  and  4.14 ). Unrepaired patients present with exertional dyspnoea, fatigue, and progressive chronic cyanosis, due to decreased pulmonary blood flow from collateral stenosis, PA stenosis, increased PVR, or increasing ventricular end diastolic pressures. 265   Cyanosis will eventually lead to multiorgan involvement (see  section 3.4.8 ). A number of complications may occur in unrepaired patients:\n•   Haemoptysis may be due to rupture of usually small collateral vessels and/or small PA thrombosis. •   Chronic heart failure is usually multifactorial and may be due to chronic cyanosis, early excessive pulmonary blood flow, increased PVR, RV dysfunction, AR, and other causes. •   Progressive dilation of the ascending aorta with increasing AR (rarely aortic dissection). •   Endocarditis can be particularly compromising in patients with limited cardiovascular reserve and those with significant cyanosis. •   Arrhythmia and SCD are not uncommon. •   Segmental PAH. 46\n4.11.3 Diagnostic work-up See  section 3.3  for general principles.\n•   Clinical findings: cyanosis in unrepaired patients may be profound, even with minimal physical effort. Continuous murmurs at the back suggest MAPCAs. ECG findings include right-axis deviation and RVH. Chest X-ray may show a boot-shaped cardiac contour (‘empty PA bay’) with abnormal, decreased pulmonary vascular- ity (alternating with some areas of increased vascularity through large MAPCAs). •   Echocardiography: findings in repaired patients depend on the type of repair (see  sections 4.10  and  4.14 ). For unrepaired patients, absence of direct flow from the RV to PA, with continu- ous flow on multiple sites on colour Doppler from the MAPCAs, may be seen. 3D echocardiography can further aid in delineating anatomic pathology and biventricular size and function. TOE is useful in certain patients to evaluate valve anatomy when trans- thoracic imaging is challenging or when IE is suspected. 266\n•   CMR, CCT, and cardiac catheterization are required to deter- mine sources of pulmonary blood supply and size of PAs, to assess MAPCAs, and obtain haemodynamics. In repaired patients, CMR is used for requirements similar to patients with TOF [for RV volumes and function, PR, size, shape, and expansion of the PAs, and the size of the ascending aorta, and for residual shunt (Qp:Qs)]. 3D rotational angiography and 3D overlay imaging, as\nESC Guidelines 615\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ..................................................................................................................................................................... well as X-ray and magnetic resonance imaging fusion, aid in preci- sion assessment. 267\n4.11.4 Surgical/catheter interventional treatment For follow-up and intervention in patients with Fallot-like repair with transannular patch, see  section 4.10 ; for patients with repair using a valved RV \u0002 PA conduit, see  section 4.14 . Patients with pulmonary atresia  þ  VSD surviving unrepaired to adulthood, or with previous palliative procedures, may actually bene- fit from modern surgical or interventional procedures. 268 , 269   Patients with good-sized confluent PAs and those with large MAPCAs ana- tomically suitable for unifocalization, who have not developed severe PVD due to protecting stenosis, should be considered for surgery. Many unrepaired patients may, however, not be suitable for further surgery, mainly because of the complexity of their pulmonary vascu- lature. It is important to appreciate that while cardiac surgery may improve clinical status or prognosis (the latter is purely speculative), it is also a major cause of mortality.\nCatheter intervention may include balloon dilation/stenting of col- lateral vessels to enhance pulmonary blood flow. 270   On the other hand, patients with severe haemoptysis may require coiling of rup- tured collateral vessels.\nSurvival depends on the complexity of the pulmonary malforma- tions and the results of surgical repair. Survival in palliated patients is significantly lower and has been reported as 60% at 20-year follow- up. Heart-lung transplantation could possibly be an option for highly selected individuals.\n4.11.5 Follow-up recommendations Patients with pulmonary atresia  þ  VSD should have periodic follow- up in a specialized ACHD centre (at least once a year). For the man- agement of cyanosis-related multiorgan involvement, see  section 3.4.8 . Patients with segmental PAH may be considered for targeted PAH therapy; see  section 3.4.3 . 271 , 272\nSymptoms such as dyspnoea, increasing cyanosis, change in the shunt murmur, heart failure, or arrhythmias warrant special attention and should necessitate an earlier review and assessment for intervention.\n4.11.6 Additional considerations\n•   Exercise/sports: those with excellent haemodynamics should be encouraged to exercise regularly, avoiding only extreme isomet- ric exercise. Those with less optimal haemodynamics will be more functionally limited. Extremes of exertion should be avoided, but regular low-intensity physical activity (walking, swim- ming, even cycling) should be encouraged. •   Pregnancy: the risk of pregnancy in repaired patients with good haemodynamics and no history of arrhythmias is low. The risk increases with hypoxaemia, PAH, ventricular dysfunction, heart failure symptoms, and arrhythmias (see  section 3.5.7 ). As micro- deletion 22q11 is fairly common with this defect, patients should be checked before pregnancy.\n•   IE prophylaxis: recommended only for high-risk patients (includ- ing all unrepaired patients; see  section 3.4.6 ).\n",
      "keywords": [
        "anatomy",
        "pulmonary",
        "should be considered",
        "adult",
        "septal",
        "physical activity",
        "age",
        "defect",
        "atresia",
        "scd",
        "diastolic",
        "aortic",
        "arrhythmia",
        "terms",
        "population",
        "background",
        "echocardiography",
        "introduction",
        "ecg",
        "underlying",
        "heart failure",
        "exercise",
        "patients",
        "recommended",
        "may be considered",
        "stenosis",
        "catheterization",
        "angiography",
        "ventricular",
        "heterogeneous"
      ],
      "tables": []
    },
    {
      "number": "40",
      "title": "4.12 Transposition of the great arteries 4.12.1 Introduction and background TGA is characterized by AV concordance and ventriculo-arterial dis- cordance: the aorta originates from the RV, the PA from ",
      "start_page": 53,
      "end_page": 57,
      "content": "4.12.2 Atrial switch operation 4.12.2.1 Clinical presentation after atrial switch Older adults with a simple TGA have a Mustard or Senning atrial switch procedure. The most common complications are:\n•   Systemic RV dysfunction and failure. •   Secondary progressive TR (systemic AV valve). •   Bradycardia and chronotropic incompetence due to loss of sinus rhythm; AV conduction is usually intact. •   Supraventricular tachyarrhythmia, typically cavotricuspid isthmus-dependent flutter, followed by macro-reentry circuit related to surgical incisions/scars; AF may occur at older age. High heart rates are often haemodynamically poorly tolerated because of the inability to increase preload, a consequence of the (restrictive) atrial baffles. Bradycardia due to SND can promote AT. •   Ventricular tachyarrhythmias: primary polymorphic VT or VF due to poor ventricular function and heart failure-related mecha- nism, or monomorphic VT due to scar/incision/patch-related reentry in repaired complex TGA; secondary VT or VF, pre- ceded by supraventricular tachycardia (SVT) with rapid conduc- tion and consecutive myocardial ischaemia due to the very low stroke volume associated with the SVT. •   Baffle stenosis, either superior baffle (most common) or inferior baffle obstruction. •   Baffle leakage, with either L \u0002 R shunt giving rise to pulmonary overflow or R \u0002 L shunting in the presence of distal flow obstruc- tion, with cyanosis or paradoxical embolism. •   Pulmonary veins/venous atrial obstruction, most often at the site where the pulmonary veins connect to the pulmonary venous atrium/RA.\n616 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n©ESC 2020\nFigure 9  Management of transposition of the great arteries: long-term complications to address during follow-up. Ao = aorta; AV = atrioventricular; IVC = inferior caval vein; LA = left atrium; LV = left ventricle; LVOT = left ventricular (subpulmonary) outflow tract; PS = pulmonary stenosis (supravalvular/pulmonary artery branch); PV = pulmonary vein; PVA = pulmonary venous atrium; RA = right atrium; RV = right ven- tricle; SCD = sudden cardiac death; SN-dysf. = sinus node dysfunction; SVA = systemic venous atrium; SVC = superior vena cava; TV = tricuspid valve.\nESC Guidelines 617\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ....................................................................................................................................................................... •   LVOTO can develop due to bulging of the interventricular sep- tum towards the low-pressure subpulmonic LV, frequently asso- ciated with systolic anterior motion of the mitral valve. •   PH can become manifest, sometimes decades after the atrial switch procedure; it is usually post-capillary 273   but PAH may be present too. •   Death due to heart failure or sudden death, probably caused by arrhythmia.\nIn larger series with follow-up of up to 40 years, survival is 60 \u0002 75%. 274 , 275   Event-free survival is as low as 20%. 276 , 277   Exercise capacity is usually reduced by inadequate increase in cardiac output: chronotropic incompetence, reduced preload resulting from the rel- atively narrowed and/or non-compliant baffles  \u0002  inherent to the atrial switch operation  \u0002  and diminished RV function.\n4.12.2.2 Diagnostic work-up See  section 3.3  for general principles. Clinical evaluation must include looking for signs of venous conges- tion. A swollen head and neck are a sign of superior baffle obstruc- tion. Oedema of the legs, varices, hepatomegaly, and liver cirrhosis are seen in inferior baffle obstruction. Stenosis, even complete obstruction, can be asymptomatic due to an effective bypass circula- tion provided by the azygos or hemiazygos vein. An ejection-type systolic murmur suggests subpulmonary outflow tract obstruction, and a systolic regurgitant-type murmur suggests regurgitation of the systemic TV. ECG findings include RVH and, not uncommonly, narrow QRS escape rhythm, without visible P waves.\n•   Echocardiography is the first-line diagnostic modality, providing information on size and systolic function of the subpulmonic and systemic ventricles, subpulmonary outflow tract obstruction, TR, leakage or obstruction of the atrial baffles, and assessment of pul- monary venous return. Signs of PH are often subtle  \u0002  decreased flattening of the interventricular septum in systole and an abnor- mally wide PA  \u0002  and can be difficult to recognize. Suspicion of PH dictates diagnostic heart catheterization to exclude/confirm PH as it may impact management. Contrast echocardiography can demonstrate baffle leakage  \u0002  present in up to 50% in non- selected and asymptomatic patients  \u0002  or baffle obstruction. 278\nInjection of contrast into the upper limbs frequently misses a leak in the inferior systemic venous baffle; this can only be excluded by injection into one of the femoral veins. TOE is useful for evalu- ation of baffles. •   CMR provides more reliable and more robust quantitative assessment of systemic RV systolic function than echocardiogra- phy, and of patency of the atrial baffles. Size of the great arteries can be measured reliably; an abnormally wide PA and/or large subpulmonary LV may indicate PH. Shunt related to baffle leak can be quantified (Qp:Qs). Small baffle leaks not leading to a rele- vant shunt are difficult to detect with CMR (contrast echocar- diography is superior). Late gadolinium enhancement in the systemic RV predicts clinical outcome. 279\n•   Exclusion of superior baffle stenosis or baffle leak (and treat- ment) is essential before PM/ICD implantation or placing new/\nadditional pacemaker wires through the superior baffle. An alter- native to CMR and CCT for assessment of the superior baffle is contrast injection in the right arm and fluoroscopy. •   CPET is important in longitudinal follow-up for serial assessment of exercise capacity and chronotropic incompetence. It also can ‘unmask’ baffle leakage (desaturation) that is asymptomatic at rest. •   Holter monitoring, event recorder, and EP testing are indicated for selected patients if bradycardia and/or tachyarrhythmias are suspected. •   Cardiac catheterization is indicated when non-invasive assess- ment is inconclusive or when suspicion of PH requires evaluation (see  section 3.3.5 ).\n4.12.2.3 Medical treatment\n•   Systemic RV systolic dysfunction: there are no data to support the hypothesis that ACE inhibitors, ARBs, beta blockers, or aldosterone antagonists  \u0002  alone or in combination  \u0002  improve outcome. 280   No solid recommendation can currently be made. •   Systemic RV failure: in the case of overt heart failure, diuretics relieve symptoms. Although no benefit has been demonstrated for conventional heart failure medical therapy in patients with systemic RVs, more symptomatic patients may benefit from pre- scription of ‘classical’ heart failure medication. •   Arrhythmia: drugs that lower heart rate should be used with cau- tion, since after atrial switch, patients are prone to bradycardia and SND. •   PH: the exact mechanism of PH must be elucidated before con- sideration of medical treatment. Post-capillary PH late after atrial switch operation seems to be most common, with the conse- quence that specific pulmonary vasodilator therapy is contraindi- cated but pre-capillary PH may be present, too. Thus, careful haemodynamic evaluation is crucial.\n4.12.2.4 Surgical/catheter interventional treatment Electrophysiology testing, ablation, cardiac resynchronization ther- apy, and implantable cardioverter defibrillators. General principles, also valid for patients with the atrial switch pro- cedure, are discussed in  section 3.4.2 . 32 , 37\n•   EP studies and interventions are complicated because baffles interfere with normal access to the atria. The dominant mecha- nism of supraventricular arrhythmias is cavotricuspid isthmus atrial flutter, often requiring baffle puncture to achieve isthmus block. Alternatively, remote magnetic navigation can be used for retrograde access to the pulmonary venous atrium. Conventional retrograde transaortic route access in adults is usu- ally not successful to achieve isthmus block. TOE guidance is rec- ommended when puncture of a baffle is indicated. Programmed electrical stimulation for risk stratification is not useful. •   Pacemakers: see  section 3.4.2 .\nIndications for intervention are summarized in the Recommendations for surgical and catheter intervention in TGA after atrial switch operation  table.\n618 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.12.3 Arterial switch operation 4.12.3.1 Clinical presentation after arterial switch Young adults with a simple TGA will probably have had an arterial switch operation. The most common complications are:\n•   Neo-aortic root dilatation, resulting in AR. •   Supravalvular PS and pulmonary branch stenosis (unilaterally or bilaterally), a consequence of the position of the pulmonary bifur- cation anterior to the ascending aorta in the Lecompte technique and the dilatation of the neo-aortic root. •   LV dysfunction and ventricular arrhythmias are rare but may occur; both may be related to problems with the coronary arteries, 281   which were reimplanted in the neo-aorta. •   Acute angle of the aortic arch, which may lead to functional obstruction and hypertension.\nSurvival up to 30 years is excellent (>90% of hospital survivors 282 ) and event-free survival is fair (60 \u0002 80% 283 \u0002 285 ). A large majority of these patients are asymptomatic. As a rule, exercise capacity is mildly reduced, but it can be normal. The incidence of late coronary artery- related problems is reported to be very low, 286 , 287   which makes it questionable whether routine screening of coronary arteries is justified.\n4.12.3.2 Diagnostic work-up See  section 3.3  for general principles. Clinical findings of AR or PS may be present.\n•   Echocardiography is the key diagnostic modality, providing infor- mation on LV function (global and regional); stenosis at the arte- rial anastomotic sites, most commonly PS; neo-aortic valve regurgitation; dimension of the neo-aortic root and proximal ascending aorta; and the acute angulation of the aortic arch. RV systolic function can be assessed and, if possible, peak RV systolic pressure (RVSP) should be measured (TR velocity). Due to its position: far anteriorly and just behind the sternum, echocardio- graphic visualization of the bifurcation and both branches is rarely possible. •   Stress echocardiography is used to assess stress-induced wall- motion abnormalities. •   CMR provides more reliable quantitative assessment of ventricu- lar volumes, EF, and neo-aortic dilatation or regurgitation. Pulmonary trunk and branches can be visualized, together with their relation to the (dilated) neo-aortic root. Flow distribution between left and right lung can be calculated. Stress CMR is an alternative technique to assess myocardial perfusion and possible coronary artery compromise, where clinically indicated. •   CCT is the preferred technique for non-invasive imaging of coro- nary arteries, including the ostia, when stenosis is suspected. The reported low incidence of coronary-related problems makes it questionable whether routine screening for coronary artery pathologies (with whatever modality) can be justified. 286 , 287\n•   Nuclear techniques are no longer used as first-choice imaging modality but may still have a role if other techniques are not avail- able or lead to inconclusive or contradictory results. •   Cardiac catheterization, including coronary angiography, is indi- cated in the case of LV dysfunction and suspicion of myocardial ischaemia. In the case of severe pulmonary branch stenosis and\nRecommendations for intervention in transposition of the great arteries after atrial switch operation\nRecommendations Class a Level b\nIndications for surgical intervention\nIn  symptomatic  patients with pulmonary venous atrium obstruction, surgical repair\n(catheter intervention rarely possible) is\nrecommended.\nI C\nIn  symptomatic  patients with bafﬂe stenosis not amenable to catheter intervention, surgical\nrepair is recommended.\nI C\nIn  symptomatic  patients with bafﬂe leaks not amenable to catheter-based closure, surgical\nrepair is recommended.\nI C\nIn patients with severe systemic (tricuspid) AV\nvalve regurgitation, without signiﬁcant ventric- ular systolic dysfunction (EF >40%), valve\nrepair or replacement should be considered,\nregardless of symptoms .\nIIa C\nPA banding in adults, as LV training with subse-\nquent arterial switch procedure, is not\nrecommended.\nIII C\nIndications for catheter intervention\nIn  symptomatic  patients with bafﬂe stenosis,\nstenting is recommended when technically\nfeasible.\nI C\nIn  symptomatic  patients with bafﬂe leaks and cyanosis at rest or during exercise, or with\nstrong suspicion of paradoxical emboli, stent-\ning (covered) or device closure is recom- mended when technically feasible.\nI C\nIn patients with bafﬂe leaks and symptoms due\nto L \u0002 R shunt, stenting (covered) or device closure is recommended when technically\nfeasible.\nI C\nIn  asymptomatic  patients with bafﬂe leaks with\nsubstantial ventricular volume overload due to L \u0002 R shunt, stenting (covered) or device clo-\nsure should be considered when technically\nfeasible.\nIIa C\nIn patients with a bafﬂe leak who require a\nPM/ICD, closure of the bafﬂe leak with a cov-\nered stent should be considered, when techni- cally feasible, prior to insertion of transvenous\nleads.\nIIa C\nIn  asymptomatic  patients with bafﬂe stenosis,\nstenting may be considered when technically feasible.\nIIb C\nAV = atrioventricular; EF = ejection fraction; ICD = implantable cardioverter deﬁbrillator; L \u0002 R = left-to-right; LV = left ventricle/ventricular; PA = pulmonary artery; PM = pacemaker. a Class of recommendation. b Level of evidence.\nESC Guidelines 619\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ inconclusive non-invasive assessment or suspected PAH, cardiac catheterization is indicated.\n4.12.3.3 Surgical/catheter interventional treatment Indications for intervention are summarized in the  Recommendations for interventions in TGA after arterial switch operation  table.\nRVOTO can be subvalvular, valvular (both rare), or supravalvular (most common). Indications for treatment are similar to those described in  section 4.8 , but different anatomies may require different approaches.\n4.12.4 Rastelli-type operation 4.12.4.1 Clinical presentation after Rastelli-type repair Adults with TGA, VSD, and PS (complex transposition) have often had a Rastelli-type repair. The VSD patch directs blood from the LV to the aorta and the RV is connected to the PA with a valved conduit. Variants of the Rastelli technique, sharing the same principle, are the re´paration  \u0002 a l’etage ventriculaire and Nikaidoh techniques. Common complications are:\n•   Stenosis or regurgitation of the valved conduit between the RV and the PA. •   LVOTO, i.e. obstruction of the flow from the LV to the aorta. •   Residual VSD. •   AR. •   LV dysfunction. •   Arrhythmias, both ventricular and supraventricular. •   Endocarditis of the valved conduit. •   Death, either sudden (arrhythmia) or due to heart failure.\nThe few long-term outcome studies report 20-year survival <60% and 20-year event-free survival 20 \u0002 30%. Replacement of the conduit between the RV and PA is the most common indication for\nreoperation. Relief of LVOTO is the second most common, followed by closure of a residual VSD. 288   Endocarditis of the valved conduit is relatively common.\nExercise capacity is mildly to substantially diminished. Repeat rein- tervention, surgical or percutaneous, is the fate of most patients with a Rastelli-type repair.\n4.12.4.2 Diagnostic work-up See  section 3.3  for general principles. Clinical findings may suggest conduit stenosis, residual VSD, TR, mitral regurgitation, or AR.\n•   Echocardiography: the connection between the posteriorly posi- tioned LV and the anteriorly positioned (due to the TGA) aortic valve, aortic valve function, and aortic root diameters should be assessed. The anatomy and function of the conduit between the RV and the pulmonary trunk must be visualized and assessed with Doppler interrogation. RV pressure assessed with Doppler measurement of TR jet velocity is of particular importance because the Doppler technique often overestimates the pressure gradient across the RV \u0002 PA conduit. •   CMR provides a more robust quantification of LV and RV vol- umes, aortic diameters, and EF. The RV \u0002 PA conduit, often diffi- cult to visualize by echocardiogram, and peripheral PAs can be readily seen and measured with CMR. In the presence of a resid- ual VSD, Qp:Qs can be calculated. •   Cardiac catheterization may be required for haemodynamic assessment of conduit stenosis. Angiography can be helpful for assessing the level of stenosis and peripheral PA stenosis.\n4.12.4.3 Surgical/catheter interventional treatment For indications for treatment of conduit stenosis, see  section 4.14 . If L \u0002 R shunting through a residual VSD causes symptoms or sub- stantial LV volume overload, surgical/catheter treatment should be performed (IC recommendation).\n4.12.5 Follow-up recommendations (irrespective of type of repair) All patients with TGA, regardless of the type of operation, should be seen at least annually in a specialized ACHD centre, with attention given to the specific issues previously described ( see sections 4.12.2.1, 4.12.3.1 and 4.12.4.1 ).\n4.12.6 Additional considerations (irrespective of type of repair)\n•   Exercise/pregnancy/IE prophylaxis: see  sections 3.4.6, 3.5.5  and 3.5.7 .\n",
      "keywords": [
        "originates",
        "ejection fraction",
        "should be considered",
        "older",
        "bradycardia",
        "sudden cardiac death",
        "pacemaker",
        "systolic",
        "tachycardia",
        "transposition",
        "age",
        "mitral regurgitation",
        "tricuspid",
        "characterized",
        "arteries",
        "hypertension",
        "cordance",
        "scd",
        "risk stratification",
        "aortic",
        "arrhythmia",
        "icd",
        "background",
        "echocardiography",
        "level b",
        "introduction",
        "ecg",
        "ventriculo",
        "heart failure",
        "systolic dysfunction"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 619",
          "page_number": 56,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIndications for surgical intervention |  | \nIn symptomatic patients with pulmonary\nvenous atrium obstruction, surgical repair\n(catheter intervention rarely possible) is\nrecommended. | I | C\nIn symptomatic patients with baffle stenosis not\namenable to catheter intervention, surgical\nrepair is recommended. | I | C\nIn symptomatic patients with baffle leaks not\namenable to catheter-based closure, surgical\nrepair is recommended. | I | C\nIn patients with severe systemic (tricuspid) AV\nvalve regurgitation, without significant ventric-\nular systolic dysfunction (EF >40%), valve\nrepair or replacement should be considered,\nregardless of symptoms. | IIa | C\nPA banding in adults, as LV training with subse-\nquent arterial switch procedure, is not\nrecommended. | III | C\nIndications for catheter intervention |  | \nIn symptomatic patients with baffle stenosis,\nstenting is recommended when technically\nfeasible. | I | C\nIn symptomatic patients with baffle leaks and\ncyanosis at rest or during exercise, or with\nstrong suspicion of paradoxical emboli, stent-\ning (covered) or device closure is recom-\nmended when technically feasible. | I | C\nIn patients with baffle leaks and symptoms due\nto L\u0002R shunt, stenting (covered) or device\nclosure is recommended when technically\nfeasible. | I | C\nIn asymptomatic patients with baffle leaks with\nsubstantial ventricular volume overload due to\nL\u0002R shunt, stenting (covered) or device clo-\nsure should be considered when technically\nfeasible. | IIa | C\nIn patients with a baffle leak who require a\nPM/ICD, closure of the baffle leak with a cov-\nered stent should be considered, when techni-\ncally feasible, prior to insertion of transvenous\nleads. | IIa | C\nIn asymptomatic patients with baffle stenosis,\nstenting may be considered when technically\nfeasible. | IIb | C",
          "bbox": [
            47.045652347140845,
            86.47422485351562,
            289.22323130412275,
            665.0551888602121
          ],
          "function_potential": "raw"
        },
        {
          "title": "620 ESC Guidelines",
          "page_number": 57,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nStenting or surgery (depending on substrate) is\nrecommended for coronary artery stenosis\ncausing ischaemia. | I | C\nNeo-aortic root surgery should be considered\nwhen the neo-aortic root is >55 mm, providing\naverage adult stature (for neo-aortic valve replace-\nment for severe neo-aortic AR see valvular heart\ndisease guidelines with special considerationsc). | IIa | C\nStenting should be considered for PA branch\nstenosis, regardless of symptoms, if >50% diam-\neter narrowing and RVSP >50 mmHg and/or\nrelated reduced lung perfusion are present. | IIa | C",
          "bbox": [
            42.60677194595337,
            165.27720947265624,
            284.9793737074908,
            335.84523010253906
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "41",
      "title": "4.13 Congenitally corrected transposition of the great arteries 4.13.1 Introduction and background ccTGA, or discordant atrio-ventricular and ventriculo-arterial con- nections, is uncommon. The ventri",
      "start_page": 57,
      "end_page": 59,
      "content": "Recommendations for intervention in transposition of the great arteries after arterial switch operation\nRecommendations Class a Level b\nStenting or surgery (depending on substrate) is\nrecommended for coronary artery stenosis causing ischaemia.\nI C\nNeo-aortic root surgery should be considered\nwhen the neo-aortic root is >55 mm, providing average adult stature (for neo-aortic valve replace-\nment for severe neo-aortic AR see valvular heart\ndisease guidelines with special considerations c ).\nIIa C\nStenting should be considered for PA branch stenosis, regardless of symptoms, if >50% diam-\neter narrowing and RVSP >50 mmHg and/or\nrelated reduced lung perfusion are present.\nIIa C\nAR = aortic regurgitation; ESC = European Society of Cardiology; PA = pulmo- nary artery; RVSP = right ventricular systolic pressure. a Class of recommendation. b Level of evidence. c When applying the 2017 ESC/EACTS valvular heart disease Guidelines 25  for the decision to operate, it has to be taken into account that this is a reoperation and technically more difﬁcult.\n620 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. .................................................................................................... with usual or mirror-image atrial arrangement. Abnormal base-apex orientation, especially dextrocardia (apex of the heart pointed to the right), is common (20%). Associated lesions are common (80 \u0002 90%): VSD (70%), PS (40%), dysplastic systemic TV (e.g. Ebstein-like malformation). The position of the AV node (sometimes multiple AV nodes), and the course of the bundle of His, are often abnormal and lead to AV conduction abnormalities. The anterior and lateral displacement of a fragile His bundle is important to recognize during EP studies and catheter interventions.\n4.13.2 Clinical presentation and natural history The natural history and clinical presentation are determined by asso- ciated malformations. Patients with associated lesions reaching adult- hood have either been operated upon [closure of VSD, relief of PS or (rarely) TV repair or replacement] or have a balanced physiology. Patients with isolated ccTGA rarely develop complications before adulthood. Late complications are:\n•   Systemic RV dysfunction and failure. •   Progressive TR (systemic AV valve). •   LVOTO. •   Complete AV block (2% loss of AV conduction per year); it is more common after VSD repair and/or TV replacement and may occur during pregnancy. •   VTs (extremely rare).\nLife expectancy is reduced:  \u0003 50% of patients with associated lesions were alive at the age of 40 years; without associated lesions, \u0003 50% of patients were alive at the age of 60 years. Patients die from congestive heart failure or die suddenly, presumably due to VT/VF, regardless of the presence of advanced heart failure.\n4.13.3 Diagnostic work-up See  section 3.3  for general principles.\n•   Clinical findings may include murmurs of TR, VSD, and/or PS. •   ECG may reveal a prolonged PR interval or a complete heart block. Early septal activation from right to left may cause deep Q waves in II, III, aVF, and V1 \u0002 V3. Reversal of the normal precordial progression may be seen as a QR pattern in V1 and rS in V6. Wolff \u0002 Parkinson \u0002 White syndrome is present in 2 \u0002 4% of patients. •   Chest X-ray may show an abnormally straight left heart border due to the leftward and anterior position of the ascending aorta, dextroposition with apex to the right (20%), or mesocardia (rela- tively common). •   Echocardiography is the key diagnostic modality, demonstrating double discordance and identifying associated anomalies (Ebstein-like malformation of the TV and TR, VSD, LVOTO, and PS). Systolic RV and LV function and severity of TR can be quali- tatively assessed. •   CMR provides intracardiac and great vessel anatomy and is indi- cated for quantification of ventricular volumes, mass, and EF, especially since echocardiographic assessment of systolic func- tion in systemic RVs is difficult and less reliable. •   Holter monitoring, event recorder, and EP testing may be indi- cated for detection of arrhythmias, progressive AV block, and for risk assessment for SCD.\n•   Cardiac catheterization is indicated when non-invasive assessment is inconclusive, or PH requires evaluation (see  section 3.4.5 ).\n4.13.4 Medical treatment There are no data to support the hypothesis that ACE inhibitors, ARBs, beta blockers or aldosterone antagonists, alone or in combination, improve outcome. 280   Routine prescription of these medications to prevent heart failure/improve outcome is not recommended.\n•   Diuretics may provide relief of symptoms if overt heart failure is present. Although there is no proven benefit from heart failure medical therapy, in terms of outcome in patients with systemic RVs, ‘classical’ heart failure medications or ARBs may provide some benefit in more symptomatic patients. 289   A systemic RV morphology is not a contraindication for a ventricular assist device. The coarse trabecularization of the RV apex may deserve special consideration, since it may block the inflow cannula. Selective myomectomy should be considered.\n4.13.5 Surgical/catheter interventional treatment Catheter intervention may be recommended for PA stenosis or con- duit stenosis, which can be dilated or stented. However, a residual LVOTO may have a beneficial effect on the dilated subaortic RV and subaortic AV (tricuspid) valve regurgitation because of the septal shift. If complete heart block occurs, AV sequential pacing is the standard. Fixation of the pacemaker wire in the smooth-walled LV is difficult and requires a screw-in electrode. There are some data sug- gesting that biventricular pacing with a second ventricular wire through the (normally connecting) coronary sinus behind the sub- aortic RV may lead to a better preservation of RV systolic function than LV pacing alone. 290\nRecommendations for intervention in congenitally cor- rected transposition of the great arteries\nRecommendations Class a Level b\nIn  symptomatic  patients with severe TR and pre-\nserved or mildly impaired systemic RV systolic function (EF >40%), TV replacement is indicated.\nI C\nIn  asymptomatic  patients with severe TR and pro-\ngressive systemic RV dilatation and/or mildly impaired systemic RV systolic function (EF >40%),\nTV replacement should be considered.\nIIa C\nBiventricular pacing should be considered in case\nof complete AV block or >40% ventricular pacing requirement.\nIIa C\nIn  symptomatic  patients with severe TR and more\nthan mildly reduced systemic RV systolic function (EF <_40%), TV replacement may be considered.\nIIb C\nAV = atrioventricular; EF = ejection fraction; RV = right ventricle/ventricular; TR = tricuspid regurgitation; TV = tricuspid valve. a Class of recommendation. b Level of evidence.\nESC Guidelines 621\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................. The most challenging questions are TR, RV dysfunction, and when to implant a TV and/or an ICD. In contrast to the situation in the paediatric age group, in which double switch is an established treat- ment option in case of systemic RV failure, this approach is very rarely successful in adults. Systemic AV valve (tricuspid) regurgitation is frequently the focus of surgical treatment. Repair is rarely feasible and, as a rule, valve replacement is the treatment of choice. Pre-operative systemic RVEF <_40%, PAP >50 mmHg, AF, and New York Heart Association (NYHA) class III to IV are associated with late mortality. 291\n4.13.6 Follow-up recommendations Patients with ccTGA need lifelong follow-up in a specialized ACHD centre at annual intervals, particularly because of conduction distur- bances and subaortic ventricular and subaortic AV valve dysfunction. For arrhythmias, see  section 3.4.2 .\n4.13.7 Additional considerations\n•   Exercise/sports: symptomatic patients with ccTGA and pre- served RVEF should avoid high-intensity sports and preferably not do more than moderate-static and moderate-intensity sports. Patients with significant associated lesions and/or decreased subaortic RV function should be restricted to low- static and low-intensity sports. •   Pregnancy: risk depends on functional status, ventricular function, systemic AV valve function, presence of arrhythmias (especially AV block), and associated lesions (see  section 3.5.7 ).\n",
      "keywords": [
        "ejection fraction",
        "should be considered",
        "contraindication",
        "congenitally",
        "discordant",
        "nections",
        "pacemaker",
        "systolic",
        "cctga",
        "transposition",
        "age",
        "tricuspid",
        "arteries",
        "scd",
        "nyha",
        "aortic",
        "icd",
        "class iii",
        "corrected",
        "valve replacement",
        "background",
        "atrio",
        "echocardiography",
        "level b",
        "introduction",
        "ecg",
        "ventriculo",
        "heart failure",
        "exercise",
        "ventri"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 621",
          "page_number": 58,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nIn symptomatic patients with severe TR and pre-\nserved or mildly impaired systemic RV systolic\nfunction (EF >40%), TV replacement is indicated. | I | C\nIn asymptomatic patients with severe TR and pro-\ngressive systemic RV dilatation and/or mildly\nimpaired systemic RV systolic function (EF >40%),\nTV replacement should be considered. | IIa | C\nBiventricular pacing should be considered in case\nof complete AV block or >40% ventricular pacing\nrequirement. | IIa | C\nIn symptomatic patients with severe TR and more\nthan mildly reduced systemic RV systolic function\n(EF <40%), TV replacement may be considered.\n_ | IIb | C",
          "bbox": [
            311.4618265252364,
            500.8992197672526,
            553.7917026617588,
            684.670185634068
          ],
          "function_potential": "raw"
        },
        {
          "title": "622 ESC Guidelines",
          "page_number": 59,
          "content": " |  | Levelb\nRecommendations | Classa | \n |  | \nSymptomatic patients with RVSP >60 mmHg\n(may be lower in case of reduced flow) and/or\nsevere PRc should undergo intervention with\npreference for catheter intervention (TPVI) if\nanatomically feasible. | I | C\nAsymptomatic patients with severe RVOTO and/\nor severe PR should be considered for interven-\ntion, preferably catheter intervention (TPVI) if\nanatomically feasible, when at least one of the\nfollowing criteria is present:\n• Decrease in objective exercise capacity\n(CPET).\n• Progressive RV dilation to RVESVi\n>80 mL/m2, and/or RVEDVi >160 mL/m2, and/\n_ _\nor progression of TR to at least moderate.\n• Progressive RV systolic dysfunction.\n• RVSP >80 mmHg. | IIa | C",
          "bbox": [
            306.98376816969653,
            408.0192860921224,
            549.386560900458,
            636.9847573673023
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "42",
      "title": "4.14 Right ventricular to pulmonary artery conduit 4.14.1 Introduction and background Conduits establish the continuity between the RV and the PA in com- plex defects when the native outflow tract is ",
      "start_page": 59,
      "end_page": 60,
      "content": "Complications include outgrowth, progressive obstruction with and without regurgitation, endocarditis, and aneurysms or pseudoaneurysms. Clinical presentation may include exertional dyspnoea, palpita- tions, syncope, and SCD.\n4.14.2 Diagnostic work-up See  section 3.3  for general principles. Clinical findings may include a precordial thrill, prominent A wave of the jugular veins, and systolic murmur. Conduit calcification may be seen on chest X-ray.\n•   Echocardiography is the first-line diagnostic tool providing size, shape, and function of both ventricles, PR, TR, and associated lesions. Gradients across the conduit may be difficult to measure and unreliable. RV pressure derived from TR velocity should be used to assess conduit stenoses. •   CMR is used to quantify conduit stenosis and/or regurgitation, RV volumes and mass, and to assess PAs. •   CMR/CCT is helpful for coronary artery anatomy and proximity of the RV/conduit, and other structures to the retro sternum. •   Catheterization with haemodynamic assessment is always required if intervention is considered. Angiography provides information on the level of stenosis, peripheral PA stenoses, and coronary anatomy (anomalies/abnormal course).\n4.14.3 Surgical/catheter interventional treatment Balloon dilation/stent implantation have been reported to be safe and to prolong the lifespan of failing conduits. 294 , 295   Percutaneous pulmo- nary valve implantation has now become the treatment of choice for dysfunctional valves, if technically feasible. Current exclusions for TPVI include occluded systemic veins, active infection, unsuitable out- flow tract morphology, and unfavourable coronary anatomy (com- pression by the expanded implant). Surgery is preferred when additional interventions are considered (tricuspid annuloplasty). Longitudinal data are more important for timing of reintervention than single measurements.\nRecommendations for intervention in right ventricular to pulmonary artery conduits\nRecommendations Class a Level b\nSymptomatic  patients with RVSP >60 mmHg\n(may be lower in case of reduced ﬂow) and/or\nsevere PR c   should undergo intervention with preference for catheter intervention (TPVI) if\nanatomically feasible.\nI C\nAsymptomatic  patients with severe RVOTO and/\nor severe PR should be considered for interven- tion, preferably catheter intervention (TPVI) if\nanatomically feasible, when at least one of the\nfollowing criteria is present: •   Decrease in objective exercise capacity\n(CPET). •   Progressive RV dilation to RVESVi >_80 mL/m 2 , and/or RVEDVi >_160 mL/m 2 , and/\nor progression of TR to at least moderate. •   Progressive RV systolic dysfunction. •   RVSP >80 mmHg.\nIIa C\nCPET = cardiopulmonary exercise testing; CMR = cardiovascular magnetic reso- nance; PR = pulmonary regurgitation; RV = right ventricle/ventricular; RVEDVi = right ventricular end diastolic volume indexed; RVESVi = right ventricular end systolic volume indexed; RVOTO = right ventricular outﬂow tract obstruction; RVSP = right ventricular systolic pressure; TPVI = transcatheter pulmonary valve implantation; TR = tricuspid regurgitation. a Class of recommendation. b Level of evidence. c Regurgitant fraction by CMR >30 \u0002 40%.\n622 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.14.4 Follow-up recommendations Regular follow-up in a specialized ACHD centre at least every year is recommended. Special attention should be given to exercise capacity (CPET), RVSP (conduit gradient), RV function, TR, and arrhythmias.\n4.14.5 Additional considerations\n•   Exercise/sports: no restrictions are required in asymptomatic patients with mild obstruction. High-risk patients with high RV pressure must limit themselves to low-intensity activity/sports and avoid isometric exercise. Other patients should limit them- selves according to symptoms. •   Pregnancy: maternal and foetal risks are driven by the underlying congenital heart defect and severity of RVOTO, arrhythmia, and heart failure (see  section 3.5.7 ). •   IE prophylaxis: recommended in all patients (see  section 3.4.6 ).\n",
      "keywords": [
        "pulmonary",
        "should be considered",
        "tract",
        "conduit",
        "conduits",
        "systolic",
        "defects",
        "when",
        "establish",
        "outflow",
        "native",
        "plex",
        "tricuspid",
        "scd",
        "syncope",
        "diastolic",
        "arrhythmia",
        "background",
        "continuity",
        "artery",
        "between",
        "echocardiography",
        "level b",
        "introduction",
        "heart failure",
        "systolic dysfunction",
        "exercise",
        "recommended",
        "right",
        "stenosis"
      ],
      "tables": []
    },
    {
      "number": "43",
      "title": "4.15 Univentricular heart This section deals with unoperated and palliated univentricular heart (UVH). For patients after Fontan operation see  section 4.16 .",
      "start_page": 60,
      "end_page": 60,
      "content": "4.15.1 Introduction and background The term ‘UVH’ summarizes a variety of malformations where either the RV or LV is missing or, if present, is hypoplastic and thus not ame- nable for biventricular repair, such as:\n•   Tricuspid atresia. •   Hypoplastic right heart syndrome variants, e.g. pulmonary atresia with intact ventricular septum variants. •   Hypoplastic left heart syndrome (HLHS) variants, including mitral atresia. •   Double-inlet LV. •   Double-inlet RV. •   Extreme forms of unbalanced complete AV septal defects. •   Single ventricle with undefined morphology.\n",
      "keywords": [
        "patients",
        "univentricular",
        "unoperated",
        "operation",
        "fontan",
        "after",
        "palliated",
        "tricuspid",
        "section",
        "heart",
        "deals"
      ],
      "tables": []
    },
    {
      "number": "44",
      "title": "These malformations are always associated with additional intra- and/or extracardiac lesions such as:",
      "start_page": 60,
      "end_page": 60,
      "content": "•   ASD, VSD, AVSD, PDA. •   AS (valvular, subvalvular). •   Aortic arch anomalies: hypoplasia, interruption, coarctation. •   PS (valvular, subvalvular), pulmonary atresia. •   PA anomalies: peripheral stenosis, hypoplasia, one-sided absence. •   Discordant connections, malposition of the great arteries. •   AV valve stenosis, regurgitation, overriding, straddling. •   LA or RA isomerism, abnormal systemic or pulmonary venous connections. •   Left SVC, absent innominate vein, absent right SVC, absent infra- hepatic IVC with azygos or hemiazygos continuity. •   Aortic-to-pulmonary collateral arteries. •   Polysplenia or asplenia.\nDetailed anatomic description is beyond the scope of these guide- lines and can be found in textbooks. Owing to the lack of data, rec- ommendations are mainly based on expert consensus. 296 \u0002 300   When presenting as adults, the vast majority of patients with these condi- tions will have undergone previous palliation with some type of systemic-to-PA shunt, cavopulmonary connection (Glenn), or now\npreferably a Fontan operation or one of its modifications; the latter is covered in  section 4.16 .\n",
      "keywords": [
        "lesions",
        "aortic",
        "associated",
        "always",
        "stenosis",
        "extracardiac",
        "additional",
        "these",
        "such",
        "intra",
        "malformations"
      ],
      "tables": []
    },
    {
      "number": "45",
      "title": "Two different haemodynamic situations can be identified:",
      "start_page": 60,
      "end_page": 62,
      "content": "•   No anatomic restriction to pulmonary blood flow: if pulmonary circulation remains unmodified (i.e. no surgery), many patients will die in childhood due to intractable heart failure. Those who survive this period will have developed severe PVD. This will be a main determinant of long-term outcome. Many will have had pul- monary banding to restrict pulmonary blood flow in early child- hood. An effective banding will protect against PVD, while allowing enough pulmonary blood flow to limit the degree of cya- nosis. A banding that is too loose will result in pulmonary over- flow and PVD despite the banding. If the banding is too tight, pulmonary blood flow will be extremely limited, resulting in severe cyanosis. •   Obstruction to pulmonary blood flow (frequently valvular and/or subvalvular PS or atresia): sometimes the obstruction is such that the pulmonary circulation is adequate (not excessive, thus avoid- ing development of PH, and not too restricted, thus without extreme cyanosis). These balanced situations are the exception but allow survival into adulthood without having surgery. Most patients have a very restricted pulmonary blood flow, necessitat- ing a systemic-to-PA shunt operation in childhood  \u0002  most com- monly Blalock \u0002 Taussig (subclavian to PA), rarely Waterston or Potts (ascending or descending aorta to PA, respectively). If a systemic-to-PA shunt is too large, pulmonary overflow will result in PVD at adult age. If the shunt is too small, patients will be extremely cyanotic. Beyond infancy, an anastomosis between the SVC and PA is a possibility: the classical Glenn anastomosis to the right PA (historical) or an end-to-side anastomosis with the PA, creating a bidirectional cavopulmonary anastomosis. An adequate shunt will lead to a balanced situation.\n4.15.2 Clinical presentation and natural history Depending on the extent of pulmonary blood flow, presence or absence of PVD, and ventricular function, patients may present with various degrees of cyanosis and congestive heart failure. Exercise abil- ity is generally substantially reduced (with exceptions); complete AV block, arrhythmias (supraventricular, but also ventricular, SCD not unusual), stroke, brain abscess, and thromboembolism can occur. Endocarditis is relatively common in this population. For more details, see  section 3.4.8 . Cyanosis is typically present in patients with UVH without a Fontan operation. Arterial oxygen saturation commonly ranges from 75 \u0002 85% but may, in exceptional cases with ideally balanced circula- tions, reach values >90%. Patients may present with progressive obstruction towards the aorta. This will lead to ventricular hypertrophy and, eventually, to reduced cardiac output. Progressive obstruction towards the PA will cause progressive cyanosis. In Glenn patients, worsening cyanosis may also be due to development of pulmonary arteriovenous malfor- mations or IVC-to-SVC collaterals. The UVH has to accommodate both systemic and pulmonary venous return. This chronic volume overload will lead to a high likeli- hood of ventricular failure relatively early in life. AV valve regurgita- tion may develop or progress, if present previously. The already\nESC Guidelines 623\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ........................................................\ndiminished exercise capacity will deteriorate further. Eventually, overt heart failure may develop, in addition to the cyanosis. In rare cases, with a well-balanced haemodynamic situation, ven- tricular dysfunction does not develop, and survival until the fifth, sixth, and even seventh decade has been reported.\n4.15.3 Diagnostic work-up See  section 3.3  for general principles. Clinical findings include central cyanosis, clubbing of fingers and toes, and often an asymmetric chest with a precordial heave at the side where the heart lies in the chest. Scoliosis is a common problem. The second heart sound is typically single, but the rest of the auscultation depends on the associated abnormalities. ECG may reveal rhythm or conduction disturbances. Atrial reentrant tachycar- dia with 2:1 block and only modest tachycardia may be easily overlooked.\n•   TTE is the key diagnostic technique, providing information on anatomy and monitoring of cardiac function during follow-up. The segmental approach is required in the echocardiographic exami- nation; UVHs are always complex and can present with a wide range of abnormalities in situs, orientation, and connections. Fundamental TTE parameters/issues/items in the diagnosis of UVHs are: -  Abdominal and atrial situs. -  Position of the heart in the chest and position of the apex. -  Veno-atrial, AV, and ventriculo-arterial connections. -  Morphological and haemodynamic information has to be obtained on the entire heart. -  Exact anatomy of the ventriculo-arterial connection and its functional status has to be assessed, with special focus on obstruction towards the aorta or pulmonary vascular bed. -  AV valve function should be evaluated, with special focus on regurgitation. -  Ventricular function/hypertrophy. -  ASD/VSD type, size, number, location. -  Ascending aorta, aortic arch, and descending aorta; detect/ exclude coarctation. -  PAs  \u0002  common trunk, branches, and sources of pulmonary blood supply. -  Visualization of shunts (Blalock \u0002 Taussig, Waterston, etc.). TOE may be indicated in cases of inadequate TTE images. •   CMR is the imaging modality of choice for extracardiac anatomy, including veno-atrial and ventriculo-arterial connections (CCT is an alternative). Detailed morphological information of intracar- diac anatomy can also be obtained. CMR is also the method of choice for quantification of ventricular volumes, EF, and relative distribution of blood flow in the left and right lungs. •   Cardiac catheterization is required when intervention is consid- ered for haemodynamic assessment, in particular PAP and trans- pulmonary gradient (PVR is often difficult to assess in this setting). It is mandatory when patients are evaluated for a Fontan operation. Evaluation of systemic-to-PA or Glenn shunts  \u0002  and their sequelae (stenosis of the pulmonary branches) and other vascular anomalies (arteriovenous collateral vessels, fistulas, etc.) \u0002  may also require catheterization.\nInterventional treatment, such as pulmonary valvotomy to increase pulmonary blood flow in cases of severe PS, is debatable. If the clinical situation is stable, the (frequently high) risk of any type of surgical intervention should be weighed very carefully against the possible benefit. A Fontan operation can only be considered in very well selected patients (see  section 4.16 ). For patients with severe cya- nosis, with decreased pulmonary blood flow without elevated PVR, a bidirectional Glenn shunt (SVC-to-PA) can be an option. If a systemic-to-pulmonary shunt (e.g. arteriovenous axillary fistula or systemic artery pulmonary shunt) is the only option (bidirectional Glenn shunt not sufficient or PAP not low enough for this shunt), the benefit of increased pulmonary blood flow should be weighed against increased volume load to the systemic ventricle. For transplantation, previous sternotomies/thoracotomies, aorto-pulmonary collaterals, and the multisystem nature of cya- notic CHD are technical and medical challenges and limit the outcome.\nSpecial considerations and recommendations for inter- vention in univentricular heart\nRecommendations Class a Level b\nIt is recommended that adults with unoperated\nor palliated UVHs undergo careful evaluation in specialized centres, including multimodality\nimaging as well as invasive work-up to decide\nwhether they may beneﬁt from surgical or inter- ventional procedures.\nI C\nOnly well-selected symptomatic cyanotic\npatients, after careful evaluation [low pulmonary\nvascular resistances, adequate function of the AV valve(s), preserved ventricular function],\nshould be considered candidates for a Fontan\ncirculation.\nIIa C\nPatients with increased pulmonary blood ﬂow\n\u0002  unlikely at adult age  \u0002  should be considered\nfor PA banding or tightening of a previously placed band.\nIIa C\nPatients with severe cyanosis and decreased pul-\nmonary blood ﬂow, but without elevated PVR\nor PAP, should be considered for a bidirectional Glenn shunt.\nIIa C\nPatients with severe cyanosis and decreased pul-\nmonary blood ﬂow not suitable for a Glenn shunt may be considered for a systemic-to-PA\nshunt.\nIIb C\nHeart transplantation and heart-lung transplan-\ntation should be considered when there is no conventional surgical option in patients with\npoor clinical status.\nIIa C\nAV = atrioventricular; PA = pulmonary artery; PAP = pulmonary artery pressure; PVR = pulmonary vascular resistance; UVH = univentricular heart. a Class of recommendation. b Level of evidence.\n624 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ................................................................................................................................................................. 4.15.4 Conservative management See  sections 3.4.3  and  3.4.8  for haematological management and the role of targeted therapy in PVD.\n4.15.5 Follow-up recommendations Regular evaluation is required in a specialized ACHD centre. Frequency is individualized, but at least yearly, with physical exami- nation, measurement of oxygen saturation, laboratory tests (haema- tological indices, iron status, liver function, kidney function, etc.), ECG, X-ray, and echocardiography (see also  section 3.4.8 ). CMR and an exercise test are required at least once at adult age and at further intervals timed according to baseline findings.\n4.15.6 Additional considerations\n•   Exercise/sports: as a rule, patients do not have an elevated risk of death during exercise, but they do have a substantially reduced exercise capacity. Recreational sports can be considered at a symptom-limited level. •   Pregnancy: contraindicated in patients with severely reduced pul- monary blood flow or with severe PVD, or if ventricular function is poor. Cyanosis poses a significant risk to the foetus, with a live birth unlikely (<12%) if oxygen saturation is <85% 106   (see  section 3.5.7 ). •   For contraception, a combined oral contraceptive pill must be avoided because of the risk of thrombogenicity and throm- boembolism. Progestogen-only pills and progestogen-eluting intrauterine devices or implantation systems provide safe contra- ception with a smaller cardiovascular risk. •   IE prophylaxis: indicated in all patients (see  section 3.4.6 ).\n",
      "keywords": [
        "should be considered",
        "haemodynamic",
        "tachycardia",
        "identified",
        "different",
        "age",
        "scd",
        "aortic",
        "situations",
        "echocardiography",
        "level b",
        "ecg",
        "heart failure",
        "exercise",
        "recommended",
        "may be considered",
        "stenosis",
        "catheterization",
        "cardiovascular risk"
      ],
      "tables": [
        {
          "title": "624 ESC Guidelines",
          "page_number": 61,
          "content": "Recommendations | Classa | Levelb\nIt is recommended that adults with unoperated\nor palliated UVHs undergo careful evaluation in\nspecialized centres, including multimodality\nimaging as well as invasive work-up to decide\nwhether they may benefit from surgical or inter-\nventional procedures. | I | C\nOnly well-selected symptomatic cyanotic\npatients, after careful evaluation [low pulmonary\nvascular resistances, adequate function of the\nAV valve(s), preserved ventricular function],\nshould be considered candidates for a Fontan\ncirculation. | IIa | C\nPatients with increased pulmonary blood flow\n\u0002 unlikely at adult age \u0002 should be considered\nfor PA banding or tightening of a previously\nplaced band. | IIa | C\nPatients with severe cyanosis and decreased pul-\nmonary blood flow, but without elevated PVR\nor PAP, should be considered for a bidirectional\nGlenn shunt. | IIa | C\nPatients with severe cyanosis and decreased pul-\nmonary blood flow not suitable for a Glenn\nshunt may be considered for a systemic-to-PA\nshunt. | IIb | C\nHeart transplantation and heart-lung transplan-\ntation should be considered when there is no\nconventional surgical option in patients with\npoor clinical status. | IIa | C",
          "bbox": [
            307.81919652765447,
            82.39541625976562,
            548.9221229553223,
            438.6245844914363
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "46",
      "title": "4.16 Patients after Fontan operation 4.16.1 Introduction and background The Fontan operation was introduced in 1968 and has become the definitive treatment for suitable patients with a range of cardia",
      "start_page": 62,
      "end_page": 64,
      "content": "The natural history and outcome of other palliations for hearts with a ‘single ventricle’ are poor, so that the Fontan is usually\nundertaken in all patients in whom the haemodynamics are suitable. It is now appreciated that the operative mortality and subsequent outcome depend on the suitability of the circulation and adherence to defined criteria. Strict selection gives the best early and late results, with operative mortality of <5% in modern series and includes low PVR and PAP (mean <15 mmHg), preserved ventricular function, adequate PA size, no relevant AV valve regurgitation, and normal rhythm. A ‘fenestration’ has been performed in selected or all cases by some centres to allow for shunting of deoxygenated blood to the systemic circulation at atrial level, aiming to improve the cardiac out- put at the expense of cyanosis. 303   Fontan operation, when consid- ered late in adults, is not always the palliation of choice because of the limited long-term outcome.\n4.16.2 Clinical presentation and natural history The lack of a subpulmonary ventricle results in chronic systemic venous hypertension, markedly altered pulmonary haemodynamics, and a chronically ‘preload-deprived’ ventricle. A number of important problems have emerged during long-term follow-up. Although 10- year survival may approach 90%, it should be appreciated that a pre- mature decline in cardiovascular performance, with reduced survival, is inevitable even in the best Fontan patients. 304   Important haemody- namic issues contributing to late Fontan failure include a progressive decline in systemic ventricular function, AV valve regurgitation, a rise in PVR, atrial enlargement, pulmonary venous obstruction, progres- sively restrictive subaortic VSD, and the consequences of chronic systemic venous hypertension including hepatic congestion and dys- function. 305   Further complications include atrial and PA thrombus formation, development of pulmonary arteriovenous malformations, systemic arterial-to-pulmonary venous or systemic arterial-to- pulmonary arterial connection, and systemic-to-pulmonary venous collaterals.\nAfter the Fontan operation, the majority of patients do well during childhood and adolescence, although exercise capacity is reduced when measured objectively. However, clinical complications may subsequently develop, with a progressive decline in exercise per- formance and heart failure, cyanosis, chronic venous insufficiency, and development of important arrhythmias, especially in patients with a classical Fontan operation. 306   By 10 years after a Fontan opera- tion,  \u0003 20% of patients have supraventricular tachyarrhythmias (including typically IART and atrial flutter, but also AF and focal AT). 307   Bradycardia due to SND may facilitate occurrence of AT. The incidence of AT is lower after total cavopulmonary connection than atriopulmonary connection, and lower after extracardiac con- duit than intracardiac conduit. 308   Atrial tachyarrythmias with rapid conduction are associated with SCD.\nThe spectrum of Fontan-associated liver disease is wide and includes both hepatic congestion and severe fibrosis, with signs of portal hypertension and hyperenhancing nodules as well as hepato- cellular carcinoma. 309\nProtein-losing enteropathy is a rare but important complication and results in peripheral oedema, pleural effusions, and ascites. It can be diagnosed by documentation of low serum albumin and elevated\nESC Guidelines 625\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ................................................................................................................................................................... a 1-antitrypsin levels in the stool. 310   It has traditionally been associ- ated with a very poor prognosis (5-year survival <50%) but a more recent study reported a 5-year survival of 88%; however, treatment remains challenging. 311   Plastic bronchitis and lymphatic system dys- function may further complicate prognosis.\nFor more details, see a recently published extensive review. 312\n4.16.3 Diagnostic work-up See  section 3.3  for general principles. Clinical findings include commonly mild, non-pulsatile jugular venous distension. Significant jugular venous distension and hepato- megaly, however, raise suspicion of Fontan obstruction or ventricular failure. ECG frequently shows junctional rhythm or atrial arrhythmias. Pleural effusion on chest X-ray raises suspicion of protein-losing enteropathy.\n•   Echocardiography is the first-line diagnostic tool, providing infor- mation on ventricular and valve function. To image the Fontan pathway, TOE or other imaging modalities are generally required. •   Annual blood tests should include haematology, serum albumin, and liver and renal function. When protein losing enteropathy is suspected,  a 1-antitrypsin clearance must be calculated. •   CMR is helpful for evaluation of the Fontan pathway, collaterals, and pulmonary veins (e.g. right pulmonary vein obstruction by enlarged RA) and for thrombus, all of which CCT can also pro- vide. CCT requires experience to mitigate streaming artefact and false positive diagnosis of thrombus. CMR is regularly performed for ventricular volumes, Fontan pathway patency and flows, to evaluate AV valve regurgitation, subaortic obstruction, myocar- dial fibrosis, and for detection of thrombus. •   As liver dysfunction, liver cirrhosis, and hepatocellular carcinoma have been recognized as typical complications in this setting, reg- ular liver imaging (ultrasound, computed tomography, magnetic resonance) and laboratory assessment should be performed. •   Cardiac catheterization should be performed at a low threshold in cases of unexplained oedema, exercise deterioration, new- onset arrhythmia, cyanosis, and haemoptysis. It provides informa- tion on ventricular and valvular function, haemodynamics includ- ing PVR, and Fontan obstruction and anomalous vascular connections (see  section 4.16.2 ). Integration with CMR for flows (cardiac output) may allow more precise measurement of PVR.\n4.16.4 Medical treatment\n•   Anticoagulation: right atrial blood stasis and disturbed coagula- tion may predispose to thrombosis. The potential for subclinical, recurrent pulmonary embolism (eventually leading to a rise in PVR) and systemic embolism have led to a recommendation, by some, for lifelong anticoagulation. There is, however, no evidence of benefit, and practice varies between centres. Anticoagulation is indicated in the presence, or with a history, of atrial thrombus, atrial arrhythmias, or thromboembolic events. Although NOACs have been reported to be safe in selected Fontan patients, 79\nrobust prospective efficacy data are lacking and thus these drugs cannot currently be recommended as standard therapy. •   Antiarrhythmic therapy: loss of sinus rhythm may precipitate rapid haemodynamic decline and atrial arrhythmias. Sustained atrial arrhythmia with rapid AV conduction should be considered a medical emergency. Electrical cardioversion is the mainstay of treatment, as drug therapy is often ineffective. Amiodarone may be effective in preventing recurrence, but it has many long-term side effects. Sotalol can be an alternative. There should be a low threshold for radiofrequency ablation, although these are difficult arrhythmias to treat in the catheterization laboratory. 313\nAntitachycardia atrial PMs may assist. If AV pacing is required, this will need an epicardial approach. Occurrence of arrhythmias should prompt haemodynamic evaluation. In addition, a proactive approach of EP evaluation and ablation therapy (where appropri- ate) should be considered, including Fontan conversion with con- comitant arrhythmia surgery. ICD therapy may be considered in selected patients. See  section 3.4.2 . •   Therapy of protein losing enteropathy: medical therapy remains challenging and various treatments have been proposed (after exclusion of haemodynamic problems) including salt restriction, high protein diet, diuretics, ACE inhibitors (may be poorly toler- ated), steroids, albumin infusion, chronic subcutaneous heparin, creation of a fenestration (by interventional catheter), and even- tually, consideration of transplantation. •   Pulmonary vasodilators: ERAs and PDE-5 inhibitors may be con- sidered in selected patients with elevated pulmonary pressure/ resistance in the absence of elevated ventricular end diastolic pressure. Data on the routine use of these medications in Fontan patients are limited at present. A randomized trial of the ERA bosentan has demonstrated significantly improved cardiopulmo- nary exercise capacity in 75 adults with Fontan physiology. 314\n4.16.5 Surgical/interventional treatment Patients with a ‘failing Fontan’ (with a combination of intractable arrhythmia, right atrial dilation, worsening AV valve regurgitation, deterioration of ventricular function, and/or atrial thrombus) should be considered for surgery. 315   While patients with failing systemic ventricular function may benefit from heart transplantation (per- formed in experienced settings), patients with preserved systemic ventricular function, atrial arrhythmia, and impaired flow dynamics in the Fontan pathway may benefit from conversion to extracardiac total cavopulmonary connection and concomitant cryoablation. 316\nThe latter has provided good early results in a very experienced set- ting, but is associated with surgical mortality and ongoing morbidity, with the need for both continued drug therapy and pacemaker implantation in the majority of cases. 317   If performed late, conversion may be less likely to result in a good outcome, and cardiac transplan- tation may be required. However, the best timing for a conversion remains a matter of uncertainty. In selected adult patients, it may be appropriate to consider device closure of a fenestration if there is sig- nificant cyanosis, but this may also worsen the patient’s condition. Catheter intervention may also be required in the case of flow obstruction, or anomalous vascular connections.\n626 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................\n4.16.6 Follow-up recommendations As a result of these many complex issues, the care of Fontan patients is one of the major challenges for ACHD practitioners. All Fontan patients should be followed in specialized ACHD centres, usually at least annually, with echocardiography, ECG, blood tests, and exercise testing. Intervals for CMR and hepatic ultrasound (or computed tomography) must be decided on an individual basis. For adults, it appears reasonable to perform a baseline hepatic assessment with magnetic resonance imaging at the first visit to guide the frequency and mode of follow-up based on the degree of pre-existing hepatic changes. In addition, yearly follow-up hepatic assessments including, for example, liver ultrasound and alpha-fetoprotein measurement, should be considered after consultation with local hepatology services. Comprehensive assessment is mandatory for patients with mani- festations of the ‘failing Fontan’ complex, with particular care to\nexclude even minor obstructions to cavopulmonary flow and pulmo- nary venous return, which may have a major haemodynamic impact.\n4.16.7 Additional considerations\n•   Exercise/sports: after Fontan operation, patients have significantly reduced exercise capacity as part of their circulation. However, moderate symptom-limited aerobic exercise is to be recom- mended according to current recommendations to improve musculatory strength and quality of life. 24\n•   Pregnancy: patients with a Fontan circulation and any complica- tion should be advised against pregnancy. Successful pregnancy is possible in selected patients, although with significant maternal morbidity, especially heart failure and arrhythmia, but also throm- boembolic complications. Therapeutic anticoagulants should be considered, balanced against the risk of bleeding, which is also higher in these patients. Intensive monitoring, including after delivery, is mandatory. There is a high miscarriage rate of 27 \u0002 55% and a high rate of prematurity and intrauterine growth restriction. Whether pregnancy with its volume loading has an adverse effect on the long-term outcome of women with a single ventricle remains to be elucidated. •   IE prophylaxis: only recommended in patients with a recent redo Fontan (<6 months), cyanosis, a prosthetic valve, residual patch leak, or prior endocarditis.\n",
      "keywords": [
        "should be considered",
        "bradycardia",
        "prosthetic valve",
        "pacemaker",
        "anticoagulation",
        "pulmonary embolism",
        "hypertension",
        "scd",
        "diet",
        "become",
        "definitive",
        "diastolic",
        "arrhythmia",
        "icd",
        "operation",
        "fontan",
        "introduced",
        "background",
        "range",
        "echocardiography",
        "introduction",
        "ecg",
        "heart failure",
        "suitable",
        "cardia",
        "exercise",
        "patients",
        "treatment",
        "recommended",
        "may be considered"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 627",
          "page_number": 64,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nSustained atrial arrhythmia with rapid AV con-\nduction is a medical emergency and should be\npromptly treated with electrical cardioversion. | I | C\nAnticoagulation is indicated in the presence, or\nwith a history, of atrial thrombus, atrial arrhyth-\nmias, or thromboembolic events. | I | C\nIt is recommended that women with a Fontan\ncirculation and any complication are coun-\nselled against pregnancy. | I | C\nCardiac catheterization is recommended at a\nlow threshold in cases of unexplained oedema,\nexercise deterioration, new-onset arrhythmia,\ncyanosis, and haemoptysis. | I | C\nIn patients with arrhythmias, a proactive\napproach of electrophysiologic evaluation and\nablation (where appropriate) should be\nconsidered. | IIa | C\nRegular liver imaging (ultrasound, computed\ntomography, magnetic resonance) should be\nconsidered. | IIa | C\nEndothelin receptor antagonists and phospho-\ndiesterase-5 inhibitors may be considered in\nselected patients with elevated pulmonary\npressure/resistance in the absence of elevated\nventricular end diastolic pressure. | IIb | C\nIn selected patients with significant cyanosis,\ndevice closure of a fenestration may be con-\nsidered but requires careful evaluation before\nintervention to exclude induction of systemic\nvenous pressure increase or fall in cardiac\noutput. | IIb | C",
          "bbox": [
            47.06791453207693,
            86.47422485351562,
            289.5170044979807,
            491.06416756766185
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "47",
      "title": "4.17 Coronary anomalies 4.17.1 Introduction and background Coronary anomalies include anomalous aortic origin of a coronary artery (AAOCA), anomalous coronary artery from the PA (ACAPA), and coronary ",
      "start_page": 64,
      "end_page": 65,
      "content": "4.17.1.1 Anomalous coronary artery from the pulmonary artery Although many congenital coronary anomalies are benign, natural history studies of anomalous left coronary artery from the PA (ALCAPA) document poor outcome if untreated. 318   ACAPA results in low oxygen levels in the coronary artery, coronary steal syndrome, and myocardial ischaemia. ALCAPA can present as a silent or symp- tomatic myocardial infarction, LV dysfunction, VTs, or even SCD. Patients may also primarily present with volume overload due to L \u0002 R shunt causing heart failure symptoms. However, anomalous right coronary artery from the PA (ARCAPA) has frequently been diagnosed incidentally. Dual coronary system repair, including coro- nary button transfer with or without an interposition graft, is pre- ferred. A coronary artery bypass graft (CABG) with closure of the ACAPA should be reserved for those in whom coronary transfer is not feasible.\n4.17.1.2 Anomalous aortic origin of a coronary artery Natural history studies are lacking regarding untreated patients with AAOCA. The debate about management is ongoing, in particular in patients with an interarterial course of an anomalous coronary artery. Risk assessment for SCD is difficult because of the lack of data. Autopsy series show that most patients are young (<35 years) and die during, or shortly after, exercise. Myocardial fibrosis has been demonstrated, suggesting myocardial ischaemia may play a role. Left coronary artery arising from the opposite (right) sinus is less\nSpecial considerations and recommendations for inter- vention after Fontan operation\nRecommendations Class a Level b\nSustained atrial arrhythmia with rapid AV con-\nduction is a medical emergency and should be promptly treated with electrical cardioversion.\nI C\nAnticoagulation is indicated in the presence, or\nwith a history, of atrial thrombus, atrial arrhyth- mias, or thromboembolic events.\nI C\nIt is recommended that women with a Fontan\ncirculation and any complication are coun-\nselled against pregnancy.\nI C\nCardiac catheterization is recommended at a\nlow threshold in cases of unexplained oedema,\nexercise deterioration, new-onset arrhythmia, cyanosis, and haemoptysis.\nI C\nIn patients with arrhythmias, a proactive\napproach of electrophysiologic evaluation and\nablation (where appropriate) should be considered.\nIIa C\nRegular liver imaging (ultrasound, computed\ntomography, magnetic resonance) should be considered.\nIIa C\nEndothelin receptor antagonists and phospho-\ndiesterase-5 inhibitors may be considered in\nselected patients with elevated pulmonary pressure/resistance in the absence of elevated\nventricular end diastolic pressure.\nIIb C\nIn selected patients with signiﬁcant cyanosis, device closure of a fenestration may be con-\nsidered but requires careful evaluation before\nintervention to exclude induction of systemic venous pressure increase or fall in cardiac\noutput.\nIIb C\nAV = atrioventricular. a Class of recommendation. b Level of evidence.\nESC Guidelines 627\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. .......................................................................................\ncommon, but more malignant than the right coronary artery from the left sinus. High orifice, ostial stenosis, slit-like/fish-mouth-shaped orifice, acute-angle take-off, intramural course and its length, or inter- arterial course and hypoplasia of the proximal coronary artery have been associated with myocardial ischaemia and have all been pro- posed as risk factors. 319 \u0002 322\nRisk stratification must also include age (<35 years) and level of exercise (e.g. competitive sports). There is very limited evidence that surgery in asymptomatic middle-aged patients provides any survival benefit or modifies the SCD risk. 323 , 324\n4.17.1.3 Coronary artery fistulae A coronary artery fistula, whether congenital or acquired, is an abnormal connection between a coronary artery and cardiac cham- ber or vessel. Small fistulae have a good prognosis without treatment. Medium or large fistulae are associated with long-term complications (angina, myocardial infarction, arrhythmias, heart failure, and endo- carditis). The presence of symptoms, complications, and a significant shunt are the main indications for percutaneous or surgical closure.\n4.17.2 Diagnostic evaluation CCT is the preferred technique for the evaluation of high-risk anat- omy, including features such as an intramural course and orifice anomalies (slit-like orifice, acute-angle take-off, orifice >1 cm above the sinotubular junction). Assessment of physical stress-induced ischaemia using advanced imaging modalities is the key to decision making. 4.17.3 Surgical treatment Indications for surgery are summarized in the Recommendations for the management of patients with anomalous coronary arteries table.\n",
      "keywords": [
        "should be considered",
        "anticoagulation",
        "age",
        "include",
        "scd",
        "risk stratification",
        "coronary",
        "diastolic",
        "aortic",
        "arrhythmia",
        "anomalous",
        "origin",
        "background",
        "artery",
        "acapa",
        "introduction",
        "level b",
        "anomalies",
        "heart failure",
        "exercise",
        "recommended",
        "may be considered",
        "stenosis",
        "catheterization",
        "aaoca",
        "ablation",
        "coronary artery"
      ],
      "tables": [
        {
          "title": "628 ESC Guidelines",
          "page_number": 65,
          "content": "Surgery should be considered in asympto-\nmatic patients with AAOCA (right or left)\nand evidence of myocardial ischaemia. | IIa | C | \nSurgery should be considered in asympto-\nmatic patients with AAOLCA and no evi-\ndence of myocardial ischaemia but a high-\nrisk anatomy.c | IIa | C | \nSurgery may be considered for symptomatic\npatients with AAOCA even if there is no\nevidence of myocardial ischaemia or high-\nrisk anatomy.c | IIb | C | \nSurgery may be considered for asymptomatic\npatients with AAOLCA without myocardial\nischaemia and without high-risk anatomyc\nwhen they present at young age (<35 years). | IIb | C | \nSurgery is not recommended for AAORCA in\nasymptomatic patients without myocardial\nischaemia and without high-risk anatomy.c | III | C | ",
          "bbox": [
            306.7975969314575,
            59.87817600795201,
            553.0920322963169,
            281.75416346958707
          ],
          "function_potential": "raw"
        },
        {
          "title": "628 ESC Guidelines",
          "page_number": 65,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nNon-pharmacological functional imaging\n(e.g. nuclear study, echocardiography, or\nCMR with physical stress) is recommended\nin patients with coronary anomalies to con-\nfirm/exclude myocardial ischaemia. | I | C | \nAnomalous coronary arteries from the pulmonary artery |  |  | \nSurgery is recommended in patients with\nALCAPA. | I | C | \nSurgery is recommended in patients with\nARCAPA and symptoms attributable to\nanomalous coronary artery. | I | C | \nSurgery should be considered for ARCAPA\nin asymptomatic patients with ventricular\ndysfunction, or myocardial ischaemia attrib-\nutable to coronary anomaly. | IIa | C | \nAnomalous aortic origin of the coronary artery |  |  | \nSurgery is recommended for AAOCA in\npatients with typical angina symptoms who\npresent with evidence of stress-induced\nmyocardial ischaemia in a matching territory\nor high-risk anatomy.c | I | C | ",
          "bbox": [
            42.54126984732492,
            433.3213612874349,
            287.60301298253677,
            716.7021615164621
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "48",
      "title": "5 Quality indicators",
      "start_page": 65,
      "end_page": 66,
      "content": "The overall aim of this new edition of the ESC Clinical Practice Guidelines for ACHD is to assist caregivers in their daily practice for the benefit of patients. In a next step, it is important to analyse the adaptation of, and the adherence to, these Guidelines in practice, a process that can be envisaged using Quality Indicators (QIs). QIs are sets of measures that enable the quantification of adher- ence to Guideline recommendations and provide a mechanism for measuring opportunities to improve cardiovascular care and out- comes. 325   QIs show important differences from Clinical Practice Guidelines. For instance, the latter are recommendations for care to apply prospectively to individual patients, whereas QIs are applied retrospectively to a group of patients to assess if a care process was delivered or not. 325\nQIs are derived from evidence, feasible, concretely interpret- able, and usable. 326   The goal of QIs is to improve quality of health care, and they have been increasingly used by health authorities, professional organisations, healthcare payers, as well as the public. 327 \u0002 329\nThe process of development and defining QIs for the management of specific ACHD items has been initiated during the Guideline writ- ing process and results will be published later in a dedicated document.\nRecommendations for the management of patients with anomalous coronary arteries\nRecommendations Class a Level b\nNon-pharmacological functional imaging (e.g. nuclear study, echocardiography, or\nCMR with physical stress) is recommended\nin patients with coronary anomalies to con- ﬁrm/exclude myocardial ischaemia.\nI C\nAnomalous coronary arteries from the pulmonary artery\nSurgery is recommended in patients with\nALCAPA. I C\nSurgery is recommended in patients with ARCAPA and symptoms attributable to\nanomalous coronary artery.\nI C\nSurgery should be considered for ARCAPA in asymptomatic patients with ventricular\ndysfunction, or myocardial ischaemia attrib-\nutable to coronary anomaly.\nIIa C\nAnomalous aortic origin of the coronary artery\nSurgery is recommended for AAOCA in\npatients with typical angina symptoms who\npresent with evidence of stress-induced myocardial ischaemia in a matching territory\nor high-risk anatomy. c\nI C\nContinued\nSurgery should be considered in  asympto-\nmatic  patients with AAOCA (right or left)\nand evidence of myocardial ischaemia.\nIIa C\nSurgery should be considered in  asympto- matic  patients with AAOLCA and no evi-\ndence of myocardial ischaemia but a high- risk anatomy. c\nIIa C\nSurgery may be considered for symptomatic\npatients with AAOCA even if there is no\nevidence of myocardial ischaemia or high- risk anatomy. c\nIIb C\nSurgery may be considered for  asymptomatic\npatients with AAOLCA without myocardial ischaemia and without high-risk anatomy c\nwhen they present at young age (<35 years).\nIIb C\nSurgery is not recommended for AAORCA in\nasymptomatic patients without myocardial ischaemia and without high-risk anatomy. c III C\nAAOCA = anomalous aortic origin of a coronary artery; AAOLCA = anomalous aortic origin of the left coronary artery; AAORCA = anomalous aortic origin of the right coronary artery; ALCAPA = anomalous left coronary artery from the pulmonary artery; ARCAPA = anomalous right coronary artery from the pulmo- nary artery; CMR = cardiovascular magnetic resonance. a Class of recommendation. b Level of evidence. c High-risk anatomy includes features such as an intramural course and oriﬁce anomalies (slit-like oriﬁce, acute-angle take-off, oriﬁce >1 cm above the sinotubu- lar junction).\n628 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 6 Gaps in evidence\n",
      "keywords": [
        "aortic",
        "quality",
        "age",
        "recommended",
        "should be considered",
        "may be considered",
        "guideline",
        "indicators",
        "echocardiography",
        "level b",
        "coronary artery"
      ],
      "tables": []
    },
    {
      "number": "49",
      "title": "6.1 General aspects 6.1.1 Organization of care and patient evaluation",
      "start_page": 66,
      "end_page": 66,
      "content": "•   Congenital heart defects are arbitrarily classified into lesions of different complexities (mild, moderate, severe;  Table  4 ). The val- idity of this classification for clinical management and risk stratifi- cation remains to be investigated in large registries. •   Minimal volumes of patients under care at each ACHD expert centre, and the necessary staff resources for an optimal outcome, need to be defined. •   Relevant outcome measures, over and above mortality, need to be determined to measure quality of care. •   The role of neurohormones to estimate disease severity and tim- ing of interventions is not yet fully established and needs to be defined.\n6.1.2 Heart failure\n•   The pathophysiology/mechanism of heart failure, especially in those with a systemic RV and Fontan circulation, is incompletely understood and needs further study to find better ways for pre- vention and treatment. •   Indications for application of standard heart failure treatment in both acute and chronic settings need to be better defined. •   The prediction and course of heart failure needs to be better defined to improve indications and timing of ventricular assist device/transplantation. •   Large-scale collaborative international prospective registries on medical and device therapy in ACHD are needed and support for the set up and practical implementation is required.\n6.1.3 Arrhythmia\n•   Dedicated scoring systems to assess the indication for anticoagu- lation in the setting of atrial arrhythmias are needed for moderate and complex CHD. •   Targeting slow-conducting anatomical isthmuses by catheter ablation has been highly effective to control monomorphic VT in repaired tetralogy of Fallot. Whether catheter mapping can con- tribute to individualized risk stratification in patients without spontaneous VTs in repaired tetralogy of Fallot and related defects requires further research. •   The potential loss of accessibility to slow-conducting anatomical isthmuses by catheter ablation after re-valving rTOF and related defects is of concern. Whether patients without documented VT benefit from preventive ablation before or during re-valving should be studied. •   Indications for pacing and CRT in ACHD patients are mainly derived from adults with anatomically normal hearts with ischae- mic or dilated cardiomyopathy and are not adapted to the diver- sity of structural and functional CHD substrates. The selection of CRT candidates, CRT application, and optimal pacing sites for the different CHD substrates requires further research.\n6.1.4 Pulmonary arterial hypertension\n•   The impact of medical PAH therapy on survival of patients with Eisenmenger syndrome requires further study.\n•   The role of upfront combination therapy in PAH-CHD requires further attention. •   Limited experience is available for prostacyclin therapy in patients with PAH-CHD and needs further investigation.\n6.1.5 Cyanotic patients\n•   The benefit of routine anticoagulation, in the absence of any strong risk factor for thromboembolic complications (e.g. atrial arrhythmias), is controversial and requires further study.\n",
      "keywords": [
        "aspects",
        "risk factor",
        "arrhythmia",
        "indication",
        "general",
        "hypertension",
        "crt",
        "risk stratification",
        "organization",
        "ablation",
        "patient",
        "evaluation",
        "cardiomyopathy",
        "anticoagulation",
        "care",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "50",
      "title": "6.2 Specific lesions 6.2.1 Shunt lesions",
      "start_page": 66,
      "end_page": 67,
      "content": "•   Late outcome after device closure requires further study, partic- ularly of arrhythmias. •   The impact of shunt closure on long-term outcome of patients with PAH remains an area of uncertainty; further research is required to better define the thresholds for treatment recommendations.\n6.2.2 Left ventricular outflow tract obstruction and coarctation\n•   The optimal timing of intervention in asymptomatic severe LVOTO requires further study. •   Transcatheter aortic valve implantation is rapidly evolving; its role in ACHD needs further refinement. •   According to the 2018 ESC Guidelines for the management of arterial hypertension, 190   definitions of hypertension in patients with repaired CoA are the same as in general arterial hyperten- sion and patients should be managed according to the general guidelines: evidence for this strategy is lacking and prospective studies are required.\n6.2.3 Aortopathies\n•   Estimation of the risk for aortic dissection and definition of the threshold for prophylactic surgery in HTAD based on diameter alone is suboptimal and calls for a more personalized approach. Whether the type of underlying gene defect is helpful in this stratification requires further study. •   Current prophylactic treatment regimens in HTAD patients include beta blockers and ARBs. Either in monotherapy or combined, neither one prevents further growth of the aorta. The search for new and better treatment targets should continue.\n6.2.4 Right ventricular outflow tract obstruction\n•   Criteria for concomitant TV repair at the time of RVOT surgery require refinement. •   The identification of patients with low-gradient RVOTO who have severe stenosis and would benefit from intervention requires improvement. •   The criteria for identification of RVOTO patients who would benefit from reintervention for residual PR requires further research. •   The role of an EP study for risk stratification for SCD is contro- versial in patients with rTOF and needs further study.\nESC Guidelines 629\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 6.2.5 Ebstein anomaly\n•   The identification of asymptomatic Ebstein patients with severe TR who would benefit from TV surgery requires further improvement. •   The identification of Ebstein patients at risk for late life- threatening arrhythmias needs to be improved.\n6.2.6 Tetralogy of Fallot\n•   Optimal timing of PVRep for asymptomatic patients with signifi- cant PR needs to be further improved. •   Long-term follow-up studies after TPVI are required to increase knowledge about valve durability, consequences of stent frac- tures, and occurrence of endocarditis. •   The identification of rTOF patients at risk for late life-threatening arrhythmias, who would benefit from ICD implantation as pri- mary prevention, needs to be improved. •   The effect of medical treatment on RV dilatation and/or dysfunc- tion in rTOF patients needs to be established.\n6.2.7 Transposition of the great arteries\n•   The potential benefit of classical heart failure medical therapy and biventricular pacing in patients with a systemic RV after an atrial switch procedure requires further study. •   Risk stratification for SCD and indications for primary ICD implantation after atrial switch require refinement. •   After an arterial switch procedure, the risk of dissection/rupture of neo-aortic root aneurysms requires further study to refine the recommendations for prophylactic surgery. •   Long-term follow-up after arterial switch is required to study the risk for development of CAD after reimplantation of the coro- nary arteries into the neo-aortic root.\n6.2.8 Congenitally corrected transposition of the great arteries\n•   The definition of optimal timing for TV replacement in patients with severe asymptomatic TR requires more data. •   The potential benefit of pulmonary banding for the preservation of systemic ventricular function requires further study.\n6.2.9 Univentricular heart and Fontan operation\n•   The role of medication, including pulmonary vasodilators, in Fontan patients is not clear and requires further study. •   The effects of pregnancy on long-term maternal outcome must be better established. •   Physiological determinants of long-term outcome in Fontan patients, including the role of the lymphatic system, requires more research.\n6.2.10 Coronary anomalies\n•   Identification of adult patients with coronary anomalies (AAOCA, ACAPA) who are at risk for SCD, and for whom sur- gery provides benefit at adult age, requires further research.\n",
      "keywords": [
        "lesions",
        "aortic",
        "icd",
        "age",
        "stenosis",
        "hypertension",
        "scd",
        "risk stratification",
        "specific",
        "shunt",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "51",
      "title": "7 Key messages",
      "start_page": 67,
      "end_page": 67,
      "content": "",
      "keywords": [
        "messages"
      ],
      "tables": []
    },
    {
      "number": "52",
      "title": "7.1 General aspects 7.1.1 Organization of care and patient evaluation",
      "start_page": 67,
      "end_page": 68,
      "content": "•   Special structural and organizational healthcare requirements are necessary to meet the needs of ACHD patients. •   Multimodality imaging is key for adequate assessment of overall anatomy and ventricular and valvular function, and quantification of blood flow, including perfusion distribution. •   Objective exercise testing is an important tool for determining the timing of interventions and reinterventions. •   Cardiac catheterization remains key for the assessment of hae- modynamics, in particular, PAP and vascular resistance.\n7.1.2 Heart failure\n•   The key treatment for heart failure in ACHD patients remains its prevention by optimizing haemodynamics and heart rhythm. This requires systematic follow-up in specialized centres to facilitate timely intervention. •   In a biventricular circulation, standard heart failure treatment can be extrapolated to ACHD patients with a systemic LV and may be applied in patients with a systemic RV, although it remains uncertain whether the known benefits of treating a failing LV can be expected. Pathophysiology of patients with an atrial switch, and especially with a UVH and Fontan palliation, differs markedly from a ‘regular circulation’ and standard heart failure therapy has to be applied cautiously. •   Timely referral and consultation with ACHD and heart failure specialists in a centre with a transplant service and ACHD exper- tise is recommended, especially in those with moderate and severe complexity CHD.\n7.1.3 Arrhythmia\n•   In all patients, evaluation for a reversible cause of an arrhythmia and for new or residual haemodynamic abnormalities should be performed. •   Maintenance of sinus rhythm is the aim in most ACHD patients. •   For optimal chronic arrhythmia management, referral to a centre with a multidisciplinary team and expertise in ACHD-related arrhythmias is mandatory. •   Patients with documented arrhythmias or at high risk for post- procedural arrhythmias considered for percutaneous or surgical (re)interventions should be discussed in a multidisciplinary team with expertise in interventions  and  invasive treatment of arrhythmias.\n7.1.4 Pulmonary arterial hypertension\n•   PAH in CHD is a progressive disease with poor prognosis. •   High suspicion of PAH, and regular assessment for the presence of PAH in patients with shunt lesions, after defect closure is recommended. •   Proactive treatment is required in all PAH patients, including those with Eisenmenger syndrome. •   Women with CHD and confirmed pre-capillary PH should be counselled against pregnancy.\n630 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 7.1.5 Cyanotic patients\n•   Cyanotic patients present with a multisystem disorder and are at risk for both bleeding and thrombotic complications, causing a therapeutic dilemma. •   Routine phlebotomies must be avoided as they put patients at risk for iron-deficient anaemia and cerebrovascular complica- tions. Therapeutic phlebotomy is only indicated in the presence of moderate/severe hyperviscosity symptoms. •   Cyanotic patients have a very balanced, but fragile, pathophysiol- ogy and any intervention puts the patient at high risk; all interven- tions must therefore be performed in an ACHD expert centre. •   Prophylactic measures are the mainstay of care to prevent and avoid complications.\n",
      "keywords": [
        "aspects",
        "exercise",
        "arrhythmia",
        "recommended",
        "catheterization",
        "general",
        "hypertension",
        "patient",
        "organization",
        "evaluation",
        "care",
        "heart failure"
      ],
      "tables": []
    },
    {
      "number": "53",
      "title": "7.2 Specific lesions 7.2.1 Shunt lesions",
      "start_page": 68,
      "end_page": 72,
      "content": "•   Treatment decisions require careful evaluation of ventricular vol- ume overload and pulmonary circulation. •   In patients with non-invasive signs of elevated PAP, heart cathe- terization with assessment of PVR is mandatory. •   In the presence of PVR >_5 WU, ASD closure should be avoided. VSD and PDA closure may only be considered in selected patients with significant shunt after careful evaluation in an ACHD and PH expert centre. •   Device closure is the treatment of choice when technically feasible.\n7.2.2 Left ventricular outflow tract obstruction\n•   The strongest indications for surgery remain symptoms and LV dysfunction. •   Exercise testing should be performed in patients with severe obstruction who do not report symptoms in order to confirm asymptomatic status. •   In congenital valvular AS, associated aortic disease (ascending aortic dilatation and/or CoA) needs to be excluded.\n7.2.3 Aortic coarctation\n•   Correct blood pressure measurement (right arm, ambulatory) is essential in the follow-up of patients with CoA. •   The decision to (re)intervene depends on blood pressure, gra- dient, and stenosis morphology. •   Stenting is the treatment of choice when technically feasible.\n7.2.4 Aortopathies\n•   Lifelong surveillance is essential in all HTAD patients and should include imaging of the entire aorta, as well as assessment of valvu- lar and myocardial function. •   The aortic diameter at which surgery should be performed depends on the underlying disease and presence of risk factors.\n7.2.5 Right ventricular outflow tract obstruction\n•   RVOTO may be overestimated by the flow velocity across the obstruction, particularly when the narrowing is elongated, or stenosis is present in series (e.g. subvalvular and valvular).\nTherefore, cross-checking with RV pressure estimated from TR velocity is required. •   Catheter intervention is the treatment of choice for patients with non-dysplastic valvular PS (balloon valvuloplasty) and with peripheral PS (often with stent implantation). •   The indication for intervention is more restrictive whenever a valve substitute is required because of its long-term implications for complications and requirement for reintervention.\n7.2.6 Ebstein anomaly\n•   Timing of surgery remains challenging and this operation should only be performed by surgeons with specific experience in this lesion. •   Valve repair is the preferred technique whenever feasible.\n7.2.7 Tetralogy of Fallot\n•   Significant PR and/or RVOTO, RV and LV dysfunction, and arrhythmias are common long-term complications. •   Possible risk factors associated with any ventricular arrhythmia and SCD in rTOF are QRS duration >180 ms, LV systolic or dia- stolic dysfunction, RV dysfunction, inducible VT at programmed electrical stimulation, and history of atrial arrhythmia. •   The optimal timing for intervention in asymptomatic severe PR remains challenging. Normalization of RV size becomes unlikely when the end diastolic volume index exceeds 160 mL/m 2 , but this cut-off for reintervention may not correlate with clinical benefit. •   TPVI has become the treatment of choice for RVOT reinterven- tion when anatomically feasible.\n7.2.8 Transposition of the great arteries\n•   Systemic ventricular failure, secondary systemic AV valve regurgi- tation, arrhythmia, and baffle stenosis and/or leakage are com- mon long-term complications that need to be addressed after atrial switch operation. •   Outcome of morbidity has markedly improved with introduction of the arterial switch operation. Dilatation of the neo-aortic root with or without significant regurgitation of the neo-aortic valve, supravalvular PS, and pulmonary branch stenosis mostly occur during infancy, but may need reintervention during adulthood. •   New LV systolic dysfunction and/or arrhythmias after arterial switch require full evaluation, including exclusion of ostial/proxi- mal stenoses of the reimplanted coronary arteries. •   Failure of the RV-to-PA conduit (stenosis, regurgitation, or both) is the predominant long-term complication requiring reinterven- tion after the Rastelli operation.\n7.2.9 Congenitally corrected transposition of the great arteries\n•   Systemic RV failure, systemic AV valve regurgitation, AV block, and atrial arrhythmia are common late complications. •   Systemic AV valve regurgitation is an important driver of late out- come and, when severe, should be addressed before systemic RV function becomes impaired.\nESC Guidelines 631\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. .............................................\n. ..\n7.2.10 Univentricular heart and Fontan operation\n•   Although quality of life is well preserved in many Fontan patients, all require regular intensive follow-up at an ACHD expert centre as they are at risk of developing multiple severe complications including arrhythmia, heart failure, hepatic disease, and protein- losing enteropathy. •   Low pulmonary artery pressure is mandatory for a good func- tioning Fontan circulation and a low threshold for invasive hae- modynamic assessment is recommended when dysfunction is suspected, or complications occur. •   Arrhythmias are poorly tolerated and require immediate action. •   Pregnancy is feasible in selected patients with well-functioning Fontan circulation but there is a high risk of miscarriage and preg- nancy should be managed in an ACHD expert centre.\n•   Surveillance for liver problems is mandatory in all Fontan patients.\n7.2.11 Coronary anomalies\n•   CCT is the preferred technique for the evaluation of high-risk anatomy including features such as an intramural course and ori- fice anomalies (slit-like orifice, acute-angle take-off, orifice >1 cm above the sinotubular junction). •   Assessment of stress-induced ischaemia, by means of advanced imaging modalities with physical stress, is the key for decision making. •   In patients with coronary fistulae, the presence of symptoms, complications, and a significant shunt are the main indications for percutaneous or surgical closure.\n8 ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations Class a Level b\nTreatment of arrhythmias in adult congenital heart disease\nIn patients with moderate and severe CHD complexity ( Table  4 ) and documented arrhythmias, referral to a centre with a multidisciplinary team and expertise in ACHD patients and ACHD-related arrhythmia is indicated. I C\nIn CHD patients with documented arrhythmias or at high risk for post-procedural arrhythmias (e.g. ASD closure at older age)\nconsidered for percutaneous or surgical (re)interventions, referral to a centre with a multidisciplinary team with expertise in\nthese interventions and in invasive treatment of arrhythmias is indicated.\nI C\nIn mild CHD, catheter ablation is recommended over long-term medical therapy for symptomatic, sustained recurrent SVT\n(AVNRT, AVRT, AT, and IART), or if SVT is potentially related to SCD ( Table  7 ). I C\nCatheter ablation is indicated as adjunctive therapy to ICDs in patients who present with recurrent monomorphic VT, inces-\nsant VT, or electrical storm not manageable by medical therapy or ICD reprogramming. I C\nICD implantation is indicated in adults with CHD who are survivors of an aborted cardiac arrest due to VF or haemodynami-\ncally untolerated VT after evaluation to deﬁne the cause of the event and exclusion of reversible causes. I C\nICD implantation is indicated in adults with CHD and sustained VT after haemodynamic evaluation and repair when indicated.\nEP evaluation is required to identify patients in whom catheter ablation or surgical ablation may be beneﬁcial as adjunctive treatment or in whom it may offer a reasonable alternative.\nI C\nTreatment of pulmonary arterial hypertension associated with congenital heart disease\nIt is recommended that patients with CHD and conﬁrmed pre-capillary PH are counselled against pregnancy. I C\nRisk assessment is recommended in all patients with PAH-CHD. I C\nIn low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH, initial oral combination therapy or sequential combination therapy is recommended and high-risk patients should be treated with initial combination therapy\nincluding parenteral prostanoids.\nI A\nAtrial septal defect (native and residual)\nIn patients with evidence of RV volume overload and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation of PVR <3 WU in case of such signs) or LV disease, ASD closure is recommended regardless of symptoms. I B\nDevice closure is recommended as the method of choice for secundum ASD closure when technically suitable. I C\nIn elderly patients not suitable for device closure, it is recommended to carefully weigh the surgical risk against the potential\nbeneﬁt of ASD closure. I C\nIn patients with non-invasive signs of PAP elevation, invasive measurement of PVR is mandatory. I C\nIn patients with LV disease, it is recommended to perform balloon testing and carefully weigh the beneﬁt of eliminating L \u0002 R\nshunt against the potential negative impact of ASD closure on outcome due to an increase in ﬁlling pressure (taking closure,\nfenestrated closure, and no closure into consideration).\nI C\nASD closure is not recommended in patients with Eisenmenger physiology, patients with PAH and PVR >_5 WU despite tar-\ngeted PAH treatment, or desaturation on exercise. III C\nContinued\n632 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\nVentricular septal defect (native and residual)\nIn patients with evidence of LV volume overload and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation\nof PVR <3 WU in case of such signs), VSD closure is recommended regardless of symptoms. I C\nVSD closure is not recommended in patients with Eisenmenger physiology and patients with severe PAH (PVR >_5 WU) pre- senting with desaturation on exercise. III C\nAtrioventricular septal defect\nSurgical repair is not recommended in patients with Eisenmenger physiology and patients with PAH (PVR >_5 WU) presenting\nwith desaturation on exercise. III C\nSurgical closure is recommended in patients with signiﬁcant RV volume overload and should only be performed by a congeni- tal cardiac surgeon. I C\nValve surgery, preferably AV valve repair, is recommended in symptomatic patients with moderate to severe AV valve regur-\ngitation and should be performed by a congenital cardiac surgeon. I C\nIn asymptomatic patients with severe left-sided AV valve regurgitation, valve surgery is recommended when LVESD >_45 mm and/or LVEF <_60% provided other causes of LV dysfunction are excluded. I C\nPatent ductus arteriosus\nIn patients with evidence of LV volume overload and no PAH (no non-invasive signs of PAP elevation or invasive conﬁrmation\nof PVR <3 WU in case of such signs), PDA closure is recommended regardless of symptoms. I C\nDevice closure is recommended as the method of choice when technically suitable. I C\nPDA closure is not recommended in patients with Eisenmenger physiology and patients with lower limb desaturation on\nexercise. III C\nValvular aortic stenosis\nIntervention is recommended in all symptomatic patients with severe high-gradient AS (mean gradient >_40 mmHg). I B\nIntervention is indicated in patients with severe low-ﬂow, low-gradient (mean gradient <40 mmHg) AS with reduced EF and\nevidence of ﬂow (contractile) reserve excluding pseudosevere AS. I C\nIntervention is indicated in asymptomatic patients with severe AS and an abnormal exercise test showing symptoms on exer-\ncise clearly related to AS. I C\nIntervention is indicated in asymptomatic patients with severe AS and systolic LV dysfunction (LVEF <50%) not due to\nanother cause. I C\nSurgery is recommended when patients with severe AS undergo surgery of the ascending aorta or of another valve, or\nCABG. I C\nSupravalvular aortic stenosis\nIn patients with symptoms (spontaneous or on exercise test) and mean Doppler gradient >_40 mmHg, surgery is\nrecommended. I C\nIn patients with mean Doppler gradient <40 mmHg, surgery is recommended when one or more of the following ﬁndings are present: •   Symptoms attributable to obstruction (exertional dyspnoea, angina, syncope). •   LV systolic dysfunction (EF <50% without other explanation). •   Surgery required for signiﬁcant CAD or valvular disease.\nI C\nSubaortic stenosis\nIn symptomatic patients (spontaneous or on exercise test) with a mean Doppler gradient >_40 mmHg or severe AR, surgery is\nrecommended. I C\nCoarctation and re-coarctation of the aorta\nRepair of coarctation or re-coarctation (surgically or catheter based) is indicated in hypertensive patients with an increased\nnon-invasive gradient between upper and lower limbs conﬁrmed with invasive measurement (peak-to-peak >_20 mmHg) with\npreference for catheter treatment (stenting) when technically feasible.\nI C\nAortic surgery in aortopathies\nAortic valve repair, using the reimplantation or remodelling with aortic annuloplasty technique, is recommended in young\npatients with Marfan syndrome or related HTAD with aortic root dilation and tricuspid aortic valves when performed by\nexperienced surgeons.\nI C\nSurgery is indicated in patients with Marfan syndrome who have aortic root disease with a maximal aortic sinus diameter >_50 mm. I C\nContinued\nESC Guidelines 633\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\nRight ventricular outﬂow tract obstruction\nIn valvular PS, balloon valvuloplasty is the intervention of choice, if anatomically suitable. I C\nProvided that no valve replacement is required, RVOTO intervention at any level is recommended regardless of symptoms\nwhen the stenosis is severe (Doppler peak gradient is >64 mmHg). I C\nIf surgical valve replacement is the only option, it is indicated in patients with severe stenosis who are symptomatic. I C\nIf surgical valve replacement is the only option in patients with severe stenosis who are asymptomatic, it is indicated in the\npresence of one or more of the following:\n\u0004  Objective decrease in exercise capacity. \u0004  Decreasing RV function and/or progression of TR to at least moderate.\n\u0004  RVSP >80 mmHg.\n\u0004  R \u0002 L shunting via an ASD or VSD.\nI C\nEbstein anomaly\nSurgical repair is recommended in patients with severe TR and symptoms or objective deterioration of exercise capacity. I C\nIt is recommended that surgical repair is performed by a congenital surgeon with speciﬁc experience in Ebstein surgery. I C\nIf there is an indication for TV surgery, ASD/PFO closure is recommended at the time of valve repair if it is expected to be\nhaemodynamically tolerated. I C\nIn patients with symptomatic arrhythmias or pre-excitation on the ECG, electrophysiologic testing followed by ablation ther- apy, if feasible, or surgical treatment of the arrhythmias in the case of planned heart surgery is recommended. I C\nAfter repair of tetralogy of Fallot\nPVRep is recommended in symptomatic patients with severe PR and/or at least moderate RVOTO. I C\nIn patients with no native outﬂow tract, catheter intervention (TPVI) should be preferred if anatomically feasible. I C\nTransposition of the great arteries after atrial switch operation\nIn  symptomatic  patients with pulmonary venous atrium obstruction, surgical repair (catheter intervention rarely possible) is\nrecommended. I C\nIn  symptomatic  patients with bafﬂe stenosis not amenable to catheter intervention, surgical repair is recommended. I C\nIn  symptomatic  patients with bafﬂe leaks not amenable to catheter-based closure, surgical repair is recommended. I C\nPA banding in adults, as LV training with subsequent arterial switch procedure, is not recommended. III C\nIn  symptomatic  patients with bafﬂe stenosis, stenting is recommended when technically feasible. I C\nIn  symptomatic  patients with bafﬂe leaks and cyanosis at rest or during exercise, or with strong suspicion of paradoxical\nemboli, stenting (covered) or device closure is recommended when technically feasible. I C\nIn patients with bafﬂe leaks and symptoms due to L \u0002 R shunt, stenting (covered) or device closure is recommended when technically feasible. I C\nTransposition of the great arteries after arterial switch operation\nStenting or surgery (depending on substrate) is recommended for coronary artery stenosis causing ischaemia. I C\nCongenitally corrected transposition of the great arteries\nIn  symptomatic  patients with severe TR and preserved or mildly impaired systemic RV systolic function (EF >40%), TV replace- ment is indicated. I C\nRight ventricular to pulmonary artery conduits\nSymptomatic  patients with RVSP >60 mmHg (may be lower in case of reduced ﬂow) and/or severe PR should undergo inter-\nvention with preference for catheter intervention (TPVI) if anatomically feasible. I C\nUniventricular heart\nIt is recommended that adults with unoperated or palliated UVHs undergo careful evaluation in specialized centres, including\nmultimodality imaging as well as invasive work-up to decide whether they may beneﬁt from surgical or interventional\nprocedures.\nI C\nAfter Fontan operation\nSustained atrial arrhythmia with rapid AV conduction is a medical emergency and should be promptly treated with electrical\ncardioversion. I C\nAnticoagulation is indicated in the presence, or with a history, of atrial thrombus, atrial arrhythmias, or thromboembolic\nevents. I C\nIt is recommended that women with a Fontan circulation and any complication are counselled against pregnancy. I C\nCardiac catheterization is recommended at a low threshold in cases of unexplained oedema, exercise deterioration, new-\nonset arrhythmia, cyanosis, and haemoptysis. I C\nContinued\n634 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. .............................................................................................. 9 Appendix\n",
      "keywords": [
        "older",
        "valve repair",
        "systolic",
        "specific",
        "anticoagulation",
        "age",
        "tricuspid",
        "hypertension",
        "scd",
        "blood pressure",
        "syncope",
        "lvef",
        "diastolic",
        "lesions",
        "aortic",
        "arrhythmia",
        "icd",
        "valve replacement",
        "level b",
        "elderly",
        "ecg",
        "heart failure",
        "systolic dysfunction",
        "exercise",
        "recommended",
        "stenosis",
        "indication",
        "catheterization",
        "ablation",
        "aortic stenosis"
      ],
      "tables": [
        {
          "title": "632 ESC Guidelines",
          "page_number": 69,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nTreatment of arrhythmias in adult congenital heart disease |  |  | \nIn patients with moderate and severe CHD complexity (Table 4) and documented arrhythmias, referral to a centre with a\nmultidisciplinary team and expertise in ACHD patients and ACHD-related arrhythmia is indicated. | I | C | \nIn CHD patients with documented arrhythmias or at high risk for post-procedural arrhythmias (e.g. ASD closure at older age)\nconsidered for percutaneous or surgical (re)interventions, referral to a centre with a multidisciplinary team with expertise in\nthese interventions and in invasive treatment of arrhythmias is indicated. | I | C | \nIn mild CHD, catheter ablation is recommended over long-term medical therapy for symptomatic, sustained recurrent SVT\n(AVNRT, AVRT, AT, and IART), or if SVT is potentially related to SCD (Table 7). | I | C | \nCatheter ablation is indicated as adjunctive therapy to ICDs in patients who present with recurrent monomorphic VT, inces-\nsant VT, or electrical storm not manageable by medical therapy or ICD reprogramming. | I | C | \nICD implantation is indicated in adults with CHD who are survivors of an aborted cardiac arrest due to VF or haemodynami-\ncally untolerated VT after evaluation to define the cause of the event and exclusion of reversible causes. | I | C | \nICD implantation is indicated in adults with CHD and sustained VT after haemodynamic evaluation and repair when indicated.\nEP evaluation is required to identify patients in whom catheter ablation or surgical ablation may be beneficial as adjunctive\ntreatment or in whom it may offer a reasonable alternative. | I | C | \nTreatment of pulmonary arterial hypertension associated with congenital heart disease |  |  | \nIt is recommended that patients with CHD and confirmed pre-capillary PH are counselled against pregnancy. | I | C | \nRisk assessment is recommended in all patients with PAH-CHD. | I | C | \nIn low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH, initial oral combination therapy or\nsequential combination therapy is recommended and high-risk patients should be treated with initial combination therapy\nincluding parenteral prostanoids. | I | A | \nAtrial septal defect (native and residual) |  |  | \nIn patients with evidence of RV volume overload and no PAH (no non-invasive signs of PAP elevation or invasive confirmation\nof PVR <3 WU in case of such signs) or LV disease, ASD closure is recommended regardless of symptoms. | I | B | \nDevice closure is recommended as the method of choice for secundum ASD closure when technically suitable. | I | C | \nIn elderly patients not suitable for device closure, it is recommended to carefully weigh the surgical risk against the potential\nbenefit of ASD closure. | I | C | \nIn patients with non-invasive signs of PAP elevation, invasive measurement of PVR is mandatory. | I | C | \nIn patients with LV disease, it is recommended to perform balloon testing and carefully weigh the benefit of eliminating L\u0002R\nshunt against the potential negative impact of ASD closure on outcome due to an increase in filling pressure (taking closure,\nfenestrated closure, and no closure into consideration). | I | C | \nASD closure is not recommended in patients with Eisenmenger physiology, patients with PAH and PVR >5 WU despite tar-\n_\ngeted PAH treatment, or desaturation on exercise. | III | C | ",
          "bbox": [
            42.49642283121745,
            285.9762288411458,
            551.9618787263569,
            726.566181727818
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 633",
          "page_number": 70,
          "content": "Ventricular septal defect (native and residual) |  |  | \nIn patients with evidence of LV volume overload and no PAH (no non-invasive signs of PAP elevation or invasive confirmation\nof PVR <3 WU in case of such signs), VSD closure is recommended regardless of symptoms. | I | C | \nVSD closure is not recommended in patients with Eisenmenger physiology and patients with severe PAH (PVR >5 WU) pre-\n_\nsenting with desaturation on exercise. | III | C | \nAtrioventricular septal defect |  |  | \nSurgical repair is not recommended in patients with Eisenmenger physiology and patients with PAH (PVR >5 WU) presenting\n_\nwith desaturation on exercise. | III | C | \nSurgical closure is recommended in patients with significant RV volume overload and should only be performed by a congeni-\ntal cardiac surgeon. | I | C | \nValve surgery, preferably AV valve repair, is recommended in symptomatic patients with moderate to severe AV valve regur-\ngitation and should be performed by a congenital cardiac surgeon. | I | C | \nIn asymptomatic patients with severe left-sided AV valve regurgitation, valve surgery is recommended when LVESD >45 mm\n_\nand/or LVEF <60% provided other causes of LV dysfunction are excluded.\n_ | I | C | \nPatent ductus arteriosus |  |  | \nIn patients with evidence of LV volume overload and no PAH (no non-invasive signs of PAP elevation or invasive confirmation\nof PVR <3 WU in case of such signs), PDA closure is recommended regardless of symptoms. | I | C | \nDevice closure is recommended as the method of choice when technically suitable. | I | C | \nPDA closure is not recommended in patients with Eisenmenger physiology and patients with lower limb desaturation on\nexercise. | III | C | \nValvular aortic stenosis |  |  | \nIntervention is recommended in all symptomatic patients with severe high-gradient AS (mean gradient >40 mmHg).\n_ | I | B | \nIntervention is indicated in patients with severe low-flow, low-gradient (mean gradient <40 mmHg) AS with reduced EF and\nevidence of flow (contractile) reserve excluding pseudosevere AS. | I | C | \nIntervention is indicated in asymptomatic patients with severe AS and an abnormal exercise test showing symptoms on exer-\ncise clearly related to AS. | I | C | \nIntervention is indicated in asymptomatic patients with severe AS and systolic LV dysfunction (LVEF <50%) not due to\nanother cause. | I | C | \nSurgery is recommended when patients with severe AS undergo surgery of the ascending aorta or of another valve, or\nCABG. | I | C | \nSupravalvular aortic stenosis |  |  | \nIn patients with symptoms (spontaneous or on exercise test) and mean Doppler gradient >40 mmHg, surgery is\n_\nrecommended. | I | C | \nIn patients with mean Doppler gradient <40 mmHg, surgery is recommended when one or more of the following findings are\npresent:\n• Symptoms attributable to obstruction (exertional dyspnoea, angina, syncope).\n• LV systolic dysfunction (EF <50% without other explanation).\n• Surgery required for significant CAD or valvular disease. | I | C | \nSubaortic stenosis |  |  | \nIn symptomatic patients (spontaneous or on exercise test) with a mean Doppler gradient >40 mmHg or severe AR, surgery is\n_\nrecommended. | I | C | \nCoarctation and re-coarctation of the aorta |  |  | \nRepair of coarctation or re-coarctation (surgically or catheter based) is indicated in hypertensive patients with an increased\nnon-invasive gradient between upper and lower limbs confirmed with invasive measurement (peak-to-peak >20 mmHg) with\n_\npreference for catheter treatment (stenting) when technically feasible. | I | C | \nAortic surgery in aortopathies |  |  | \nAortic valve repair, using the reimplantation or remodelling with aortic annuloplasty technique, is recommended in young\npatients with Marfan syndrome or related HTAD with aortic root dilation and tricuspid aortic valves when performed by\nexperienced surgeons. | I | C | \nSurgery is indicated in patients with Marfan syndrome who have aortic root disease with a maximal aortic sinus diameter >50 mm.\n_ | I | C | ",
          "bbox": [
            46.98771079568302,
            59.86335754394531,
            556.4977288497122,
            693.3441903250558
          ],
          "function_potential": "raw"
        },
        {
          "title": "634 ESC Guidelines",
          "page_number": 71,
          "content": "Right ventricular outflow tract obstruction |  |  | \nIn valvular PS, balloon valvuloplasty is the intervention of choice, if anatomically suitable. | I | C | \nProvided that no valve replacement is required, RVOTO intervention at any level is recommended regardless of symptoms\nwhen the stenosis is severe (Doppler peak gradient is >64 mmHg). | I | C | \nIf surgical valve replacement is the only option, it is indicated in patients with severe stenosis who are symptomatic. | I | C | \nIf surgical valve replacement is the only option in patients with severe stenosis who are asymptomatic, it is indicated in the\npresence of one or more of the following:\n\u0004 Objective decrease in exercise capacity.\n\u0004 Decreasing RV function and/or progression of TR to at least moderate.\n\u0004 RVSP >80 mmHg.\n\u0004 R\u0002L shunting via an ASD or VSD. | I | C | \nEbstein anomaly |  |  | \nSurgical repair is recommended in patients with severe TR and symptoms or objective deterioration of exercise capacity. | I | C | \nIt is recommended that surgical repair is performed by a congenital surgeon with specific experience in Ebstein surgery. | I | C | \nIf there is an indication for TV surgery, ASD/PFO closure is recommended at the time of valve repair if it is expected to be\nhaemodynamically tolerated. | I | C | \nIn patients with symptomatic arrhythmias or pre-excitation on the ECG, electrophysiologic testing followed by ablation ther-\napy, if feasible, or surgical treatment of the arrhythmias in the case of planned heart surgery is recommended. | I | C | \nAfter repair of tetralogy of Fallot |  |  | \nPVRep is recommended in symptomatic patients with severe PR and/or at least moderate RVOTO. | I | C | \nIn patients with no native outflow tract, catheter intervention (TPVI) should be preferred if anatomically feasible. | I | C | \nTransposition of the great arteries after atrial switch operation |  |  | \nIn symptomatic patients with pulmonary venous atrium obstruction, surgical repair (catheter intervention rarely possible) is\nrecommended. | I | C | \nIn symptomatic patients with baffle stenosis not amenable to catheter intervention, surgical repair is recommended. | I | C | \nIn symptomatic patients with baffle leaks not amenable to catheter-based closure, surgical repair is recommended. | I | C | \nPA banding in adults, as LV training with subsequent arterial switch procedure, is not recommended. | III | C | \nIn symptomatic patients with baffle stenosis, stenting is recommended when technically feasible. | I | C | \nIn symptomatic patients with baffle leaks and cyanosis at rest or during exercise, or with strong suspicion of paradoxical\nemboli, stenting (covered) or device closure is recommended when technically feasible. | I | C | \nIn patients with baffle leaks and symptoms due to L\u0002R shunt, stenting (covered) or device closure is recommended when\ntechnically feasible. | I | C | \nTransposition of the great arteries after arterial switch operation |  |  | \nStenting or surgery (depending on substrate) is recommended for coronary artery stenosis causing ischaemia. | I | C | \nCongenitally corrected transposition of the great arteries |  |  | \nIn symptomatic patients with severe TR and preserved or mildly impaired systemic RV systolic function (EF >40%), TV replace-\nment is indicated. | I | C | \nRight ventricular to pulmonary artery conduits |  |  | \nSymptomatic patients with RVSP >60 mmHg (may be lower in case of reduced flow) and/or severe PR should undergo inter-\nvention with preference for catheter intervention (TPVI) if anatomically feasible. | I | C | \nUniventricular heart |  |  | \nIt is recommended that adults with unoperated or palliated UVHs undergo careful evaluation in specialized centres, including\nmultimodality imaging as well as invasive work-up to decide whether they may benefit from surgical or interventional\nprocedures. | I | C | \nAfter Fontan operation |  |  | \nSustained atrial arrhythmia with rapid AV conduction is a medical emergency and should be promptly treated with electrical\ncardioversion. | I | C | \nAnticoagulation is indicated in the presence, or with a history, of atrial thrombus, atrial arrhythmias, or thromboembolic\nevents. | I | C | \nIt is recommended that women with a Fontan circulation and any complication are counselled against pregnancy. | I | C | \nCardiac catheterization is recommended at a low threshold in cases of unexplained oedema, exercise deterioration, new-\nonset arrhythmia, cyanosis, and haemoptysis. | I | C | ",
          "bbox": [
            42.45292463580382,
            59.86335754394531,
            551.9618777952332,
            724.5312347412109
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 635",
          "page_number": 72,
          "content": "Anomalous coronary arteries |  | \nNon-pharmacological functional imaging (e.g. nuclear study, echocardiography, or CMR with physical stress) is recommended\nin patients with coronary anomalies to confirm/exclude myocardial ischaemia. | I | C\nAnomalous coronary arteries from the pulmonary artery |  | \nSurgery is recommended in patients with ALCAPA. | I | C\nSurgery is recommended in patients with ARCAPA and symptoms attributable to anomalous coronary artery. | I | C\nAnomalous aortic origin of the coronary artery |  | \nSurgery is recommended for AAOCA in patients with typical angina symptoms who present with evidence of stress-induced\nmyocardial ischaemia in a matching territory or high-risk anatomy. | I | C\nSurgery is not recommended for AAORCA in asymptomatic patients without myocardial ischaemia and without high-risk\nanatomy. | III | C",
          "bbox": [
            46.984776153564454,
            59.86335754394531,
            553.8714455997242,
            201.36317879813058
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "54",
      "title": "Author/Task Force Member Affiliations:",
      "start_page": 72,
      "end_page": 73,
      "content": "Sonya V. Babu-Narayan , NHLI, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom;  Werner Budts , Congenital and Structural Cardiology, UZ Leuven and Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium;  Massimo Chessa , ACHD Unit, Paediatric and Adult Congenital Heart Centre, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy;  Gerhard-Paul Diller , Department of Cardiology III, Adult Congenital and Valvular Heart Disease, University Hospital, Muenster, Germany; Bernard Iung , Cardiology, Bichat Hospital, Paris, France; Jolanda Kluin , Cardiothoracic Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands;  Irene M. Lang , Cardiology, Medical University of Vienna, Vienna, Austria;  Folkert Meijboom , Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands;  Philip Moons , Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium, and Institute of Health and Care Sciences, University of Gothenburg, Gothenburg, Sweden and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa;  Barbara J. M. Mulder , Cardiology, Amsterdam University Medical Center, Amsterdam, Netherlands;  Erwin Oechslin , Medicine, Division of Cardiology, Peter Munk Cardiac Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada;  Jolien W. Roos- Hesselink , Cardiology, Erasmus MC, Rotterdam, Netherlands; Markus Schwerzmann , Center for Congenital Heart Disease, Department of Cardiology, University Hospital Inselspital, University of Bern, Bern, Switzerland;  Lars Sondergaard , Cardiology,\nRigshospitalet, Copenhagen, Denmark;  Katja Zeppenfeld , Leiden University Medical Centre, Leiden, Netherlands.\nESC Committee for Practice Guidelines (CPG):  Stephan Windecker (Chairperson) (Switzerland), Victor Aboyans (France), Colin Baigent (United Kingdom), Jean-Philippe Collet (France), Veronica Dean (France), Victoria Delgado (Netherlands), Donna Fitzsimons (United Kingdom), Chris P. Gale (United Kingdom), Diederick E. Grobbee (Netherlands), Sigrun Halvorsen (Norway), Gerhard Hindricks (Germany), Bernard Iung (France), Peter Ju¨ni (Canada), Hugo A. Katus (Germany), Ulf Landmesser (Germany), Christophe Leclercq (France), Maddalena Lettino (Italy), Basil S. Lewis (Israel), Be´la Merkely (Hungary), Christian Mueller (Switzerland), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Dimitrios J. Richter (Greece), Marco Roffi (Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom), Miguel Sousa-Uva (Portugal), Rhian M. Touyz (United Kingdom).\nESC National Cardiac Societies  actively involved in the review process of the 2020 ESC Guidelines for the management of adult congenital heart disease.\nAlgeria:  Algerian Society of Cardiology, Naima Hammoudi; Armenia: Armenian Cardiologists Association, Svetlana V. Grigoryan;  Austria:  Austrian Society of Cardiology, Johannes Mair; Azerbaijan:  Azerbaijan Society of Cardiology, Galib Imanov; Belarus:  Belorussian Scientific Society of Cardiologists, Jouri Chesnov;  Belgium:  Belgian Society of Cardiology, Antoine Bondue; Bosnia and Herzegovina:  Association of Cardiologists of Bosnia and Herzegovina, Naser Nabil;  Bulgaria:  Bulgarian Society of Cardiology, Anna Kaneva;  Croatia:  Croatian Cardiac Society,\nAnomalous coronary arteries\nNon-pharmacological functional imaging (e.g. nuclear study, echocardiography, or CMR with physical stress) is recommended\nin patients with coronary anomalies to conﬁrm/exclude myocardial ischaemia. I C\nAnomalous coronary arteries from the pulmonary artery\nSurgery is recommended in patients with ALCAPA. I C\nSurgery is recommended in patients with ARCAPA and symptoms attributable to anomalous coronary artery. I C\nAnomalous aortic origin of the coronary artery\nSurgery is recommended for AAOCA in patients with typical angina symptoms who present with evidence of stress-induced\nmyocardial ischaemia in a matching territory or high-risk anatomy. I C\nSurgery is not recommended for AAORCA in asymptomatic patients without myocardial ischaemia and without high-risk anatomy. III C\nAAOCA = anomalous aortic origin of a coronary artery; AAORCA anomalous aortic origin of the right coronary artery; ACHD = adult congenital heart disease; ALCAPA = anomalous left coronary artery from the pulmonary artery; ARCAPA = anomalous right coronary artery from the pulmonary artery; AR = aortic regurgitation; AS = aortic stenosis; ASD = atrial septal defect; AT = atrial tachycardia; AV = atrioventricular; AVNRT = atrioventricular node reentrant tachycardia; AVRT = atrioventricular reentrant tachycardia; AVSD = atrioventricular septal defect; CABG = coronary artery bypass graft; CAD = coronary artery disease; CHD = congenital heart disease; CMR = cardiovas- cular magnetic resonance; ECG = electrocardiogram; EF = ejection fraction; EP = electrophysiology/electrophysiological; HTAD = heritable thoracic aortic disease; IART= intraatrial reentrant tachycardia; ICD = implantable cardioverter deﬁbrillator; L \u0002 R = left-to-right; LV = left ventricle/ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end systolic diameter; PAH = pulmonary arterial hypertension; PAP = pulmonary arterial pressure; PAH-CHD = pulmonary arterial hypertension asso- ciated with congenital heart disease; PDA = patent ductus arteriosus; PFO = patent foramen ovale; PH = pulmonary hypertension; PR = pulmonary regurgitation; PS = pulmo- nary stenosis; PVR = pulmonary vascular resistance; PVRep = pulmonary valve replacement; R \u0002 L = right-to-left; RV = right ventricle/ventricular; RVOTO = right ventricular outﬂow tract obstruction; RVSP = right ventricular systolic pressure; SCD = sudden cardiac death; SVT = supraventricular tachycardia; TPVI = transcatheter pulmonary valve implantation; TR = tricuspid regurgitation; TV = tricuspid valve; UVH = univentricular heart; VF = ventricular ﬁbrillation; VSD = ventricular septal defect; VT = ventricular tachy- cardia; WU = Wood units; a Class of recommendation. b Level of evidence.\nESC Guidelines 635\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ Margarita Brida;  Cyprus:  Cyprus Society of Cardiology, Ourania Hadjisavva;  Czech Republic:  Czech Society of Cardiology, Jana Rubackova-Popelova;  Denmark:  Danish Society of Cardiology, Dorte Guldbrand Nielsen;  Egypt:  Egyptian Society of Cardiology, Maiy Hamdy El Sayed;  Estonia:  Estonian Society of Cardiology, Raili Ermel;  Finland:  Finnish Cardiac Society, Juha Sinisalo;  France:  French Society of Cardiology, Jean-Benoit Thambo;  Georgia:  Georgian Society of Cardiology, Zviad Bakhutashvili;  Germany:  German Cardiac Society, Claudia Walther;  Greece:  Hellenic Society of Cardiology, George Giannakoulas;  Hungary:  Hungarian Society of Cardiology, Olga Hajnalka B \u0003 alint;  Ireland:  Irish Cardiac Society, Christopher J. Lockhart;  Israel:  Israel Heart Society, Amiram Nir; Italy:  Italian Federation of Cardiology, Adriano Murrone;  Kosovo (Republic of ) :  Kosovo Society of Cardiology, Artan Ahmeti; Kyrgyzstan:  Kyrgyz Society of Cardiology, Olga Lunegova;  Latvia: Latvian Society of Cardiology, Ainars Rudzitis;  Lebanon:  Lebanese Society of Cardiology, Zakhia Saliba;  Lithuania:  Lithuanian Society of Cardiology, Lina Gumbiene;  Luxembourg:  Luxembourg Society of Cardiology, Kerstin Wagner;  Malta:  Maltese Cardiac Society, Maryanne Caruana; Montenegro: Montenegro Society of Cardiology, Nebojsa Bulatovic;  Morocco:  Moroccan Society of Cardiology, Rachida Amri;  Netherlands:  Netherlands Society of Cardiology, Berto J. Bouma;  North Macedonia:  North Macedonian Society of Cardiology, Elizabeta Srbinovska-Kostovska;  Norway: Norwegian Society of Cardiology, Mette-Elise Estensen;  Poland: Polish Cardiac Society, Lidia Tomkiewicz-Pajak;  Romania:  Romanian Society of Cardiology, Ioan Mircea Coman;  Russian Federation: Russian Society of Cardiology, Olga Moiseeva;  San Marino:  San Marino Society of Cardiology, Marco Zavatta;  Serbia:  Cardiology Society of Serbia, Anastazija Stojsic-Milosavljevic;  Slovakia:  Slovak Society of Cardiology, Iveta Simkova;  Slovenia:  Slovenian Society of Cardiology, Katja Prokselj;  Spain:  Spanish Society of Cardiology, Pastora Gallego;  Sweden:  Swedish Society of Cardiology, Bengt Johansson;  Switzerland:  Swiss Society of Cardiology, Matthias Greutmann;  Tunisia:  Tunisian Society of Cardiology and Cardio- Vascular Surgery, Essia Boughzela;  Ukraine:  Ukrainian Association of Cardiology, Yuriy Sirenko;  United Kingdom of Great Britain and Northern Ireland:  British Cardiovascular Society, Louise Coats.\n",
      "keywords": [
        "ejection fraction",
        "force",
        "sudden cardiac death",
        "electrocardiogram",
        "systolic",
        "tachycardia",
        "author",
        "member",
        "tricuspid",
        "hypertension",
        "scd",
        "pulmonary hypertension",
        "lvef",
        "aortic",
        "icd",
        "valve replacement",
        "affiliations",
        "echocardiography",
        "ecg",
        "recommended",
        "stenosis",
        "task",
        "aortic regurgitation",
        "aortic stenosis",
        "coronary artery"
      ],
      "tables": []
    },
    {
      "number": "55",
      "title": "10 References",
      "start_page": 73,
      "end_page": 73,
      "content": "",
      "keywords": [
        "references"
      ],
      "tables": []
    },
    {
      "number": "56",
      "title": "1. Camm AJ, Lu¨scher TF, Maurer G, Serruys PW, European Society of Cardiology. The ESC Textbook of Cardiovascular Medicine . 3rd ed. Oxford/New York: Oxford University Press; 2019. 2. van der Linde D,",
      "start_page": 73,
      "end_page": 73,
      "content": "",
      "keywords": [
        "serruys",
        "york",
        "textbook",
        "society",
        "press",
        "linde",
        "cardiology",
        "european",
        "cardiovascular",
        "maurer",
        "medicine",
        "camm",
        "oxford",
        "university",
        "scher"
      ],
      "tables": []
    },
    {
      "number": "57",
      "title": "7. Moons P, Meijboom FJ, Baumgartner H, Trindade PT, Huyghe E, Kaemmerer H, Working ESC Group on Grown-up Congenital Heart Disease. Structure and activities of adult congenital heart disease programme",
      "start_page": 73,
      "end_page": 74,
      "content": "636 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 22. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL, ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).  Eur Heart J  2015; 36 :3075 \u0002 3128. 23. Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA. Exercise intolerance in adult congenital heart disease: comparative severity, cor- relates, and prognostic implication.  Circulation  2005; 112 :828 \u0002 835. 24. Budts W, Borjesson M, Chessa M, van Buuren F, Trigo Trindade P, Corrado D, Heidbuchel H, Webb G, Holm J, Papadakis M. Physical activity in adolescents and adults with congenital heart defects: individualized exercise prescription.  Eur Heart J  2013; 34 :3669 \u0002 3674. 25. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Munoz D, Rosenhek R, Sjogren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL, ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart dis- ease.  Eur Heart J  2017; 38 :2739 \u0002 2791. 26. Baggen VJ, van den Bosch AE, Eindhoven JA, Schut AW, Cuypers JA, Witsenburg M, de Waart M, van Schaik RH, Zijlstra F, Boersma E, Roos-Hesselink JW. Prognostic value of N-terminal pro-B-type natriuretic peptide, troponin-T, and growth-differentiation factor 15 in adult congenital heart disease.  Circulation 2017; 135 :264 \u0002 279. 27. Van De Bruaene A, Hickey EJ, Kovacs AH, Crean AM, Wald RM, Silversides CK, Redington AN, Ross HJ, Alba AC, Billia F, Nair K, Benson L, Horlick E, Osten M, Colman J, Heggie J, Oechslin EN, Roche SL. Phenotype, management and predic- tors of outcome in a large cohort of adult congenital heart disease patients with heart failure.  Int J Cardiol  2018; 252 :80 \u0002 87. 28. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart dis- ease: enhanced understanding of the relationship between hypoxia and natriu- retic peptide secretion.  Circulation  2004; 109 :2872 \u0002 2877. 29. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, Babu- Narayan S, Wort SJ, Dimopoulos K, Gatzoulis MA. Survival prospects and cir- cumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre.  Circulation  2015; 132 :2118 \u0002 2125. 30. Budts W, Roos-Hesselink J, Radle-Hurst T, Eicken A, McDonagh TA, Lambrinou E, Crespo-Leiro MG, Walker F, Frogoudaki AA. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.  Eur Heart J  2016; 37 :1419 \u0002 1427. 31. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart fail- ure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC.  Eur Heart J 2016; 37 :2129 \u0002 2200. 32. Hernandez-Madrid A, Paul T, Abrams D, Aziz PF, Blom NA, Chen J, Chessa M, Combes N, Dagres N, Diller G, Ernst S, Giamberti A, Hebe J, Janousek J, Kriebel T, Moltedo J, Moreno J, Peinado R, Pison L, Rosenthal E, Skinner JR, Zeppenfeld K, ESC Scientific Document Group. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital Heart Disease, endorsed by HRS, PACES, APHRS, and SOLAECE. Europace 2018; 20 :1719 \u0002 1753. 33. Van De Bruaene A, Meier L, Droogne W, De Meester P, Troost E, Gewillig M, Budts W. Management of acute heart failure in adult patients with congenital heart disease.  Heart Fail Rev  2018; 23 :1 \u0002 14. 34. Zeppenfeld K, Schalij MJ, Bartelings MM, Tedrow UB, Koplan BA, Soejima K, Stevenson WG. Catheter ablation of ventricular tachycardia after repair of con- genital heart disease: electroanatomic identification of the critical right ventricu- lar isthmus.  Circulation  2007; 116 :2241 \u0002 2252. 35. Kapel GF, Reichlin T, Wijnmaalen AP, Piers SR, Holman ER, Tedrow UB, Schalij MJ, Stevenson WG, Zeppenfeld K. Re-entry using anatomically determined isth- muses: a curable ventricular tachycardia in repaired congenital heart disease.  Circ Arrhythm Electrophysiol  2015; 8 :102 \u0002 109. 36. Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis.  Cardiovasc Res  2004; 61 :208 \u0002 217.\n",
      "keywords": [
        "huyghe",
        "adult",
        "structure",
        "heart",
        "physical activity",
        "tachycardia",
        "disease",
        "programme",
        "kaemmerer",
        "meijboom",
        "troponin",
        "grown",
        "ventricular tachycardia",
        "baumgartner",
        "trindade",
        "moons",
        "group",
        "working",
        "congenital",
        "heart failure",
        "exercise",
        "activities",
        "ablation"
      ],
      "tables": []
    },
    {
      "number": "58",
      "title": "37. Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, Daniels CJ, Deal BJ, Dearani JA, Groot N, Dubin AM, Harris L, Janousek J, Kanter RJ, Karpawich PP, Perry JC, Seslar SP, Shah MJ, Sil",
      "start_page": 74,
      "end_page": 77,
      "content": "ESC Guidelines 637\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. .......................................................................................................................................................................... receiving advanced therapy for pulmonary arterial hypertension.  Circulation 2010; 121 :20 \u0002 25. 52. Rondelet B, Dewachter C, Kerbaul F, Kang X, Fesler P, Brimioulle S, Naeije R, Dewachter L. Prolonged overcirculation-induced pulmonary arterial hyperten- sion as a cause of right ventricular failure.  Eur Heart J  2012; 33 :1017 \u0002 1026. 53. Gabriels C, De Meester P, Pasquet A, De Backer J, Paelinck BP, Morissens M, Van De Bruaene A, Delcroix M, Budts W. A different view on predictors of pul- monary hypertension in secundum atrial septal defect. Int J Cardiol 2014; 176 :833 \u0002 840. 54. Goetschmann S, Dibernardo S, Steinmann H, Pavlovic M, Sekarski N, Pfammatter JP. Frequency of severe pulmonary hypertension complicating \"isolated\" atrial septal defect in infancy.  Am J Cardiol  2008; 102 :340 \u0002 342. 55. Akagi S, Kasahara S, Sarashina T, Nakamura K, Ito H. Treat-and-repair strategy is a feasible therapeutic choice in adult patients with severe pulmonary arterial hypertension associated with a ventricular septal defect: case series.  Eur Heart J Case Rep  2018; 2 :1 \u0002 7. 56. Bush A, Busst CM, Haworth SG, Hislop AA, Knight WB, Corrin B, Shinebourne EA. Correlations of lung morphology, pulmonary vascular resistance, and out- come in children with congenital heart disease.  Br Heart J  1988; 59 :480 \u0002 485. 57. Kannan BR, Sivasankaran S, Tharakan JA, Titus T, Kumar Ajith Francis, VK Krishnamoorthy, B Harikrishnan, KM Padmakumar, S Nair, R K. Long-term out- come of patients operated for large ventricular septal defects with increased pul- monary vascular resistance.  Indian Heart J  2003; 55 :161 \u0002 166. 58. Lopes AA, O’Leary PW. Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac dis- ease.  Cardiol Young  2009; 19 :431 \u0002 435. 59. Neutze JM, Ishikawa T, Clarkson PM, Calder AL, Barratt-Boyes BG, Kerr AR. Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance.  Am J Cardiol  1989; 63 :327 \u0002 331. 60. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease \u0002 long-term follow-up and prediction of outcome after surgical correction.  Circulation  1987; 76 :1037 \u0002 1042. 61. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta- analysis of randomized controlled trials in pulmonary arterial hypertension.  Eur Heart J  2009; 30 :394 \u0002 403. 62. Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.  Lancet Respir Med  2016; 4 :291 \u0002 305. 63. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grunig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ, AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hyper- tension.  N Engl J Med  2015; 373 :834 \u0002 844. 64. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV. Selexipag for the treatment of pulmonary arterial hypertension.  N Engl J Med  2015; 373 :2522 \u0002 2533. 65. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension.  N Engl J Med  2013; 369 :809 \u0002 818. 66. Skoro-Sajer N, Gerges C, Balint OH, Kohalmi D, Kaldararova M, Simkova I, Jakowitsch J, Gabriel H, Baumgartner H, Gerges M, Sadushi-Kolici R, Celermajer DS, Lang IM. Subcutaneous treprostinil in congenital heart disease-related pul- monary arterial hypertension.  Heart  2018; 104 :1195 \u0002 1199. 67. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M, Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syn- drome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation  2006; 114 :48 \u0002 54. 68. Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, He J, Papadakis K, Pulido T, Galie N, MAESTRO Study Investigators. Evaluation of macitentan in patients with Eisenmenger syndrome.  Circulation  2019; 139 :51 \u0002 63. 69. D’Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabro R. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.  Int J Cardiol  2012; 155 :378 \u0002 382. 70. Fuller SM, He X, Jacobs JP, Pasquali SK, Gaynor JW, Mascio CE, Hill KD, Jacobs ML, Kim YY. estimating mortality risk for adult congenital heart surgery: an analy- sis of The Society of Thoracic Surgeons Congenital Heart Surgery Database.  Ann Thorac Surg  2015; 100 :1728 \u0002 1735; discussion 1735 \u0002 1726. 71. O’Brien SM, Clarke DR, Jacobs JP, Jacobs ML, Lacour-Gayet FG, Pizarro C, Welke KF, Maruszewski B, Tobota Z, Miller WJ, Hamilton L, Peterson ED, Mavroudis C, Edwards FH. An empirically based tool for analyzing mortality\nassociated with congenital heart surgery. J Thorac Cardiovasc Surg 2009; 138 :1139 \u0002 1153. 72. Horer J, Roussin R, LeBret E, Ly M, Abdullah J, Marzullo R, Pabst von Ohain J, Belli E. Validation of the grown-ups with congenital heart disease score.  Heart 2018; 104 :1019 \u0002 1025. 73. Karamlou T, Diggs BS, Person T, Ungerleider RM, Welke KF. National practice patterns for management of adult congenital heart disease: operation by pedia- tric heart surgeons decreases in-hospital death.  Circulation  2008; 118 :2345 \u0002 2352. 74. Chessa M, Baumgartner H, Michel-Behnke I, Berger F, Budts W, Eicken A, Sondergaard L, Stein J, Wiztsemburg M, Thomson J. ESC Working Group Position Paper: transcatheter adult congenital heart disease interventions: organ- ization of care - recommendations from a Joint Working Group of the European Society of Cardiology (ESC), European Association of Pediatric and Congenital Cardiology (AEPC), and the European Association of Percutaneous Cardiac Intervention (EAPCI).  Eur Heart J  2019; 40 :1042 \u0002 1048. 75. Haas NA, Bach S, Vcasna R, Laser KT, Sandica E, Blanz U, Jakob A, Dietl M, Fischer M, Kanaan M, Lehner A. The risk of bacterial endocarditis after percuta- neous and surgical biological pulmonary valve implantation.  Int J Cardiol 2018; 268 :55 \u0002 60. 76. Kuijpers JM, Koolbergen DR, Groenink M, Peels KCH, Reichert CLA, Post MC, Bosker HA, Wajon E, Zwinderman AH, Mulder BJM, Bouma BJ. Incidence, risk factors, and predictors of infective endocarditis in adult congenital heart disease: focus on the use of prosthetic material.  Eur Heart J  2017; 38 :2048 \u0002 2056. 77. Ostergaard L, Valeur N, Ihlemann N, Bundgaard H, Gislason G, Torp-Pedersen C, Bruun NE, Sondergaard L, Kober L, Fosbol EL. Incidence of infective endocarditis among patients considered at high risk.  Eur Heart J  2018; 39 :623 \u0002 629. 78. Thornhill MH, Jones S, Prendergast B, Baddour LM, Chambers JB, Lockhart PB, Dayer MJ. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions.  Eur Heart J  2018; 39 :586 \u0002 595. 79. Pujol C, Niesert AC, Engelhardt A, Schoen P, Kusmenkov E, Pittrow D, Ewert P, Kaemmerer H. Usefulness of direct oral anticoagulants in adult congenital heart disease.  Am J Cardiol  2016; 117 :450 \u0002 455. 80. Yang H, Bouma BJ, Dimopoulos K, Khairy P, Ladouceur M, Niwa K, Greutmann M, Schwerzmann M, Egbe A, Scognamiglio G, Budts W, Veldtman G, Opotowsky AR, Broberg CS, Gumbiene L, Meijboom FJ, Rutz T, Post MC, Moe T, Lipczynska M, Tsai SF, Chakrabarti S, Tobler D, Davidson W, Morissens M, van Dijk A, Buber J, Bouchardy J, Skoglund K, Christersson C, Kronvall T, Konings TC, Alonso-Gonzalez R, Mizuno A, Webb G, Laukyte M, Sieswerda GTJ, Shafer K, Aboulhosn J, Mulder BJM. Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart dis- ease? Results of a worldwide study.  Int J Cardiol  2019; 299 :123 \u0002 130 81. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antago- nist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 :1330 \u0002 1393. 82. Oechslin E. Hematological management of the cyanotic adult with congenital heart disease.  Int J Cardiol  2004; 97  (Suppl 1):109 \u0002 115. 83. Oechslin E. Management of adults with cyanotic congenital heart disease.  Heart 2015; 101 :485 \u0002 494. 84. Broberg CS, Bax BE, Okonko DO, Rampling MW, Bayne S, Harries C, Davidson SJ, Uebing A, Khan AA, Thein S, Gibbs JS, Burman J, Gatzoulis MA. Blood viscos- ity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease.  J Am Coll Cardiol  2006; 48 :356 \u0002 365. 85. Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, Brunner-La Rocca HP. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation  2005; 112 :1106 \u0002 1112. 86. Perloff JK. Systemic complications of cyanosis in adults with congenital heart dis- ease. Hematologic derangements, renal function, and urate metabolism.  Cardiol Clin  1993; 11 :689 \u0002 699. 87. Engelfriet P, Boersma E, Oechslin E, Tijssen J, Gatzoulis MA, Thilen U, Kaemmerer H, Moons P, Meijboom F, Popelova J, Laforest V, Hirsch R, Daliento L, Thaulow E, Mulder B. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease.  Eur Heart J  2005; 26 :2325 \u0002 2333. 88. Hjortshoj CMS, Kempny A, Jensen AS, Sorensen K, Nagy E, Dellborg M, Johansson B, Rudiene V, Hong G, Opotowsky AR, Budts W, Mulder BJ, Tomkiewicz-Pajak L, D’Alto M, Prokselj K, Diller GP, Dimopoulos K, Estensen ME, Holmstrom H, Turanlahti M, Thilen U, Gatzoulis MA, Sondergaard L. Past and current cause-specific mortality in Eisenmenger syndrome.  Eur Heart J 2017; 38 :2060 \u0002 2067. 89. Kempny A, Hjortshoj CS, Gu H, Li W, Opotowsky AR, Landzberg MJ, Jensen AS, Sondergaard L, Estensen ME, Thilen U, Budts W, Mulder BJ, Blok I, Tomkiewicz- Pajak L, Szostek K, D’Alto M, Scognamiglio G, Prokselj K, Diller GP, Dimopoulos\n638 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ......................................................................................................................................................................... K, Wort SJ, Gatzoulis MA. Predictors of death in contemporary adult patients with Eisenmenger syndrome: a multicenter study. Circulation 2017; 135 :1432 \u0002 1440. 90. Sakazaki H, Niwa K, Echigo S, Akagi T, Nakazawa M. Predictive factors for long- term prognosis in adults with cyanotic congenital heart disease \u0002 Japanese multi- center study.  Int J Cardiol  2007; 120 :72 \u0002 78. 91. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease.  J Am Coll Cardiol  1996; 28 :768 \u0002 772. 92. Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R, Vachiery JL, Paelinck B, Morissens M, Budts W. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J 2011; 32 :2790 \u0002 2799. 93. Diller GP, Alonso-Gonzalez R, Kempny A, Dimopoulos K, Inuzuka R, Giannakoulas G, Castle L, Lammers AE, Hooper J, Uebing A, Swan L, Gatzoulis M, Wort SJ. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease target- ing therapy.  Heart  2012; 98 :736 \u0002 742. 94. Reardon LC, Williams RJ, Houser LS, Miner PD, Child JS, Aboulhosn JA. Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the Eisenmenger syndrome.  Am J Cardiol  2012; 110 :1523 \u0002 1526. 95. Cantor WJ, Harrison DA, Moussadji JS, Connelly MS, Webb GD, Liu P, McLaughlin PR, Siu SC. Determinants of survival and length of survival in adults with Eisenmenger syndrome.  Am J Cardiol  1999; 84 :677 \u0002 681. 96. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S. Eisenmenger syndrome. Factors relating to deterioration and death.  Eur Heart J  1998; 19 :1845 \u0002 1855. 97. Jensen AS, Idorn L, Thomsen C, von der Recke P, Mortensen J, Sorensen KE, Thilen U, Nagy E, Kofoed KF, Ostrowski SR, Sondergaard L. Prevalence of cere- bral and pulmonary thrombosis in patients with cyanotic congenital heart dis- ease.  Heart  2015; 101 :1540 \u0002 1546. 98. Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart.  J Am Coll Cardiol 1999; 34 :223 \u0002 232. 99. Perloff JK, Hart EM, Greaves SM, Miner PD, Child JS. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension.  Am J Cardiol  2003; 92 :182 \u0002 187. 100. Silversides CK, Granton JT, Konen E, Hart MA, Webb GD, Therrien J. Pulmonary thrombosis in adults with Eisenmenger syndrome.  J Am Coll Cardiol 2003; 42 :1982 \u0002 1987. 101. Broberg CS, Ujita M, Prasad S, Li W, Rubens M, Bax BE, Davidson SJ, Bouzas B, Gibbs JS, Burman J, Gatzoulis MA. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity.  J Am Coll Cardiol  2007; 50 :634 \u0002 642. 102. Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease.  Circulation  1993; 87 :1954 \u0002 1959. 103. Wand O, Guber E, Guber A, Epstein Shochet G, Israeli-Shani L, Shitrit D. Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial.  Chest  2018; 154 :1379 \u0002 1384. 104. Broberg CS, Uebing A, Cuomo L, Thein SL, Papadopoulos MG, Gatzoulis MA. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines.  Heart  2007; 93 :1599 \u0002 1603. 105. Harinck E, Hutter PA, Hoorntje TM, Simons M, Benatar AA, Fischer JC, de Bruijn D, Meijboom EJ. Air travel and adults with cyanotic congenital heart dis- ease.  Circulation  1996; 93 :272 \u0002 276. 106. Presbitero P, Somerville J, Stone S, Aruta E, Spiegelhalter D, Rabajoli F. Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus. Circulation  1994; 89 :2673 \u0002 2676. 107. Engelfriet P, Mulder BJ. Gender differences in adult congenital heart disease. Neth Heart J  2009; 17 :414 \u0002 417. 108. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart dis- ease in the general population: changing prevalence and age distribution. Circulation  2007; 115 :163 \u0002 172. 109. Oliver JM, Gallego P, Gonzalez AE, Garcia-Hamilton D, Avila P, Alonso A, Ruiz- Cantador J, Peinado R, Yotti R, Fernandez-Aviles F. Impact of age and sex on survival and causes of death in adults with congenital heart disease.  Int J Cardiol 2017; 245 :119 \u0002 124. 110. Zomer AC, Ionescu-Ittu R, Vaartjes I, Pilote L, Mackie AS, Therrien J, Langemeijer MM, Grobbee DE, Mulder BJ, Marelli AJ. Sex differences in hospital mortality in adults with congenital heart disease: the impact of reproductive health.  J Am Coll Cardiol  2013; 62 :58 \u0002 67. 111. Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, Vliegen HW, van Dijk AP, Bouma BJ, Grobbee DE, Mulder BJ. Gender and outcome in adult congenital heart disease.  Circulation  2008; 118 :26 \u0002 32. 112. D’Alto M, Budts W, Diller GP, Mulder B, Egidy Assenza G, Oreto L, Ciliberti P, Bassareo PP, Gatzoulis MA, Dimopoulos K. Does gender affect the prognosis\nand risk of complications in patients with congenital heart disease in the mod- ern era?  Int J Cardiol  2019; 290 :156 \u0002 161. 113. Meijboom LJ, Timmermans J, Zwinderman AH, Engelfriet PM, Mulder BJ. Aortic root growth in men and women with the Marfan’s syndrome.  Am J Cardiol 2005; 96 :1441 \u0002 1444. 114. Sluman MA, Zomer AC, Vaartjes I, Bouma BJ, Mulder BJ. Congenital heart dis- ease may hurt men more than women in job participation.  Int J Cardiol 2014; 172 :230 \u0002 232. 115. Goossens E, Stephani I, Hilderson D, Gewillig M, Budts W, Van Deyk K, Moons P, SWITCH(2) Investigators. Transfer of adolescents with congenital heart dis- ease from pediatric cardiology to adult health care: an analysis of transfer desti- nations.  J Am Coll Cardiol  2011; 57 :2368 \u0002 2374. 116. Larsson L, Johansson B, Sandberg C, Apers S, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, Sluman MA, Wang JK, Jackson JL, Khairy P, Cook SC, Alday L, Eriksen K, Dellborg M, Berghammer M, Rempel G, Menahem S, Caruana M, Tomlin M, Soufi A, Fernandes SM, White K, Callus E, Kutty S, Moons P, APPROACH-IS Consortium; International Society for Adult Congenital Heart Disease (ISACHD). Geographical variation and predictors of physical activity level in adults with congenital heart disease.  Int J Cardiol Heart Vasc  2019; 22 :20 \u0002 25. 117. van der Bom T, Mulder BJ, Meijboom FJ, van Dijk AP, Pieper PG, Vliegen HW, Konings TC, Zwinderman AH, Bouma BJ. Contemporary survival of adults with congenital heart disease.  Heart  2015; 101 :1989 \u0002 1995. 118. Afilalo J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Marelli AJ. Geriatric congenital heart disease: burden of disease and predictors of mortality.  J Am Coll Cardiol  2011; 58 :1509 \u0002 1515. 119. Tutarel O, Kempny A, Alonso-Gonzalez R, Jabbour R, Li W, Uebing A, Dimopoulos K, Swan L, Gatzoulis MA, Diller GP. Congenital heart disease beyond the age of 60: emergence of a new population with high resource uti- lization, high morbidity, and high mortality.  Eur Heart J  2014; 35 :725 \u0002 732. 120. Bhatt AB, Foster E, Kuehl K, Alpert J, Brabeck S, Crumb S, Davidson WR, Jr., Earing MG, Ghoshhajra BB, Karamlou T, Mital S, Ting J, Tseng ZH, American Heart Association Council on Clinical Cardiology. Congenital heart disease in the older adult: a scientific statement from the American Heart Association. Circulation  2015; 131 :1884 \u0002 1931. 121. Greutmann M, Tobler D, Colman JM, Greutmann-Yantiri M, Librach SL, Kovacs AH. Facilitators of and barriers to advance care planning in adult congenital heart disease.  Congenit Heart Dis  2013; 8 :281 \u0002 288. 122. Troost E, Roggen L, Goossens E, Moons P, De Meester P, Van De Bruaene A, Budts W. Advanced care planning in adult congenital heart disease: transitioning from repair to palliation and end-of-life care.  Int J Cardiol  2019; 279 :57 \u0002 61. 123. Gibbs JS, McCoy AS, Gibbs LM, Rogers AE, Addington-Hall JM. Living with and dying from heart failure: the role of palliative care.  Heart  2002; 88  (Suppl 2):ii36 \u0002 ii39. 124. Crossland DS, Jackson SP, Lyall R, Hamilton JR, Hasan A, Burn J, O’Sullivan JJ. Life insurance and mortgage application in adults with congenital heart disease. Eur J Cardiothorac Surg  2004; 25 :931 \u0002 934. 125. Pickup L, Bowater S, Thorne S, Clift P, Hudsmith L. Travel insurance in adult congenital heart disease - do they declare their condition?  Int J Cardiol 2016; 223 :316 \u0002 317. 126. Sluman MA, Apers S, Bouma BJ, van Melle JP, Peels CH, Post MC, Waskowsky WM, Moons P, Mulder BJ. Uncertainties in insurances for adults with congenital heart disease.  Int J Cardiol  2015; 186 :93 \u0002 95. 127. Sluman MA, Apers S, Sluiter JK, Nieuwenhuijsen K, Moons P, Luyckx K, Kovacs AH, Thomet C, Budts W, Enomoto J, Yang HL, Jackson JL, Khairy P, Cook SC, Subramanyan R, Alday L, Eriksen K, Dellborg M, Berghammer M, Mattsson E, Mackie AS, Menahem S, Caruana M, Gosney K, Soufi A, Fernandes SM, White KS, Callus E, Kutty S, Bouma BJ, Mulder BJM, APPROACH-IS consortium tISfACHDI. Education as important predictor for successful employment in adults with congenital heart disease worldwide. Congenit Heart Dis 2019; 14 :362 \u0002 371. 128. Opic P, Utens EM, Cuypers JA, Witsenburg M, van den Bosch A, van Domburg R, Bogers AJ, Boersma E, Pelliccia A, Roos-Hesselink JW. Sports participation in adults with congenital heart disease.  Int J Cardiol  2015; 187 :175 \u0002 182. 129. Pelliccia A, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi A, Borjesson M, Carre F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, van-Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thiene G, Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology, Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of\nESC Guidelines 639\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26 :1422 \u0002 1445. 130. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, Ford I, Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B, Kjeldsen KP, Longrois D, Luscher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).  Eur Heart J  2014; 35 :2383 \u0002 2431. 131. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare GF. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease.  Circulation  2018:CIR0000000000000603. 132. van Hagen IM, Boersma E, Johnson MR, Thorne SA, Parsonage WA, Escribano Subias P, Lesniak-Sobelga A, Irtyuga O, Sorour KA, Taha N, Maggioni AP, Hall R, Roos-Hesselink JW, ROPAC investigators and EORP team. Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology. Eur J Heart Fail 2016; 18 :523 \u0002 533. 133. Sliwa K, van Hagen IM, Budts W, Swan L, Sinagra G, Caruana M, Blanco MV, Wagenaar LJ, Johnson MR, Webb G, Hall R, Roos-Hesselink JW, ROPAC inves- tigators. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology.  Eur J Heart Fail  2016; 18 :1119 \u0002 1128. 134. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac Disease (ROPAC).  Eur Heart J  2019; 40 :3848 \u0002 3855. 135. van Hagen IM, Roos-Hesselink JW, Donvito V, Liptai C, Morissens M, Murphy DJ, Galian L, Bazargani NM, Cornette J, Hall R, Johnson MR. Incidence and pre- dictors of obstetric and fetal complications in women with structural heart dis- ease.  Heart  2017; 103 :1610 \u0002 1618. 136. Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease.  Eur Heart J  2015; 36 :1728 \u0002 1734, 1734a \u0002 1734b. 137. Humaidan P, Nelson SM, Devroey P, Coddington CC, Schwartz LB, Gordon K, Frattarelli JL, Tarlatzis BC, Fatemi HM, Lutjen P, Stegmann BJ. Ovarian hypersti- mulation syndrome: review and new classification criteria for reporting in clini- cal trials.  Hum Reprod  2016; 31 :1997 \u0002 2004. 138. Kametas NA, McAuliffe F, Krampl E, Chambers J, Nicolaides KH. Maternal car- diac function in twin pregnancy.  Obstet Gynecol  2003; 102 :806 \u0002 815. 139. Opic P, Roos-Hesselink JW, Cuypers JA, Witsenburg M, van den Bosch A, van Domburg RT, Bogers AJ, Utens EM. Sexual functioning is impaired in adults with congenital heart disease.  Int J Cardiol  2013; 168 :3872 \u0002 3877. 140. De Backer J, Bondue A, Budts W, Evangelista A, Gallego P, Jondeau G, Loeys B, Pena ML, Teixido-Tura G, van de Laar I, Verstraeten A, Roos Hesselink J. Genetic counselling and testing in adults with congenital heart disease: a con- sensus document of the ESC Working Group of Grown-Up Congenital Heart Disease, the ESC Working Group on Aorta and Peripheral Vascular Disease and the European Society of Human Genetics. Eur J Prev Cardiol 2019:2047487319854552. 141. Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, Mital S, Priest JR, Pu WT, Roberts A, Ware SM, Gelb BD, Russell MW, American Heart Association Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Genomic and Precision Medicine. Genetic basis for congenital heart disease: revisited: a scientific statement from the American Heart Association.  Circulation  2018; 138 :e653 \u0002 e711. 142. Nyboe C, Karunanithi Z, Nielsen-Kudsk JE, Hjortdal VE. Long-term mortality in patients with atrial septal defect: a nationwide cohort-study.  Eur Heart J 2018; 39 :993 \u0002 998. 143. Gatzoulis MA, Freeman MA, Siu SC, Webb GD, Harris L. Atrial arrhythmia after surgical closure of atrial septal defects in adults.  N Engl J Med 1999; 340 :839 \u0002 846. 144. Murphy JG, Gersh BJ, McGoon MD, Mair DD, Porter CJ, Ilstrup DM, McGoon DC, Puga FJ, Kirklin JW, Danielson GK. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years.  N Engl J Med 1990; 323 :1645 \u0002 1650. 145. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH, Utens EM, Bogers AJ, Simoons ML. Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A prospective follow-up study of 21-33 years.  Eur Heart J 2003; 24 :190 \u0002 197.\n",
      "keywords": [
        "janousek",
        "dubin",
        "khairy",
        "older",
        "shah",
        "cecchin",
        "genetic",
        "guideline",
        "physical activity",
        "cohen",
        "harris",
        "daniels",
        "dearani",
        "gender",
        "age",
        "perry",
        "hypertension",
        "hare",
        "groot",
        "pulmonary hypertension",
        "aortic",
        "arrhythmia",
        "sex",
        "balaji",
        "atrial fibrillation",
        "heart failure",
        "seslar",
        "exercise",
        "karpawich",
        "berul"
      ],
      "tables": []
    },
    {
      "number": "59",
      "title": "146. Attie F, Rosas M, Granados N, Zabal C, Buendia A, Calderon J. Surgical treat- ment for secundum atrial septal defects in patients >40 years old. A random- ized clinical trial.  J Am Coll Cardiol ",
      "start_page": 77,
      "end_page": 78,
      "content": "640 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 166. Malhotra SP, Lacour-Gayet F, Mitchell MB, Clarke DR, Dines ML, Campbell DN. Reoperation for left atrioventricular valve regurgitation after atrioventricu- lar septal defect repair. Ann Thorac Surg 2008; 86 :147 \u0002 151; discussion 151 \u0002 142. 167. Drenthen W, Pieper PG, van der Tuuk K, Roos-Hesselink JW, Voors AA, Mostert B, Mulder BJ, Moons P, Ebels T, van Veldhuisen DJ, Investigators Zahara. Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects.  Eur Heart J 2005; 26 :2581 \u0002 2587. 168. Fisher RG, Moodie DS, Sterba R, Gill CC. Patent ductus arteriosus in adults \u0002 - long-term follow-up: nonsurgical versus surgical treatment.  J Am Coll Cardiol 1986; 8 :280 \u0002 284. 169. Harrison DA, Benson LN, Lazzam C, Walters JE, Siu S, McLaughlin PR. Percutaneous catheter closure of the persistently patent ductus arteriosus in the adult.  Am J Cardiol  1996; 77 :1094 \u0002 1097. 170. John S, Muralidharan S, Jairaj PS, Mani GK, Babuthaman, Krishnaswamy S, Sukumar IP, Cherian G. The adult ductus: review of surgical experience with 131 patients.  J Thorac Cardiovasc Surg  1981; 82 :314 \u0002 319. 171. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med  2000; 343 :611 \u0002 617. 172. Tzemos N, Therrien J, Yip J, Thanassoulis G, Tremblay S, Jamorski MT, Webb GD, Siu SC. Outcomes in adults with bicuspid aortic valves. JAMA 2008; 300 :1317 \u0002 1325. 173. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, Lancellotti P, LeFevre M, Miller F, Jr., Otto CM. Recommendations on the echo- cardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.  Eur Heart J Cardiovasc Imaging  2017; 18 :254 \u0002 275. 174. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S, PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.  N Engl J Med  2010; 363 :1597 \u0002 1607. 175. Thourani VH, Suri RM, Gunter RL, Sheng S, O’Brien SM, Ailawadi G, Szeto WY, Dewey TM, Guyton RA, Bavaria JE, Babaliaros V, Gammie JS, Svensson L, Williams M, Badhwar V, Mack MJ. Contemporary real-world outcomes of surgi- cal aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients.  Ann Thorac Surg  2015; 99 :55 \u0002 61. 176. Michelena HI, Della Corte A, Prakash SK, Milewicz DM, Evangelista A, Enriquez-Sarano M. Bicuspid aortic valve aortopathy in adults: incidence, etiol- ogy, and clinical significance.  Int J Cardiol  2015; 201 :400 \u0002 407. 177. Urban Z, Zhang J, Davis EC, Maeda GK, Kumar A, Stalker H, Belmont JW, Boyd CD, Wallace MR. Supravalvular aortic stenosis: genetic and molecular dissec- tion of a complex mutation in the elastin gene.  Hum Genet  2001; 109 :512 \u0002 520. 178. Summers RM, Andrasko-Bourgeois J, Feuerstein IM, Hill SC, Jones EC, Busse MK, Wise B, Bove KE, Rishforth BA, Tucker E, Spray TL, Hoeg JM. Evaluation of the aortic root by MRI: insights from patients with homozygous familial hyper- cholesterolemia.  Circulation  1998; 98 :509 \u0002 518. 179. Greutmann M, Tobler D, Sharma NC, Vonder Muhll I, Mebus S, Kaemmerer H, Schuler PK, Deanfield JE, Beauchesne L, Salehian O, Hoffmann A, Golovatyuk V, Oechslin EN, Silversides CK. Cardiac outcomes in adults with supravalvar aortic stenosis.  Eur Heart J  2012; 33 :2442 \u0002 2450. 180. Aboulhosn J, Child JS. Echocardiographic evaluation of congenital left ventricu- lar outflow obstruction.  Echocardiography  2015; 32 Suppl 2 :S140 \u0002 S147. 181. Roemers R, Kluin J, de Heer F, Arrigoni S, Bokenkamp R, van Melle J, Ebels T, Hazekamp M. Surgical correction of supravalvar aortic stenosis: 52 years’ expe- rience.  World J Pediatr Congenit Heart Surg  2018; 9 :131 \u0002 138. 182. van der Linde D, Takkenberg JJ, Rizopoulos D, Heuvelman HJ, Budts W, van Dijk AP, Witsenburg M, Yap SC, Bogers AJ, Silversides CK, Oechslin EN, Roos- Hesselink JW. Natural history of discrete subaortic stenosisin adults: a multi- centre study.  Eur Heart J  2013; 34 :1548 \u0002 1556. 183. Choudhary P, Canniffe C, Jackson DJ, Tanous D, Walsh K, Celermajer DS. Late outcomes in adults with coarctation of the aorta.  Heart  2015; 101 :1190 \u0002 1195. 184. Padang R, Dennis M, Semsarian C, Bannon PG, Tanous DJ, Celermajer DS, Puranik R. Detection of serious complications by MR imaging in asymptomatic young adults with repaired coarctation of the aorta. Heart Lung Circ 2014; 23 :332 \u0002 338. 185. Ringel RE, Vincent J, Jenkins KJ, Gauvreau K, Moses H, Lofgren K, Usmani K. Acute outcome of stent therapy for coarctation of the aorta: results of the coarctation of the aorta stent trial.  Catheter Cardiovasc Interv  2013; 82 :503 \u0002 510. 186. Taggart NW, Minahan M, Cabalka AK, Cetta F, Usmani K, Ringel RE, COAST II Investigators. Immediate outcomes of covered stent placement for treatment or prevention of aortic wall injury associated with coarctation of the aorta (COAST II).  JACC Cardiovasc Interv  2016; 9 :484 \u0002 493.\n",
      "keywords": [
        "ized",
        "echo",
        "septal",
        "years",
        "coll",
        "genetic",
        "rosas",
        "zabal",
        "trial",
        "aortic stenosis",
        "clinical",
        "aortic",
        "valve replacement",
        "attie",
        "surgical",
        "mri",
        "random",
        "echocardiography",
        "ment",
        "granados",
        "patients",
        "stenosis",
        "buendia",
        "secundum",
        "calderon",
        "cardiol",
        "treat",
        "atrial",
        "defects"
      ],
      "tables": []
    },
    {
      "number": "60",
      "title": "187. Ungerleider RM, Pasquali SK, Welke KF, Wallace AS, Ootaki Y, Quartermain MD, Williams DA, Jacobs JP. Contemporary patterns of surgery and outcomes for aortic coarctation: an analysis of the Socie",
      "start_page": 78,
      "end_page": 79,
      "content": "ESC Guidelines 641\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ root dimensions in persons >/=15 years of age. Am J Cardiol 2012; 110 :1189 \u0002 1194. 202. Franken R, El Morabit A, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Marquering H, Planken NR, Zwinderman AH, Mulder BJ, Groenink M. Increased aortic tortuosity indicates a more severe aortic phenotype in adults with Marfan syndrome.  Int J Cardiol  2015; 194 :7 \u0002 12. 203. Morris SA, Orbach DB, Geva T, Singh MN, Gauvreau K, Lacro RV. Increased vertebral artery tortuosity index is associated with adverse outcomes in chil- dren and young adults with connective tissue disorders. Circulation 2011; 124 :388 \u0002 396. 204. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome.  N Engl J Med  1994; 330 :1335 \u0002 1341. 205. Teixido-Tura G, Forteza A, Rodriguez-Palomares J, Gonzalez Mirelis J, Gutierrez L, Sanchez V, Ibanez B, Garcia-Dorado D, Evangelista A. Losartan versus atenolol for prevention of aortic dilation in patients with Marfan syn- drome.  J Am Coll Cardiol  2018; 72 :1613 \u0002 1618. 206. Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D, Tubach F, Dupuis-Girod S, Plauchu H, Barthelet M, Sassolas F, Pangaud N, Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE, Faivre L, Odent S, Basquin A, Habib G, Collignon P, Boileau C, Jondeau G. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2015; 36 :2160 \u0002 2166. 207. Pitcher A, Emberson J, Lacro RV, Sleeper LA, Stylianou M, Mahony L, Pearson GD, Groenink M, Mulder BJ, Zwinderman AH, De Backer J, De Paepe AM, Arbustini E, Erdem G, Jin XY, Flather MD, Mullen MJ, Child AH, Forteza A, Evangelista A, Chiu HH, Wu MH, Sandor G, Bhatt AB, Creager MA, Devereux RB, Loeys B, Forfar JC, Neubauer S, Watkins H, Boileau C, Jondeau G, Dietz HC, Baigent C. Design and rationale of a prospective, collaborative meta- analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: a report from the Marfan Treatment Trialists’ Collaboration.  Am Heart J  2015; 169 :605 \u0002 612. 208. David TE, Feindel CM, David CM, Manlhiot C. A quarter of a century of experi- ence with aortic valve-sparing operations. J Thorac Cardiovasc Surg 2014; 148 :872 \u0002 879; discussion 879 \u0002 880. 209. Groenink M, Mulder BJ. How to treat Marfan syndrome: an update.  Eur Heart J 2016; 37 :986 \u0002 987. 210. Isselbacher EM, Bonaca MP, Di Eusanio M, Froehlich J, Bassone E, Sechtem U, Pyeritz R, Patel H, Khoynezhad A, Eckstein HH, Jondeau G, Ramponi F, Abbasi M, Montgomery D, Nienaber CA, Eagle K, Lindsay ME, International Registry of Aortic Dissection Investigators. Recurrent aortic dissection: observations from the International Registry of Aortic Dissection. Circulation 2016; 134 :1013 \u0002 1024. 211. Mimoun L, Detaint D, Hamroun D, Arnoult F, Delorme G, Gautier M, Milleron O, Meuleman C, Raoux F, Boileau C, Vahanian A, Jondeau G. Dissection in Marfan syndrome: the importance of the descending aorta.  Eur Heart J 2011; 32 :443 \u0002 449. 212. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve.  N Engl J Med  2014; 370 :1920 \u0002 1929. 213. Michelena HI, Desjardins VA, Avierinos JF, Russo A, Nkomo VT, Sundt TM, Pellikka PA, Tajik AJ, Enriquez-Sarano M. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community.  Circulation  2008; 117 :2776 \u0002 2784. 214. Detaint D, Michelena HI, Nkomo VT, Vahanian A, Jondeau G, Sarano ME. Aortic dilatation patterns and rates in adults with bicuspid aortic valves: a com- parative study with Marfan syndrome and degenerative aortopathy.  Heart 2014; 100 :126 \u0002 134. 215. Oliver JM, Alonso-Gonzalez R, Gonzalez AE, Gallego P, Sanchez-Recalde A, Cuesta E, Aroca A, Lopez-Sendon JL. Risk of aortic root or ascending aorta complications in patients with bicuspid aortic valve with and without coarcta- tion of the aorta.  Am J Cardiol  2009; 104 :1001 \u0002 1006. 216. Galian-Gay L, Carro Hevia A, Teixido-Tura G, Rodriguez Palomares J, Gutierrez-Moreno L, Maldonado G, Gonzalez-Alujas MT, Sao-Aviles A, Gallego P, Calvo-Iglesias F, Bermejo J, Robledo-Carmona J, Sanchez V, Saura D, Sevilla T, Burillo-Sanz S, Guala A, Garcia-Dorado D, Evangelista A, BICUSPID investi- gators. Familial clustering of bicuspid aortic valve and its relationship with aortic dilation in first-degree relatives.  Heart  2019; 105 :603 \u0002 608. 217. Silberbach M, Roos-Hesselink JW, Andersen NH, Braverman AC, Brown N, Collins RT, De Backer J, Eagle KA, Hiratzka LF, Johnson WH, Jr., Kadian-Dodov D, Lopez L, Mortensen KH, Prakash SK, Ratchford EV, Saidi A, van Hagen I, Young LT, American Heart Association Council on Cardiovascular Disease in the Young, Council on Genomic and Precision Medicine, Council on Peripheral Vascular Disease. Cardiovascular health in Turner syndrome: a scientific state- ment from the American Heart Association. Circ Genom Precis Med 2018; 11 :e000048.\n",
      "keywords": [
        "aortic",
        "contemporary",
        "age",
        "williams",
        "jacobs",
        "surgery",
        "outcomes",
        "coarctation",
        "analysis",
        "ootaki",
        "pasquali",
        "patterns",
        "quartermain",
        "ungerleider",
        "wallace",
        "socie",
        "welke"
      ],
      "tables": []
    },
    {
      "number": "61",
      "title": "218. Carlson M, Airhart N, Lopez L, Silberbach M. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: report of the international Turner syn",
      "start_page": 79,
      "end_page": 80,
      "content": "642 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ 238. Wald RM, Valente AM, Marelli A. Heart failure in adult congenital heart disease: emerging concepts with a focus on tetralogy of Fallot.  Trends Cardiovasc Med 2015; 25 :422 \u0002 432. 239. Bokma JP, Winter MM, van Dijk AP, Vliegen HW, van Melle JP, Meijboom FJ, Post MC, Berbee JK, Boekholdt SM, Groenink M, Zwinderman AH, Mulder BJM, Bouma BJ. effect of losartan on right ventricular dysfunction: results from the double-blind, randomized REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in adults with repaired tetralogy of Fallot.  Circulation  2018; 137 :1463 \u0002 1471. 240. Valente AM, Gauvreau K, Assenza GE, Babu-Narayan SV, Schreier J, Gatzoulis MA, Groenink M, Inuzuka R, Kilner PJ, Koyak Z, Landzberg MJ, Mulder B, Powell AJ, Wald R, Geva T. Contemporary predictors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort.  Heart  2014; 100 :247 \u0002 253. 241. Geva T, Mulder B, Gauvreau K, Babu-Narayan SV, Wald RM, Hickey K, Powell AJ, Gatzoulis MA, Valente AM. preoperative predictors of death and sustained ventricular tachycardia after pulmonary valve replacement in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort.  Circulation 2018; 138 :2106 \u0002 2115. 242. Kapel GF, Sacher F, Dekkers OM, Watanabe M, Blom NA, Thambo JB, Derval N, Schalij MJ, Jalal Z, Wijnmaalen AP, Zeppenfeld K. Arrhythmogenic anatomical isthmuses identified by electroanatomical mapping are the substrate for ventric- ular tachycardia in repaired Tetralogy of Fallot.  Eur Heart J  2017; 38 :268 \u0002 276. 243. Huntgeburth M, Germund I, Geerdink LM, Sreeram N, Udink Ten Cate FEA. Emerging clinical applications of strain imaging and three-dimensional echocar- diography for the assessment of ventricular function in adult congenital heart disease.  Cardiovasc Diagn Ther  2019; 9 :S326 \u0002 S345. 244. Babu-Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, Davlouros PA, Khan M, Ho SY, Pennell DJ, Gatzoulis MA. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome.  Circulation  2006; 113 :405 \u0002 413. 245. Khairy P, Landzberg MJ, Gatzoulis MA, Lucron H, Lambert J, Marcon F, Alexander ME, Walsh EP. Value of programmed ventricular stimulation after tetralogy of Fallot repair: a multicenter study.  Circulation  2004; 109 :1994 \u0002 2000. 246. Babu-Narayan SV, Diller GP, Gheta RR, Bastin AJ, Karonis T, Li W, Pennell DJ, Uemura H, Sethia B, Gatzoulis MA, Shore DF. Clinical outcomes of surgical pul- monary valve replacement after repair of tetralogy of Fallot and potential prog- nostic value of preoperative cardiopulmonary exercise testing.  Circulation 2014; 129 :18 \u0002 27. 247. Bokma JP, Geva T, Sleeper LA, Babu Narayan SV, Wald R, Hickey K, Jansen K, Wassall R, Lu M, Gatzoulis MA, Mulder BJ, Valente AM. A propensity score- adjusted analysis of clinical outcomes after pulmonary valve replacement in tet- ralogy of Fallot.  Heart  2018; 104 :738 \u0002 744. 248. Oosterhof T, Meijboom FJ, Vliegen HW, Hazekamp MG, Zwinderman AH, Bouma BJ, van Dijk AP, Mulder BJ. Long-term follow-up of homograft function after pulmonary valve replacement in patients with tetralogy of Fallot.  Eur Heart J  2006; 27 :1478 \u0002 1484. 249. Heng EL, Gatzoulis MA, Uebing A, Sethia B, Uemura H, Smith GC, Diller GP, McCarthy KP, Ho SY, Li W, Wright P, Spadotto V, Kilner PJ, Oldershaw P, Pennell DJ, Shore DF, Babu-Narayan SV. Immediate and midterm cardiac remodeling after surgical pulmonary valve replacement in adults with repaired tetralogy of Fallot: a prospective cardiovascular magnetic resonance and clinical study.  Circulation  2017; 136 :1703 \u0002 1713. 250. Bokma JP, Winter MM, Oosterhof T, Vliegen HW, van Dijk AP, Hazekamp MG, Koolbergen DR, Groenink M, Mulder BJ, Bouma BJ. Preoperative thresholds for mid-to-late haemodynamic and clinical outcomes after pulmonary valve replace- ment in tetralogy of Fallot.  Eur Heart J  2016; 37 :829 \u0002 835. 251. Mongeon FP, Ben Ali W, Khairy P, Bouhout I, Therrien J, Wald RM, Dallaire F, Bernier PL, Poirier N, Dore A, Silversides C, Marelli A. Pulmonary valve replacement for pulmonary regurgitation in adults with tetralogy of Fallot: a meta-analysis \u0002 a report for the writing committee of the 2019 update of the Canadian Cardiovascular Society Guidelines for the management of adults with congenital heart disease.  Can J Cardiol  2019; 35 :1772 \u0002 1783. 252. Bokma JP, Winter MM, Oosterhof T, Vliegen HW, van Dijk AP, Hazekamp MG, Koolbergen DR, Groenink M, Mulder BJ, Bouma BJ. Individualised prediction of pulmonary homograft durability in tetralogy of Fallot. Heart 2015; 101 :1717 \u0002 1723. 253. Abbas JR, Hoschtitzky JA. Which is the best tissue valve used in the pulmonary position, late after previous repair of tetralogy of Fallot?  Interact Cardiovasc Thorac Surg  2013; 17 :854 \u0002 860. 254. Egbe AC, Crestanello J, Miranda WR, Connolly HM. Thoracic aortic dissection in tetralogy of Fallot: a review of the national inpatient sample database.  J Am Heart Assoc  2019; 8 :e011943. 255. Daily JA, Tang X, Angtuaco M, Bolin E, Lang SM, Collins RT, 2nd. Transcatheter versus surgical pulmonary valve replacement in repaired tetralogy of Fallot.  Am J Cardiol  2018; 122 :498 \u0002 504.\n",
      "keywords": [
        "valve",
        "tachycardia",
        "turner",
        "report",
        "lopez",
        "syndrome",
        "bicuspid",
        "ventricular tachycardia",
        "aortic",
        "valve replacement",
        "international",
        "silberbach",
        "enlargement",
        "dissection",
        "carlson",
        "heart failure",
        "airhart",
        "exercise",
        "associated",
        "moderate"
      ],
      "tables": []
    },
    {
      "number": "62",
      "title": "256. Georgiev S, Ewert P, Tanase D, Hess J, Hager A, Cleuziou J, Meierhofer C, Eicken A. A low residual pressure gradient yields excellent long-term outcome after percutaneous pulmonary valve implanta",
      "start_page": 80,
      "end_page": 81,
      "content": "ESC Guidelines 643\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ............................................................................................................................................................................ history of the Mustard procedure: long-term outcome up to 40 years.  Eur Heart J  2014; 35 :1666 \u0002 1674. 277. Vejlstrup N, Sorensen K, Mattsson E, Thilen U, Kvidal P, Johansson B, Iversen K, Sondergaard L, Dellborg M, Eriksson P. Long-term outcome of Mustard/Senning correction for transposition of the great arteries in Sweden and Denmark. Circulation  2015; 132 :633 \u0002 638. 278. De Pasquale G, Bonassin Tempesta F, Lopes BS, Babic D, Oxenius A, Seeliger T, Gruner C, Tanner FC, Biaggi P, Attenhofer Jost C, Greutmann M. High prevalence of baffle leaks in adults after atrial switch operations for transposition of the great arteries. Eur Heart J Cardiovasc Imaging 2017; 18 :531 \u0002 535. 279. Rydman R, Gatzoulis MA, Ho SY, Ernst S, Swan L, Li W, Wong T, Sheppard M, McCarthy KP, Roughton M, Kilner PJ, Pennell DJ, Babu-Narayan SV. Systemic right ventricular fibrosis detected by cardiovascular magnetic resonance is asso- ciated with clinical outcome, mainly new-onset atrial arrhythmia, in patients after atrial redirection surgery for transposition of the great arteries.  Circ Cardiovasc Imaging  2015; 8 :e002628. 280. Zaragoza-Macias E, Zaidi AN, Dendukuri N, Marelli A. Medical therapy for systemic right ventricles: a systematic review (part 1) for the 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73 :1564 \u0002 1578. 281. Ou P, Khraiche D, Celermajer DS, Agnoletti G, Le Quan Sang KH, Thalabard JC, Quintin M, Raisky O, Vouhe P, Sidi D, Bonnet D. Mechanisms of coronary complications after the arterial switch for transposition of the great arteries.  J Thorac Cardiovasc Surg  2013; 145 :1263 \u0002 1269. 282. Losay J, Touchot A, Serraf A, Litvinova A, Lambert V, Piot JD, Lacour-Gayet F, Capderou A, Planche C. Late outcome after arterial switch operation for trans- position of the great arteries.  Circulation  2001; 104 :I-121 \u0002  I-126. 283. Kempny A, Wustmann K, Borgia F, Dimopoulos K, Uebing A, Li W, Chen SS, Piorkowski A, Radley-Smith R, Yacoub MH, Gatzoulis MA, Shore DF, Swan L, Diller GP. Outcome in adult patients after arterial switch operation for transpo- sition of the great arteries.  Int J Cardiol  2013; 167 :2588 \u0002 2593. 284. Khairy P, Clair M, Fernandes SM, Blume ED, Powell AJ, Newburger JW, Landzberg MJ, Mayer JE, Jr. Cardiovascular outcomes after the arterial switch operation for D-transposition of the great arteries. Circulation 2013; 127 :331 \u0002 339. 285. Tobler D, Williams WG, Jegatheeswaran A, Van Arsdell GS, McCrindle BW, Greutmann M, Oechslin EN, Silversides CK. Cardiac outcomes in young adult survivors of the arterial switch operation for transposition of the great arteries. J Am Coll Cardiol  2010; 56 :58 \u0002 64. 286. Tobler D, Motwani M, Wald RM, Roche SL, Verocai F, Iwanochko RM, Greenwood JP, Oechslin EN, Crean AM. Evaluation of a comprehensive cardio- vascular magnetic resonance protocol in young adults late after the arterial switch operation for d-transposition of the great arteries.  J Cardiovasc Magn Reson  2014; 16 :98. 287. van Wijk SWH, van der Stelt F, Ter Heide H, Schoof PH, Doevendans PAFM, Meijboom FJ, Breur JMPJ. Sudden death due to coronary artery lesions long- term after the arterial switch operation: a systematic review.  Can J Cardiol 2017; 33 :1180 \u0002 1187. 288. Hazekamp MG, Gomez AA, Koolbergen DR, Hraska V, Metras DR, Mattila IP, Daenen W, Berggren HE, Rubay JE, Stellin G, European Congenital Heart Surgeons Association. Surgery for transposition of the great arteries, ventricular septal defect and left ventricular outflow tract obstruction: European Congenital Heart Surgeons Association multicentre study.  Eur J Cardiothorac Surg  2010; 38 :699 \u0002 706. 289. van Dissel AC, Winter MM, van der Bom T, Vliegen HW, van Dijk APJ, Pieper PG, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJM, Bouma BJ. Long-term clinical outcomes of valsartan in patients with a systemic right ventricle: follow-up of a multicenter randomized controlled trial.  Int J Cardiol 2019; 278 :84 \u0002 87. 290. Hofferberth SC, Alexander ME, Mah DY, Bautista-Hernandez V, del Nido PJ, Fynn-Thompson F. Impact of pacing on systemic ventricular function in L-trans- position of the great arteries.  J Thorac Cardiovasc Surg  2016; 151 :131 \u0002 138. 291. Mongeon FP, Connolly HM, Dearani JA, Li Z, Warnes CA. Congenitally cor- rected transposition of the great arteries ventricular function at the time of sys- temic atrioventricular valve replacement predicts long-term ventricular function.  J Am Coll Cardiol  2011; 57 :2008 \u0002 2017. 292. Caldarone CA, McCrindle BW, Van Arsdell GS, Coles JG, Webb G, Freedom RM, Williams WG. Independent factors associated with longevity of prosthetic pulmonary valves and valved conduits. J Thorac Cardiovasc Surg 2000; 120 :1022 \u0002 1030; discussion 1031. 293. Mohammadi S, Belli E, Martinovic I, Houyel L, Capderou A, Petit J, Planche C, Serraf A. Surgery for right ventricle to pulmonary artery conduit obstruction: risk factors for further reoperation.  Eur J Cardiothorac Surg  2005; 28 :217 \u0002 222.\n",
      "keywords": [
        "gradient",
        "pulmonary",
        "implanta",
        "yields",
        "guideline",
        "valve",
        "georgiev",
        "tanase",
        "outcome",
        "percutaneous",
        "cleuziou",
        "ewert",
        "term",
        "arrhythmia",
        "residual",
        "valve replacement",
        "eicken",
        "excellent",
        "meierhofer",
        "hess",
        "pressure",
        "long",
        "after",
        "coronary artery",
        "hager"
      ],
      "tables": []
    },
    {
      "number": "63",
      "title": "294. Peng LF, McElhinney DB, Nugent AW, Powell AJ, Marshall AC, Bacha EA, Lock JE. Endovascular stenting of obstructed right ventricle-to-pulmonary artery con- duits: a 15-year experience.  Circulatio",
      "start_page": 81,
      "end_page": 83,
      "content": "644 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n. ................................................................. Nosal M, Tlaskal T, Rubay J, Lazarov S, Kadner A, Hraska V, Fragata J, Pozzi M, Sarris G, Michielon G, di Carlo D, Ebels T. Surgical options after Fontan failure. Heart  2016; 102 :1127 \u0002 1133. 317. Mavroudis C, Deal BJ, Backer CL, Stewart RD, Franklin WH, Tsao S, Ward KM, DeFreitas RA. J. Maxwell Chamberlain Memorial Paper for congenital heart surgery. 111 Fontan conversions with arrhythmia surgery: surgical lessons and outcomes.  Ann Thorac Surg  2007; 84 :1457 \u0002 1465; discussion 1465 \u0002 1466. 318. Yau JM, Singh R, Halpern EJ, Fischman D. Anomalous origin of the left coronary artery from the pulmonary artery in adults: a comprehensive review of 151 adult cases and a new diagnosis in a 53-year-old woman.  Clin Cardiol 2011; 34 :204 \u0002 210. 319. Opolski MP, Pregowski J, Kruk M, Witkowski A, Kwiecinska S, Lubienska E, Demkow M, Hryniewiecki T, Michalek P, Ruzyllo W, Kepka C. Prevalence and characteristics of coronary anomalies originating from the opposite sinus of Valsalva in 8,522 patients referred for coronary computed tomography angiog- raphy.  Am J Cardiol  2013; 111 :1361 \u0002 1367. 320. Mainwaring RD, Reddy VM, Reinhartz O, Petrossian E, MacDonald M, Nasirov T, Miyake CY, Hanley FL. Anomalous aortic origin of a coronary artery: medium-term results after surgical repair in 50 patients.  Ann Thorac Surg 2011; 92 :691 \u0002 697. 321. Frommelt PC, Sheridan DC, Berger S, Frommelt MA, Tweddell JS. Ten-year experience with surgical unroofing of anomalous aortic origin of a coronary artery from the opposite sinus with an interarterial course.  J Thorac Cardiovasc Surg  2011; 142 :1046 \u0002 1051. 322. Jegatheeswaran A, Devlin PJ, McCrindle BW, Williams WG, Jacobs ML, Blackstone EH, DeCampli WM, Caldarone CA, Gaynor JW, Kirklin JK, Lorber RO, Mery CM, St Louis JD, Molossi S, Brothers JA. Features associated with myocardial ischemia in anomalous aortic origin of a coronary artery: a\nCongenital Heart Surgeons’ Society study. J Thorac Cardiovasc Surg 2019; 158 :822 \u0002 834 e823. 323. Grani C, Benz DC, Steffen DA, Clerc OF, Schmied C, Possner M, Vontobel J, Mikulicic F, Gebhard C, Pazhenkottil AP, Gaemperli O, Hurwitz S, Kaufmann PA, Buechel RR. Outcome in middle-aged individuals with anomalous origin of the coronary artery from the opposite sinus: a matched cohort study.  Eur Heart J  2017; 38 :2009 \u0002 2016. 324. Krasuski RA, Magyar D, Hart S, Kalahasti V, Lorber R, Hobbs R, Pettersson G, Blackstone E. Long-term outcome and impact of surgery on adults with coro- nary arteries originating from the opposite coronary cusp. Circulation 2011; 123 :154 \u0002 162. 325. Spertus JA, Eagle KA, Krumholz HM, Mitchell KR, Normand S-LT. American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care.  Circulation  2005; 111 :1703 \u0002 1712. 326. National Quality Forum. Measure evaluation criteria. http://www.qualityforum. org/Measuring_Performance/Submitting_Standards/Measure_Evaluation_ Criteria.aspx#comparison . (25 March 2020). 327. Bhatt DL, Drozda JP, Shahian DM, Chan PS, Fonarow GC, Heidenreich PA, Jacobs JP, Masoudi FA, Peterson ED, Welke KF. ACC/AHA/STS statement on the future of registries and the performance measurement enterprise.  J Am Coll Cardiol  2015; 66 :2230 \u0002 2245. 328. Lindauer PK, Remus D, Roman S, Rothberg MB, Banjamin EM, Ma A, Bratzler DW. Public reporting and pay for performance in hospital quality improve- ment.  N Engl J Med  2007; 356 :486 \u0002 496. 329. Raleigh VS, Foot C.  Getting the Measure of Quality. Opportunities and Challenges . London: The King’s Fund; 2010.\nESC Guidelines 645\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\nDownloaded from https://academic.oup.com/eurheartj/article/42/6/563/5898606 by guest on 14 January 2026\n",
      "keywords": [
        "pulmonary",
        "peng",
        "year",
        "bacha",
        "obstructed",
        "lock",
        "marshall",
        "duits",
        "stenting",
        "circulatio",
        "aortic",
        "nugent",
        "ventricle",
        "arrhythmia",
        "artery",
        "mcelhinney",
        "right",
        "endovascular",
        "experience",
        "powell",
        "coronary artery"
      ],
      "tables": []
    },
    {
      "number": "64",
      "title": "LITTMANN RATING 9/10",
      "start_page": 84,
      "end_page": 84,
      "content": "",
      "keywords": [
        "rating",
        "littmann"
      ],
      "tables": []
    },
    {
      "number": "65",
      "title": "LITTMANN RATING 10+",
      "start_page": 84,
      "end_page": 84,
      "content": "Delivering to 20+ European Countries.\n",
      "keywords": [
        "rating",
        "littmann"
      ],
      "tables": []
    },
    {
      "number": "66",
      "title": "FREE CASE ANY LITTMANN ®  CORE",
      "start_page": 84,
      "end_page": 84,
      "content": "FREECASE\nadd code at the checkout to apply\nSHOP NOW\n",
      "keywords": [
        "core",
        "free",
        "case",
        "littmann"
      ],
      "tables": []
    },
    {
      "number": "67",
      "title": "FREE CASE ANY LITTMANN ®  CARD IV",
      "start_page": 84,
      "end_page": 84,
      "content": "FREECASE\nadd code at the checkout to apply\nSHOP NOW\nTo deliver the best  patient care, you need the tools  to match.\nLittmann® Cardiology IV ™ & Littmann® CORE Digital Stethoscopes\nKeep your tools safe with laser engraving.\n♥☺♫★♠\n",
      "keywords": [
        "free",
        "case",
        "littmann",
        "card"
      ],
      "tables": []
    }
  ]
}